

A

- Aaronson NK, *see* Madalinska JB
 Abanto ZU, *see* Hislop TG
 Abbruzzese JL, *see* Crane CH
 see Dragovich T
 see Li D
 see Ratain MJ
 Abdalla EK, *see* Ribero D
 see Vauthey J-N
 Abdalla EK, Vauthey J-N. Improved Survival After Resection of Colorectal Liver Metastases (correspondence), 2679
 Abdel-Rahman MH, Yang Y, Zhou X-P, Craig EL, Davidorf FH, Eng C. High Frequency of Submicroscopic Hemizygous Deletion Is a Major Mechanism of Loss of Expression of *PTEN* in Uveal Melanoma, 288
 Abdi E, *see* Rosen LS
 Abdulkarim B, *see* Gabos Z
 Abdulrahman R, *see* Timmerman R
 Abemayor E, *see* Li Y
 Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyan NS, Feit K, Ackerman J, De Jager RL, Eckhardt SG, O'Reilly EM. Randomized Phase III Study of Exatecan and Gemcitabine Compared With Gemcitabine Alone in Untreated Advanced Pancreatic Cancer, 4441
 Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard J-Y, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB. Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma, 4293
 Abouafia DM, *see* Dezube BJ
 Abraham B, *see* Grabar S
 Abrahamsson J, *see* Saarinen-Pihkala UM
 Abrams J, *see* Harlan LC
 Abramson N. Chronic Eosinophilic Leukemia/Hypereosinophilic Syndrome and Acute Leukemia (correspondence), 1647
 Abratt RP, *see* Ramlau R
 Abrey L, *see* Cloughesy TF
 Abrey LE, *see* Gavriliovic IT
 Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta M, DeAngelis LM. Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model, 5711
 Abuzzese E, *see* Iacobucci I
 Acheson LS, Zyzanski SJ, Stange KC, Deptowicz A, Wiesner GL. Validation of a Self-Administered, Computerized Tool for Collecting and Displaying the Family History of Cancer, 5395
 Ackerman I, *see* Wong RKS
 Ackerman J, *see* Abou-Alfa GK
 Ackland SP, *see* Wong M
 Adam M, *see* Lapillonne H
 Adam R, *see* Aloia T
 see Bilchik AJ
 see Poston G
 Adams J, *see* Berenson JR
 see Malin JL
 Adams JH, *see* Schover LR
 Adams JR, Angelotta C, Bennett CL. When the Risk of Febrile Neutropenia Is 20%, Prophylactic Colony-Stimulating Factor Use Is Clinically Effective, but Is It Cost-Effective? (editorial), 2975
 Adamson PC, *see* Fouladi M
 Adang EMM, *see* Timmer-Bonte JNH
 Adelstein DJ, *see* Pfister DG
 Adelstein DJ, LeBlanc M. Does Induction Chemotherapy Have a Role in the Management of Locoregionally Advanced Squamous Cell Head and Neck Cancer? 2624
 Adelstein DJ, Saxton JP, Rybicki LA, Esclamado RM, Wood BG, Strome M, Lavertu P, Lorenz RR, Carroll MA. Multiagent Concurrent Chemoradiotherapy for Locoregionally Advanced Squamous Cell Head and Neck Cancer: Mature Results From a Single Institution, 1064
 Adenis A, *see* Giacchetti S
 Adès L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Maloisel F, Deconinck E, Ferrant A, Thomas X, Fegueux N, Chomienne C, Dombret H, Degos L, Fenaux P. Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group, 5703
 Adesina A, *see* Thompson MC
 Adinin R, *see* Esmaeli B
 Adjei AA, *see* Erlichman C
 Adjei AA. What Is the Right Dose? The Elusive Optimal Biologic Dose in Phase I Clinical Trials (editorial), 4054
 Adusumilli J, *see* Govindarajan R
 Ae Shin S, *see* Min Park S
 Aelony Y. Raltitrexed and Pemetrexed Studies in Mesothelioma Have Not Shown Improved Quality of Life nor Prolonged Survival Compared With Effective Pleurodesis With Thoracoscopic Talc Poudrage (correspondence), 4667
 Agarwal R, *see* Murugaesu N
 Agbalika F, *see* Boulanger E
 Aggarwal BB, *see* Izzo JG
 Aghajanian C, *see* Gordon MS
 Aghili M, *see* Bourhis J
 Agostinelli C, *see* Went P
 Agrawal M, Grady C, Fairclough DL, Meropol NJ, Maynard K, Emanuel EJ. Patients' Decision-Making Process Regarding Participation in Phase I Oncology Research, 4479
 Agrawal SG, *see* Davies JK
 Aguggini S, *see* Bottini A
 Agulnik M, Oza AM, Pond GR, Siu LL. Impact and Perceptions of Mandatory Tumor Biopsies for Correlative Studies in Clinical Trials of Novel Anticancer Agents, 4801
 Agura E, *see* Hegenbart U
 Agura ED, *see* Baron F
 A'Hern R, *see* Lee CP
 Ahmed RL, Thomas W, Yee D, Schmitz KH. Randomized Controlled Trial of Weight Training and Lymphedema in Breast Cancer Survivors, 2765
 Ahmedzai SH, *see* Fearon KCH
 Ahn JS, *see* Kim HJ
 Aisner J, *see* Ettinger DS
 Aivado M, *see* Kuendgen A
 Ajani JA, *see* Izzo JG
 see Luthra R
 see Van Cutsem E
 see Wu X
 Ajani JA, Lee F-C, Singh DA, Haller DG, Lenz H-J, Benson AB III, Yanagihara R, Phan AT, Yao JC, Strumberg D. Multicenter Phase II Trial of S-1 Plus Cisplatin in Patients With Untreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, 663

AUTHOR INDEX

- Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PWT, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C, Rich TA. Phase II Trial of Preoperative Chemoradiation in Patients With Localized Gastric Adenocarcinoma (RTOG 9904): Quality of Combined Modality Therapy and Pathologic Response, 3953
- Ajani JA. Standard of Care for Gastric Cancer Based on Meta-Analysis? Treading On Thin Ice or It Is Very Nice! (correspondence), 5473
- Ajzensztejn D, Hegde VS, Lee SM. Tumor Lysis Syndrome After Treatment With Docetaxel for Non-Small-Cell Lung Cancer, 2389
- Akabani G, *see* Reardon DA
- Akdas A, *see* Hussain M
- Akerley W, *see* Fanucchi MP
- Akioka T, *see* Oka S
- Akiyama H, *see* Yanada M
- Akslen LA, *see* Bachmann IM
- Alaibac M, *see* Zinzani PL
- Al-Ali H, *see* Hegenbart U
- Albain K, *see* Robert N
- Albain KS, *see* Tanvetyanon T
see Unger JM
- Albanell J, *see* Rojo F
- Albano E, *see* Jeha S
- Alberti W, *see* Rades D
- Alberts DS, *see* Markman M
- Alberts D, *see* Ganz PA
- Alberts S, *see* Goldberg RM
- Alberts SR, *see* Steensma DP
- Alberts SR. Evolving Role of Chemotherapy in Resected Liver Metastases (editorial), 4952
- Albrecht J, *see* Scoggins CR
- Albrecht TL, *see* Eggly S
- Albrecht W, *see* Studer UE
- Alcalay A, Wun T, Khatri V, Chew HK, Harvey D, Zhou H, White RH. Venous Thromboembolism in Patients With Colorectal Cancer: Incidence and Effect on Survival, 1112
- Aldape K, *see* Cloughesy TF
- Aldape KD, *see* Wang L
- Alderfer M, *see* Kazak AE
- Aleman BMP, *see* Hoening MJ
see Noordijk EM
see van den Belt-Dusebout AW
- Alessandrino EP, *see* Gorin N-C
- Aletti GD, Cliby WA. Importance of Surgical Aggressiveness in Advanced Ovarian Cancer (correspondence), 2397
- Alexander HR, *see* Cornett WR
- Alexander LL, *see* Krueger GM
- Alexanian R, *see* Richardson PG
- Ali R, Ozkalemkas F, Ozelik T, Ozkocaman V, Ozkan A. Imatinib and Pregnancy (correspondence), 3812
- Aliff TB, *see* Pfister DG
- Alimena G, *see* Iacobucci I
- Alinari L, *see* Zinzani PL
- Al-Khater A-HM, *see* Cossor F
- Allareddy V, *see* Konety BR
- Allevi G, *see* Bottini A
- Allgeier A, *see* Mirimanoff R-O
see van den Bent MJ
- Allison DE, *see* Gordon MS
- Allmer C, *see* Philip PA
- Alloisio M, *see* Ceresoli GL
- Allred DC, *see* Ma X-J
- Almeida MTA, *see* Petrilli AS
- Al-Mulla F, Hagan S, Behbehani AI, Bitar MS, George SS, Going JJ, Curto García JJ, Scott L, Fyfe N, Murray GI, Kolch W. Raf Kinase Inhibitor Protein Expression in a Survival Analysis of Colorectal Cancer Patients, 5672
- Aloia T, Sebahgh M, Plasse M, Karam V, Lévi F, Giacchetti S, Guettier C, Azoulay D, Bismuth H, Castaing D, Adam R. Liver Histology and Surgical Outcomes After Preoperative Chemotherapy With Fluorouracil Plus Oxaliplatin in Colorectal Cancer Liver Metastases, 4983
- Aloia TA, Gershenwald JE, Andtbacka RH, Johnson MM, Schacherer CW, Ng CS, Cormier JN, Lee JE, Ross MI, Mansfield PF. Utility of Computed Tomography and Magnetic Resonance Imaging Staging Before Completion Lymphadenectomy in Patients With Sentinel Lymph Node-Positive Melanoma, 2858
- Aloia TA, Mansfield PF. In Reply (correspondence), 5178
- Alsina M, *see* Argenziano G
see Richardson PG
- Alterini R, *see* Zinzani PL
- Altman A, *see* Jeha S
- Altman AJ, *see* Gaynon PS
- Altorki NK, *see* Lilienbaum R
- Al-Tourah AJ, Tsang PWK, Skinnider BF, Hoskins PJ. Paraneoplastic Erythropoietin-Induced Polycythemia Associated With Small Lymphocytic Lymphoma, 2388
- Altschuler A, *see* Geiger AM
- Alvarez VL, *see* Mamelak AN
- Álvaro T, Lejeune M, Salvadó M-T, Lopez C, Jaén J, Bosch R, Pons LE. Immunohistochemical Patterns of Reactive Microenvironment Are Associated With Clinicobiologic Behavior in Follicular Lymphoma Patients, 5350
- Alves MTS, *see* Petrilli AS
- Amabile M, *see* Iacobucci I
- Amadori D, *see* Abou-Alfa GK
see Gennari A
- Amann G, *see* Navarro S
- Amant F, *see* Neven P
see Van Calsteren K
see Wildiers H
- Amato AA, *see* Richardson PG
- Amatruda TT, *see* Lewis KD
- Ambros IM, *see* Kerbl R
- Ambros PF, *see* Kerbl R
- Amdur RJ, *see* Liauw SL
see Mendenhall WM
- Amell N, *see* Bourhis J
- Amendola M, *see* Mitchell DG
- American Society of Clinical Oncology. Revisions of and Clarifications to the ASCO Conflict of Interest Policy, 517
- American Society of Clinical Oncology. American Society of Clinical Oncology: Revised Conflict of Interest Policy, 519
- American Society of Clinical Oncology. Reimbursement for Cancer Treatment: Coverage of Off-Label Drug Indications, 3206
- Amersi F, *see* Umetani N
- Ames MM, *see* Goetz MP
see Villablanca JG
- Amin M, *see* Argani P
- Amin S, *see* Esmaeli B
- Amorós A, *see* Hernández S
- Amorusi P, *see* Erlichman C
- Amos C, *see* Crane CH
- Amos CI, *see* Barcenas CH
see Chen S
see Wu X
- Anciaux N, *see* Giacchetti S
- Anderson C, *see* Lewis KD
- Anderson J, *see* Meza JL
- Anderson JR, *see* Lager JJ
- Anderson JR, Schonfeld TL. Patient Consent in the Era of De-Identified Research Databases (correspondence), 720
- Anderson K, *see* Hess KR
see Richardson P
- Anderson KC, *see* Barlogie B
see Richardson PG

AUTHOR INDEX

- Anderson KC, Richardson PG. In Reply (correspondence), 2968
- Anderson S, *see* Bear HD
- Anderson SJ, *see* Wapnir IL
- Anderson SJ. Some Thoughts on the Reporting of Adverse Events in Phase II Cancer Clinical Trials (editorial), 3821
- Anderson WF, *see* Kamangar F
- Anderson-Shaw L, *see* Hord JD
- Ando M, *see* Kudoh S
see Saito H
- Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, Ariyoshi Y, Fukuoka M. Predictive Factors for Interstitial Lung Disease, Antitumor Response, and Survival in Non-Small-Cell Lung Cancer Patients Treated With Gefitinib, 2549
- André N. Decisional Priority in Pediatric Oncology Revisited: Involving Children in Decision Making (correspondence), 2131
- Andre T, *see* Goldberg RM
- André T, *see* Tournigand C
- Andreesen R, *see* Mackensen A
- Andresen S, *see* Kalaycio M
- Andria M, *see* Meropol NJ
- Andrieu N, Easton DF, Chang-Claude J, Rookus MA, Brohet R, Cardis E, Antoniou AC, Wagner T, Simard J, Evans G, Peock S, Fricker J-P, Nogues C, Van't Veer L, Van Leeuwen FE, Goldgar DE. Effect of Chest X-Rays on the Risk of Breast Cancer Among *BRCA1/2* Mutation Carriers in the International *BRCA1/2* Carrier Cohort Study: A Report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group, 3361
- Androulakis N, *see* Xenidis N
- Andtbacka RH, *see* Aloia TA
- Ang K, *see* Elliott EA
- Ang KK, *see* Tsao AS
- Angelotta C, *see* Adams JR
- Anne PR, *see* Ajani JA
- Ansari R, *see* Hanna N
- Ansell SM, *see* Novak AJ
- Anthony SP, *see* Jones SE
- Antimi M, *see* Ferretti G
see Papaldo P
- Anton-Culver H, *see* Zell JA
- Antoniou AC, *see* Andrieu N
- Antoniou AC, Pharoah PDP, Easton DF, Evans DG. *BRCA1* and *BRCA2* Cancer Risks (correspondence), 3312
- Aoun M, *see* Klastersky J
- Aoun PA, *see* Mikuls TR
- Aparicio J, *see* Oliver T
- Aparicio J, Germà JR. Myths and Facts on Adjuvant Carboplatin for Stage I Seminoma (correspondence), e40
- Apostolaki S, *see* Xenidis N
- Appaji L, *see* Premalata C
- Arbuckle R, *see* Esmaeli B
- Arceci RJ, *see* Jeha S
see Widemann BC
- Arcusa À, *see* Rodríguez-Moranta F
- Argani P, Laé M, Ballard ET, Amin M, Manivel C, Hutchinson B, Reuter VE, Ladanyi M. Translocation Carcinomas of the Kidney After Chemotherapy in Childhood, 1529
- Argenziano G, Puig S, Zalaudek I, Sera F, Corona R, Alsina M, Barbato F, Carrera C, Ferrara G, Guilabert A, Massi D, Moreno-Romero JA, Muñoz-Santos C, Petrillo G, Segura S, Soyer HP, Zanchini R, Malvey J. Dermoscopy Improves Accuracy of Primary Care Physicians to Triage Lesions Suggestive of Skin Cancer, 1877
- Argyrazi K, *see* Xenidis N
- Ariyan S, *see* Scoggins CR
- Ariyoshi Y, *see* Ando M
- Armand J-P, *see* Faivre S
- Armitage JO, *see* Iqbal J
see Mikuls TR
see Smith TJ
- Armstrong DK, Brady MF. Intraperitoneal Therapy for Ovarian Cancer: A Treatment Ready for Prime Time, 4531
- Arnaud P, *see* Pène F
- Arning M, *see* Sweeney CJ
- Arnold M, *see* Mariani L
- Arnold RM, *see* Back AL
- Arnold SJ, Koczwara B. Breaking Bad News: Learning Through Experience, 5098
- Arpino G, *see* Lee AV
- Arteaga CL. Can Trastuzumab Be Effective Against Tumors With Low HER2/Neu (ErbB2) Receptors? (editorial), 3722
- Artusi R, *see* Licitra L
- Artusi T, *see* Went P
- Arun B, *see* Barcenas CH
- Arvidson J, *see* Saarinen-Pihkala UM
- Asada M, *see* Yasuda H
- Asaka-Amano Y, *see* Onoda S
- Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, Yokose T, Jiang S-X, Inoue T, Nakagawa K, Tajima K, Nagai K. Neuroendocrine Neoplasms of the Lung: A Prognostic Spectrum, 70
- Asano N, Oshiro A, Matsuo K, Kagami Y, Ishida F, Suzuki R, Kinoshita T, Shimoyama Y, Tamaru J-I, Yoshino T, Kitamura K, Fukutani H, Morishima Y, Nakamura S. Prognostic Significance of T-Cell or Cytotoxic Molecules Phenotype in Classical Hodgkin's Lymphoma: A Clinicopathologic Study, 4626
- Ascani S, *see* Went P
- Asch SM, *see* Lorenz KA
- Ashley DM, *see* Thompson MC
- Ashour Ahmed A, *see* Brenton JD
- Asmar L, *see* Blum JL
see Jones SE
see Robert N
- Asselain B, *see* Roché H
see This P
- Atherton PJ, *see* Rummans TA
- Atkins D, *see* Foekens JA
see Smid M
- Atkins JN, *see* Smalley SR
- Atri M. New Technologies and Directed Agents for Applications of Cancer Imaging, 3299
- Au A, *see* Esserman LJ
- Au P, *see* Duda DG
- Au WY, *see* Hon C
- Aubron C, *see* Pène F
- Audisio RA, *see* Repetto L
- Aul C, *see* Büchner T
- Ault P, Kantarjian H, O'Brien S, Faderl S, Beran M, Rios MB, Koller C, Giles F, Keating M, Talpaz M, Cortes J. Pregnancy Among Patients With Chronic Myeloid Leukemia Treated With Imatinib, 1204
- Aust DE, *see* Liersch T
- Auvrignon A, *see* Lapillonne H
see Rubie H
- Avery K, *see* Blazeby JM
- Avis NE, *see* Burwell SR
- Avis NE, Smith KW, Link CL, Hortobagyi GN, Rivera E. Factors Associated With Participation in Breast Cancer Treatment Clinical Trials, 1860
- Avril A, *see* Bijker N
- Awada A, *see* Bourhis J
- Axelrod R, *see* Fanucchi MP
- Axia G, Tremolada M, Pillon M, Zanesco L, Carli M. Post-Traumatic Stress Symptoms During Treatment in Mothers of Children With Leukemia (correspondence), 2216
- Ayala A, *see* Liu Q
- Ayala R, *see* Quintela-Fandino M
- Ayanian JZ, *see* Earle CC
see Keating NL

AUTHOR INDEX

Ayanian JZ, Jacobsen PB. Enhancing Research on Cancer Survivors, 5149
 Aydin S, *see* Machiels J-P
 Ayers GD, *see* Liu Q
 Ayoub J, *see* Bezjak A
 Azarnia N, *see* Lenz H-J
 Azoulay D, *see* Aloia T
 Azoulay E, *see* Pène F

B

Baas P, *see* Rademaker-Lakhai JM
 Baccarani M, *see* Cavo M
 see Iacobucci I
 see Soverini S
 Bacci F, *see* Went P
 Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, Akslen LA. EZH2 Expression Is Associated With High Proliferation Rate and Aggressive Tumor Subgroups in Cutaneous Melanoma and Cancers of the Endometrium, Prostate, and Breast, 268
 Bacillo E, *see* Papotti M
 Back AL, Arnold RM. Discussing Prognosis: “How Much Do You Want to Know?” Talking to Patients Who Are Prepared for Explicit Information, 4209
 Back AL, Arnold RM. Discussing Prognosis: “How Much Do You Want to Know?” Talking to Patients Who Do Not Want Information or Who Are Ambivalent, 4214
 Backstrom JT, *see* Silverman LR
 Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T. Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk Factors, 945
 Badruddoja M, *see* Reardon DA
 Baehner FL, *see* Paik S
 see Rangel J
 Bagg A, *see* Steere J
 Bahl G, Laskar S, Muckaden MA. Radiotherapy Alone for Nasal Natural-Killer/ T-Cell Lymphoma (correspondence), 2684
 Bai W, *see* Jubb AM
 Baile WF, Buckman R, Schapira L, Parker PA. Breaking Bad News: More Than Just Guidelines (correspondence), 3217
 Bailey C, *see* Jackman DM
 Bailey J, *see* Luthra R
 Bairati I, Meyer F. In Reply (correspondence), e10
 Bajdik CD, *see* Cheang MCU
 see Hislop TG
 Bajorin D, *see* Dalbagni G
 Bajorin DF, *see* Herbst RS
 Bajorin DF, Motzer RJ, Bosl GJ. Advances in Urologic Oncology: Results Progress From Successful Interdisciplinary Research, 5479
 Bajrovic A, *see* Rades D
 Baker AF, *see* Dragovich T
 Baker J, *see* Paik S
 Baker LH. In Reply (correspondence), 1959
 Baker M, *see* Dilts DM
 Baker SD, *see* Mita AC
 Baker SD, Sparreboom A. Predicting Vinorelbine Disposition and Toxicity: Does BSA Provide More Than a “Bad Statistical Association”? (editorial), 2412
 Balch CM, *see* Krueger GM
 Balducci L, *see* Smith TJ
 Baldus CD, Burmeister T, Martus P, Schwartz S, Gökbuget N, Bloomfield CD, Hoelzer D, Thiel E, Hofmann WK. High Expression of the ETS Transcription Factor *ERG* Predicts Adverse Outcome in Acute T-Lymphoblastic Leukemia in Adults, 4714
 Baldus CD, Thiede C, Soucek S, Bloomfield CD, Thiel E, Ehninger G. *BAALC* Expression and *FLT3* Internal Tandem Duplication Mutations in Acute

Myeloid Leukemia Patients With Normal Cytogenetics: Prognostic Implications, 790
 Balis FM, *see* Widemann BC
 Baliva G, *see* Zinzani PL
 Balkwill F, *see* Strauss SJ
 Ball L, *see* Flood KL
 Ballard ET, *see* Argani P
 Ballard-Barbash R, *see* Harlan LC
 Ballas MS, *see* Tsurutani J
 Balleine RL, *see* Wong M
 Balleisen L, *see* Büchner T
 Ballerini P, *see* Lapillonne H
 Ballman KV, *see* Brown PD
 see Buckner JC
 see Jaeckle KA
 Balneaves LG, *see* Hislop TG
 Bamberg M, *see* Herrlinger U
 see Timmermann B
 Banavali S, *see* Palled S
 Banay R, *see* Esmaeli B
 Bange J, *see* Thussbas C
 Bangerter M, *see* Kröber A
 Banham AH, *see* Bates GJ
 Bankes J, *see* Temple WJ
 Baptista MZ, Prieto VG, Chon S, Hortobagyi GN, Esteva FJ. Tamoxifen-Related Vasculitis, 3504
 Barakat RR, *see* Black D
 see Chi DS
 Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS. Randomized Double-Blind Trial of Estrogen Replacement Therapy Versus Placebo in Stage I or II Endometrial Cancer: A Gynecologic Oncology Group Study, 587
 Barats J-C, *see* du Bois A
 Barbato F, *see* Argenziano G
 Barber MD, *see* Fearon KCH
 Barbet J, *see* Chatal J-F
 see Goldenberg DM
 Barbieri F, *see* Paccagnella A
 Barcenas CH, Monawar Hosain GM, Arun B, Zong J, Zhou X, Chen J, Cortada JM, Mills GB, Tomlinson GE, Miller AR, Strong LC, Amos CI. Assessing *BRCA* Carrier Probabilities in Extended Families, 354
 Bardet E, *see* Bourhis J
 Bardet S, *see* Chatal J-F
 Bardia A, Barton DL, Prokop LJ, Bauer BA, Moynihan TJ. Efficacy of Complementary and Alternative Medicine Therapies in Relieving Cancer Pain: A Systematic Review, 5457
 Bardia A, Loprinzi CL, Goetz MP. Hand-Foot Syndrome After Dose-Dense Adjuvant Chemotherapy for Breast Cancer: A Case Series (correspondence), e18
 Bardou VJ, *see* Houvenaeghel G
 Bardwell WA, Natarajan L, Dimsdale JE, Rock CL, Mortimer JE, Hollenbach K, Pierce JP. Objective Cancer-Related Variables Are Not Associated With Depressive Symptoms in Women Treated for Early-Stage Breast Cancer, 2420
 Barentsz J, Takahashi S, Oyen W, Mus R, De Mulder P, Reznik R, Oudkerk M, Mali W. Commonly Used Imaging Techniques for Diagnosis and Staging, 3234
 Barette M, *see* Klastersky J
 Baretton GB, *see* Liersch T
 Barlogie B, *see* Richardson PG
 Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC. Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321, 929
 Barnett J, *see* Lohrisch C
 Baron A, *see* Lewis KD

AUTHOR INDEX

- Baron B, *see* Giacchetti S
see Rustin GJS
- Baron F, Storb R, Storer BE, Maris MB, Niederwieser D, Shizuru JA, Chauncey TR, Bruno B, Forman SJ, McSweeney PA, Maziarz RT, Pulsipher MA, Agura ED, Wade J, Sorrow M, Maloney DG, Sandmaier BM. Factors Associated With Outcomes in Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning After Failed Myeloablative Hematopoietic Cell Transplantation, 4150
- Barr RD, *see* McCarter H
- Barredo JC, Devidas M, Lauer SJ, Billett A, Marymont M, Pullen J, Camitta B, Winick N, Carroll W, Ritchey AK. Isolated CNS Relapse of Acute Lymphoblastic Leukemia Treated With Intensive Systemic Chemotherapy and Delayed CNS Radiation: A Pediatric Oncology Group Study, 3142
- Barrera M, *see* Maunsel E
see Speechley KN
- Barrette S, Bernstein ML, Leclerc J-M, Champagne MA, Samson Y, Brossard J, Woods WG. Treatment Complications in Children Diagnosed With Neuroblastoma During a Screening Program, 1542
- Barrier A, Boelle P-Y, Roser F, Gregg J, Tse C, Brault D, Lacaine F, Houry S, Huguier M, Franc B, Flahault A, Lemoine A, Dudoit S. Stage II Colon Cancer Prognosis Prediction by Tumor Gene Expression Profiling, 4685
- Bartelink H, *see* Bijker N
- Bartels U, *see* Larouche V
see Tabori U
- Bartlett RA, *see* Nakabayashi M
- Barton D, *see* Loprinzi CL
- Barton DL, *see* Bardia A
see Loprinzi CL
see Pockaj BA
- Barton MB, *see* Koczwara B
- Basaria S, *see* Braga-Basaria M
- Baseggio L, *see* Ghesquière H
- Baselga J, *see* Calvo E
see Rojo F
- Baselga J. Is There a Role for the Irreversible Epidermal Growth Factor Receptor Inhibitor EKB-569 in the Treatment of Cancer? A Mutation-Driven Question (editorial), 2225
- Baser ME, *see* Sharif S
- Basic H, *see* Rades D
- Basiuk J, *see* Wallace K
- Bassal M, Mertens AC, Taylor L, Neglia JP, Greffe BS, Hammond S, Ronckers CM, Friedman DL, Stovall M, Yasui YY, Robison LL, Meadows AT, Kadan-Lottick NS. Risk of Selected Subsequent Carcinomas in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study, 476
- Bast MA, *see* Mikuls TR
- Bast RC Jr, *see* Locker VG
- Bastian BC, *see* Curtin JA
- Batchelor T, Loeffler JS. Primary CNS Lymphoma, 1281
- Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH. Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse, 5373
- Batiste-Alentorn E, *see* Rodríguez-Moranta F
- Bauer A, *see* Tanner B
- Bauer BA, *see* Bardia A
- Bauer HCF, *see* Mertens F
- Bauer KS, *see* Dezube BJ
- Bauer S, *see* Ghadjar P
- Baum CM, *see* Motzer RJ
- Baum M, *see* Dowsett M
- Baunin C, *see* Rubie H
- Baxter DL, *see* Govindarajan R
- Baxter NN, *see* Johnson PM
- Bayer L, *see* Packer RJ
- Beach CL, *see* Silverman LR
- Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N. Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27, 2019
- Bear HD. Sentinel Node Micrometastases and Non-Sentinel Nodes in Breast Cancer: How Much Do We Need to Know? (editorial), 1788
- Bearden JD III, *see* Loprinzi CL
- Beazr A, *see* Ceresoli GL
see Paccagnella A
- Beaulieu N, *see* Reu FJ
- Bebb G, *see* Ho C
- Becherer A, *see* Wachter S
- Beck JT, *see* Socinski MA
- Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kam-mula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC. Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte-Associated Antigen 4, 2283
- Beck LN, *see* Lee SJ
- Beck R, *see* Ring BZ
- Beck T, *see* Hanna N
- Becker H, *see* Liersch T
- Becker K, *see* Ott K
- Becker M, *see* Lewis KD
- Beckwith JB, *see* Dome JS
- Bedano PM, Bonnin J, Einhorn LH. Metachronous Intracranial Germinoma in a Patient With a Previous Primary Mediastinal Seminoma, 2386
- Bedano PM, Brames MJ, Williams SD, Juliar BE, Einhorn LH. Phase II Study of Cisplatin Plus Epirubicin Salvage Chemotherapy in Refractory Germ Cell Tumors, 5403
- Bedenne L, *see* Gérard J-P
see Portier G
- Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG. Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group, 4738
- Bedre G, *see* Palled S
- Beerepoot LV, Radema SA, Witteveen EO, Thomas T, Wheeler C, Kempin S, Voest EE. Phase I Clinical Evaluation of Weekly Administration of the Novel Vascular-Targeting Agent, ZD6126, in Patients With Solid Tumors, 1491
- Beerepoot LV, Witteveen EO, Voest EE. In Reply (correspondence), 4040
- Beex LVAM, *see* Foekens JA
- Behbehani AI, *see* Al-Mulla F
- Behnke S, *see* Wachtel M
- Beijnen JH, *see* Rademaker-Lakhai JM
see Siegel-Lakhai WS
- Beirne DA, *see* Lee CP
- Beiske K, *see* Navarro S
- Beitsch PD, *see* Scoggins CR
- Békássy AN, *see* Saarinen-Pihkala UM
- Bekele BN, *see* Lee JJ
- Belghiti J, *see* Portier G
- Bell J, *see* Barakat RR
- Belldegrun AS, *see* Lam JS
- Bellido L, *see* Ocaña A
- Bellman F, *see* Lapillonne H
- Bello C, *see* Faivre S
- Bello CL, *see* Motzer RJ
- Belloni P, *see* Paccagnella A
- Belt R, *see* Fanucchi MP
see Robert N
- Bem J, *see* Redston M
- Benassi T, *see* Bourhis J
- Benda JA, *see* Randall ME
- Ben-David MA, *see* Pierce LJ
- Bendell JC, *see* Czito BG
- Bender DP, *see* Han LY

AUTHOR INDEX

- Bender JF, *see* Redfern CH
 Bender RA, *see* Ma X-J
 Benedetti JK, *see* Dragovich T
 see Smalley SR
 Bengtsson N-O, *see* Ejlertsen B
 Benhamou E, *see* Bourhis J
 Benigno BB, *see* Verheijen RH
 Benjamin RS, *see* Patel SR
 Benner A, *see* Kröber A
 see Thuerigen O
 Bennett CL, *see* Adams JR
 see Smith TJ
 Benoist S, *see* Nordlinger B
 Benoist S, Brouquet A, Penna C, Julié C, El Hajjam M, Chagnon S, Mitry E, Rougier P, Nordlinger B. Complete Response of Colorectal Liver Metastases After Chemotherapy: Does It Mean Cure? 3939
 Ben-Porat L, *see* Abrey LE
 see Dalbagni G
 Bensinger WI, *see* Stiff PJ
 Benson AB III, *see* Ajani JA
 see Smalley SR
 Benson MC, *see* McKiernan JM
 Bentley J, *see* Pfisterer J
 Bentz M, *see* Rücker FG
 Bentzen SM, *see* De Ruyscher D
 see Koukourakis MI
 see Rustin GJS
 Benz C, *see* Urban P
 Benz CC, *see* Kumar AS
 Beomonte Zobel B, *see* Quattrocchi CC
 Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A, Simon G. *RRM1* Modulated In Vitro and In Vivo Efficacy of Gemcitabine and Platinum in Non-Small-Cell Lung Cancer, 4731
 Beran M, *see* Ault P
 Berchuck A, *see* Guillem JG
 Berdel WE, *see* Büchner T
 see Koch P
 Berenson J, *see* Richardson PG
 Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R, Purner M, Lee S-p, Wilson J, Morrison B, Adams J, Schenkein D, Swift R. Phase I/II Trial Assessing Bortezomib and Melphalan Combination Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma, 937
 Berg S, *see* Whitney SN
 Berg SL, *see* Whitney SN
 Bergamini C, *see* Licitra L
 Berger F, *see* Ghesquières H
 Berger J, *see* Mackensen A
 Bergeron C, *see* Rubie H
 Bergh J, *see* Ejlertsen B
 see Tanner M
 Bergman DA, *see* Mikuls TR
 Bergsland EK, *see* Ko AH
 see Kulke MH
 Bergsland EK. When Does the Presence of the Target Predict Response to the Targeted Agent? (editorial), 213
 Bergstrom B, *see* Dummer R
 Berk L, *see* Elliott EA
 Berkey B, *see* Abrey LE
 see Cairncross G
 Berkman A, *see* Tummala MK
 Berman A, *see* Bonthala Wedam S
 Berman AW, *see* Lee JJ
 Bernardi C, *see* Bottini A
 Bernath AM, *see* Ingle JN
 Bernengo MG, *see* Zinzani PL
 Bernheim JL, *see* Van den Block L
 Bernier J, Vermorken JB, Koch aWM. Adjuvant Therapy in Patients With Resected Poor-Risk Head and Neck Cancer, 2629
 Bernsen HJJA, *see* van den Bent MJ
 Bernstein D, *see* Offit K
 Bernstein L, *see* Simon MS
 Bernstein M, *see* Yock TI
 Bernstein ML, *see* Barrette S
 Bernstein ML, Devidas M, Lafreniere D, Souid A-K, Meyers PA, Gebhardt M, Stine K, Nicholas R, Perlman EJ, Dubowy R, Wainer IW, Dickman PS, Link MP, Goorin A, Grier HE. Intensive Therapy With Growth Factor Support for Patients With Ewing Tumor Metastatic at Diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457—A Report From the Children's Oncology Group, 152
 Bernstein SH, *see* Fisher RI
 Bernstein ZP, *see* Chanan-Khan A
 Berretta M, *see* Di Benedetto F
 Berruti A, *see* Bottini A
 Berry DA, *see* Chen S
 Berry DL, Moinpour CM, Jiang CS, Pauler Ankerst D, Petrylak DP, Vinson LV, Lara PN, Jones S, Taplin ME, Burch PA, Hussain MHA, Crawford ED. Quality of Life and Pain in Advanced Stage Prostate Cancer: Results of a Southwest Oncology Group Randomized Trial Comparing Docetaxel and Estramustine to Mitoxantrone and Prednisone, 2828
 Berry WR, *see* Sonpavde G
 Bersani S, *see* Roldo C
 Bersiga A, *see* Bottini A
 Bertagnolli MM, *see* Raut CP
 see Redston M
 Berteloot P, *see* Van Calsteren K
 Bertelsen K, *see* Rustin GJS
 Berthold F, *see* Oberthuer A
 Berti E, *see* Zinzani PL
 Bertoli L, *see* Moll S
 Bertolini F, *see* Shaked Y
 Berton-Rigaud D, *see* Rousseau C
 Bertorelle R, *see* Brandes AA
 Bessa X, *see* Rodríguez-Moranta F
 Besson C, Canioni D, Lepage E, Pol S, Morel P, Lederlin P, Van Hoof A, Tilly H, Gaulard P, Coiffier B, Gisselbrecht C, Brousse N, Reyes F, Hermine O. Characteristics and Outcome of Diffuse Large B-Cell Lymphoma in Hepatitis C Virus-Positive Patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte Programs, 953
 Besson C, Lefrere F, Suarez F, Reyes F, Hermine O. In Reply (correspondence), 3513
 Bessudo A, *see* Redfern CH
 Bewick MA, Conlon MSC, Lafrenie RM. Polymorphisms in *XRCC1*, *XRCC3*, and *CCND1* and Survival After Treatment for Metastatic Breast Cancer, 5645
 Beyene J, *see* Dekker A
 Bézay C, *see* Henke M
 Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, Ayoub J, Lago S, de Albuquerque Ribeiro R, Gerogianni A, Cyjon A, Noble J, Laberge F, Chan RT-T, Fenton D, von Pawel J, Reck M, Shepherd FA. Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21, 3831
 Bezler M, *see* Tanner B
 Bhagwat R, *see* Palled S
 Bhakta S, *see* van Heeckeren WJ
 Bhargava P, *see* Zhu AX
 Bhattacharjee A, *see* Hayes DN
 Bianco FJ Jr, *see* Stephenson AJ
 Biason P, *see* Toffoli G
 Biason R, *see* Paccagnella A
 Biassoni L, *see* Rubie H
 Bickell NA, Wang JJ, Oluwole S, Schrag D, Godfrey H, Hiottis K, Mendez J, Guth

AUTHOR INDEX

- AA. Missed Opportunities: Racial Disparities in Adjuvant Breast Cancer Treatment, 1357
- Bidoli P, *see* Ceresoli GL
- Bieber T, *see* Reinhardt MJ
- Bielack S, *see* Kager L
- Biersack H-J, *see* Reinhardt MJ
- Biesma B, *see* Timmer-Bonte JNH
- Biganzoli E, *see* Demicheli R
- Bigner DD, *see* Reardon DA
- Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeek I, Julien J-P, Gennaro M, Rouanet P, Avril A, Fentiman IS, Bartelink H, Rutgers EJT. Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma-In-Situ: Ten-Year Results of European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853—A Study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group, 3381
- Bilchik AJ, Rosen LS, Poston G, Curley SA, Strasberg S, Saltz L, Adam R, Nordlinger B, Rougier P. In Reply (correspondence), 2218
- Billaud E, *see* Boué F
- Billett A, *see* Barredo JC
- Billheimer D, *see* Fowler K
- Billups C, *see* Furman WL
- Bilsen J, *see* Van den Block L
- Binns D, *see* Rischin D
- Birch JM, *see* Sharif S
- Bismuth H, *see* Aloia T
- Bisonni R, *see* Ruzzo A
- Bissett D, *see* Petty RD
- Bitar MS, *see* Al-Mulla F
- Bitran JD, *see* Nabhan C
- Bjarnason G, *see* Giacchetti S
- Bjelic-Radisic V, *see* Greimel ER
- Black D, *see* Yan TD
- Black D, Soslow RA, Levine DA, Tornos C, Chen SC, Hummer AJ, Bogomolny F, Olvera N, Barakat RR, Boyd J. Clinicopathologic Significance of Defective DNA Mismatch Repair in Endometrial Carcinoma, 1745
- Black NA, *see* Mikuls TR
- Black PC, Brown GA, Dinney CP. Molecular Markers of Urothelial Cancer and Their Use in the Monitoring of Superficial Urothelial Cancer, 5528
- Black WC. Randomized Clinical Trials for Cancer Screening: Rationale and Design Considerations for Imaging Tests, 3252
- Blackman DJ, Masi CM. Racial and Ethnic Disparities in Breast Cancer Mortality: Are We Doing Enough to Address the Root Causes? 2170
- Blackstock AW, Herndon JE II, Paskett ED, Miller AA, Lathan C, Niell HB, Socinski MA, Vokes EE, Green MR. Similar Outcomes Between African American and Non-African American Patients With Extensive-Stage Small-Cell Lung Carcinoma: Report From the Cancer and Leukemia Group B, 407
- Blair EYL, *see* Wong M
- Blaise A, *see* Lapillonne H
- Blaney SM, *see* Fouladi M
see Widemann BC
- Blanke CD, *see* Dragovich T
see Heinrich MC
see Unger JM
- Blansfield JA, *see* Beck KE
- Blaschke B, *see* Herrlinger U
- Blazzkowsky LS, *see* Zhu AX
- Blatt V, *see* Brandes AA
- Blazar B, *see* Stiff PJ
- Blazeby JM, Avery K, Sprangers M, Pikhart H, Fayers P, Donovan J. Health-Related Quality of Life Measurement in Randomized Clinical Trials in Surgical Oncology, 3178
- Bleiberg H, *see* Goldberg RM
see Herbst RS
see Paesmans M
see Rosa DD
- Bleijenberg G, *see* Gielissen MFM
- Bleiker EMA, *see* Madalinska JB
- Bleiweiss IJ, Nagi CS, Jaffer S. Axillary Sentinel Lymph Nodes Can Be Falsely Positive Due to Iatrogenic Displacement and Transport of Benign Epithelial Cells in Patients With Breast Carcinoma, 2013
- Bleyer A. Epoetin Versus Darbepoetin Conundrum Compromise (correspondence), e46
- Bliss JM, *see* Fallowfield LJ
- Blobe GC, *see* Czito BG
- Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed Nausea and Vomiting Continue to Reduce Patients' Quality of Life After Highly and Moderately Emetogenic Chemotherapy Despite Antiemetic Treatment, 4472
- Bloehdorn J, *see* Kröber A
- Blohmer J-U, *see* Kaufmann M
- Blomqvist C, *see* Vehmanen L
- Blood E, *see* Rajkumar SV
- Bloomfield CD, *see* Baldus CD
see Paschka P
- Blot E, *see* Ouvrier M-J
- Blot F, *see* Pène F
- Blum D, *see* Herbst RS
- Blum JL, *see* Jones SE
- Blum JL, Dees EC, Chacko A, Doane L, Ethirajan S, Hopkins J, McMahon R, Merten S, Negron A, Neubauer M, Ilegbodun D, Boehm KA, Asmar L, O'Shaughnessy JA. Phase II Trial of Capecitabine and Weekly Paclitaxel As First-Line Therapy for Metastatic Breast Cancer, 4384
- Blum RH, *see* Kraybill WG
- Blumgart LH, *see* Jarnagin WR
- Boadas J, *see* Rodríguez-Moranta F
- Boccalon M, *see* Toffoli G
- Boccia RV, *see* Glaspy J
- Bochner B, *see* Dalbagni G
- Bochner BH, *see* Parekh DJ
- Bodenstein H, *see* Kröger N
- Bodini G, *see* Bottini A
- Boehm KA, *see* Blum JL
see Jones SE
- Boelle P-Y, *see* Barrier A
- Boerma E-JG, *see* van Imhoff GW
- Boers M, *see* Herder GJM
- Boersma L, *see* De Ruyscher D
- Boersma-van Ek W, *see* van Geelen CM
- Boettger MB, *see* Spinola M
- Boezen HM, *see* van Geelen CM
- Bogaerts J, *see* Bijker N
- Bogomolny F, *see* Black D
- Boige V, *see* Pocard M
- Boilesen EC, *see* Mikuls TR
- Boiron J-M, *see* Gorin N-C
- Boiron JM, *see* Yakoub-Agha I
- Bolejack V, *see* Govindan R
- Bolonaki I, *see* Xenidis N
- Bolwell B, *see* Kalaycio M
- Bombardieri E, *see* Cascinelli N
- Bomgaars LR, *see* Jeha S
- Bonaldi L, *see* Brandes AA
- Bonanni B, *see* Guerrieri-Gonzaga A
- Bonanni B, Macis D, Maisonneuve P, Johansson HA, Gucciardo G, Oliviero P, Travaglini R, Muraca MG, Rotmensz N, Veronesi U, Decensi AU. Polymorphism in the CYP2D6 Tamoxifen-Metabolizing Gene Influences Clinical Effect but Not Hot Flashes: Data From the Italian Tamoxifen Trial (correspondence), 3708
- Bonardi S, *see* Bottini A
- Bondy ML, *see* Wang L
- Bonfrer JMG, *see* Peeters STH

AUTHOR INDEX

- Boni C, *see* Van Cutsem E
 Boni JP, *see* Erlichman C
 Bonilla F, *see* Domínguez G
 see Provencio M
 Bonner JA, Spencer SA. Postoperative Radiotherapy in Non–Small-Cell Lung Cancer Warrants Further Exploration in the Era of Adjuvant Chemotherapy and Conformal Radiotherapy (editorial), 2978
 Bonnet F, *see* Boué F
 Bonnetain F, *see* Gérard J-P
 Bonnetterre J, *see* Roché H
 Bonnini J, *see* Bedano PM
 Bonny M-A, *see* Machiels J-P
 Bono P, *see* Heinrich MC
 Bonomi P, *see* Hanna N
 see Lilienbaum R
 Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. In Reply (correspondence), 2127
 Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. In Reply (correspondence), 2129
 Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. In Reply (correspondence), 2130
 Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Statins and Cancer Risk: A Literature-Based Meta-Analysis and Meta-Regression Analysis of 35 Randomized Controlled Trials, 4808
 Bonthala Wedam S, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ, Plehn J, Doshi A, Thomasson D, McCarthy N, Koepfen H, Sherman M, Zujewski J, Camphausen K, Chen H, Swain SM. Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast Cancer, 769
 Bonura S, *see* Toffoli G
 Boogerd aW, *see* Dorresteijn LD
 Boogerd W, *see* Hooning MJ
 Bookman MA, *see* Buchholz TA
 Boonstra H, *see* Madalinska JB
 Boonstra JG, *see* Hamberg P
 Booser D, *see* Hess KR
 Boot H, *see* Siegel-Lakhai WS
 Booth CN, *see* Raab SS
 Bootsma GP, *see* Timmer-Bonte JNH
 Boracchi P, *see* Demicheli R
 Boral A, *see* Strauss SJ
 Boral AL, *see* Fisher RI
 Borasio P, *see* Papotti M
 Bordelon JH, *see* Jones SE
 Borden EC, *see* Reu FJ
 Bordow SB, *see* Haber M
 Borel C, *see* Bourhis J
 Boron M, *see* Chen HX
 Borrás AM, *see* Jackman DM
 Borroni G, *see* Zinzani PL
 Borsato ML, *see* Petrilli AS
 Bosch R, *see* Álvaro T
 Bosi C, *see* Soverini S
 Bosl GJ, *see* Bajorin DF
 see Houldsworth J
 see Kondagunta GV
 Bosly A, *see* Vey N
 Bosq J, *see* Noordijk EM
 Bosse K, *see* Gadzicki D
 Bosserman L, *see* Glaspy J
 Bosset J-F, *see* Portier G
 Bossi P, *see* Licitra L
 Bostrom BC, *see* Gaynon PS
 Bostwick JM, *see* Rummans TA
 Boswell WD, *see* Levine AM
 see O’Connell CL
 Botti C, *see* Papaldo P
 Bottini A, Generali D, Pia Brizzi M, Fox SB, Bersiga A, Bonardi S, Allevi G, Aguggini S, Bodini G, Milani M, Dionisio R, Bernardi C, Montrucchi A, Bruzzi P, Harris AL, Dogliotti L, Berruti A. Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients, 3623
 Bottomley A, *see* van Meerbeeck JP
 Bottomley A, Gaafa R, Manegold C, Burgers S, Coens C, Legrand C, Vincent M, Giaccone G, Van Meerbeeck J. Short-Term Treatment-Related Symptoms and Quality of Life: Results From an International Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study, 1435
 Botwood N, *see* Hirsch FR
 Boucharly C, *see* Rapiti E
 Bouché O, *see* Gérard J-P
 Bouche O, *see* Portier G
 Boué F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A, Bonnet F, Billaud E, Raphael M, Lancar R, Costagliola D. Phase II Trial of CHOP Plus Rituximab in Patients With HIV-Associated Non-Hodgkin’s Lymphoma, 4123
 Bouffet E, *see* Larouche V
 see Tabori U
 Bouknight RR, Bradley CJ, Luo Z. Correlates of Return to Work for Breast Cancer Survivors, 345
 Boulanger E, Gérard L, Oksenhendler E, Agbalika F. In Reply (correspondence), 209
 Bouma S, *see* Wright JR
 Bourbouloux E, *see* Rousseau C
 Bourdin S, *see* Bourhis J
 Bourhis J, Lapeyre M, Tortochaux J, Rives M, Aghili M, Bourdin S, Lesaunier F, Benassi T, Lemanski C, Geoffrois L, Lusinchi A, Verrelle P, Bardet E, Julieron M, Wibault P, Lubinski M, Benhamou E. Phase III Randomized Trial of Very Accelerated Radiation Therapy Compared With Conventional Radiation Therapy in Squamous Cell Head and Neck Cancer: A GORTEC Trial, 2873
 Bourhis J, Rivera F, Mesia R, Awada A, Geoffrois L, Borel C, Humblet Y, Lopez-Pousa A, Hitt R, Eugenia Vega Villegas M, Duck L, Rosine D, Amellal N, Schueler A, Harstrick A. Phase I/II Study of Cetuximab in Combination With Cisplatin or Carboplatin and Fluorouracil in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck, 2866
 Bourhis J. Hypoxia Response Pathways and Radiotherapy for Head and Neck Cancer (editorial), 725
 Bourhis JH, *see* Yakoub-Agha I
 Bourriel C, *see* Rousseau C
 Bowen D, *see* Vey N
 Bower M, Mazhar D, Stebbing J. Should Cervical Cancer Be an Acquired Immunodeficiency Syndrome—Defining Cancer? 2417
 Bowers DC, Liu Y, Leisenring W, McNeil E, Stovall M, Gurney JG, Robison LL, Packer RJ, Oeffinger KC. Late-Occurring Stroke Among Long-Term Survivors of Childhood Leukemia and Brain Tumors: A Report From the Childhood Cancer Survivor Study, 5277
 Bowers DC, Oeffinger KC. In Reply (correspondence), 1480
 Bowman L, *see* Malogolowkin MH
 Boyd AP, *see* Suh JH
 Boyd J, *see* Black D
 Brachman D, *see* Cairncross G
 Bradbury A, Olopade OI. The Case for Individualized Screening Recommendations for Breast Cancer (editorial), 3328
 Brade AM, Tannock IF. Scheduling of Radiation and Chemotherapy for Limited-Stage Small-Cell Lung Cancer: Repopulation As a Cause of Treatment Failure? (editorial), 1020
 Bradford C, *see* Urba S
 Bradley CJ, *see* Bouknight RR
 Bradley JD, *see* Ajani JA
 Brady M, *see* Markman M
 Brady MF, *see* Armstrong DK

AUTHOR INDEX

- Braga S, *see* Rosa DD
- Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S. Metabolic Syndrome in Men With Prostate Cancer Undergoing Long-Term Androgen-Deprivation Therapy, 3979
- Brahmer JR, *see* Carducci MA
- Brain K, Williams B, Iredale R, France L, Gray J. Psychological Distress in Men With Breast Cancer, 95
- Braiteh F, Kurzrock R. Case 1. Langerhans Cell Histiocytosis of the Thyroid, 522
- Brames MJ, *see* Bedano PM
- Brandes AA, *see* Mirimanoff R-O
see van den Bent MJ
- Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, Bertorelle R, Gardiman M, Ghimenton C, Iuzzolino P, Pession A, Blatt V, Ermani M. Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study, 4746
- Brandfield J, *see* Fleishman SB
- Brands FH, *see* Pagliarulo V
- Brandsma J, *see* Weinberger PM
- Brannon S, *see* Eckardt JR
- Brault D, *see* Barrier A
- Braun A, *see* Spinola M
- Braun V, *see* Fleishman SB
- Brawley OW. Lung Cancer and Race: Equal Treatment Yields Equal Outcome Among Equal Patients, but There Is No Equal Treatment (editorial), 332
- Brazil RM, *see* Press OW
- Breda A, *see* Lam JS
- Bredart A, *see* This P
- Bredel C, *see* Bredel M
- Bredel M, Bredel C, Juric D, Duran GE, Yu RX, Harsh GR, Vogel H, Recht LD, Scheck AC, Sikic BI. Tumor Necrosis Factor- α -Induced Protein 3 As a Putative Regulator of Nuclear Factor- κ B-Mediated Resistance to O⁶-Alkylating Agents in Human Glioblastomas, 274
- Brega N, *see* Faivre S
- Breitfeld PP, *see* Lager JJ
- Breneman JC, *see* Gaynon PS
- Brennan LV, *see* Lee SJ
- Brentjens R, *see* Lamanna N
- Brenton JD, Ashour Ahmed A, Caldas C. In Reply (correspondence), 722
- Bresalier R, *see* Luthra R
- Breslow NE, *see* Dome JS
- Brewer M, *see* Gordon MS
- Bridji B, *see* Rousseau C
- Briele HA, *see* Cornett WR
- Briemberg H, *see* Richardson PG
- Brisse H, *see* Rubie H
- Bristow RE, *see* Santillan A
- Britten CM, *see* Pashenkov M
- Brivio F, *see* Fumagalli LA
- Brizel DM, Esclamado R. Concurrent Chemoradiotherapy for Locally Advanced, Nonmetastatic, Squamous Carcinoma of the Head and Neck: Consensus, Controversy, and Conundrum, 2612
- Brock MV, *see* Engels EA
- Brockstein B, *see* Cohen EEW
- Broffman M, *see* McCulloch M
- Broffman MD, *see* McCulloch MF
- Broglio K, *see* Guarneri V
- Brohet R, *see* Andrieu N
- Brors B, *see* Oberthuer A
see Thuerigen O
- Brosjö O, *see* Mertens F
- Bross A, *see* Chow LML
- Brossard J, *see* Barrette S
- Brouquet A, *see* Benoist S
- Brousse N, *see* Besson C
- Brown AM, *see* Bear HD
- Brown G, *see* Chau I
- Brown GA, *see* Black PC
- Brown JW, Christie NA, Evans C, Egorin MJ. Case 4. Pulmonary Stent Migration and Ingestion in a Lung Cancer Patient, 1478
- Brown P, *see* Khuntia D
see Rummans TA
- Brown PD, *see* Meyers CA
- Brown PD, Jensen AW, Felten SJ, Ballman KV, Schaefer PL, Jaeckle KA, Cerhan JH, Buckner JC. Detrimental Effects of Tumor Progression on Cognitive Function of Patients With High-Grade Glioma, 5427
- Browne S, *see* Grunfeld EA
- Bruera E, Valero V, Driver L, Shen L, Willey J, Zhang T, Palmer JL. Patient-Controlled Methylphenidate for Cancer Fatigue: A Double-Blind, Randomized, Placebo-Controlled Trial, 2073
- Bruera E. Process and Content of Decision Making by Advanced Cancer Patients (editorial), 1029
- Brulport M, *see* Tanner B
- Brun EA, *see* Yan TD
- Brundage M, *see* Wong RKS
- Brunetto AL, *see* Petrilli AS
- Bruniera P, *see* Petrilli AS
- Bruno B, *see* Baron F
see Heigenbart U
- Bruzzi P, *see* Bottini A
see Gennari A
- Bryan B, *see* Konstantinopoulos PA
- Bryant J, *see* Paik S
- Bryant K, *see* McGinnis KA
- Bryon P-A, *see* Ghesquière H
- Bubley GJ, *see* Smith MR
see Taplin M-E
- Bucci MK, *see* Elliott EA
- Bucerius J, *see* Reinhardt MJ
- Buchanan D, *see* Watkins Bruner D
- Buchanan GR, *see* Journeycake JM
- Buchholz T, *see* Guarneri V
- Buchholz TA, *see* Oh JL
- Buchholz TA, Theriault RL, Niland JC, Hughes ME, Ottesen R, Edge SB, Bookman MA, Weeks JC. The Use of Radiation As a Component of Breast Conservation Therapy in National Comprehensive Cancer Network Centers, 361
- Büchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J, Schnittger S, Kern W, Tchinda J, Reichle A, Lengfelder E, Staib P, Ludwig W-D, Aul C, Eimermacher H, Balleisen L, Cristina Sauerland M, Heinecke A, Wörmann BJ, Hiddemann W. In Reply (correspondence), 5472
- Büchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J, Schnittger S, Kern W, Tchinda J, Reichle A, Lengfelder E, Staib P, Ludwig W-D, Aul C, Eimermacher H, Balleisen L, Sauerland M-C, Heinecke A, Wörmann B, Hiddemann W. Double Induction Containing Either Two Courses or One Course of High-Dose Cytarabine Plus Mitoxantrone and Postremission Therapy by Either Autologous Stem-Cell Transplantation or by Prolonged Maintenance for Acute Myeloid Leukemia, 2480
- Bucholz R, *see* Mamelak AN
- Buchval I, *see* Stein J
- Buckman R, *see* Baile WF
- Buckner J, *see* Cairncross G
- Buckner JC, *see* Brown PD
see Jaeckle KA
see Lawrence TS
- Buckner JC, Ballman KV, Michalak JC, Burton GV, Cascino TL, Schomberg PJ, Hawkins RB, Scheithauer BW, Sandler HM, Marks RS, O'Fallon JR. Phase III Trial of Carmustine and Cisplatin Compared With Carmustine Alone and Standard Radiation Therapy or Accelerated Radiation Therapy in Patients With Glioblastoma Multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials, 3871

AUTHOR INDEX

- Budd GT, *see* Ring BZ
- Buecher B, *see* Gérard J-P
- Bueno R, *see* Richards WG
- BuFalino R, *see* Cascinelli N
- Bugat R, *see* Portier G
- Buhard O, Cattaneo F, Fu Wong Y, Fan Yim S, Friedman E, Flejou J-F, Duval A, Hamelin R. Multipopulation Analysis of Polymorphisms in Five Mononucleotide Repeats Used to Determine the Microsatellite Instability Status of Human Tumors, 241
- Bühler A, *see* Kröber A
- Buhr HJ, *see* Ghadjar P
- Buist DSM, *see* Enger SM
- Bukowski RM, *see* Motzer RJ
- Bulley S, *see* Dekker A
- Bullinger L, *see* Rucker FG
- Bundy BN, *see* Barakat RR
- Bunn Jr PA, *see* Hirsch FR
- Bunn PA Jr, *see* Hanna N
see Hirsch FR
see Weiss GJ
- Buonadonna A, *see* Toffoli G
- Burch PA, *see* Berry DL
- Burger PC, *see* Packer RJ
- Burgers S, *see* Bottomley A
- Burke W, *see* Loud JT
- Burkey BB, *see* Chung CH
- Burkhardt B, Woessmann W, Zimmermann M, Kontny U, Vormoor J, Doerffel W, Mann G, Henze G, Niggli F, Ludwig W-D, Janssen D, Riehm H, Schrappe M, Reiter A. Impact of Cranial Radiotherapy on Central Nervous System Prophylaxis in Children and Adolescents With Central Nervous System–Negative Stage III or IV Lymphoblastic Lymphoma, 491
- Burkman RT, *see* Simon MS
- Burmeister T, *see* Baldus CD
see Jahnke K
- Burnett A, *see* Vey N
- Burnett AK, *see* Wheatley K
- Burnham J, *see* Pollack IF
- Burock K, *see* Kröger N
- Burstein HJ, *see* Tolanev SM
- Burstein HJ. In Reply (correspondence), 2394
- Burton GV, *see* Buckner JC
- Burwell SR, Case LD, Kaelin C, Avis NE. Sexual Problems in Younger Women After Breast Cancer Surgery, 2815
- Busam K, *see* Curtin JA
- Busch ORC, *see* Lagarde SM
- Busch R, *see* Ott K
- Butler AL, *see* Hislop TG
- Butler G, *see* Lee AYY
- Butowski NA, Sneed PK, Chang SM. Diagnosis and Treatment of Recurrent High-Grade Astrocytoma, 1273
- Buyse M, *see* de Gramont A
see Loi S
see Tournigand C
- Buzdar aA, *see* Dowsett M
- Buzdar AU, *see* Guarneri V
see Hess KR
- Buzdar AU. Topoisomerase II α Gene Amplification and Response to Anthracycline-Containing Adjuvant Chemotherapy in Breast Cancer (editorial), 2409
- Buzyn A, *see* Pène F
see Yakoub-Agha I
- Byrd DR, *see* Martins RG
- Byrd J, *see* Lichtman SM
- Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, Lampson B, Larson RA, Caligiuri MA, Heerema NA. Select High-Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy With Fludarabine and Rituximab in Chronic Lymphocytic Leukemia: Justification for Risk-Adapted Therapy, 437
- Byrne C, *see* Chanan-Khan A
- Byrne M, *see* Hanna N

C

- Cabanillas F, *see* Liu Q
- Cachin F, Prince HM, Hogg A, Ware RE, Hicks RJ. Powerful Prognostic Stratification By [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography in Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy, 3026
- Cagnoni PJ, *see* Suh JH
- Cahn JY, *see* Gorin N-C
see Yakoub-Agha I
- Cai J, *see* Pagliarulo V
- Cai Q, Gao Y-T, Chow W-H, Shu X-O, Yang G, Ji B-T, Wen W, Rothman N, Li H-L, Morrow JD, Zheng W. Prospective Study of Urinary Prostaglandin E₂ Metabolite and Colorectal Cancer Risk, 5010
- Cairncross G, *see* Mirimanoff R-O
- Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Mehta M, Curran W. Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402, 2707
- Cairo MS, *see* Eapen M
- Cairolì R, *see* Montillo M
- Cajal SR, *see* Rojo F
- Calaminici M, *see* Lee AM
- Caldas C, *see* Brenton JD
- Caligiuri MA, *see* Byrd JC
see Monk JP
- Calin GA, *see* Roldo C
- Call TG, *see* Novak AJ
see Shanafelt TD
- Callet-Bauchu E, *see* Ghesquières H
- Calvo E, Baselga J. Ethnic Differences in Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, 2158
- Camargo OP, *see* Petrilli AS
- Camerini T, *see* Cascinelli N
- Camidge DR, Eckhardt SG, Gore L. Dynamic and Modern: Bringing the Ethics of Phase I Trials Up to Date (correspondence), 5178
- Camitta B, *see* Barredo JC
- Camitta BM, *see* Eapen M
- Camoriano JK, *see* Ingle JN
- Camp RL, *see* Weinberger PM
- Campbell M, *see* Kumar AS
- Camphausen K, *see* Bonthala Wedam S
- Campion L, *see* Chatal J-F
see Rousseau C
- Campo E, *see* Iqbal J
- Campone M, *see* Roché H
see Rousseau C
- Canellos G, *see* Krueger G
- Canestrari E, *see* Ruzzo A
- Cangini D, *see* Cavo M
- Canioni D, *see* Besson C
- Canon J-L, *see* Roché H
- Cantor A, *see* Bepler G
- Cantor SB, *see* Lee JJ
see Smith TJ
- Cantù G, *see* Licitra L
- Cao G, *see* Khong P-L
- Cao H, *see* Petrik D
- Cao Y, *see* Wang L

AUTHOR INDEX

- Cao Y, Sundgren PC, Tsien CI, Chenevert TT, Junck L. Physiologic and Metabolic Magnetic Resonance Imaging in Gliomas, 1228
- Capalbo L, *see* Richards WG
- Capanu M, *see* Shah MA
- Capell P, *see* Martins RG
- Capellá G, *see* Dotor E
- Capelli P, *see* Roldo C
- Cappello N, *see* Zinzani PL
- Cappia S, *see* Papotti M
- Capra M, *see* Larouche V
- Capussotti L, *see* Vauthey J-N
- Carassiti M, *see* Quattrocchi CC
- Carbone A, *see* Cascinelli N
see Simonelli C
- Carbone DP, *see* Fanucchi MP
- Carde P, *see* Noordijk EM
- Carde P. In Reply (correspondence), 3309
- Cardillo TM, *see* Gold DV
- Cardinale D, Lamantia G, Cipolla CM. Troponin I and Cardiovascular Risk Stratification in Patients With Testicular Cancer (correspondence), 3508
- Cardis E, *see* Andrieu N
- Cardoso F, *see* Loi S
see Rosa DD
- Carducci MA, *see* Braga-Basaria M
- Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS. Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer, 4092
- Carey LA, *see* Oh DS
- Carhart RL, *see* Lu JI
- Carli M, *see* Axia G
- Carlini P, *see* Papaldo P
- Carlini P, Papaldo P, Fabi A, Felici A, Maria Ruggeri E, Milella M, Ciccarese M, Nuzzo C, Cognetti F, Ferretti G. Liver Toxicity After Treatment With Gefitinib and Anastrozole: Drug-Drug Interactions Through Cytochrome p450? (correspondence), e60
- Carola E, *see* Tournigand C
- Carpentier AF, *see* van den Bent MJ
- Carr DB, *see* Flood KL
- Carrato A, *see* Hernández S
- Carrera C, *see* Argenziano G
- Carreras E, *see* Fernández-Avilés F
- Carroll AJ, *see* Paschka P
- Carroll MA, *see* Adelstein DJ
- Carroll MB, *see* Flood KL
- Carroll RG, *see* Coughlin CM
- Carroll W, *see* Barredo JC
- Carter BA, Page DL. Sentinel Lymph Node Histopathology in Breast Cancer: Minimal Disease Versus Artifact (editorial), 1978
- Carter D, *see* Claus EB
- Carter J, *see* Chung CH
- Carter M, *see* Tabori U
- Carter WD, *see* Redfern CH
- Carvalho C, *see* Giacchetti S
- Carvalho MS, *see* Soares M
- Casadevall N, *see* Vey N
- Casanova M, *see* Ferrari A
- Cascinelli N, Bombardieri E, Bufalino R, Camerini T, Carbone A, Clemente C, Lenisa L, Mascheroni L, Maurichi A, Pennacchioli E, Patuzzo R, Santinami M, Tragni G. Sentinel and Nonsentinel Node Status in Stage IB and II Melanoma Patients: Two-Step Prognostic Indicators of Survival, 4464
- Cascino TL, *see* Buckner JC
- Cascinu S, *see* Ruzzo A
- Case LD, *see* Burwell SR
see Petrek JA
- Casselmann J, *see* Studer UE
- Cassidy J, *see* Rustin GJS
- Cassileth BR, *see* Vickers AJ
- Cassileth PA, *see* Habermann TM
- Castagnetti F, *see* Soverini S
- Castaing D, *see* Aloia T
- Castells A, *see* Rodríguez-Moranta F
- Castleberry RP, *see* Malogolowkin MH
see Marina N
- Catalano RB, *see* O'Dwyer PJ
- Catalano V, *see* Ruzzo A
- Caton A, *see* O'Connell CL
- Cattaneo F, *see* Buhard O
- Cavallo G, *see* Brandes AA
- Cavazzini L, *see* Lanza G
- Cavenagh JD, *see* Davies JK
- Cavina R, *see* Ceresoli GL
- Cavo M, Terragna C, Renzulli M, Zamagni E, Tosi P, Testoni N, Nicci C, Cangini D, Tacchetti P, Grafone T, Cellini C, Ceccolini M, Perrone G, Martinelli G, Baccarani M, Guardigni L. Poor Outcome With Front-Line Autologous Transplantation in t(4;14) Multiple Myeloma: Low Complete Remission Rate and Short Duration of Remission (correspondence), e4
- Cazzaniga M, *see* Guerrieri-Gonzaga A
- Cecchin E, *see* Toffoli G
- Ceccolini M, *see* Cavo M
- Celia Hughes M, *see* Whiteman DC
- Cellini C, *see* Cavo M
- Ceresoli G, *see* Paccagnella A
- Ceresoli GL, Chiti A, Zucali PA, Rodari M, Lutman RF, Salamina S, Incarbone M, Alloisio M, Santoro A. Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [¹⁸F]Fluorodeoxyglucose, 4587
- Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morengi E, Cavina R, Marangolo M, Soto Parra HJ, Santoro A. Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma, 1443
- Cerhan JH, *see* Brown PD
- Cerhan JR, *see* Novak AJ
- Ceribelli A, *see* Ceresoli GL
see Papaldo P
- Cerny T, *see* Strasser F
- Cervantes A, *see* Tournigand C
- Cesana G, Kim-Schulze S, Kaufman HL. In Reply (correspondence), e35
- Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL. Characterization of CD4⁺CD25⁺ Regulatory T Cells in Patients Treated With High-Dose Interleukin-2 for Metastatic Melanoma or Renal Cell Carcinoma, 1169
- Cesano A, *see* Rosen LS
see Stiff PJ
- Chabot P, *see* Wong RKS
- Chacko A, *see* Blum JL
- Chada S, *see* Fujiwara T
- Chadaram V, *see* Cornett WR
- Chaganti RSK, *see* Houldsworth J
- Chagnon S, *see* Benoist S
- Chamberlin T, *see* Nemunaitis J
- Champagne MA, *see* Barrette S
- Champlin R, *see* Tsimberidou A-M
- Chan AT, *see* Chan JA
see Meyerhardt JA
- Chan ATC, *see* Leung S-f
- Chan GCF, *see* Khong P-L
- Chan JA, *see* Meyerhardt JA
- Chan JA, Meyerhardt JA, Chan AT, Giovannucci EL, Colditz GA, Fuchs CS. Hormone Replacement Therapy and Survival After Colorectal Cancer Diagnosis, 5680
- Chan KCA, *see* Leung S-f

AUTHOR INDEX

- Chan LYS, *see* Leung S-f
 Chan RT-T, *see* Bezjak A
 Chan S, *see* Hislop TG
 Chan S-C, *see* Liu F-Y
 see Ng S-H
 Chan WC, *see* Iqbal J
 Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spaner D, Mohr A, Byrne C, Hernandez-Ilizaliturri F, Chrystal C, Starostik P, Czuczman MS. Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study, 5343
 Chang A, *see* Hirsch FR
 Chang C-H, *see* Chatal J-F
 Chang C-J, *see* Chou H-H
 Chang EL, *see* Suh JH
 Chang G-C, *see* Paz-Ares L
 Chang I, *see* Siegel-Lakshai WS
 Chang JT, *see* Liu F-Y
 Chang JT-C, *see* Ng S-H
 Chang JWC, *see* Tsai K-Y
 Chang JY, *see* Shelley Wang X
 Chang SM, *see* Butowski NA
 see Cloughesy TF
 Chang T-C, *see* Chou H-H
 Chang-Claude J, *see* Andrieu N
 Chansky K, *see* Davies AM
 see West HL
 Chao A, *see* Chou H-H
 Chao KSC, *see* Izzo JG
 Chao Y, *see* Van Cutsem E
 Chapet O, *see* Gérard J-P
 Chapman RA, *see* Barlogie B
 Chappuis PO, *see* Rapiti E
 Charbonnel B, *see* Chatal J-F
 Charnsangavej C, *see* Crane CH
 Chatal J-F, *see* Goldenberg DM
 Chatal JF, *see* Rousseau C
 Chatal J-F, Campion L, Kraeber-Bodéré F, Bardet S, Vuillez J-P, Charbonnel B, Rohmer V, Chang C-H, Sharkey RM, Goldenberg DM, Barbet J. Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti-Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group, 1705
 Chatal JF. In Reply (correspondence), e38
 Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, Tebbutt N, Hill M, Ross PJ, Massey A, Oates J. Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging-Defined Poor-Risk Rectal Cancer, 668
 Chau I, Cunningham D, Tait D, Brown G. In Reply (correspondence), 4665
 Chaudhary AK, *see* Mita AC
 Chaudhuri T, *see* Mita AC
 Chauhan N, *see* Gabos Z
 Chauncey T, *see* Hegenbart U
 Chauncey TR, *see* Baron F
 Cheang MCU, *see* Ring BZ
 Cheang MCU, Treaba DO, Speers CH, Olivotto IA, Bajdik CD, Chia SK, Goldstein LC, Gelmon KA, Huntsman D, Gilks CB, Nielsen TO, Gown AM. Immunohistochemical Detection Using the New Rabbit Monoclonal Antibody SP1 of Estrogen Receptor in Breast Cancer Is Superior to Mouse Monoclonal Antibody 1D5 in Predicting Survival, 5637
 Chehata S, *see* Yakoub-Agha I
 Chella A, *see* Paccagnella A
 Chen AB, D'Amico AV, Neville BA, Earle CC. Patient and Treatment Factors Associated With Complications After Prostate Brachytherapy, 5298
 Chen C-J, *see* Heinrich MC
 Chen C-M, *see* Cheng SH
 Chen DF, *see* Esserman LJ
 Chen H, *see* Bonthala Wedam S
 see Paschka P
 Chen HX, Mooney M, Boron M, Vena D, Mosby K, Grochow L, Jaffe C, Rubinstein L, Zwiebel J, Kaplan RS. Phase II Multicenter Trial of Bevacizumab Plus Fluorouracil and Leucovorin in Patients With Advanced Refractory Colorectal Cancer: An NCI Treatment Referral Center Trial TRC-0301, 3354
 Chen J, *see* Barcenas CH
 see Engels EA
 Chen L-T, *see* Cheng T-Y
 Chen M-G, *see* Rosen LS
 Chen M-H, *see* D'Amico AV
 Chen S, Iversen ES Jr, Parmigiani G. In Reply (correspondence), 3313
 Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A, Peterson LE, Schildkraut JM, Isaacs C, Peshkin BN, Corio C, Leondaridis L, Tomlinson G, Dutson D, Kerber R, Amos CI, Strong LC, Berry DA, Euhus DM, Parmigiani G. Characterization of *BRCA1* and *BRCA2* Mutations in a Large United States Sample, 863
 Chen SC, *see* Black D
 Chen Y-Y, *see* Esserman LJ
 Chen Z, *see* Malogolowkin MH
 see Yock TI
 Chenevert TT, *see* Cao Y
 Cheng A-L, *see* Cheng T-Y
 Cheng L-C, *see* Hon C
 Cheng SH, Horng C-F, West M, Huang E, Pittman J, Tsou M-H, Dressman H, Chen C-M, Tsai SY, Jian JJ, Liu M-C, Nevins JR, Huang AT. Genomic Prediction of Locoregional Recurrence After Mastectomy in Breast Cancer, 4594
 Cheng SK, *see* Dilts DM
 Cheng T-Y, Lin J-T, Chen L-T, Shun C-T, Wang H-P, Lin M-T, Wang T-E, Cheng A-L, Wu M-S. Association of T-Cell Regulatory Gene Polymorphisms With Susceptibility to Gastric Mucosa-Associated Lymphoid Tissue Lymphoma, 3483
 Chepeha D, *see* Urba S
 Cheret A, *see* Boué F
 Cherkassky L, *see* Reu FJ
 Chesney MJ, *see* Kris MG
 Cheung IY, *see* Cheung N-KV
 Cheung K, *see* Cesana GC
 Cheung N-KV, *see* Kushner BH
 Cheung N-KV, Sowers R, Vickers AJ, Cheung IY, Kushner BH, Gorlick R. *FCGR2A* Polymorphism Is Correlated With Clinical Outcome After Immunotherapy of Neuroblastoma With Anti-GD2 Antibody and Granulocyte Macrophage Colony-Stimulating Factor, 2885
 Chevret S, *see* Adès L
 Chew HK, *see* Alcalay A
 Chi DS, Barakat RR. Aggressive Surgery and Ovarian Cancer (correspondence), 2395
 Chia S, Clemons M, Martin L-A, Rodgers A, Gelmon K, Pond GR, Panasci L. Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II Trial, 2773
 Chia SK, *see* Cheang MCU
 Chiang SS, *see* Wu X
 Chien AJ, Goss PE. Aromatase Inhibitors and Bone Health in Women With Breast Cancer, 5305
 Childs R, *see* Yang JC
 Chilton JA, *see* Jones LA
 Chimenti S, *see* Zinzani PL
 Chin C, *see* Chow AY
 Chin T, *see* Fouladi M
 Ching Linn Y, *see* Chuah C
 Chinnery LW, *see* Kris MG
 Chintagumpala M, *see* Thompson MC
 Chir Z, *see* Yakoub-Agha I

AUTHOR INDEX

- Chirieac LR, *see* Richards WG
- Chirivella I, *see* Tournigand C
- Chisholm J, *see* Rubie H
- Chiti A, *see* Ceresoli GL
- Chittenden A, *see* Farkas Patenaude A
- Chiusa L, *see* Papotti M
- Choi YM, Mafee MF, Feldman LE. Successful Treatment of Syncope in Head and Neck Cancer With Induction Chemotherapy, 5332
- Choksi JK, *see* Socinski MA
- Chomienne C, *see* Adès L
- Chon S, *see* Baptista MZ
- Chott A, *see* Grünberger B
see Raderer M
- Chou H-H, Chang T-C, Yen T-C, Ng K-K, Hsueh S, Ma S-Y, Chang C-J, Huang H-J, Chao A, Wu T-I, Jung S-M, Wu Y-C, Lin C-T, Huang K-G, Lai C-H. Low Value of [¹⁸F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Primary Staging of Early-Stage Cervical Cancer Before Radical Hysterectomy, 123
- Chou MM, *see* Oliveira AM
- Chow AY, Chin C, Dahl G, Rosenthal DN. Anthracyclines Cause Endothelial Injury in Pediatric Cancer Patients: A Pilot Study, 925
- Chow CK, *see* Bonthala Wedam S
- Chow LML, Nathan PC, Hodgson DC, Jenkin D, Weitzman S, Grant RM, Manson D, Bross A, Doyle JJ, Danjoux C, Greenberg ML. Survival and Late Effects in Children With Hodgkin's Lymphoma Treated With MOPP/ABV and Low-Dose, Extended-Field Irradiation, 5735
- Chow W-H, *see* Cai Q
- Choyke P, *see* Bonthala Wedam S
- Christensen IJ, *see* Schmidt P
- Christiaens M-R, *see* Neven P
- Christiani DC. Genetic Susceptibility to Lung Cancer (editorial), 1651
- Christie NA, *see* Brown JW
- Christofferson E, *see* Petrik D
- Christophylakis C, *see* Xenidis N
- Chrystal C, *see* Chanan-Khan A
- Chu R, *see* Lai R
- Chuah C, Hui Lim T, Soon Tiong Lim A, Leng Tien S, Hee Lim C, Soong R, Lee F, Ching Linn Y, Tee Goh Y, Koon Cheah F, Hwai Liang Loh A. Dasatinib Induces a Response in Malignant Thymoma (correspondence), e56
- Chuai S, *see* Pham D
- Chui W-H, *see* Hon C
- Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, Jarrett C, Carter J, Murphy BA, Nettekville J, Burkey BB, Sinard R, Cmelak A, Levy S, Yarbrough WG, Slebos RJC, Hirsch FR. Increased Epidermal Growth Factor Receptor Gene Copy Number Is Associated With Poor Prognosis in Head and Neck Squamous Cell Carcinomas, 4170
- Chung Cheng Y, *see* Woodward WA
- Chung H, *see* Shanafelt T
- Chung KY, Saltz LB. In Reply (correspondence), 1957
- Church J, *see* Guillem JG
- Ciccarelli R, *see* Mignogna MD
- Ciccarese M, *see* Carlini P
- Ciezki JP, *see* Kupelian PA
- Cigler T, Goss PE. Aromatase Inhibitor Withdrawal Response in Metastatic Breast Cancer, 1955
- Cilloni D, *see* Iacobucci I
see Soverini S
- Cipolla CM, *see* Cardinale D
- Ciuleanu T, *see* Hirsch FR
- Ciuleanu T-E, *see* O'Brien MER
- Clagett B, *see* Offit K
- Clark G, *see* Bezjak A
- Clark JA, Talcott JA. Confidence and Uncertainty Long After Initial Treatment for Early Prostate Cancer: Survivors' Views of Cancer Control and the Treatment Decisions They Made, 4457
- Clark JW, *see* Kulke MH
see Meyerhardt JA
see Zhu AX
- Clark MM, *see* Rummans TA
- Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ. Recent Declines in Hormone Therapy Utilization and Breast Cancer Incidence: Clinical and Population-Based Evidence (correspondence), e49
- Clarke CL, *see* Wong M
- Clarke S, *see* Rosen LS
- Clarke SJ, *see* Michael M
- Clark-Snow R, *see* Kris MG
- Clary BM, *see* Czito BG
- Classe JM, *see* Houvenaeghel G
- Claudio Gambini, *see* Navarro S
- Claus EB, Petruzella S, Carter D, Kasl S. Quality of Life for Women Diagnosed With Breast Carcinoma in Situ, 4875
- Claus P, *see* Van Calsteren K
- Clayman GL, *see* Pfister DG
see Tsao AS
- Clear AJ, *see* Lee AM
- Cleary PD, *see* Mack JW
- Cleeland CS, *see* Shelley Wang X
- Clegg LX, *see* Harlan LC
- Clemens M, *see* Heinemann V
- Clemente C, *see* Cascinelli N
- Clemons M, *see* Chia S
- Clemons MJ, Dranitsaris G, Ooi WS, Yogendran G, Sukovic T, Wong BYL, Verma S, Pritchard KI, Trudeau M, Cole DEC. Phase II Trial Evaluating the Palliative Benefit of Second-Line Zoledronic Acid in Breast Cancer Patients With Either a Skeletal-Related Event or Progressive Bone Metastases Despite First-Line Bisphosphonate Therapy, 4895
- Clerici M, *see* Paccagnella A
- Cliby WA, *see* Aletti GD
- Cline RJW, *see* Eggly S
- Clipp EC, *see* Demark-Wahnefried W
- Closon-Dejardin M-T, *see* Gérard J-P
- Clouet M, *see* Rousseau C
- Clough RW, *see* Koontz BF
- Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, J. Raizer J, Yung WKA, Aldape K, Wright J, Lamborn KR, Prados MD. Phase II Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Either Receiving or Not Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study, 3651
- Clutter Snyder D, *see* Demark-Wahnefried W
- Cmelak A, *see* Chung CH
- Coakley F, *see* Mitchell DG
- Cobleigh M, *see* Robert N
- Coccia P, *see* Dome JS
- Codeluppi M, *see* Di Benedetto F
- Coebergh J-WW, *see* Siemes C
see Steyerberg EW
- Coens C, *see* Bottomley A
- Cognetti F, *see* Carlini P
see Ferretti G
see Gelibter AJ
see Papaldo P
- Cohen AM, *see* Nissan A
- Cohen EEW, Haraf DJ, List MA, Kocherginsky M, Mittal BB, Rosen F, Brockstein B, Williams R, Witt ME, Stenson KM, Kies MS, Vokes EE. High Survival and Organ Function Rates After Primary Chemoradiotherapy for Intermediate-Stage Squamous Cell Carcinoma of the Head and Neck Treated in a Multicenter Phase II Trial, 3438
- Cohen EEW. Role of Epidermal Growth Factor Receptor Pathway-Targeted Therapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck, 2659

AUTHOR INDEX

- Cohen HJ, *see* Demark-Wahnefried W
- Cohen JN, *see* Coughlin CM
- Cohen KS, *see* Duda DG
- Cohen S, *see* Cesana GC
- Cohn AL, *see* Lenz H-J
- Cohn DE, *see* Gordon MS
see Morrison C
- Cohn JB, *see* Habermann TM
- Cohn SL, *see* Haber M
- Coiffier B, *see* Besson C
see Ghesquière H
see Strauss SJ
- Colangelo LH, *see* Lembersky BC
- Colarossi S, *see* Soverini S
- Colasanto J, *see* Lally BE
- Colasanto JM, *see* Lally BE
- Colcher D, *see* Mamelak AN
- Cold S, *see* Ejlertsen B
see Harvey V
- Colditz aGA, *see* Newman LA
- Colditz GA, *see* Chan JA
see Meyerhardt JA
see Nekhlyudov L
- Cole DEC, *see* Clemons MJ
- Cole P, *see* Carducci MA
- Cole WC, *see* Prasad KN
- Coleman IM, *see* Lin DW
- Coleman RE, *see* Reardon DA
- Colevas AD, *see* Scharf O
- Colevas AD. Chemotherapy Options for Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck, 2644
- Colford JM Jr, *see* McCulloch MF
see McCulloch M
- Collett K, *see* Bachmann IM
- Collette L, *see* Studer UE
- Collie-Duguid ESR, *see* Petty RD
- Collins M, *see* Wong M
- Colman LK, *see* Lembersky BC
- Colosimo A, *see* Montillo M
- Coltman CA Jr, *see* Unger JM
- Comans EF, *see* Herder GJM
- Compton CC, *see* Redston M
- Conigliaro J, *see* McGinnis KA
- Conley BA. Treatment of Advanced Head and Neck Cancer: What Lessons Have We Learned? (editorial), 1023
- Conlon MSC, *see* Bewick LA
- Connors JM, *see* Foltz LM
see Iqbal J
- Conrad AJ, *see* Scoggins CR
- Conroy T, *see* Gérard J-P
- Conry R, *see* Bedikian AY
- Consentino E, *see* Petrilli AS
- Constenla M, *see* Van Cutsem E
- Conte PF, *see* Gennari A
- Coombes RC, *see* Fallowfield LJ
- Cooney MM, *see* van Heeckeren WJ
- Coosemans W, *see* De Leyn P
- Copeland L, *see* Morrison C
- Coppes MJ, *see* Dome JS
- Cordon-Cardo C, *see* Sanchez-Carbayo M
- Cordonnier C, *see* Hegenbart U
- Corio C, *see* Chen S
- Corless CL, *see* Heinrich MC
- Cormier JN, *see* Aloia TA
- Cornett WR, McCall LM, Petersen RP, Ross MI, Briele HA, Noyes RD, Sussman JJ, Kraybill WG, Kane JM III, Alexander HR, Lee JE, Mansfield PF, Pingpank JF, Winchester DJ, White RL Jr, Chadaram V, Herndon JE II, Fraker DL, Tyler DS. Randomized Multicenter Trial of Hyperthermic Isolated Limb Perfusion With Melphalan Alone Compared With Melphalan Plus Tumor Necrosis Factor: American College of Surgeons Oncology Group Trial Z0020, 4196
- Corona G, *see* Toffoli G
- Corona R, *see* Argenziano G
- Correa AM, *see* Wu X
- Correa C, *see* Harris EER
- Corry J, *see* Rischin D
- Cortada JM, *see* Barcenas CH
- Cortes J, *see* Ault P
- Cortes JE, Kantarjian H. In Reply (correspondence), 3813
- Cortes-Funes H, *see* Quintela-Fandino M
- Cortesi E, *see* Ferretti G
see Papaldo P
- Cossor F, Al-Khater A-HM, Doll DC. Laryngeal Obstruction and Hoarseness Associated With Rosai-Dorfman Disease, 1953
- Costa S, *see* du Bois A
- Costagliola D, *see* Boué F
see Grabar S
- Costantini L, *see* Lee AYY
- Costantino JP, *see* Haller DG
see Paik S
see Taghian AG
- Cote RJ, *see* Mitra AP
see Pagliarulo V
- Cotton CA, *see* Dome JS
- Couch F, *see* Goetz MP
- Coudert B, *see* Giacchetti S
- Coughlin CM, Fleming MD, Carroll RG, Pawel BR, Hogarty MD, Shan X, Vance BA, Cohen JN, Jairaj S, Lord EM, Wexler MH, Danet-Desnoyers G-aH, Pinkus JL, Pinkus GS, Maris JM, Grupp SA, Vonderheide RH. Immunosurveillance and Survivin-Specific T-Cell Immunity in Children With High-Risk Neuroblastoma, 5725
- Coupland SE, *see* Ghadjar P
- Coyle D, *see* Grunfeld E
- Coyne J, *see* Konski AA
- Coze C, *see* Rubie H
- Craig EL, *see* Abdel-Rahman MH
- Crane CH, *see* Ajani JA
see Li D
- Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, Evans DB, Tamm EP, Ng C, Pisters PWT, Charnsangavej C, Delclos ME, O'Reilly M, Lee JE, Wolff RA. Phase I Trial Evaluating the Safety of Bevacizumab With Concurrent Radiotherapy and Capecitabine in Locally Advanced Pancreatic Cancer, 1145
- Crawford ED, *see* Berry DL
see Hussain M
see Unger JM
- Crawford J, *see* Fanucchi MP
see Smith TJ
- Crawford SC, Paul J, Kaye SB, Vasey PA, Davis JA, Hay A. In Reply (correspondence), 2396
- Crawford SC, Paul J, Kaye SB, Vasey PA, Davis JA, Hay A. In Reply (correspondence), 2398
- Cresta S, *see* Heinrich MC
- Creutzig U, *see* Langebrake C
- Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeier CM, Reiter A, Ritter J, Dworzak M, Stary J, Reinhardt D. Less Toxicity by Optimizing Chemotherapy, but Not by Addition of Granulocyte Colony-Stimulating Factor in Children and Adolescents With Acute Myeloid Leukemia: Results of AML-BFM 98, 4499
- Crews KR, *see* Furman WL
- Cripps C, *see* Smalley SR
- Cristina Sauerland M, *see* Büchner T

AUTHOR INDEX

- Cristofanilli M, *see* Guarneri V
 Criswell T, *see* Monk JP
 Critchlow CW, *see* Hoque MO
 Croarkin E, *see* Lee JJ
 Croce CM, *see* Roldo C
 Crofts T, *see* O'Brien MER
 Crofts TE, *see* Eckardt JR
 Cromer JN, *see* Barlogie B
 Cronin M, *see* Paik S
 Crook J, *see* Wallace K
 Cross SJ, *see* Smith TJ
 Crowe JP, *see* Newman LA
 Crowley J, *see* Govindan R
 Crowley JC, *see* Barlogie B
 Crowley JJ, *see* Davies AM
 see Unger JM
 see West HL
 Crul M, *see* Rademaker-Lakhai JM
 see Siegel-Lakhai WS
 Cruz JJ, *see* Ocaña A
 Csiki I, Johnson DH. Did Targeted Therapy Fail Cyclooxygenase Too? (editorial), 4798
 Cuatrecasas M, *see* Dotor E
 Čučević B, *see* O'Brien MER
 Cufer T, *see* Foekens JA
 Cui X, *see* Lee AV
 Culakova E, *see* Khorana AA
 Cullen J, *see* Mandelblatt JS
 Cullen MH, *see* Johnson PWM
 Cullinan SA, *see* Lichtman SM
 Cullinane CJ, *see* Navarro S
 Cummings S, *see* Offit K
 Cunningham C, *see* Nemunaitis J
 Cunningham D, *see* Chau I
 Curiel RE, *see* Sweeney CJ
 Curley SA, *see* Bilchik AJ
 see Ellis LM
 see Vauthey J-N
 Curly T, *see* O'Connor OA
 Curran T, *see* Thompson MC
 Curran W, *see* Abrey LE
 see Cairncross G
 Curschmann J, *see* Mirimanoff R-O
 Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic Activation of KIT in Distinct Subtypes of Melanoma, 4340
 Curto García JJ, *see* Al-Mulla F
 Cushing B, *see* Marina N
 Cutler J, *see* Nemunaitis J
 Cuzick J, *see* Dowsett M
 see Sestak I
 Cyjon A, *see* Bezjak A
 Cymes K, *see* Jarnagin WR
 Czito BG, Willett CG, Bendell JC, Morse MA, Tyler DS, Fernando NH, Mantyh CR, Blobe GC, Honeycutt W, Yu D, Clary BM, Pappas TN, Ludwig KA, Hurwitz HI. Increased Toxicity With Gefitinib, Capecitabine, and Radiation Therapy in Pancreatic and Rectal Cancer: Phase I Trial Results, 656
 Czuczman MS, *see* Chanan-Khan A
- D**
- Dacre J, *see* Gaffan J
 D'Adamo D, *see* Shah MA
 Daenen SMGJ, *see* De Bont ESJM
 Daghofer F, *see* Greimel ER
 D'Agostino RB Jr, *see* Shaw EG
 Dahl G, *see* Chow AY
 Dahm A, *see* Negaard HFS
 Dahut WL, *see* Gulley JL
 Dakhil SR, *see* Barlogie B
 see Habermann TM
 see Loprinzi CL
 Dalal BI, *see* McArthur HL
 Dalbagni G, *see* Parekh DJ
 Dalbagni G, Russo P, Bochner B, Ben-Porat L, Sheinfeld J, Sogani P, Donat MS, Herr HW, Bajorin D. Phase II Trial of Intravesical Gemcitabine in Bacille Calmette-Guérin-Refractory Transitional Cell Carcinoma of the Bladder, 2729
 Daley FM, *see* Koukourakis MI
 Dalton J, *see* Thompson MC
 D'Amico AV, *see* Chen AB
 D'Amico AV, Loffredo M, Renshaw AA, Loffredo B, Chen M-H. Six-Month Androgen Suppression Plus Radiation Therapy Compared With Radiation Therapy Alone for Men With Prostate Cancer and a Rapidly Increasing Pretreatment Prostate-Specific Antigen Level, 4190
 d'Amore ESG, *see* Navarro S
 Dancey G, *see* Murugesu N
 D'Andrea AD, *see* Kennedy RD
 D'Andrea M, *see* Toffoli G
 Dane G, *see* Ramlau R
 Dane GC, *see* O'Brien MER
 Danet-Desnoyers G-aH, *see* Coughlin CM
 Danforth D, *see* Bonthala Wedam S
 Dang C, Hudis C. Can Granulocyte-Colony Stimulating Factor Worsen Anemia? (editorial), 2985
 D'Angelica M, *see* Jarnagin WR
 Daniela C, *see* Serena M
 Danjoux C, *see* Chow LML
 Darabi K, Kantamnei S, Wiernik PH. Lenalidomide-Induced Warm Autoimmune Hemolytic Anemia (correspondence), e59
 Darmon M, *see* Soares M
 Datar RH, *see* Mitra AP
 Daugherty CK, *see* Helft PR
 Dave BJ, *see* Iqbal J
 Davi A, *see* Petrilli AS
 Davidorf FH, *see* Abdel-Rahman MH
 Davidson NE, *see* Khatcheressian JL
 see Kominsky SL
 see Perez EA
 see Wolff AC
 Davies AJ, *see* Davies JK
 see Lee AM
 Davies AM, *see* Gandara DR
 Davies AM, Chansky K, Lau DHM, Leigh BR, Gaspar LE, Weiss GR, Wozniak AJ, Crowley JJ, Gandara DR. Phase II Study of Consolidation Paclitaxel After Concurrent Chemoradiation in Poor-Risk Stage III Non-Small-Cell Lung Cancer: SWOG S9712, 5242
 Davies JK, Taussig DC, Oakervee H, Davies AJ, Agrawal SG, Gribben JG, Lister TA, Cavenagh JD. Long-Term Follow-Up After Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia/Myelodysplastic Syndrome: Late CNS Relapses Despite Graft-Versus-Host Disease (correspondence), e23
 Davies SM, *see* Eapen M
 Davis ID, *see* Rosen LS
 Davis JA, *see* Crawford SC
 Davis JG, *see* Offit K
 Davis MB, *see* Whiteman DC
 Davis MP, *see* Kirkova J
 Daw NC, *see* Furman WL
 Dawson LA, *see* Pierce LJ
 Day B, *see* Mileskin L
 Dayes I, *see* Wright JR

AUTHOR INDEX

- de Albuquerque Ribeiro R, *see* Bezjak A
- de Azambuja E, *see* Rosa DD
- De Bernardi B, *see* Navarro S
- de Bono J, *see* Tolcher AW
- De Bont ESJM, Oude Nijhuis C, Gietema JA, Van der Graaf WTA, Daenen SMGJ, Vellenga E, TenVergert EM, Vermeulen KM, Groen HJM, Kamps WA. In Reply (correspondence), 1222
- de Boo TM, *see* Timmer-Bonte JNH
- de Botton S, *see* Adès L
- de Camargo B, *see* Petrilli AS
- de Graaf PW, *see* Ejlertsen B
- de Graaf SSN, *see* te Loo DMWM
- de Graeff A, *see* van der Lee ML
- de Gramont A, *see* Goldberg RM
see Tournigand C
- de Gramont A, Tournigand C, Buyse M. In Reply (correspondence), 5177
- De Greve J, *see* Abou-Alfa GK
- de Haas EC, Nuver J, Smit AJ, Sleijfer DT, Gietema JA. In Reply (correspondence), 2399
- de Haas EC, Nuver J, van den Berg MP, Smit AJ, Sleijfer DT, Gietema JA. In Reply (correspondence), 3508
- De Jager RL, *see* Abou-Alfa GK
- de Jong F, *see* Jackman DM
- de Jong FA, *see* Hamberg P
- de Jong S, *see* van Geelen CM
- de Jongh FE, *see* Loos WJ
- de Koning HJ, *see* Otto SJ
- de Korte MA, *see* Perik PJ
- de Krijger RR, *see* Vermeer-Mens JCJ
- de la Loge C, *see* Dubois D
- de la Rochefordière A, *see* This P
- De Lena M, *see* Gennari A
- De Leyn P, Lerut T, Vansteenkiste J. In Reply (correspondence), 5339
- De Leyn P, Stroobants S, De Wever W, Lerut T, Coosemans W, Decker G, Nafteux P, Van Raemdonck D, Mortelmans L, Nackaerts K, Vansteenkiste J. Prospective Comparative Study of Integrated Positron Emission Tomography-Computed Tomography Scan Compared With Remediastinoscopy in the Assessment of Residual Mediastinal Lymph Node Disease After Induction Chemotherapy for Mediastinoscopy-Proven Stage IIIA-N2 Non-Small-Cell Lung Cancer: A Leuven Lung Cancer Group Study, 3333
- De Maio J, *see* Moll S
- de Muinck Keizer-Schrama SMPF, *see* Vermeer-Mens JCJ
- De Mulder P, *see* Barentsz J
- De Muylder X, *see* Van Calsteren K
- de Oca J, *see* Dotor E
- de Paepe P, *see* Sagaert X
- De Pangher V, *see* Toffoli G
- De Paoli P, *see* Simonelli C
- De Porre P, *see* Siegel-Lakhai WS
- de Reijke T, *see* Studer UE
- De Ruvo N, *see* Di Benedetto F
- De Ruyscher D, Pijls-Johannesma M, Bentzen SM, Minken A, Wanders R, Lutgens L, Hochstenbag M, Boersma L, Wouters B, Lammering G, Vansteenkiste J, Lambin P. Time Between the First Day of Chemotherapy and the Last Day of Chest Radiation Is the Most Important Predictor of Survival in Limited-Disease Small-Cell Lung Cancer, 1057
- De Santis M, *see* Oliver T
- De Smet F, *see* Neven P
- de Vos S, *see* Fisher RI
- de Vries EG, *see* van Geelen CM
- de Vries EGE, *see* Perik PJ
- De Wever W, *see* De Leyn P
- de Wit R, *see* Loos WJ
see van den Belt-Dusebout AW
- de Wit R, Fizazi K. Controversies in the Management of Clinical Stage I Testis Cancer, 5482
- de Wolf-Peeters C, *see* Hagenbeek A
- De Wolf-Peeters C, *see* Sagaert X
- DeAngelis LM, *see* Abrey LE
see Cloughesy TF
see Gavrilovic IT
- Deapen D, *see* Simon MS
- Debatin I, *see* Gadzicki D
- Debets R, *see* Lamers CHJ
- Debois M, *see* Studer UE
- DeCaprio JA, *see* Poulin DL
- Decensi A, *see* Guerrieri-Gonzaga A
- Decensi AU, *see* Bonanni B
- Decker G, *see* De Leyn P
- Deconinck E, *see* Adès L
- DeConti R, *see* Bedikian AY
- Deeg HJ, *see* Leisenring W
- Dees EC, *see* Blum JL
- Defachelles AS, *see* Rubie H
- Degos L, *see* Adès L
- Dehée A, *see* Lapillonne H
- Dehner LP, *see* Priest JR
- Deiana G, *see* Mariani L
- Deinlein F, *see* Timmermann B
- Deitcher SR, *see* Moll S
- Dejaco C, Duftner C, Schirmer M. Induction of Tolerance in Autoimmune Diseases Rather Than Cure of Cancer by Interleukin-2 Therapy (correspondence), e34
- Dekker A, Bulley S, Beyene J, Dupuis LL, Doyle JJ, Sung L. Meta-Analysis of Randomized Controlled Trials of Prophylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor After Autologous and Allogeneic Stem Cell Transplantation, 5207
- Dekkers RJ, *see* Richards WG
- Del Conte G, *see* Ceresoli GL
- Del Giudice P, *see* Grabar S
- Del Mastro L, Venturini M. Fertility Preservation Strategies for Breast Cancer Patients (correspondence), 4220
- Delabie J, *see* Iqbal J
- DeLaney TF, *see* Kraybill WG
- Delbaldo C, *see* Faivre S
- Delclos ME, *see* Crane CH
- Delecroix V, *see* Rousseau C
- Delforge M, *see* Van Calsteren K
- Delgado C, *see* Ocaña A
- Delgado S, *see* Rodríguez-Moranta F
- Deliens L, *see* Van den Block L
- Delorenzi M, *see* Urban P
- Delozier T, *see* Roché H
- DeLuca J, *see* Timmerman R
- Dem A, *see* Hoque MO
- Demark-Wahnefried W, Clipp EC, Morey MC, Pieper CF, Sloane R, Clutter Snyder D, Cohen HJ. Lifestyle Intervention Development Study to Improve Physical Function in Older Adults With Cancer: Outcomes From Project LEAD, 3465
- Demark-Wahnefried W, Pinto BM, Gritz ER. Promoting Health and Physical Function Among Cancer Survivors: Potential for Prevention and Questions That Remain, 5125
- Demark-Wahnefried W. Cancer Survival: Time to Get Moving? Data Accumulate Suggesting a Link Between Physical Activity and Cancer Survival (editorial), 3517
- DeMatteo RP, *see* Jarnagin WR
- Demetri G, *see* Smith TJ
- Demetri GD, *see* Heinrich MC
see Herbst RS
see Raut CP
- Demetri GD, Heinrich MC. In Reply (correspondence), 3715
- Demicheli R, Biganzoli E, Boracchi P, Greco M, Hrushesky WJM, Retsky MW.

AUTHOR INDEX

- Allometric Scaling Law Questions the Traditional Mechanical Model for Axillary Lymph Node Involvement in Breast Cancer, 4391
- Dempsey PJ, *see* Hess KR
- den Eynde MV, *see* Pocard M
- Denduluri N, *see* Walshe JM
- Dennis M, *see* Vey N
- Dennis PA, *see* Tsurutani J
- Densmore JJ, *see* Redfern CH
- Dent S, *see* Grunfeld E
- Dentchev T, *see* Steensma DP
- DePauw S, *see* McCarter H
- DePrimo S, *see* Faivre S
- DePrimo SE, *see* Motzer RJ
- Deptowicz A, *see* Acheson LS
- DeRaffele G, *see* Cesana GC
- Dere RC, *see* Gordon MS
- Derigs G, *see* Illerhaus G
- Derynck MK, *see* Gordon MS
- Desai AA, *see* Ratain MJ
- Desai J, *see* Raut CP
- Desai M, *see* McKiernan JM
- Desch CE, *see* Smith TJ
- Deschepper R, *see* Van den Block L
- Desfachelles AS, *see* Oberlin O
- Desjardins A, *see* Reardon DA
- DesRosiers C, *see* Timmerman R
- Desta Z, *see* Goetz MP
- Detterbeck FC, *see* Lally BE
- Deuson RR, *see* Bloechl-Daum B
- Deutsch M, *see* Taghian AG
- Devi L, *see* Premalata C
- Devidas M, *see* Barredo JC
see Bernstein ML
- Devillers A, *see* Rousseau C
- DeVol E, *see* Nemunaitis J
- Devos AS, *see* Vermeer-Mens JJC
- DeWald GW, *see* Shanafelt TD
- Dewald GW, *see* Shanafelt TD
- Dezube BJ, *see* Konstantinopoulos PA
- Dezube BJ, Krown SE, Lee JY, Bauer KS, Aboulafia aDM. Randomized Phase II Trial of Matrix Metalloproteinase Inhibitor COL-3 in AIDS-Related Kaposi's Sarcoma: An AIDS Malignancy Consortium Study, 1389
- Dhami M, *see* Meropol NJ
- Dharan B, *see* Ramlau R
- Dhawan R, *see* Dubois D
- D'hooghe T, *see* Wildiers H
- Di Benedetto F, De Ruvo N, Berretta M, Masetti M, Montalti R, Di Sandro S, Quintini C, Codeluppi M, Tirelli U, Gerunda GE. Don't Deny Liver Transplantation to HIV Patients With Hepatocellular Carcinoma in the Highly Active Antiretroviral Therapy Era (correspondence), e26
- Di Cosimo S, *see* Papaldo P
- Di Filippo F, *see* Papaldo P
- Di Iulio J, *see* Michael M
- Di Lauro L, *see* Papaldo P
- Di Sandro S, *see* Di Benedetto F
- Di Segni S, *see* Gelibter AJ
- Di Simone L, *see* Firenzuoli F
- di Tomaso E, *see* Duda DG
- Diasio RB, *see* Meropol NJ
- Dickinson F, *see* Rubie H
- Dickman PS, *see* Bernstein ML
- Dieckmann K, *see* Oliver T
- Dielwart MFH, *see* Peeters STH
- Dierkesmann R, *see* Spinola M
- Dietl B, *see* Schäfer C
- Dietmaier W, *see* Goecke T
- Digianni L, *see* Farkas Patenaude A
- DiGianni LS, *see* Farkas Patenaude A
- Dignam JJ, *see* Polite BN
- Dignam JJ. The Ongoing Search for the Sources of the Breast Cancer Survival Disparity (editorial), 1326
- Dijkman R, Tensen CP, Jordanova ES, Knijnenburg J, Hoefnagel JJ, Mulder AA, Rosenberg C, Raap AK, Willemze R, Suzhai K, Vermeer MH. Array-Based Comparative Genomic Hybridization Analysis Reveals Recurrent Chromosomal Alterations and Prognostic Parameters in Primary Cutaneous Large B-Cell Lymphoma, 296
- Diller L, *see* George RE
- Diller LR, *see* Recklitis CJ
- Dillman RO, *see* Nemunaitis J
- Dillon SR, *see* Novak AJ
- Dilts DM, Sandler AB. Invisible Barriers to Clinical Trials: The Impact of Structural, Infrastructural, and Procedural Barriers to Opening Oncology Clinical Trials, 4545
- Dilts DM, Sandler AB, Baker M, Cheng SK, George SL, Karas KS, McGuire S, Menon GS, Reusch J, Sawyer D, Scoggins M, Wu A, Zhou K, Schilsky RL. Processes to Activate Phase III Clinical Trials in a Cooperative Oncology Group: The Case of Cancer and Leukemia Group B, 4553
- Dimitrijevic S, *see* Heinrich MC
- Dimsdale JE, *see* Bardwell WA
- Ding K, *see* Wong RKS
- Ding L, *see* Ma X-J
- Dinkloh N, *see* Jaster M
- Dinney CP, *see* Black PC
- Dionisio R, *see* Bottini A
- DiRienzo A, *see* Maitland ML
- Dirk Noyes R, *see* Scoggins CR
- Dirnhofer S, *see* Heinrich MC
- Dische S, *see* Koukourakis MI
- Disis ML, *see* Goodell V
- Dito E, *see* Ko AH
- Dixon JM, *see* Ellis MJ
- Djafari L, *see* Rubie H
- Djavan B, *see* Wachter S
- Djulgovic B, *see* Fisher RI
- Do K-A, *see* Esmaeli B
see Tsimberidou A-M
- Doane L, *see* Blum JL
- Dobrozemsky G, *see* Wachter S
- Dobs AS, *see* Braga-Basaria M
- Doerffel W, *see* Burkhardt B
- Dogliotti L, *see* Bottini A
- Doherty R, *see* James PA
- Döhner H, *see* Kröber A
see Rücker FG
- Döhner K, *see* Rücker FG
- Doi T, *see* Rojo F
- Dolbeault S, *see* This P
- Doliny P, *see* Hurley J
- Doll DC, *see* Cossor F
- Dollarhide S, *see* Lewis KD
- Domain D, *see* Oh JL
- Dombret H, *see* Adès L
see Vey N
- Dome JS, *see* Furman WL
- Dome JS, Cotton CA, Perlman EJ, Breslow NE, Kalapurakal JA, Ritchey ML, Grundy PE, Malogolowkin M, Beckwith JB, Shamberger RC, Haase GM, Coppes MJ, Coccia P, Kletzel M, Weetman RM, Donaldson M, Macklis RM, Green DM. Treatment of Anaplastic Histology Wilms' Tumor: Results From the Fifth National Wilms' Tumor Study, 2352
- Domínguez G, García JM, Peña C, Silva J, García V, Martínez L, Maximiano C, Gómez ME, Rivera JA, García-Andrade C, Bonilla F. ΔTAp73 Upregulation

- Correlates With Poor Prognosis in Human Tumors: Putative In Vivo Network Involving p73 Isoforms, p53, and E2F-1, 805
- Donahue BR, *see* Packer RJ
- Donald E, *see* Hirsch FR
- Donaldson M, *see* Dome JS
- Donaldson SS, *see* Yock TI
- Donaldson SS, Laningham F, Graham Fisher P. Advances Toward an Understanding of Brainstem Gliomas, 1266
- Donat MS, *see* Dalbagni G
- Donat SM, *see* Raj GV
- Donehower RC, *see* Philip PA
- Donnelly B, *see* Hussain M
- Donohue JH, *see* Ajani JA
- Donovan J, *see* Blazeby JM
- Donskov F, von der Maase H. Impact of Immune Parameters on Long-Term Survival in Metastatic Renal Cell Carcinoma, 1997
- Donskov F, von der Maase H. In Reply (correspondence), 4219
- Dores GM, *see* Kamangar F
- Dormady SP, Mariappan MR, Kao D, Gotlib J. Use of Urine Flow Cytometry to Verify Relapse of Burkitt's Lymphoma in the Genitourinary System, 4515
- Dornbusch HJ, *see* Kerbl R
- Dorresteijn LD, Stewart FA, Boogerd W. Stroke As a Late Treatment Effect of Hodgkin's Disease (correspondence), 1480
- Dorresteijn LDA, *see* Hooning MJ
- Dorval M, *see* Farkas Patenaude A
- dos Santos TM, *see* Petrilli AS
- Doshi A, *see* Bonthala Wedam S
- Dotan ZA, *see* Stephenson AJ
- Dotor E, Cuatrecasas M, Martínez-Iniesta M, Navarro M, Vilardell F, Guinó E, Pareja L, Figueras A, Molleví DG, Serrano T, de Oca J, Peinado MA, Moreno V, Germà JR, Capellà G, Villanueva A. Tumor Thymidylate Synthase 1494del6 Genotype As a Prognostic Factor in Colorectal Cancer Patients Receiving Fluorouracil-Based Adjuvant Treatment, 1603
- Douay L, *see* Lapillonne H
- Douer D, *see* Schiller GJ
- Douillard J-Y, *see* Abou-Alfa GK
see Paz-Ares L
- Doutriaux I, *see* Rousseau C
- Dowell JM, *see* Reardon DA
see Redston M
- Dowlati A, *see* van Heeckeren WJ
- Dowsett M, *see* Ellis MJ
see Smith IE
- Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M, Buzdar A. In Reply (correspondence), 1482
- Dowsett M, Urruticoechea A, Smith IE. In Reply (correspondence), 3809
- Dowsett M. Estrogen Receptor: Methodology Matters (editorial), 5626
- Doyle JJ, *see* Chow LML
see Dekker A
see Eapen M
- Drach J, *see* Raderer M
- Dragani TA, *see* Spinola M
- Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Benedetti JK, Baker AF, Hackett CB, Urba SG, Zaner KS, Blanke CD, Abbuzzese JL. Phase II Trial of Erlotinib in Gastroesophageal Junction and Gastric Adenocarcinomas: SWOG 0127, 4922
- Dralle H, *see* Machens A
- Dranitsaris G, *see* Clemons MJ
- Dreicer R, *see* Garcia JA
- Drescher CW, *see* Goodell V
- Dressman H, *see* Cheng SH
- Dreyfus F, *see* Vey N
- Drijkoningen M, *see* Neven P
- Driver L, *see* Bruera E
- Droller M, *see* Ferrari AC
- Dror Michaelson M, *see* Motzer RJ
- Drotar D, *see* Neff Greenley R
- Dryden MJ, *see* Oh JL
- du Bois A, *see* Gore M
see Greimel ER
see Pfisterer J
- du Bois A, Weber B, Rochon J, Meier W, Goupil A, Olbricht S, Barats J-C, Kuhn W, Orfeuvre H, Wagner U, Richter B, Lueck H-J, Pfisterer J, Costa S, Schroeder W, Kimmig R, Pujade-Lauraine E. Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Inter-group Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, 1127
- Dua RS, Isacke CM, Gui GPH. The Intraductal Approach to Breast Cancer Biomarker Discovery, 1209
- Duan Z, *see* Giordano SH
- Dubois D, Dhawan R, van de Velde H, Esseltine D, Gupta S, Viala M, de la Loge C. Descriptive and Prognostic Value of Patient-Reported Outcomes: The Bortezomib Experience in Relapsed and Refractory Multiple Myeloma, 976
- DuBois RN. Cyclooxygenase-2 Selective Inhibitors and Prostate Cancer: What Is the Clinical Benefit? (editorial), 2691
- Duboway R, *see* Bernstein ML
- Dubreucq L, *see* Klastersky J
- Duchesne GM, Syme R, Howell D. How Early Is Early: Androgen Deprivation for Prostate-Specific Antigen Relapse in Prostate Cancer (correspondence), 2964
- Duck L, *see* Bourhis J
- Ducreux M, *see* Gérard J-P
- Duda DG, Cohen KS, di Tomaso E, Au P, Klein RJ, Scadden DT, Willett CG, Jain ARK. Differential CD146 Expression on Circulating Versus Tissue Endothelial Cells in Rectal Cancer Patients: Implications for Circulating Endothelial and Progenitor Cells As Biomarkers for Antiangiogenic Therapy, 1449
- Dudczak R, *see* Wachter S
- Duddalwar V, *see* O'Connell CL
- Dudkin L, *see* Fouladi M
- Dudoit S, *see* Barrier A
- Duerk J, *see* van Heeckeren WJ
- Duffy A, *see* Horgan AM
- Duffy T, *see* Noronha V
- Duftner C, *see* DeJaco C
- Dummer R, Garbe C, Thompson JA, Eggermont AM, Yoo K, Maier T, Bergstrom B. Randomized Dose-Escalation Study Evaluating Peginterferon Alfa-2a in Patients With Metastatic Malignant Melanoma, 1188
- Dumpit R, *see* Lin DW
- Dunham CP, *see* Miller CR
- Dunnwald LK, *see* Linden HM
- Dunst J, *see* Rades D
see Weiss C
- Dupouy N, *see* Noordijk EM
- Dupuis LL, *see* Dekker A
- Duran GE, *see* Bredel M
- Durand J-B, *see* Guarneri V
- Durie B, *see* Barlogie B
- Dutson D, *see* Chen S
- Duval A, *see* Buhard O
- Dworzak M, *see* Creutzig U
see Langebrake C
- Dy S, *see* Lorenz KA
- Dziadziuszko R, *see* Hirsch FR

E

- Eapen M, Rubinstein P, Zhang M-J, Camitta BM, Stevens C, Cairo MS, Davies SM, Doyle JJ, Kurtzberg J, Pulsipher MA, Ortega JJ, Scaradavou A, Horowitz MM, Wagner JE. Comparable Long-Term Survival After Unrelated and

AUTHOR INDEX

- HLA-Matched Sibling Donor Hematopoietic Stem Cell Transplantations for Acute Leukemia in Children Younger Than 18 Months, 145
- Earle CC, *see* Chen AB
see Lathan CS
see Meyerhardt JA
see Punglia RS
see Steyerberg EW
- Earle CC, Ayanian JZ. Looking Back From Death: The Value of Retrospective Studies of End-of-Life Care (editorial), 838
- Earle CC. Do Unto Others (editorial), 3331
- Earle CC. Failing to Plan Is Planning to Fail: Improving the Quality of Care With Survivorship Care Plans, 5112
- Eastham JA, *see* Stephenson AJ
- Easton DF, *see* Andrieu N
see Antoniou AC
- Ebbert JO, *see* Yang P
- Ebell W, *see* Schrauder A
- Eberhard DA, *see* Gordon MS
- Ebihara S, *see* Yasuda H
- Eccles D, *see* Evans DGR
- Eckardt JR, von Pawel J, Papai Z, Tomova A, Tzekova V, Crofts TE, Brannon S, Wissel P, Ross G. Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment for Chemotherapy-Naive Patients With Extensive-Disease Small-Cell Lung Cancer, 2044
- Eckhardt SG, *see* Abou-Alfa GK
see Camidge DR
see Tolcher AW
- Edelmann J, *see* Tanner B
- Edge SB, *see* Buchholz TA
- Edington HD, *see* Moschos SJ
- Edlund P, *see* Ejlertsen B
- Edwards MJ, *see* Scoggins CR
- Edwards R, *see* Sestak I
- Egan J, *see* Braga-Basaria M
- Egger SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P. Renal Cell Carcinoma Recurrence After Nephrectomy for Localized Disease: Predicting Survival From Time of Recurrence, 3101
- Eggermont AM, *see* Dummer R
- Eggermont AMM. Reaching First Base in the Treatment of Metastatic Melanoma (editorial), 4673
- Eggle S, Penner L, Albrecht TL, Cline RJW, Foster T, Naughton M, Peterson A, Ruckdeschel JC. Discussing Bad News in the Outpatient Oncology Clinic: Rethinking Current Communication Guidelines, 716
- Eggle S, Penner LA, Albrecht TL, Cline RJW, Foster T, Naughton M, Peterson A, Ruckdeschel JC. In Reply (correspondence), 3217
- Eghbali H, *see* Hagenbeek A
see Noordijk EM
- Egorin aMJ, *see* Brown JW
- Egorin MJ, *see* Lichtman SM
- Eguchi K, *see* Onoda S
see Saito H
see Seki N
- Ehninger G, *see* Baldus CD
see Kröger N
- Eichler F, *see* Roché H
- Eiermann W, *see* Kaufmann M
- Eilertsen AL, *see* Negaard HFS
- Eils R, *see* Oberthuer A
see Thuerigen O
- Eimermacher H, *see* Büchner T
- Einhorn L, *see* Hanna N
- Einhorn LH, *see* Bedano PM
see Bedano PM
see Hanna NH
see Lewis DA
see Weiss GJ
- Einhorn LH, Foster RS. Bleomycin, Etoposide, and Cisplatin for Three Cycles Compared With Etoposide and Cisplatin for Four Cycles in Good-Risk Germ Cell Tumors: Is There a Preferred Regimen? (correspondence), 2597
- Einsele H, *see* Heinemann V
- Eisbruch A, *see* Urba S
- Eisbruch aA, *see* Rosenthal DI
- Eisen A, *see* Chen S
see Pierce LJ
- Eisen T, *see* Lee CP
see Parton M
see Ratain MJ
- Eisenberg B, *see* Kraybill WG
- Eisenberg BL, *see* Heinrich MC
- Eisenhauer E, *see* Pfisterer J
see Rustin GJS
- Ejlertsen B, Mouridsen HT, Jensen M-B, Bengtsson N-O, Bergh J, Cold S, Edlund P, Ewertz M, de Graaf PW, Kamby C, Nielsen DL. Similar Efficacy for Ovarian Ablation Compared With Cyclophosphamide, Methotrexate, and Fluorouracil: From a Randomized Comparison of Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer, 4956
- Ekstrand B, *see* Govindan R
- El Hajjam M, *see* Benoist S
- Elashoff D, *see* Li Y
- El-Deiry WS, Sigman CC, Kelloff GJ. Imaging and Oncologic Drug Development, 3261
- Elder DE, *see* Fears TR
- Elias D, *see* Portier G
- Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE. Endogenous Steroid Hormone Concentrations and Risk of Breast Cancer: Does the Association Vary by a Woman's Predicted Breast Cancer Risk? 1823
- Eliasziv M, *see* Temple WJ
- El-Khoueiry A, *see* Govindarajan R
- Elkin EB, Hurria A, Mitra N, Schrag D, Panageas KS. Adjuvant Chemotherapy and Survival in Older Women With Hormone Receptor-Negative Breast Cancer: Assessing Outcome in a Population-Based, Observational Cohort, 2757
- Elledge RM. Tales From a Targeted Therapy (editorial), 1323
- Elliott EA, Wright JR, Swann RS, Nguyen-Tân F, Takita C, Bucci MK, Garden AS, Kim H, Hug EB, Ryu J, Greenberg M, Saxton JP, Ang K, Berk L. Phase III Trial of an Emulsion Containing Trolamine for the Prevention of Radiation Dermatitis in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck: Results of Radiation Therapy Oncology Group Trial 99-13, 2092
- Ellis A, *see* Michael M
- Ellis GK, *see* Linden HM
- Ellis LM, *see* Crane CH
- Ellis LM, Curley SA, Grothey A. In Reply (correspondence), 2593
- Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM. Estrogen-Independent Proliferation Is Present in Estrogen-Receptor *HER2*-Positive Primary Breast Cancer After Neoadjuvant Letrozole, 3019
- Ellis MJ. Functional Analysis of the Breast Cancer Genome (editorial), 1649
- Ellis P, *see* Hanna N
- Ellison G, *see* Hirsch FR
- Elmore JG, *see* Geiger AM
- Elomaa I, *see* Vehmanen L
- Ely K, *see* Chung CH
- El-Zammar O, *see* Mukhopadhyay S
- El-Zein R, *see* Wang L
- Emanuel EJ, *see* Agrawal M
see Malin JL
see Pentz RD
- Emanuela B, *see* Serena M
- Emerich J, *see* Pfisterer J
- Emi N, *see* Yanada M
- Emmanouilides C, *see* Stiff PJ

AUTHOR INDEX

- Emmenegger U, *see* Shaked Y
 Emmons KM, *see* Geiger AM
 Enas N, *see* Carducci MA
 Enck RE, *see* Tsai SC
 End D, *see* Widemann BC
 Endo JO, *see* Mikuls TR
 Eng C, *see* Abdel-Rahman MH
 see Patterson AR
 see Vauthey J-N
 Eng P, *see* Toh C-K
 Engehausen DG, *see* Weiss C
 Engel C, *see* Goecke T
 Engels EA, Brock MV, Chen J, Hooker CM, Gillison M, Moore RD. Elevated Incidence of Lung Cancer Among HIV-Infected Individuals, 1383
 Engenhart-Cabiblic R, *see* Rades D
 Enger SM, Thwin SS, Buist DSM, Field T, Frost F, Geiger AM, Lash TL, Prout M, Ulcickas Yood M, Wei F, Silliman RA. Breast Cancer Treatment of Older Women in Integrated Health Care Settings, 4377
 Engert A, *see* Strauss SJ
 Enrico G, *see* Serena M
 Ensor J, *see* Izzo JG
 Enzinger PC, *see* Kulke MH
 see Kulke MH
 see Meyerhardt JA
 see Zhu AX
 Epenetos AA, *see* Verheijen RH
 Epner E, *see* Fisher RI
 Eppenberger U, *see* Urban P
 Eppenberger-Castori S, *see* Urban P
 Epstein AM, *see* Malin JL
 Erikstein B, *see* Tanner M
 Erlander MG, *see* Ma X-J
 Erlichman C, *see* Philip PA
 Erlichman C, Hidalgo M, Boni JP, Martins P, Quinn SE, Zacharchuk C, Amorusi P, Adjei AA, Rowinsky EK. Phase I Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors, 2252
 Ermani M, *see* Brandes AA
 Ernestus K, *see* Oberthuer A
 Ernst G, *see* Strasser F
 Ernstoff MS, *see* Taplin M-E
 Errante D, *see* Toffoli G
 Erskine CL, *see* Knutson KL
 Esclamado R, *see* Brizel DM
 Esclamado RM, *see* Adelstein DJ
 Esker DA, *see* Flood KL
 Esmaeli B, Amin S, Valero V, Adinin R, Arbuckle R, Banay R, Do K-A, Rivera E. Prospective Study of Incidence and Severity of Epiphora and Canalicular Stenosis in Patients With Metastatic Breast Cancer Receiving Docetaxel, 3619
 España P, *see* Provencio M
 Esperou H, *see* Yakoub-Agha I
 Espina BM, *see* Levine AM
 Esseltine D, *see* Dubois D
 see Richardson PG
 Esser S, *see* Pashenkov M
 Esserman LJ, *see* Kumar AS
 Esserman LJ, Kumar AS, Herrera AF, Leung J, Au A, Chen Y-Y, Moore DH, Chen DF, Hellawell J, Wolverton D, Hwang ES, Hylton NM. Magnetic Resonance Imaging Captures the Biology of Ductal Carcinoma In Situ, 4603
 Estes NC, *see* Smalley SR
 Esteva FJ, *see* Baptista MZ
 see Guarneri V
 Estopinal NC, *see* Ring BZ
 Ethier AM, *see* Whitney SN
 Ethirajan S, *see* Blum JL
 Etienne P-L, *see* Tournigand C
 Eto Y, *see* Fujiwara T
 Ettinger DS, *see* Kraybill WG
 Ettinger DS, Aisner J. Changing Face of Small-Cell Lung Cancer: Real and Artifact (editorial), 4526
 Etzel CJ, *see* Wu X
 Eubanks Jackson K, *see* Schover LR
 Eugenia Vega Villegas M, *see* Bourhis J
 Euhus DM, *see* Chen S
 Evans C, *see* Brown JW
 Evans DB, *see* Crane CH
 see Ellis MJ
 see Li D
 Evans DG, *see* Antoniou AC
 see Stirling D
 Evans DGR, *see* Sharif S
 Evans DGR, Lalloo F, Eccles D. Optimal Selection of Individuals for BRCA Mutation Testing (correspondence), 3311
 Evans G, *see* Andrieu N
 Evans GD, Lalloo F, Mak T, Speake D, Hill J. Is It Time to Abandon Microsatellite Instability As a Pre-Screen for Selecting Families for Mutation Testing for Mismatch Repair Genes? (correspondence), 1960
 Evans S, *see* Wong M
 Ewertz M, *see* Ejlersen B
 Ewing M, *see* Timmerman R
 Exner GU, *see* Kager L
- F**
- Fabi A, *see* Carlini P
 Facchinetti F, *see* Modena P
 Faderl S, *see* Ault P
 Fairclough DL, *see* Agrawal M
 see Shelley Wang X
 Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand J-P, Scigalla P, Raymond E. Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer, 25
 Fakhrai H, *see* Nemunaitis J
 Fakhry C, Gillison ML. Clinical Implications of Human Papillomavirus in Head and Neck Cancers, 2606
 Falconi M, *see* Roldo C
 Falini B, *see* Went P
 Falke T, *see* Verheijen RH
 Fallowfield LJ, Bliss JM, Porter LS, Price MH, Snowdon CF, Jones SE, Coombes RC, Hall E. Quality of Life in the Intergroup Exemestane Study: A Randomized Trial of Exemestane Versus Continued Tamoxifen After 2 to 3 Years of Tamoxifen in Postmenopausal Women With Primary Breast Cancer, 910
 Falvella FS, *see* Spinola M
 Fan C, *see* Oh DS
 Fan W-y, *see* McCulloch MF
 Fan Yim S, *see* Buhard O
 Fanucchi MP, Fossella FV, Belt R, Natale R, Fidianni P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, Kelly K, Limentani SA, Crawford J, Reimers H-J, Axelrod R, Kashala O, Sheng S, Schiller JH. Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non-Small-Cell Lung Cancer, 5025
 Faratian D, *see* Ellis MJ
 Farkas Patenaude A, Dorval M, Digianni L, Schneider KA, Chittenden A, Garber JE. In Reply (correspondence), 2970
 Farkas Patenaude A, Dorval M, DiGianni LS, Schneider KA, Chittenden A, Garber JE. Sharing BRCA1/2 Test Results With First-Degree Relatives: Factors Predicting Who Women Tell, 700
 Farlow D, *see* Wong M
 Fasola S, *see* Lapillonne H

AUTHOR INDEX

- Fathi A-R, *see* Mariani L
- Faulkner J, *see* Hussain M
- Fauq AH, *see* Pockaj BA
- Favaretto A, *see* Paccagnella A
- Favaretto AG, *see* Ceresoli GL
- Fayad L, *see* Liu Q
- Fayers P, *see* Blazeby JM
- Fayyad R, *see* Lilenbaum R
- Fearon KCH, Barber MD, Moses AG, Ahmedzai SH, Taylor GS, Tisdale MJ, Murray GD. Double-Blind, Placebo-Controlled, Randomized Study of Eicosapentaenoic Acid Diester in Patients With Cancer Cachexia, 3401
- Fears TR, Guerry D IV, Pfeiffer RM, Sagebiel RW, Elder DE, Halpern A, Holly EA, Hartge P, Tucker MA. Identifying Individuals at High Risk of Melanoma: A Practical Predictor of Absolute Risk, 3590
- Febbo PG, Kantoff PW. Noise and Bias in Microarray Analysis of Tumor Specimens (editorial), 3719
- Fedele S, *see* Mignogna MD
- Feeny D, *see* McCarter H
- Fegueur N, *see* Adès L
- Fehlauer F, *see* Rades D
- Feit K, *see* Abou-Alfa GK
- Feldman AL, *see* Beck KE
- Feldman LE, *see* Choi YM
- Felici A, *see* Carlini P
see Ferretti G
- Felman P, *see* Ghesquière H
- Felten SJ, *see* Brown PD
- Fenaux P, *see* Adès L
see Vey N
- Feng L, *see* Tsao AS
- Feng Q, *see* Hoque MO
- Feng S, *see* Mandelblatt J
- Fenoglio-Preiser CM, *see* Dragovich T
- Fentiman IS, *see* Bijker N
- Fenton D, *see* Bezjak A
- Fenton R, *see* Badros A
- Feremans W, *see* Vey N
- Fernández-Avilés F, Carreras E, Urbano-Ispizua A, Rovira M, Martínez C, Gaya A, Granell M, Ramiro L, Gallego C, Hernando A, Segura S, García L, González M, Valverde M, Montserrat E. Case-Control Comparison of At-Home to Total Hospital Care for Autologous Stem-Cell Transplantation for Hematologic Malignancies, 4855
- Fernandez-del Castillo C, *see* Ferrone CR
- Fernandez-del Castillo C, Ferrone CR, Warshaw AL. In Reply (correspondence), 5611
- Fernando NH, *see* Czito BG
- Ferner R, *see* Sharif S
- Ferrant A, *see* Adès L
- Ferrara G, *see* Argenziano G
- Ferrari A, Casanova M. Specification on the Definition of Adult-Type Soft Tissue Sarcoma (correspondence), 4042
- Ferrari AC, Stone NN, Kurek R, Mulligan E, McGregor R, Stock R, Unger P, Tunn U, Kaisary A, Droller M, Hall S, Renneberg H, Livak KJ, Gallagher RE, Mandeli J. Molecular Load of Pathologically Occult Metastases in Pelvic Lymph Nodes Is an Independent Prognostic Marker of Biochemical Failure After Localized Prostate Cancer Treatment, 3081
- Ferrari VA, *see* Harris EER
- Ferraz Gonçalves JA. Sedation and Expertise in Palliative Care (correspondence), e44
- Ferrell BR, Winn R. Medical and Nursing Education and Training Opportunities to Improve Survivorship Care, 5142
- Ferrer L, *see* Rousseau C
- Ferrero J-M, *see* Roché H
- Ferretti G, *see* Carlini P
see Papaldo P
- Ferretti G, Felici A, Simona Pino M, Cognetti F. Does CTLA4 Influence the Suppressive Effect of CD25+CD4+ Regulatory T Cells? (correspondence), 5469
- Ferretti G, Lopez M, Terzoli E, Cortesi E, Antimi M, Marolla P, Giannarelli D, Cognetti F, Papaldo P. Myeloid Toxicity in Breast Cancer Patients Receiving Adjuvant Chemotherapy: What Is the Appropriate Use of Filgrastim? (correspondence), 5618
- Ferretti G, Papaldo P. Can the Addition of Prophylactic Filgrastim Be Considered Cost Effective in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide? (correspondence), 5615
- Ferrone CR, *see* Fernandez-del Castillo C
- Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-del Castillo C, Warshaw AL. Perioperative CA19-9 Levels Can Predict Stage and Survival in Patients With Resectable Pancreatic Adenocarcinoma, 2897
- Feuerhake F, *see* Illerhaus G
- Feusner J, *see* Razzouk BI
- Feyer P, *see* Kris MG
- Ficarelli R, *see* Ruzzo A
- Fidias P, *see* Fanucchi MP
- Field T, *see* Enger SM
- Fierro MT, *see* Zinzani PL
- Figer A, *see* Abou-Alfa GK
see Tournigand C
- Figueiredo M, *see* Mandelblatt J
- Figlin RA, *see* Lam JS
see Motzer RJ
- Figuera A, *see* Dotor E
- Filiaci VL, *see* Randall ME
see Randall ME
- Filioussi K, *see* Bonovas S
- Findlay BP, *see* Goldberg RM
see Perez EA
- Finegold M, *see* Malogolowkin MH
- Fink K, *see* Cairncross G
- Fink KL, *see* Cloughesy TF
- Fink SR, *see* Shanafelt TD
- Fink U, *see* Ott K
- Finke J, *see* Illerhaus G
- Finkelstein D, *see* Chen S
see Thompson MC
- Finkelstein DM, *see* Ferrone CR
- Finkelstein MJ, *see* Priest JR
- Finlay JL, *see* Pollack IF
- Finocchiaro G, *see* Modena P
- Fioretta G, *see* Rapti E
- Fiori E, *see* Gentilucci UV
- Firenzuoli F, Gori L, Di Simone L, Morsuillo M. Important Bias in the *Astragalus* Meta-Analysis (correspondence), 3215
- Fischer B, *see* Gadzicki D
- Fischer M, *see* Oberthuer A
- Fischer R, *see* Spinola M
- Fisher B, *see* Bear HD
see Mirimanoff R-O
see Smalley SR
see Wapnir IL
- Fisher R, *see* Rischin D
- Fisher RI, *see* Habermann TM
see Khorana AA
see Press OW
- Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O'Connor OA, Shi H, Boral AL, Goy A. Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma, 4867
- Fisher SG, *see* Pfister DG
- Fishkin PAS, *see* Ingle JN
- Fitch T, *see* Philip PA

AUTHOR INDEX

- Fitch TR, *see* Loprinzi CL
see Pockaj BA
- Fiveash JB, *see* Mamelak AN
- Fizazi K, *see* de Wit R
- Flahault A, *see* Barrier A
- Flaherty KT, *see* Ratain MJ
see Veronese ML
- Flamant C, *see* Lapillonne H
- Flannery A, *see* Hirsch FR
- Fleckenstein D, *see* Heinemann V
- Fleig WE, *see* Wagner AD
- Fleishman SB, Retkin R, Brandfield J, Braun V. The Attorney As the Newest Member of the Cancer Treatment Team, 2123
- Flejou J-F, *see* Buhard O
- Fleming GF, *see* Gordon MS
- Fleming GF. Major Progress for a Less Common Cancer (editorial), 6
- Fleming MD, *see* Coughlin CM
- Flemming C, *see* Haber M
- Flentje M, *see* Huber RM
- Flesch M, *see* Tournigand C
- Fleshman JM, *see* Redston M
- Fleshner N, *see* Wallace K
- Fletcher aSW, *see* Geiger AM
- Fletcher CDM, *see* Heinrich MC
see Raut CP
- Fletcher J, *see* Timmerman R
- Fletcher JA, *see* Heinrich MC
- Flockhart DA, *see* Goetz MP
- Flomenberg N, *see* Tsai SC
- Flood KL, Carroll MB, Le CV, Ball L, Esker DA, Carr DB. Geriatric Syndromes in Elderly Patients Admitted to an Oncology–Acute Care for Elders Unit, 2298
- Flores AM, *see* Rocha Lima CMSP
- Flowers MED, *see* Leisenring W
- Flynn HC, *see* Shanafelt TD
- Flynn PJ, *see* Perez EA
see Pockaj BA
- Focan C, *see* Giacchetti S
- Fode K, *see* Schmidt H
- Fodor M, *see* Van Cutsem E
- Foekens JA, *see* Smid M
- Foekens JA, Atkins D, Zhang Y, Sweep FCGJ, Harbeck N, Paradiso A, Cufer T, Sieuwerts AM, Talantov D, Span PN, Tjan-Heijnen VCG, Zito AF, Specht K, Hoefler H, Golouh R, Schittulli F, Schmitt M, Beex LVAM, Klijn JGM, Wang Y. Multicenter Validation of a Gene Expression–Based Prognostic Signature in Lymph Node–Negative Primary Breast Cancer, 1665
- Fogler WE, *see* Kulke MH
- Foltz LM, Song KW, Connors JM. Hodgkin’s Lymphoma in Adolescents, 2520
- Fong DYT, *see* Khong P-L
- Fong K-W, *see* Toh C-K
- Fong Y, *see* Jarnagin WR
- Fonseca R, *see* Rajkumar SV
- Fontana A, *see* Gelibter AJ
- Foo K, *see* Michael M
- Fook-Chong SMC, *see* Low WK
- Forastiere AA, *see* Pfister DG
- Forastiere AA, Trotti A, Pfister DG, Grandis aJR. Head and Neck Cancer: Recent Advances and New Standards of Care, 2603
- Forbes J, *see* Sestak I
- Forestier E, *see* Saarinen-Pihkala UM
- Forman SJ, *see* Baron F
- Formanek M, *see* Grünberger B
see Raderer M
- Forni M, *see* Modena P
- Fortin A, *see* Suh JH
see Wong RKS
- Fossà SD, *see* Oldenburg J
- Fossella FV, *see* Fanucchi MP
- Foster RS, *see* Einhorn LH
see Lewis DA
- Foster T, *see* Eggly S
- Fouladi M, Furman WL, Chin T, Freeman BB III, Dudkin L, Stewart CF, Krailo MD, Speights R, Ingle AM, Houghton PJ, Wright J, Adamson PC, Blaney SM. Phase I Study of Depsipeptide in Pediatric Patients With Refractory Solid Tumors: A Children’s Oncology Group Report, 3678
- Fowler J, *see* Randall ME
- Fowler JM, *see* Morrison C
- Fowler K, Poehling K, Billheimer D, Hamilton R, Wu H, Mulder J, Frangoul H. Hospice Referral Practices for Children With Cancer: A Survey of Pediatric Oncologists, 1099
- Fox E, *see* Widemann BC
- Fox SB, *see* Bates GJ
see Bottini A
- Fox SC. Controlling Emesis: What Is It Worth? (correspondence), 5617
- Fraker DL, *see* Cornett WR
- Franc B, *see* Barrier A
see Matthay KK
- Francart J, Legrand C, Sylvester R, Van Glabbeke M, van Meerbeek JP, Robert A. Progression-Free Survival Rate As Primary End Point for Phase II Cancer Clinical Trials: Application to Mesothelioma—The EORTC Lung Cancer Group, 3007
- France L, *see* Brain K
- Franceschi E, *see* Brandes AA
- Francesco Grasso R, *see* Quattrocchi CC
- Franchi D, *see* Guerrieri-Gonzaga A
- Francis CW, *see* Khorana AA
- Francis LK. Learning to Listen: A Fellow’s Experience, 3209
- Franckson T, *see* Pashenkov M
- Francois É, *see* Gérard J-P
- Frangoul H, *see* Fowler K
- Frankel S, *see* O’Connor OA
- Franklin J, *see* Jeha S
- Franklin WA, *see* Hirsch FR
see West HL
- Frantz GD, *see* Jubb AM
- Franzius C, *see* Kager L
- Fraser Symmans W, *see* Hess KR
- Fraumeni M, *see* Lai R
- Frazier AL, *see* Marina N
- Frazier M, *see* Li D
- Freeman BB III, *see* Fouladi M
- Freireich EJ, *see* Tsimberidou A-M
- Frenay M, *see* van den Bent MJ
- Fretz C, *see* von Moos R
- Frick M, *see* Kröger N
- Fricke J-P, *see* Andrieu N
- Frickhofen N, *see* Illerhaus G
- Friebel T, *see* Chen S
- Friedman AH, *see* Reardon DA
- Friedman DL, *see* Bassal M
see Leisenring W
- Friedman E, *see* Buhard O
see Pierce LJ
- Friedman HS, *see* Reardon DA
see Reardon DA
- Friedrichs N, *see* Goecke T
- Fröhling S, *see* Rucker FG
- Frost F, *see* Enger SM
- Frost MH, *see* Rummans TA
- Froster U, *see* Gadzicki D
- Frugé E, *see* Whitney SN
- Frustaci S, *see* Toffoli G

AUTHOR INDEX

- Fryer CJ, *see* Yock TI
 Fu H-H, *see* Hsu Y-C
 Fu Wong Y, *see* Buhard O
 Fuchs CS, *see* Chan JA
 see Goldberg RM
 see Kulke MH
 see Meyerhardt JA
 Fuchs L, *see* Robert N
 Fuchs M, *see* Heinemann V
 Fujiwara T, Tanaka N, Kanazawa S, Ohtani S, Saijo Y, Nukiwa T, Yoshimura K, Sato T, Eto Y, Chada S, Nakamura H, Kato H. Multicenter Phase I Study of Repeated Intratumoral Delivery of Adenoviral p53 in Patients With Advanced Non–Small-Cell Lung Cancer, 1689
 Fujiwara Y, *see* Gega M
 Fukuda H, *see* Tsuchiya N
 Fukuhara T, *see* Inoue A
 Fukuoka J, *see* Tsurutani J
 Fukuoka M, *see* Ando M
 see Kudoh S
 see Saito H
 Fukutani H, *see* Asano N
 Fuller C, *see* Thompson MC
 Fuller GN, *see* Wang L
 Fultz SL, *see* McGinnis KA
 Fumagalli LA, Brivio F. Immunotherapy and Prognostic Factors (correspondence), 4218
 Fumoleau P, *see* Roché H
 Fung ASM, *see* Khong P-L
 Furlong W, *see* McCarter H
 Furman WL, *see* Fouladi M
 Furman WL, Crews KR, Billups C, Wu J, Gajjar AJ, Daw NC, Patrick CC, Rodríguez-Galindo C, Stewart CF, Dome JS, Panetta JC, Houghton PJ, Santana VM. Cefixime Allows Greater Dose Escalation of Oral Irinotecan: A Phase I Study in Pediatric Patients With Refractory Solid Tumors, 563
 Fuso L, *see* Ponzzone R
 Fyfe N, *see* Al-Mulla F
 Fyles A, *see* Wong RKS
 Fynan TM, *see* Noronha V
- G**
- Gaafa R, *see* Bottomley A
 Gaarenstroom KN, *see* Madalinska JB
 Gabarre J, *see* Boué F
 Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, Abdulkarim B. Prognostic Significance of Human Epidermal Growth Factor Receptor Positivity for the Development of Brain Metastasis After Newly Diagnosed Breast Cancer, 5658
 Gadd MA, *see* Wong JS
 Gardner H, *see* Kager L
 see Schrauder A
 Gadzicki D, Wingen LU, Teige B, Horn D, Bosse K, Kreuz F, Goecke T, Schäfer D, Voigtländer T, Fischer B, Froster U, Welling B, Debatin I, Weber BHF, Schönbuchner I, Nippert I, Schlegelberger B. Communicating *BRCA1* and *BRCA2* Genetic Test Results (correspondence), 2969
 Gafà R, *see* Lanza G
 Gaffan J, Dacre J, Jones A. Educating Undergraduate Medical Students About Oncology: A Literature Review, 1932
 Gaffan J, Dacre J, Jones A. In Reply (correspondence), 5334
 Gaffney DK, *see* Pierce LJ
 Gagel RF, *see* Guillem JG
 Gagnon B, Mayo NE, Laurin C, Hanley JA, McDonald N. Identification in Administrative Databases of Women Dying of Breast Cancer, 856
 Gahres N, *see* Badros A
 Gaiger A, *see* Raderer M
 Gaion F, *see* Toffoli G
 Gajjar A, *see* Packer RJ
 see Thompson MC
 Gajjar AJ, *see* Furman WL
 Gajra A, *see* Lu JI
 Galimberti V. International Breast Cancer Study Group Trial of Sentinel Node Biopsy (correspondence), 210
 Gallagher JG, *see* Pockaj BA
 Gallagher M, *see* Veronese ML
 Gallagher RE, *see* Ferrari AC
 Gallamini A, *see* Went P
 Gallego C, *see* Fernández-Avilés F
 Gallegos-Ruiz MI, *see* Janmaat ML
 Galligioni E, *see* Toffoli G
 Galsky MD, *see* Sonpavde G
 Galusha DH, *see* Smith BD
 Gamarra S, *see* Quintela-Fandino M
 Gamble G, *see* Rummans TA
 Ganame J, *see* Van Calsteren K
 Gandara aDR, *see* Paz-Ares L
 Gandara DR, *see* Davies AM
 see Unger JM
 see West HL
 Gandara DR, Davies AM. Oral Second-Line Chemotherapy for Advanced Non–Small-Cell Lung Cancer: The Bottom Line (editorial), 2700
 Gangarosa LM, *see* Stinchcombe TE
 Ganti AK, Sahmoun AE, Panwalkar AW, Tendulkar KK, Potti A. Hormone Replacement Therapy Is Associated With Decreased Survival in Women With Lung Cancer, 59
 Ganz PA, *see* Herbst RS
 see Mandelblatt JS
 see Rowland JH
 see Silliman RA
 Ganz PA, Kwan L, Somerfield MR, Alberts D, Garber JE, Offit K, Lippman SM. The Role of Prevention in Oncology Practice: Results from a 2004 Survey of American Society of Clinical Oncology Members, 2948
 Ganz PA. Monitoring the Physical Health of Cancer Survivors: A Survivorship-Focused Medical History, 5105
 Gao F, *see* Toh C-K
 Gao J, *see* McCulloch MF
 see McCulloch M
 Gao Y-T, *see* Cai Q
 Garbe C, *see* Dummer R
 Garber JE, *see* Farkas Patenaude A
 see Ganz PA
 see Pierce LJ
 García AA, *see* Gordon MS
 García JA, Dreicer R. Systemic Chemotherapy for Advanced Bladder Cancer: Update and Controversies, 5545
 García JF, *see* Bates GJ
 García JM, *see* Domínguez G
 García L, *see* Fernández-Avilés F
 García V, *see* Domínguez G
 García-Andrade C, *see* Domínguez G
 Garden A, *see* Konski AA
 Garden AS, *see* Elliott EA
 see Tsao AS
 Gardiman M, *see* Brandes AA
 Garg MB, *see* Wong M
 Garin E, *see* Rousseau C
 Garrity ER, *see* Tanvetyanon T
 Garufi C, *see* Giacchetti S
 Garufi C, Maria Ettore G, Vanni B, Torsello A, Terzoli E. Neoadjuvant Chemotherapy for Metastatic Colon Cancer: Too Much Caution and Still Too Much to Be Assessed (correspondence), 2217

AUTHOR INDEX

- Gascoyne RD, *see* Habermann TM
see Iqbal J
- Gaspar LE, *see* Davies AM
- Gattamaneni HR, *see* Sharif S
- Gatter KC, *see* Koukourakis MI
- Gattermann N, *see* Kuendgen A
- Gaulard P, *see* Besson C
- Gautam A, *see* Bepler G
- Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-Term Follow-Up of High-Dose Methotrexate-Based Therapy With and Without Whole Brain Irradiation for Newly Diagnosed Primary CNS Lymphoma, 4570
- Gaya A, *see* Fernández-Avilés F
- Gayko U, *see* Rosen LS
- Gaynon PS, *see* Jeha S
- Gaynon PS, Harris RE, Altman AJ, Bostrom BC, Breneman JC, Hawks R, Steele D, Zipf T, Stram DO, Villaluna D, Trigg ME. Bone Marrow Transplantation Versus Prolonged Intensive Chemotherapy for Children With Acute Lymphoblastic Leukemia and an Initial Bone Marrow Relapse Within 12 Months of the Completion of Primary Therapy: Children's Oncology Group Study CCG-1941, 3150
- Gebert J, *see* Goecke T
- Gebhard S, *see* Tanner B
- Gebhardt M, *see* Bernstein ML
- Gebhardt MC, *see* Yock TI
- Gega M, Yanagi H, Yoshikawa R, Noda M, Ikeuchi H, Tsukamoto K, Oshima T, Fujiwara Y, Gondo N, Tamura K, Utsunomiya J, Hashimoto-Tamaoki T, Yamamura T. Successful Chemotherapeutic Modality of Doxorubicin Plus Dacarbazine for the Treatment of Desmoid Tumors in Association With Familial Adenomatous Polyposis, 102
- Geiger AM, *see* Enger SM
- Geiger AM, West CN, Nekhlyudov L, Herrinton LJ, Liu I-LA, Altschuler A, Rolnick SJ, Harris EL, Greene SM, Elmore JG, Emmons KM, Fletcher aSW. Contentment With Quality of Life Among Breast Cancer Survivors With and Without Contralateral Prophylactic Mastectomy, 1350
- Geisinger KR, *see* Raab SS
- Gelibter AJ, Lonardi S, Di Segni S, Fontana A, Loupakis F, Cognetti F, Labianca R. Are Dose-Finding Studies Still Necessary When Targeted Therapy Is Associated With Chemotherapy? (correspondence), 4668
- Gelman R, *see* Wong JS
- Gelmon K, *see* Chia S
see Lohrisch C
- Gelmon KA, *see* Cheang MCU
- Genc M, *see* Ozyar E
- Gencarelli A, *see* Lamanna N
- Generali D, *see* Bottini A
- Genet D, *see* Giacchetti S
- Genève J, *see* Roché H
- Genitori L, *see* Modena P
- Gennari A, Amadori D, De Lena M, Nanni O, Bruzzi P, Lorusso V, Manzione L, Conte PF. Lack of Benefit of Maintenance Paclitaxel in First-Line Chemotherapy in Metastatic Breast Cancer, 3912
- Gennaro M, *see* Bijker N
- Gentile T, *see* Stiff PJ
- Gentilucci UV, Santini D, Vincenzi B, Fiori E, Picardi A, Tonini G. Chemotherapy-Induced Steatohepatitis in Colorectal Cancer Patients (correspondence), 5467
- Geoffrois L, *see* Bourhis J
- Georgala A, *see* Klastersky J
- George DJ, *see* Motzer RJ
- George RE, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger RC, Pulsipher M, Grupp SA, Diller L. High-Risk Neuroblastoma Treated With Tandem Autologous Peripheral-Blood Stem Cell-Supported Transplantation: Long-Term Survival Update, 2891
- George S, *see* Raut CP
- George SL, *see* Dilts DM
- George SS, *see* Al-Mulla F
- Georgoulas V, *see* Xenidis N
- Gérard J-P, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin M-T, Untereiner M, Leduc B, Francois É, Maurel J, Seitz J-F, Buecher B, Mackiewicz R, Ducreux M, Bedenne L. Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203, 4620
- Gérard L, *see* Boulanger E
- Gerber DE, Grossman SA, Streiff MB. Management of Venous Thromboembolism in Patients With Primary and Metastatic Brain Tumors, 1310
- Germà JR, *see* Aparicio J
see Dotor E
- Germing U, *see* Kuendgen A
- Gerogianni A, *see* Bezjak A
- Gershenson DM, *see* Han LY
- Gershenwald JE, *see* Aloia TA
- Gerunda GE, *see* Di Benedetto F
- Gervais R, *see* Ramlau R
- Gesierich W, *see* Heinemann V
- Geyer CE Jr, *see* Bear HD
see Paik S
see Wapnir IL
- Geyer S, *see* Shanafelt TD
- Ghadimi BM, *see* Liersch T
- Ghadjar P, *see* Scheibenbogen C
- Ghadjar P, Coupland SE, Na I-K, Noutsias M, Letsch A, Stroux A, Bauer S, Buhr HJ, Thiel E, Scheibenbogen C, Keilholz U. Chemokine Receptor CCR6 Expression Level and Liver Metastases in Colorectal Cancer, 1910
- Ghalie R, *see* Govindan R
- Ghesquière H, Berger F, Felman P, Callet-Bauchu E, Bryon P-A, Traverse-Glehen A, Thieblemont C, Baseggio L, Michallet A-S, Coiffier B, Salles G. Clinicopathologic Characteristics and Outcome of Diffuse Large B-Cell Lymphomas Presenting With an Associated Low-Grade Component at Diagnosis, 5234
- Ghimenton C, *see* Brandes AA
- Giacchetti S, *see* Aloia T
- Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, Smaaland R, Focan C, Coudert B, Humblet Y, Luc Canon J, Adenis A, Lo Re G, Carvalho C, Schueller J, Anciaux N, Lentz M-A, Baron B, Gorlia T, Lévi F. Phase III Trial Comparing 4-Day Chronomodulated Therapy Versus 2-Day Conventional Delivery of Fluorouracil, Leucovorin, and Oxaliplatin As First-Line Chemotherapy of Metastatic Colorectal Cancer: The European Organization for Research and Treatment of Cancer Chronotherapy Group, 3562
- Giaccia AJ, *see* Petrik D
- Giaccone G, *see* Bottomley A
see Janmaat ML
- Giammarile F, *see* Rubie H
- Gianguaspero F, *see* Modena P
- Giannarelli D, *see* Ferretti G
see Papaldo P
- Giannoulia P, *see* Soverini S
- Giard S, *see* Houvenaeghel G
- Giardiello F, *see* Guillem JG
- Giatromanolaki A, *see* Koukourakis MI
- Gielissen MFM, Verhagen S, Witjes F, Bleijenberg G. Effects of Cognitive Behavior Therapy in Severely Fatigued Disease-Free Cancer Patients Compared With Patients Waiting for Cognitive Behavior Therapy: A Randomized Controlled Trial, 4882
- Gieseler F, *see* Heinemann V
- Gietema JA, *see* De Bont ESJM
see de Haas EC
see Perik PJ
see van den Belt-Dusebout AW
- Gifford D, *see* Lin DW
- Giguere JK, *see* Lembersky BC

AUTHOR INDEX

- Gilbert MR, *see* Cloughesy TF
see Lang FF
see Wang L
- Gilbert MR, Lang FF. Anaplastic Oligodendroglial Tumors: A Tale of Two Trials (editorial), 2689
- Gilbertson RJ, *see* Thompson MC
- Giles F, *see* Ault P
- Giles FJ, *see* Tsimberidou A-M
- Giles GG, *see* Southey MC
- Gilks CB, *see* Cheang MCU
see Hayes DN
- Gill PS, *see* Levine AM
- Gillespie A, *see* Widemann BC
- Gillespie JE, *see* Sharif S
- Gilligan D, *see* Spiro SG
- Gilligan T, Oh WK, Kantoff PW. Carboplatin for Stage I Seminoma (correspondence), 2971
- Gillison M, *see* Engels EA
- Gillison ML, *see* Fakhry C
- Gillison ML. Human Papillomavirus and Prognosis of Oropharyngeal Squamous Cell Carcinoma: Implications for Clinical Research in Head and Neck Cancers (editorial), 5623
- Gilsanz F, *see* Quintela-Fandino M
- Ginsberg MS, *see* Motzer RJ
- Ginsburg D, *see* Grunfeld E
- Giordani P, *see* Ruzzo A
- Giordano F, *see* Modena P
- Giordano SH, *see* Oh JL
- Giordano SH, Duan Z, Kuo Y-F, Hortobagyi GN, Goodwin JS. Use and Outcomes of Adjuvant Chemotherapy in Older Women With Breast Cancer, 2750
- Giordano SH, Hortobagyi GN. Leuprolide Acetate Plus Aromatase Inhibition for Male Breast Cancer (correspondence), e42
- Giovanni M, *see* Serena M
- Giovannucci EL, *see* Chan JA
see Meyerhardt JA
- Gipson T, *see* Tummala MK
- Girardi J, *see* Rummans TA
- Girinsky T, *see* Noordijk EM
- Gisselbrecht C, *see* Besson C
see Boué F
- Giuliano AE, *see* Umetani N
- Giusti RM, *see* Loud JT
- Giustini L, *see* Ruzzo A
- Giusto M, *see* Toffoli G
- Glaser SL, *see* Clarke CA
- Glaspay J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi G. Randomized Comparison of Every-2-Week Darbepoetin Alfa and Weekly Epoetin Alfa for the Treatment of Chemotherapy-Induced Anemia: The 20030125 Study Group Trial, 2290
- Glisson BS, *see* Tsao AS
- Gloghini A, *see* Simonelli C
- Glomstein A, *see* Saarinen-Pihkala UM
- Gluz O, *see* Kröger N
- Glynn-Jones R, Sebag-Montefiore D. Role of Neoadjuvant Chemotherapy in Rectal Cancer: Interpretation of the EXPERT Study (correspondence), 4664
- Gnani A, *see* Soverini S
- Gobbi M, *see* Iacobucci I
- Gockerman JP, *see* Koontz BF
- Godfrey H, *see* Bickell NA
- Godfrey T, *see* Meropol NJ
- Goecke T, *see* Gadzicki D
- Goecke T, Schulmann K, Engel C, Holinski-Feder E, Pagenstecher C, Schackert HK, Kloor M, Kunstmann E, Vogelsang H, Keller G, Dietmaier W, Mangold E, Friedrichs N, Propping P, Krüger S, Gebert J, Schmiegel W, Rueschoff J, Loeffler M, Moeslein G. Genotype-Phenotype Comparison of German *MLH1* and *MSH2* Mutation Carriers Clinically Affected With Lynch Syndrome: A Report by the German HNPCC Consortium, 4285
- Goemaere NNT, *see* Vermeer-Mens JG
- Goere D, *see* Pocard M
- Goëss G, *see* Pashenkov M
- Goetz A, *see* Mita AC
- Goetz MP, *see* Bardia A
- Goetz MP, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch F, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN. In Reply (correspondence), 3709
- Goetzl M, *see* McKiernan JM
- Goff LK, *see* Lee AM
- Goffin JR, Talavera JR. Overstated Conclusions of a Pooled Analysis of Bevacizumab in Colon Cancer (correspondence), 528
- Going JJ, *see* Al-Mulla F
- Gökbuget N, *see* Baldus CD
- Gold DP, *see* Redfern CH
- Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM. New MUC1 Serum Immunoassay Differentiates Pancreatic Cancer From Pancreatitis, 252
- Gold P, *see* Lenz H-J
- Gold PJ, *see* Meropol NJ
- Goldberg RM, *see* Ryan DP
- Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts S. Randomized Controlled Trial of Reduced-Dose Bolus Fluorouracil Plus Leucovorin and Irinotecan or Infused Fluorouracil Plus Leucovorin and Oxaliplatin in Patients With Previously Untreated Metastatic Colorectal Cancer: A North American Intergroup Trial, 3347
- Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, Rothenberg ML, Green E, Sargent DJ. Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bi-monthly in Elderly Patients With Colorectal Cancer, 4085
- Goldberg RM. Intensive Surveillance After Stage II or III Colorectal Cancer: Is It Worth It? (editorial), 330
- Goldenberg DM, *see* Chatal J-F
see Gold DV
see Liersch T
see Strauss SJ
- Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal J-F. Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy, 823
- Goldgar DE, *see* Andrieu N
- Goldhirsch A, *see* Kaufmann M
- Goldman S, *see* Jeha S
- Goldspiel B, Wiernikowski J. Comment on ASCO-ESMO Consensus Statement on Quality Cancer Care (correspondence), 5613
- Goldstein L, *see* Morrow M
- Goldstein LC, *see* Cheang MCU
- Goldstraw P. Selection of Patients for Surgery After Induction Chemotherapy for N2 Non-Small-Cell Lung Cancer (editorial), 3317
- Golmard JL, *see* Yakoub-Agha I
- Goloubeva O, *see* Badros A
- Golouh R, *see* Foekens JA
- Gómez HL, *see* Hess KR
- Gómez ME, *see* Domínguez G
- Gomez-Fernandez C, *see* Hurley J
- Gonda MA, *see* Mamelak AN
- Gondo N, *see* Gega M
- Gonen M, *see* Jarnagin WR
- Gonnermann M, *see* Heinemann V
- González M, *see* Fernández-Avilés F
- Gonzalez R, *see* Lewis KD
- Gonzalez-Angulo AM, *see* Guarneri V
see Hanrahan EO
- Goodell V, Salazar LG, Urban N, Drescher CW, Gray H, Swensen RE, McIntosh

AUTHOR INDEX

- MW, Disis ML. Antibody Immunity to the p53 Oncogenic Protein Is a Prognostic Indicator in Ovarian Cancer, 762
- Goodman K, *see* Knutson KL
- Goodrich DW, *see* Chanan-Khan A
- Goodson WH, Moore DH, Waldman FM. Ki-67 Correlates With In Vivo Bromodeoxyuridine Labeling Index in Operable Breast Cancer (correspondence), 3809
- Goodwin JS, *see* Giordano SH
- Goorin A, *see* Bernstein ML
- Gordon B, *see* Jeha S
- Gordon HS, Street RL Jr, Sharf BF, Kelly PA, Soucek J. Racial Differences in Trust and Lung Cancer Patients' Perceptions of Physician Communication, 904
- Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY. Clinical Activity of Pertuzumab (rhuMab 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status, 4324
- Gore L, *see* Camidge DR
- Gore M, *see* Bedikian AY
see Parton M
see Ratain MJ
- Gore M, du Bois A, Vergote I. Intraperitoneal Chemotherapy in Ovarian Cancer Remains Experimental, 4528
- Gore ME, *see* Lee CP
- Gori L, *see* Firenzuoli F
- Gorin N-C, Labopin M, Boiron J-M, Theorin N, Littlewood T, Slavin S, Greinix H, Cahn JY, Alessandrino EP, Rambaldi A, Nagler A, Polge E, Rocha V. Results of Genoidentical Hemopoietic Stem Cell Transplantation With Reduced Intensity Conditioning for Acute Myelocytic Leukemia: Higher Doses of Stem Cells Infused Benefit Patients Receiving Transplants in Second Remission and Beyond—The Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation, 3959
- Gorlia T, *see* Giacchetti S
see Mirimanoff R-O
see van den Bent MJ
- Gorlick R, *see* Cheung N-KV
- Gorospe G III, *see* Levine AM
- Goss PE, *see* Chien AJ
see Cigler T
see Perez EA
see Whelan TJ
- Gosse H, *see* Huber RM
- Gotay CC. Increasing Trial Generalizability, 846
- Gotlib J, *see* Dormady SP
- Goto H, *see* Ohmiya N
- Goto I, *see* Kudoh S
- Goto K, *see* Niho S
- Goudier M-J, *see* Roché H
- Goupil A, *see* du Bois A
- Govindan R, *see* Fanucchi MP
see Hanna N
see Teck Lim W
- Govindan R, Crowley J, Schwartzberg L, Kennedy P, Williams C, Ekstrand B, Sandler A, Jaunakais D, Bolejack V, Ghalie R. Phase II Trial of Bexarotene Capsules in Patients With Advanced Non-Small-Cell Lung Cancer After Failure of Two or More Previous Therapies, 4848
- Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J. Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database, 4539
- Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI. Reversible Posterior Leukoencephalopathy Syndrome Induced by RAF Kinase Inhibitor BAY 43-9006 (correspondence), e48
- Gower NH, *see* Spiro SG
- Gown AM, *see* Cheang MCU
- Goy A, *see* Fisher RI
- Goydos JS, *see* Scoggins CR
- Grabar S, Abraham B, Mahamat A, Del Giudice P, Rosenthal E, Costagliola D. Differential Impact of Combination Antiretroviral Therapy in Preventing Kaposi's Sarcoma With and Without Visceral Involvement, 3408
- Grabbe S, *see* Pashenkov M
- Grady C, *see* Agrawal M
- Graf N, *see* Creutzig U
- Grafone T, *see* Cavo M
- Graham Fisher P, *see* Donaldson SS
- Graham J, *see* Waterston AM
- Gralla RJ, *see* Kris MG
- Gralow JR, *see* Linden HM
- Grandis aJR, *see* Forastiere AA
- Grandis JR, *see* Kalyankrishna S
see Lai SY
- Granell M, *see* Fernández-Avilés F
- Grann VR, *see* Neugut AI
- Grant RM, *see* Chow LML
- Gratama JW, *see* Lamers CHJ
- Gratecos N, *see* Yakoub-Agha I
- Gratwohl A, *see* Hegenbart U
- Grau C, *see* Nielsen HM
- Gray H, *see* Goodell V
- Gray J, *see* Brain K
- Grazia Bernengo M, *see* Zinzani PL
- Grazia Ghi M, *see* Paccagnella A
- Graziano F, *see* Ruzzo A
- Graziano SL, *see* Lu JI
see Mukhopadhyay S
- Greco FA, *see* Hainsworth JD
- Greco M, *see* Demicheli R
- Green AC, *see* Whiteman DC
- Green DM, *see* Dome JS
- Green E, *see* Goldberg RM
- Green MR, *see* Blackstock AW
- Green SJ, *see* Hutchins LF
- Greenberg M, *see* Elliott EA
- Greenberg ML, *see* Chow LML
see Spiegler BJ
- Greene MH, *see* Loud JT
- Greene SM, *see* Geiger AM
- Grefe B, *see* Malogolowkin MH
- Grefe BS, *see* Bassal M
- Gregg J, *see* Barrier A
- Gregory Sorensen A. Magnetic Resonance As a Cancer Imaging Biomarker, 3274
- Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, du Bois A. Randomized Study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group Comparing Quality of Life in Patients With Ovarian Cancer Treated With Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel, 579
- Greiner TC, *see* Iqbal J
- Greinix H, *see* Gorin N-C
see Hegenbart U
- Greipp PR, *see* Barlogie B
see Rajkumar SV
- Greskovich JF, *see* Ajani JA
- Gretschel S, *see* Jüttner S
- Grever MR, *see* Byrd JC
- Gribben JG, *see* Byrd JC
see Davies JK
see Lee AM
- Grier HE, *see* Bernstein ML
see Mack JW
see Yock TI

AUTHOR INDEX

- Griesinger F, *see* Langebrake C
- Griffin T, *see* Jeha S
- Griffith KA, *see* Jagsi R
see Newman LA
- Griffith OL, Melck A, Jones SJM, Wiseman SM. Meta-Analysis and Meta-Review of Thyroid Cancer Gene Expression Profiling Studies Identifies Important Diagnostic Biomarkers, 5043
- Grisold W, *see* van den Bent MJ
- Gritz ER, *see* Demark-Wahnefried W
- Grochow L, *see* Chen HX
- Groen HJM, *see* De Bont ESJM
see Herder GJM
- Grogan TM, *see* Iqbal J
- Groshen S, *see* Matthay KK
see Pagliarulo V
- Groshen SG, *see* Levine AM
- Gross CP, *see* Smith BD
- Gross JA, *see* Novak AJ
- Grossi F, *see* Ceresoli GL
- Grossman SA, *see* Gerber DE
- Grote DM, *see* Novak AJ
- Grothe W, *see* Wagner AD
- Grothey A, *see* Ellis LM
see Wagner AD
- Grotzinger KM, *see* Ramlau R
- Groult V, *see* Harvey V
- Group IBCS. Randomized Trial Comparing Axillary Clearance Versus No Axillary Clearance in Older Patients With Breast Cancer: First Results of International Breast Cancer Study Group Trial 10-93, 337
- Group IBCS. Multicycle Dose-Intensive Chemotherapy for Women With High-Risk Primary Breast Cancer: Results of International Breast Cancer Study Group Trial 15-95, 370
- Groves MD, *see* Cloughesy TF
- Gruber S, *see* Guillem JG
- Gruenberger B, *see* Gruenberger T
- Gruenberger T, Gruenberger B, Scheithauer W. Neoadjuvant Therapy With Bevacizumab (correspondence), 2592
- Grunberg SM, *see* Koeller JM
see Kris MG
- Grünberger B, Wöhrer S, Streubel B, Formanek M, Petkov V, Puespoek A, Haefner M, Hejna M, Jaeger U, Chott A, Raderer AM. Antibiotic Treatment Is Not Effective in Patients Infected With *Helicobacter pylori* Suffering From Extragastic MALT Lymphoma, 1370
- Grundy PE, *see* Dome JS
- Grunfeld E, *see* Khatcheressian JL
- Grunfeld E, Levine MN, Julian JA. In Reply (correspondence), 3711
- Grunfeld E, Levine MN, Julian JA, Coyle D, Szechtman B, Mirsky D, Verma S, Dent S, Sawka C, Pritchard KI, Ginsburg D, Wood M, Whelan T. Randomized Trial of Long-Term Follow-Up for Early-Stage Breast Cancer: A Comparison of Family Physician Versus Specialist Care, 848
- Grunfeld E. Looking Beyond Survival: How Are We Looking at Survivorship? 5166
- Grunfeld EA, Maher EJ, Browne S, Ward P, Young T, Vivat B, Walker G, Wilson C, Potts HW, Westcombe AM, Richards MA, Ramirez AJ. Advanced Breast Cancer Patients' Perceptions of Decision Making for Palliative Chemotherapy, 1090
- Grupp SA, *see* Coughlin CM
see George RE
- Grzybicki DM, *see* Raab SS
- Gu C, *see* Lee AYY
- Gu J, *see* Wu X
- Guadagnoli E, *see* Keating NL
- Guadagnolo BA, Punglia RS, Kuntz KM, Mauch PM, Ng AK. Cost-Effectiveness Analysis of Computerized Tomography in the Routine Follow-Up of Patients After Primary Treatment for Hodgkin's Disease, 4116
- Guardigni L, *see* Cavo M
- Guarneri V, Broglio K, Kau S-W, Cristofanilli M, Buzzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM. Prognostic Value of Pathologic Complete Response After Primary Chemotherapy in Relation to Hormone Receptor Status and Other Factors, 1037
- Guarneri V, Lenihan DJ, Valero V, Durand J-B, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Long-Term Cardiac Tolerability of Trastuzumab in Metastatic Breast Cancer: The M.D. Anderson Cancer Center Experience, 4107
- Gucciardo G, *see* Bonanni B
- Guerci A, *see* Adès L
see Vey N
- Gurrero AS, *see* Jubb AM
- Guerrieri-Gonzaga A, Robertson C, Bonanni B, Serrano D, Cazzaniga M, Mora S, Gulisano M, Johansson H, Intra M, Latronico A, Franchi D, Pelosi G, Johnson K, Decensi A. Preliminary Results on Safety and Activity of a Randomized, Double-Blind, 2 × 2 Trial of Low-Dose Tamoxifen and Fenretinide for Breast Cancer Prevention in Premenopausal Women, 129
- Guerry D IV, *see* Fears TR
- Guertzoni L, *see* Lanza G
- Guettier C, *see* Aloia T
- Gui GPH, *see* Dua RS
- Guido C, *see* Serena M
- Guilabert A, *see* Argenziano G
- Guillem JG, *see* Nissan A
- Guillem JG, Wood WC, Moley JF, Berchuck A, Karlan BY, Mutch DG, Gagel RF, Weitzel J, Morrow M, Weber BL, Giardiello F, Rodriguez-Bigas MA, Church J, Gruber S, Offit K. ASCO/SSO Review of Current Role of Risk-Reducing Surgery in Common Hereditary Cancer Syndromes, 4642
- Guimbaud R, *see* Portier G
- Guinó E, *see* Dotor E
- Gulisano M, *see* Guerrieri-Gonzaga A
- Gulley JL, Parnes HL, Wright J, Dahut WL. Early Treatment Gets the Benefit (correspondence), 5172
- Gumerlock PH, *see* West HL
- Gupta S, *see* Dubois D
- Gurney H, *see* Wong M
- Gurney H. Developing a New Framework for Dose Calculation (editorial), 1489
- Gurney JG, *see* Bowers DC
- Gurtler V, *see* Michael M
- Guruangan S, *see* Reardon DA
- Gustafson P, *see* Mertens F
- Gustafsson G, *see* Saarinen-Pihkala UM
- Gutberlet M, *see* Jaster M
- Guth AA, *see* Bickell NA
- Gutheil J, *see* Rosen LS
- Gutheil JC, *see* Redfern CH
- Guthrie B, *see* Mamelak AN
- Guthrie T Jr, *see* Hanna N
- Guthrie TH, *see* Redfern CH
- Guttenberger R, *see* Illerhaus G
- Guttridge D, *see* Monk JP
- Guzman C, *see* Quintela-Fandino M
- Gwede C, *see* Konski AA

H

- Haag C, *see* Heinemann V
- Haarmann C, *see* Pashenkov M
- Haas R, *see* Kuendgen A
- Haas S, *see* Oberthuer A
- Haase GM, *see* Dome JS
- Haaxma-Reiche H, *see* van den Bent MJ
- Haber M, Smith J, Bordow SB, Flemming C, Cohn SL, London WB, Marshall GM, Norris MD. Association of High-Level *MRP1* Expression With Poor

- Clinical Outcome in a Large Prospective Study of Primary Neuroblastoma, 1546
- Habermann TM, *see* Mikuls TR
- Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ. Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma, 3121
- Hablitz DM, *see* Mamelak AN
- Habuchi T, *see* Tsuchiya N
- Hackett CB, *see* Dragovich T
- Hackshaw AK, *see* Spiro SG
- Haefner M, *see* Grünberger B
- Haerting J, *see* Wagner AD
- Haeussinger K, *see* Spinola M
- Haferlach T, *see* Büchner T
- Haffty BG, *see* Lally BE
see Lally BE
see Pierce LJ
see Smith BD
see Weinberger PM
- Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D. Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer, 5652
- Hafner S, *see* Kröber A
- Hagan JP, *see* Roldo C
- Hagan S, *see* Al-Mulla F
- Hagemeister FB, *see* Liu Q
- Hagenbeek A, *see* Noordijk EM
- Hagenbeek A, Eghbali H, Monfardini S, Vitolo U, Hoskin PJ, de Wolf-Peeters C, MacLennan K, Staab-Renner E, Kalmus J, Schott A, Teodorovic I, Negrouk A, van Glabbeke M, Marcus R. Phase III Intergroup Study of Fludarabine Phosphate Compared With Cyclophosphamide, Vincristine, and Prednisone Chemotherapy in Newly Diagnosed Patients With Stage III and IV Low-Grade Malignant Non-Hodgkin's Lymphoma, 1590
- Hagendoorn L, *see* Scoggins CR
- Hagerty K, *see* Lee SJ
- Hahn M, *see* Thuerigen O
- Haid A, *see* Knauer M
- Hainsworth JD, *see* Gordon MS
see Schiller GJ
- Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II Trial of Paclitaxel, Carboplatin, and Etoposide in Advanced Poorly Differentiated Neuroendocrine Carcinoma: A Minnie Pearl Cancer Research Network Study, 3548
- Hait W, *see* Haffty BG
- Hajek RA, *see* Jones LA
- Halberg F, *see* Khatcheressian JL
- Hale KE, *see* Zhu AX
- Hall E, *see* Fallowfield LJ
- Hall MJ, Olopade OI. Disparities in Genetic Testing: Thinking Outside the BRCA Box, 2197
- Hall S, *see* Ferrari AC
- Haller DG, *see* Ajani JA
see Smalley SR
- Haller DG, O'Connell MJ, Sargent D, Costantino JP, Wolmark N. Sam Wieand, PhD, 4523
- Haller DG. JCO and the Public Trust (editorial), 323
- Halm U. Perioperative CA19-9 Levels Can Predict Stage and Survival in Patients With Resectable Pancreatic Adenocarcinoma (correspondence), 5610
- Halpern A, *see* Fears TR
- Haluska FG, *see* Bedikian AY
- Halvorsen OJ, *see* Bachmann IM
- Hamberg P, de Jong FA, Boonstra JG, van Doorn J, Verweij J, Sleijfer S. Non-Islet-Cell Tumor Induced Hypoglycemia in Patients With Advanced Gastrointestinal Stromal Tumor Possibly Worsened By Imatinib (correspondence), e30
- Hambleton J, *see* Kabbinarvar FF
- Hamelin R, *see* Buhard O
- Hamilton C, *see* Nemunaitis J
- Hamilton R, *see* Fowler K
- Hamilton RL, *see* Pollack IF
- Hamilton S, *see* Locker GY
- Hammond LA, *see* Mita AC
see Tolcher AW
- Hammond S, *see* Bassal M
- Hammouch F, *see* Machiels J-P
- Han C, *see* Bates GJ
- Han J-Y, Lim H-S, Shin ES, Yoo Y-K, Park YH, Lee J-E, Jang I-J, Ho Lee D, Lee JS. Comprehensive Analysis of *UGT1A* Polymorphisms Predictive for Pharmacokinetics and Treatment Outcome in Patients With Non-Small-Cell Lung Cancer Treated With Irinotecan and Cisplatin, 2237
- Han Kim J, *see* Lee J
- Han LY, Landen CN Jr, Kamat AA, Lopez A, Bender DP, Mueller P, Schmandt R, Gershenson DM, Sood AK. Preoperative Serum Tissue Factor Levels Are an Independent Prognostic Factor in Patients With Ovarian Carcinoma, 755
- Hanafusa T, *see* Oka S
- Hancock BW, *see* Johnson PWM
see Lee CP
see Mudie NY
- Hänel M, *see* Kröger N
- Hankinson SE, *see* Eliassen AH
- Hanley JA, *see* Gagnon B
- Hanna N, *see* Mohiuddin M
see Weiss GJ
- Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A. Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer, 2038
- Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Jänne PA, Bonomi P. Phase II Trial of Cetuximab in Patients With Previously Treated Non-Small-Cell Lung Cancer, 5253
- Hanna N. In Reply (correspondence), 5175
- Hanna NH, Einhorn LH. Postoperative Chemotherapy for N2 Non-Small-Cell Lung Cancer: Conclusions Are Not Black and White, but Gray (correspondence), 5611
- Hannon P, *see* Hord JD
- Hanrahan EO, Valero V, Gonzalez-Angulo AM, Hortobagyi GN. Prognosis and Management of Patients With Node-Negative Invasive Breast Carcinoma That Is 1 cm or Smaller in Size (stage 1; T1a,bN0M0): A Review of the Literature, 2113
- Hans CP, *see* Iqbal J
- Hansen M, *see* Bloechl-Daum B
- Hanson J, *see* Gabos Z
see Rummans TA
- Hanson JP, *see* Socinski MA
- Hanssens M, *see* Van Calsteren K
- Hantel A, *see* Meyerhardt JA
- Hao D, *see* Herbst RS
see Tolcher AW
- Haqq C, *see* Rangel J
- Hara S, *see* Oka S
- Harada M, *see* Nonami A
see Onoda S
- Harada N, *see* Nonami A
- Haraf DJ, *see* Cohen EEW
- Harbeck N, *see* Foekens JA
see Thussbas C
- Harder B, *see* Novak AJ
- HariGOPal M, *see* Weinberger PM
- Hariharan S, *see* Hanna N
see Lilenbaum R
- Harik SI, *see* Govindarajan R

AUTHOR INDEX

- Harker G, *see* Abou-Alfa GK
- Harlan LC, Clegg LX, Abrams J, Stevens JL, Ballard-Barbash R. Community-Based Use of Chemotherapy and Hormonal Therapy for Early-Stage Breast Cancer: 1987-2000, 872
- Harmon DC, *see* Kraybill WG
- Harper PG, *see* Spiro SG
- Harris AL, *see* Bates GJ
see Bottini A
see Koukourakis MI
- Harris EE, *see* Pierce LJ
- Harris EER, Correa C, Hwang W-T, Liao J, Litt HI, Ferrari VA, Solin LJ. Late Cardiac Mortality and Morbidity in Early-Stage Breast Cancer Patients After Breast-Conservation Treatment, 4100
- Harris EL, *see* Geiger AM
- Harris J, *see* Konski AA
see Kraybill WG
see Locker GY
see Rosa DD
- Harris JR, *see* Wong JS
- Harris L, *see* Haffty BG
- Harris M, *see* James PA
- Harris RE, *see* Gaynon PS
- Harrison LB, *see* Pfister DG
- Harsh GR, *see* Bredel M
- Harstrick A, *see* Bourhis J
- Hart LL, *see* Lilenbaum R
see Socinski MA
- Hartge P, *see* Fears TR
- Hartigan PM, *see* Richards WG
- Hartmann LC, *see* Knutson KL
- Harvey D, *see* Alcalay A
- Harvey V, Mouridsen H, Semiglazov V, Jakobsen E, Voznyi E, Robinson BA, Grovet V, Murawsky M, Cold S. Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast Cancer, 4963
- Hasenclever D, *see* Tanner B
- Hashimoto-Tamaoki T, *see* Gega M
- Haskell CM, *see* Pentz RD
- Hauff W, *see* Raderer M
- Haukaas SA, *see* Bachmann IM
- Hauri D, *see* Studer UE
- Häusler P, *see* Liersch T
- Hausner PF, *see* Tummala MK
- Hawes D, *see* Pagliarulo V
- Hawes SE, *see* Hoque MO
- Hawkins C, *see* Tabori U
- Hawkins RB, *see* Buckner JC
- Hawks R, *see* Gaynon PS
- Hawley S, *see* Lin DW
- Hay A, *see* Crawford SC
- Hayashi M, *see* Tobinai K
- Hayes D, *see* Smith IE
- Hayes DF, *see* Locker GY
- Hayes DF, Picard MH. Heart of Darkness: The Downside of Trastuzumab (editorial), 4056
- Hayes DN, Monti S, Parmigiani G, Gilks CB, Naoki K, Bhattacharjee A, Socinski MA, Perou C, Meyerson M. Gene Expression Profiling Reveals Reproducible Human Lung Adenocarcinoma Subtypes in Multiple Independent Patient Cohorts, 5079
- Hayostek C, *see* Mohiuddin M
- He X, *see* Oh DS
- He X-H, *see* Li Y-X
- Heaney M, *see* Lamanna N
- Heaney ML, *see* O'Connor OA
- Hecht JL, Mutter GL. Molecular and Pathologic Aspects of Endometrial Carcinogenesis, 4783
- Hee Lim C, *see* Chuah C
- Hee Park Y, *see* Lee J
- Heekin KC. The Discussion Group for Mortals, 4661
- Heelan RT, *see* Milton DT
- Heemsbergen WD, *see* Peeters STH
- Heerema NA, *see* Byrd JC
- Hegde VS, *see* Ajzensztejn D
- Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shizuru JA, Greinix H, Cordonnier C, Rio B, Gratwohl A, Lange T, Al-Ali H, Storer B, Maloney D, McSweeney P, Chauncey T, Agura E, Bruno B, Maziarz RT, Petersen F, Storb R. Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors, 444
- Heilmann C, *see* Saarinen-Pihkala UM
- Heinecke A, *see* Büchner T
- Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R. Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer, 3946
- Heinrich B, *see* Heinemann V
- Heinrich MC, *see* Demetri GD
- Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CDM, Sandau K, McDougall K, Ou W-b, Chen C-J, Fletcher JA. Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors, 4764
- Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, Hirte H, Cresta S, Koslin DB, Corless CL, Dirnhofer S, van Oosterom AT, Nikolova Z, Dimitrijevic S, Fletcher JA. Clinical and Molecular Studies of the Effect of Imatinib on Advanced Aggressive Fibromatosis (desmoid tumor), 1195
- Heintz APM, *see* van der Lee ML
- Heinze S, *see* Sohlbach K
- Hejna M, *see* Grünberger B
- Helft PR, Daugherty CK. Are We Taking Without Giving in Return? The Ethics of Research-Related Biopsies and the Benefits of Clinical Trial Participation (editorial), 4793
- Helgeson VS, *see* Scheier MF
- Hellawell J, *see* Esserman LJ
- Henderson IC. Axillary Surgery: Clinical Judgment Required (editorial), 325
- Hengstler JG, *see* Tanner B
- Henke M, Mattern D, Pepe M, Bézay C, Weissenberger C, Werner M, Pajonk F. Do Erythropoietin Receptors on Cancer Cells Explain Unexpected Clinical Findings? 4708
- Henry-Amar M, *see* Noordijk EM
- Henze G, *see* Burkhardt B
- Herbst RS, *see* Carducci MA
- Herbst RS, Bajorin DF, Bleiberg H, Blum D, Hao D, Johnson BE, Ozols RF, Demetri GD, Ganz PA, Kris MG, Levin B, Markman M, Raghavan D, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Vokes EE, Winn RJ, Mayer RJ. Clinical Cancer Advances 2005: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology, 190
- Herder GJM, Kramer H, Hoekstra OS, Smit EF, Pruim J, van Tinteren H, Comans EF, Verboom P, Uyl-de Groot CA, Welling A, Paul MA, Boers M, Postmus PE, Teule GJ, Groen HJM. Traditional Versus Up-Front [¹⁸F] Fluorodeoxyglucose–Positron Emission Tomography Staging of Non-Small-Cell Lung Cancer: A Dutch Cooperative Randomized Study, 1800
- Hermann J, *see* Creutzfeldt U
- Hermes M, *see* Tanner B
- Hermine O, *see* Besson C
- Hernández S, Knowles EL, Lloreta J, Kogevinas M, Amorós A, Tardón A, Carrato A, Serra C, Malats N, Real FX. Prospective Study of *FGFR3* Mutations As a Prognostic Factor in Nonmuscle Invasive Urothelial Bladder Carcinomas, 3664
- Hernandez-Ilizaliturri F, *see* Chanan-Khan A

AUTHOR INDEX

- Hernando A, *see* Fernández-Avilés F
 Herndon JE II, *see* Blackstock AW
 see Cornett WR
 see Kemeny NE
 see Reardon DA
 Hero B, *see* Oberthuer A
 Herr H, *see* Raj GV
 Herr HW, *see* Dalbagni G
 Herrera AF, *see* Esserman LJ
 Herrinton LJ, *see* Clarke CA
 see Geiger AM
 Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann R-D, Steinbach JP, Hundsberger T, Wick W, Meyermann R, Tan T-C, Sommer C, Bamberg M, Reifenberger G, Weller M. Phase II Trial of Lomustine Plus Temozolomide Chemotherapy in Addition to Radiotherapy in Newly Diagnosed Glioblastoma: UKT-03, 4412
 Herrmann K, *see* Ott K
 Herrmann R, *see* Heinrich MC
 Herrstedt J, *see* Bloechl-Daum B
 Hersey P, *see* Bedikian AY
 Hersh EM, *see* Bedikian AY
 Hershberg RM, *see* Small EJ
 Hershman D, *see* Sparano JA
 Hershman DL, *see* Neugut AI
 Hertel J, *see* Jüttner S
 Hesdorffer C, *see* Cesana GC
 Heseltine D, *see* Meyerhardt JA
 Hesketh PJ, *see* Koeller JM
 see Kris MG
 Hess KR, *see* Guarneri V
 see Li D
 see Wang L
 Hess KR, Anderson K, Fraser Symmans W, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gómez HL, Hortobagyi GN, Puztai L. Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, 4236
 Hess M, *see* Liu Q
 Hewitt M, *see* Rowland JH
 Hewitt SM, *see* Bonthala Wedam S
 see Tsurutani J
 Heymach JV, *see* Kulke MH
 Hezel M, *see* Jarnagin WR
 Hicks DG, *see* Ring BZ
 Hicks RJ, *see* Cachin F
 see Leahy MF
 see Michael M
 see Rischin D
 Hidalgo M, *see* Erlichman C
 Hiddemann W, *see* Büchner T
 Higano C, *see* Hussain M
 Higano CS, *see* Small EJ
 Higashi Y, *see* Takahashi M
 Higgins CD, *see* Mudie NY
 Higgins SA, *see* Haffty BG
 Hildebrandt B, *see* Kuendgen A
 Hilgers R, *see* Kretschmer L
 Hill DA, *see* Priest JR
 Hill J, *see* Evans GD
 Hill M, *see* Chau I
 Hillan KJ, *see* Jubb AM
 Hillman BJ. Introduction to the Special Issue on Medical Imaging in Oncology (correspondence), 3223
 Hillner B, *see* Smith TJ
 Hills RK, *see* Wheatley K
 Hilpert F, *see* Greimel ER
 Hilsenbeck SG, *see* Ma X-J
 Hinds PS, *see* Razzouk BI
 Hinke A, *see* Heinemann V
 Hiotis K, *see* Bickell NA
 Hiraiwa T, *see* Oka S
 Hiramatsu SH, *see* Umetani N
 Hirata Y, *see* Oka S
 Hirooka Y, *see* Ohmiya N
 Hirsch FR, *see* Chung CH
 Hirsch FR, Varella-García M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N, Holloway B. Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non-Small-Cell Lung Cancer, 5034
 Hirsch FR, Varella-García M, Franklin WA, Bunn Jr PA. In Reply (correspondence), 1220
 Hirte H, *see* Heinrich MC
 see Pfisterer J
 Hisata M, *see* Takahashi M
 Hislop TG, Bajdik CD, Balneaves LG, Holmes A, Chan S, Wu E, Abanto ZU, Butler AL. Physical and Emotional Health Effects and Social Consequences After Participation in a Low-Fat, High-Carbohydrate Dietary Trial for More Than 5 Years, 2311
 Hitt R, *see* Bourhis J
 see Quintela-Fandino M
 Hittelman WN, *see* Izzo JG
 see Wu X
 Hitzler JK, *see* Spiegler BJ
 Ho C, Bebb G, Murray N. In Reply (correspondence), 3214
 Ho L, *see* Crane CH
 Ho Lee D, *see* Han J-Y
 see Lee J
 Ho Yun Y, *see* Min Park S
 Hoare S, *see* Strauss SJ
 Hobson R, *see* Rubie H
 Hochstenbag M, *see* De Ruyscher D
 Hockenberry M, *see* Razzouk BI
 see Whitney SN
 Höcker M, *see* Jüttner S
 Hodgson DC, *see* Chow LML
 Hoefler H, *see* Foekens JA
 see Thussbas C
 Hoefnagel JJ, *see* Dijkman R
 Hoekstra OS, *see* Herder GJM
 Hoelzer D, *see* Baldus CD
 Hoelzer DF, *see* Strauss SJ
 Hoff PM, *see* Vauthey J-N
 Hoffman B, Stovall E. Survivorship Perspectives and Advocacy, 5154
 Hoffmann M, *see* Raderer M
 Hofman A, *see* Siemes C
 Hofmann WK, *see* Baldus CD
 Hogan TF, *see* Steensma DP
 Hogarty MD, *see* Coughlin CM
 Hogg A, *see* Cachin F
 Hogg TL, *see* Thompson MC
 Hogikyan N, *see* Urba S
 Holden L, *see* Murugaesu N
 Holden SN, *see* Jubb AM
 Holinski-Feder E, *see* Goecke T
 Holland JF, *see* Silverman LR
 Hollema H, *see* van Geelen CM
 Hollenbach K, *see* Bardwell WA
 Hollenstein J, *see* Madalinska JB
 Hollis D, *see* Lichtman SM
 see Meyerhardt JA
 see Ryan DP

AUTHOR INDEX

- Hollis DR, *see* Kemeny NE
Holloway B, *see* Hirsch FR
Holly EA, *see* Fears TR
Holman PR, *see* Redfern CH
Holmes A, *see* Hislop TG
Holmes AJ, *see* Jackman DM
Holmes EJ, *see* Pollack IF
Holmes FA, *see* Jones SE
Holmes MD, *see* Kroenke CH
 see Meyerhardt JA
 see Nekhlyudov L
Holmgren EB, *see* Jubb AM
Holstege A, *see* Heinemann V
Homesley H, *see* Moll S
Hon C, Chui W-H, Cheng L-C, Shek TW, Jones BM, Au WY. Thymoma Associated With Keratoconjunctivitis, Lichen Planus, Hypogammaglobulinemia, and Absent Circulating B Cells, 2960
Honeycutt W, *see* Czito BG
Hong H-S, *see* Tsai K-Y
Hooker CM, *see* Engels EA
Hoon DSB, *see* Umetani N
Hoon Lee J, *see* Lee J
Hoening MJ, Dorresteijn LDA, Aleman BMP, Kappelle AC, Klijn JGM, Boogerd W, van Leeuwen FE. Decreased Risk of Stroke Among 10-Year Survivors of Breast Cancer, 5388
Hoos A, *see* Nissan A
Hopkins J, *see* Blum JL
Hopkins U, *see* Sparano JA
Hopper JL, *see* Southey MC
Hoque MO, Feng Q, Toure P, Dem A, Critchlow CW, Hawes SE, Wood T, Jeronimo C, Rosenbaum E, Stern J, Yu M, Trink B, Kiviat NB, Sidransky D. Detection of Aberrant Methylation of Four Genes in Plasma DNA for the Detection of Breast Cancer, 4262
Hord JD, *see* Razzouk BI
Hord JD, Rehman W, Hannon P, Anderson-Shaw L, Schmidt ML. Do Parents Have the Right to Refuse Standard Treatment for Their Child With Favorable-Prognosis Cancer? Ethical and Legal Concerns, 5454
Horgan AM, Kenny C, Duffy A, O'Reilly S. Case 1. Unusual Complications of a Hickman Catheter, 1474
Horgan D, *see* Lamanna N
Horgan K, *see* Zhu AX
Hörmann M, *see* Pashenkov M
Hormigo A, *see* Gavrilovic IT
Horn B, *see* Matthay KK
Horn D, *see* Gadzicki D
Hornedo J, *see* Quintela-Fandino M
Horng C-F, *see* Cheng SH
Horning SJ, *see* Habermann TM
Horning SJ, Mellstedt H. Introduction: ASCO-ESMO Consensus Statement on Quality Cancer Care, 3497
Horning SJ. ASCO Core Values: Essential to Progress in Innovative, Quality Cancer Care (editorial), 5629
Hornor L, *see* Levine AM
Horowitz MM, *see* Eapen M
Horsman DE, *see* Iqbal J
Hortobagyi GN, *see* Avis NE
 see Baptista MZ
 see Giordano SH
 see Guarneri V
 see Hanrahan EO
 see Hess KR
 see Kaufmann M
 see Woodward WA
Horwitz S, *see* O'Connor OA
Hoschander S, *see* Sparano JA
Hoskin PJ, *see* Hagenbeek A
 see Mudie NY
 see Rades D
Hoskins JM, *see* Michael M
 see Wong M
Hoskins PJ, *see* Al-Tourah AJ
Hotta T, *see* Tobinai K
Houghton J, *see* Dowsett M
Houghton PJ, *see* Fouladi M
 see Furman WL
Houldsworth J, Korkola JE, Bosl GJ, Chaganti RSK. Biology and Genetics of Adult Male Germ Cell Tumors, 5512
Houry S, *see* Barrier A
Houvenaeghel G, Nos C, Mignotte H, Classe JM, Giard S, Rouanet P, Lorca FP, Jacquemier J, Bardou VJ. Micrometastases in Sentinel Lymph Node in a Multicentric Study: Predictive Factors of Nonsentinel Lymph Node Involvement—Groupe Des Chirurgiens De La Federation Des Centres De Lutte Contre Le Cancer, 1814
Howard SC, *see* Metzger ML
Howell D, *see* Duchesne GM
Howell T, *see* Dowsett M
Hoyal CR, *see* Spinola M
Hricak H, *see* Mitchell DG
Hrusak O, *see* Langebrake C
Hrushesky WJM, *see* Demicheli R
Hsu AAL, *see* Toh C-K
Hsu Y-C, Fu H-H, Jeng Y-M, Lee P-H, Yang S-D. Proline-Directed Protein Kinase F_A Is a Powerful and Independent Prognostic Predictor for Progression and Patient Survival of Hepatocellular Carcinoma, 3780
Hsueh S, *see* Chou H-H
Hu E, *see* Gaspy J
Hu Z, *see* Oh DS
Huang A, *see* Larouche V
Huang AT, *see* Cheng SH
Huang E, *see* Cheng SH
Huang H-J, *see* Chou H-H
Huang K-G, *see* Chou H-H
Huang M, *see* Wu X
Huber A, *see* Reinhardt MJ
Huber RM, Flentje M, Schmidt M, Pöllinger B, Gosse H, Willner J, Ulm K. Simultaneous Chemoradiotherapy Compared With Radiotherapy Alone After Induction Chemotherapy in Inoperable Stage IIIA or IIIB Non-Small-Cell Lung Cancer: Study CTRT99/97 by the Bronchial Carcinoma Therapy Group, 4397
Huber SM, *see* Temple WJ
Hudes GR, *see* Motzer RJ
Hudis C, *see* Dang C
Hudson MM, *see* Metzger ML
Hug EB, *see* Elliott EA
Hugh J, *see* Gabos Z
Hughes Halbert C, *see* Rebeck TR
Hughes ME, *see* Buchholz TA
Hughes MS, *see* Beck KE
Hughes R, *see* Lorenz KA
Huguier M, *see* Barrier A
Huh J, *see* Lee J
Hui EP, *see* Leung S-f
Hui Lim T, *see* Chuah C
Huizenga H, *see* van Tol-Geerdink JJ
Humblet Y, *see* Bourhis J
 see Giacchetti S
 see Van Calsteren K
Hummel M, *see* Jahnke K
Hummer AJ, *see* Black D
Hundsberger T, *see* Herrlinger U
Hung H, *see* Lin DW

- Hunt KK, *see* Oh JL
 Huntsman D, *see* Cheang MCU
 Hurd DD, *see* Barlogie B
 Hurley J, Doliny P, Reis I, Silva O, Gomez-Fernandez C, Velez P, Pauletti G, Pegram MD, Slamon DJ. Docetaxel, Cisplatin, and Trastuzumab As Primary Systemic Therapy for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced Breast Cancer, 1831
 Hurria A, *see* Elkin EB
 see Smith BD
 Hurwitz H, *see* Abou-Alfa GK
 Hurwitz HI, *see* Czito BG
 see Jubb AM
 Huschka M, *see* Rummans TA
 Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D. Absolute Prostate-Specific Antigen Value After Androgen Deprivation Is a Strong Independent Predictor of Survival in New Metastatic Prostate Cancer: Data From Southwest Oncology Group Trial 9346 (INT-0162), 3984
 Hussain MHA, *see* Berry DL
 Hutchins LF, *see* Unger JM
 Hutchins LF, Green SJ. In Reply (correspondence), 2392
 Hutchinson B, *see* Argani P
 Hutson TE, *see* Sonpavde G
 Hwai Liang Loh A, *see* Chuah C
 Hwang ES, *see* Esserman LJ
 Hwang W-T, *see* Harris EER
 Hylton N. Dynamic Contrast-Enhanced Magnetic Resonance Imaging As an Imaging Biomarker, 3293
 Hylton NM, *see* Esserman LJ
 Hyman WJ, *see* Jones SE
- I**
- Iacobelli S, *see* Giacchetti S
 Iacobucci I, *see* Soverini S
 Iacobucci I, Rosti G, Amabile M, Poerio A, Soverini S, Cilloni D, Testoni N, Abruzzese E, Montefusco E, Ottaviani E, Iuliano F, Russo D, Gobbi M, Alimena G, Martino B, Terragna C, Pane F, Saglio G, Baccarani M, Martinelli G. Comparison Between Patients With Philadelphia-Positive Chronic Phase Chronic Myeloid Leukemia Who Obtained a Complete Cytogenetic Response Within 1 Year of Imatinib Therapy and Those Who Achieved Such a Response After 12 Months of Treatment, 454
 Iammarino NK, *see* Jones LA
 Iasonos A, *see* Raj GV
 Ibrahim N, *see* Hess KR
 Ichikawa T, *see* Tsuchiya N
 Ichinose Y, *see* Saito H
 Ifrah N, *see* Yakoub-Agha I
 Ignatius Ou S-H, *see* Zell JA
 Ihorst G, *see* Illerhaus G
 Ikawa Y, *see* Saikawa Y
 Ikeuchi H, *see* Gega M
 Il Lee S, *see* Lee J
 Ilegbodun D, *see* Blum JL
 see Robert N
 Iliopoulos O. Molecular Biology of Renal Cell Cancer and the Identification of Therapeutic Targets, 5593
 Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, Frickhofen N, Feuerhake F, Volk B, Finke J. High-Dose Chemotherapy With Autologous Stem-Cell Transplantation and Hyperfractionated Radiotherapy As First-Line Treatment of Primary CNS Lymphoma, 3865
 Ilson DH, *see* Shah MA
 In Bae S, *see* Reu FJ
 Incarbone M, *see* Ceresoli GL
 Incrocci L, *see* Peeters STH
 Ingle AM, *see* Fouladi M
 Ingle JN, *see* Goetz MP
 see Perez EA
 see Whelan TJ
 Ingle JN, Suman VJ, Rowland KM, Mirchandani D, Bernath AM, Camoriano JK, Fishkin PAS, Nikcevich DA, Perez EA. Fulvestrant in Women With Advanced Breast Cancer After Progression on Prior Aromatase Inhibitor Therapy: North Central Cancer Treatment Group Trial N0032, 1052
 Innocenti F, Vokes EE, Ratain MJ. Irinogenetics: What Is the Right Star? (editorial), 2221
 Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N, Watanabe H, Saijo Y, Nukiwa T. Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations, 3340
 Inoue D, *see* Yasuda H
 Inoue T, *see* Asamura H
 International Bladder Cancer Nomogram Consortium Postoperative Nomogram Predicting Risk of Recurrence After Radical Cystectomy for Bladder Cancer, 3967
 International Breast Cancer Study Group Tamoxifen After Adjuvant Chemotherapy for Premenopausal Women With Lymph Node–Positive Breast Cancer: International Breast Cancer Study Group Trial 13-93, 1332
 Intra M, *see* Guerrieri-Gonzaga A
 Intropido L, *see* Montillo M
 Iqbal J, Neppalli VT, Wright G, Dave BJ, Horsman DE, Rosenwald A, Lynch J, Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Campo E, Ott G, Müller-Hermelink HK, Delabie J, Jaffe ES, Grogan TM, Connors JM, M. Vose J, Armitage JO, Staudt LM, Chan WC. *BCL2* Expression Is a Prognostic Marker for the Activated B-Cell–Like Type of Diffuse Large B-Cell Lymphoma, 961
 Iredale R, *see* Brain K
 Irwin D, *see* Richardson PG
 Isaacs C, *see* Chen S
 see Pierce LJ
 Isacke CM, *see* Dua RS
 Ishida F, *see* Asano N
 Ishikawa Y, *see* Asamura H
 Ishizawa K, *see* Yasuda H
 Ishizawa K-i, *see* Tobinai K
 Ishizuka T, *see* Kaira K
 Isitt J, *see* Stiff PJ
 Ismael GFV, *see* Rosa DD
 Isobe H, *see* Onoda S
 Isola J, *see* Tanner M
 Isorna S, *see* Studer UE
 Itoh A, *see* Ohmiya N
 Iuliano F, *see* Iacobucci I
 Iuzzolino P, *see* Brandes AA
 Iversen ES, *see* Chen S
 Iversen ES Jr, *see* Chen S
 Iversen PO, *see* Negaard HFS
 Izquierdo N, *see* Ocaña A
 Izzo J, *see* Luthra R
 Izzo JG, Malhotra U, Wu T-T, Ensor J, Luthra R, Lee JH, Swisher SG, Liao Z, Chao KSC, Hittelman WN, Aggarwal BB, Ajani JA. Association of Activated Transcription Factor Nuclear Factor κ B With Chemoradiation Resistance and Poor Outcome in Esophageal Carcinoma, 748
- J**
- Jacksz R, *see* Kaufmann M
 Jackisch C, *see* Kröger N
 see Pfisterer J
 Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borrás AM, Bailey C, de Jong F, Jänne PA, Johnson BE. Response and Resistance in a Non–Small-

AUTHOR INDEX

- Cell Lung Cancer Patient With an Epidermal Growth Factor Receptor Mutation and Leptomeningeal Metastases Treated With High-Dose Gefitinib, 4517
- Jacobs AD, *see* Lembersky BC
- Jacobsen PB, *see* Ayanian JZ
- Jacobson JS, *see* Neugut AI
- Jacquemier J, *see* Houvenaghel G
- Jaeckle KA, *see* Brown PD
- Jaeckle KA, Ballman KV, Rao RD, Jenkins RB, Buckner JC. Current Strategies in Treatment of Oligodendroglioma: Evolution of Molecular Signatures of Response, 1246
- Jaeger U, *see* Grünberger B
see Reinhardt MJ
- Jaén J, *see* Álvaro T
- Jaffe C, *see* Chen HX
- Jaffe CC. Measures of Response: RECIST, WHO, and New Alternatives, 3245
- Jaffe ES, *see* Iqbal J
- Jaffer S, *see* Bleiweiss IJ
- Jagannath S, *see* Richardson PG
- Jager PL, *see* Perik PJ
- Jäger U, *see* Raderer M
- Jagsi R, Griffith KA, Koelling T, Roberts R, Pierce LJ. Stroke Rates and Risk Factors in Patients Treated With Radiation Therapy for Early-Stage Breast Cancer, 2779
- Jahnke K, Hummel M, Korfel A, Burmeister T, Kiewe P, Klasen HA, Müller H-H, Stein H, Thiel E. Detection of Subclinical Systemic Disease in Primary CNS Lymphoma by Polymerase Chain Reaction of the Rearranged Immunoglobulin Heavy-Chain Genes, 4754
- Jain aRK, *see* Duda DG
- Jairaj S, *see* Coughlin CM
- Jaklitsch MT, *see* Richards WG
- Jakob C, *see* Liersch T
- Jakobsen E, *see* Harvey V
- James LE, *see* Spiro SG
- James MG, *see* Lee CP
- James PA, Doherty R, Harris M, Mukesh BN, Milner A, Young M-A, Scott C. Optimal Selection of Individuals for *BRCA* Mutation Testing: A Comparison of Available Methods, 707
- James PA, Doherty R, Harris M, Young M-A, Scott C. In Reply (correspondence), 3311
- Janakiraman N, *see* Redfern CH
- Jandl T, *see* Pashenkov M
- Jang I-J, *see* Han J-Y
- Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, Meijer GA, Vervenne WL, Richel DJ, Van Groeningen C, Giaccone G. Predictive Factors for Outcome in a Phase II Study of Gefitinib in Second-Line Treatment of Advanced Esophageal Cancer Patients, 1612
- Janmaat ML, Rodriguez JA, Giaccone G. In Reply (correspondence), 5466
- Jänne PA, *see* Hanna N
see Jackman DM
see Richards WG
- Jänne PA. Gefitinib for Epidermal Growth Factor Receptor Mutant Lung Cancers: Searching for a Weapon of Mass Destruction (editorial), 3319
- Janosky JE, *see* Raab SS
- Janssen D, *see* Burkhardt B
- Janssen I, *see* Modena P
- Jarnagin WR, Klimstra DS, Hezel M, Gonen M, Fong Y, Roggin K, Cymes K, DeMatteo RP, D'Angelica M, Blumgart LH, Singh B. Differential Cell Cycle-Regulatory Protein Expression in Biliary Tract Adenocarcinoma: Correlation With Anatomic Site, Pathologic Variables, and Clinical Outcome, 1152
- Jarrett C, *see* Chung CH
- Jarutirasarn SG, *see* Berenson JR
- Jaster M, Gutberlet M, Dinkloh N, Schneider P, Schultheiss H-P, Morguet AJ. Ventricular Tachycardia Indicating Cardiac Involvement in Metastatic Leiomyosarcoma, 3502
- Jatoi I, *see* Newman LA
- Jaunakais D, *see* Govindan R
- Jayaprakash N, *see* Widemann BC
- Jayson GC, *see* Rosa DD
- Jefford M, *see* Michael M
- Jeha S, Gaynon PS, Razzouk BI, Franklin J, Kadota R, Shen V, Luchtman-Jones L, Rytting M, Bomgaars LR, Rheingold S, Ritchey K, Albano E, Arceci RJ, Goldman S, Griffin T, Altman A, Gordon B, Steinherz L, Weitman S, Steinherz P. Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia, 1917
- Jelinek D, *see* Shanafelt TD
- Jelinek DF, *see* Novak AJ
see Shanafelt TD
- Jen J, *see* Tsurutani J
- Jeng Y-M, *see* Hsu Y-C
- Jenkin D, *see* Chow LML
- Jenkins MA, *see* Southey MC
- Jenkins R, *see* Cairncross G
see Schover LR
- Jenkins RB, *see* Jaeckle KA
see Perez EA
see Shanafelt TD
- Jensen AR, *see* Nielsen HM
- Jensen AW, *see* Brown PD
- Jensen DC, *see* Raab SS
- Jensen M-B, *see* Ejlertsen B
- Jeong J-H, *see* Taghian AG
see Wapnir IL
- Jeronimo C, *see* Hoque MO
- Jessup JM, *see* Locker GY
- Jesus-Garcia R, *see* Petrilli AS
- Jeter SC, *see* Wolff AC
- Jewell SD, *see* Redston M
- Jewett M, *see* Wallace K
- Ji B-T, *see* Cai Q
- Jian JJ, *see* Cheng SH
- Jiang CS, *see* Berry DL
- Jiang S-X, *see* Asamura H
- Jiao L, *see* Li D
- Jimeno A, *see* Quintela-Fandino M
- Jin J, *see* Li Y-X
- Jin Kim H, *see* Lee J
- Jinnai I, *see* Yanada M
- Jobling T, *see* Verheijen RH
- Joe AY, *see* Reinhardt MJ
- Joe J, *see* Weinberger PM
- Joel SP, *see* Strauss SJ
- Joensuu H, *see* Heinrich MC
- Joffe S, *see* Pentz RD
- Joffe S, Miller FG. Rethinking Risk-Benefit Assessment for Phase I Cancer Trials, 2987
- Joffe S, Miller FG. In Reply (correspondence), 5179
- Johansen JS, *see* Schmidt H
- Johansson H, *see* Guerrieri-Gonzaga A
- Johansson HA, *see* Bonanni B
- John M, *see* Braga-Basaria M
- John WJ, *see* Paz-Ares L
- Johnson BE, *see* Herbst RS
see Jackman DM
- Johnson DH, *see* Csiki I
- Johnson DH. ASCO in the 21st Century: Challenges and Opportunities—ASCO Presidential Address 2005, 1967
- Johnson K, *see* Guerrieri-Gonzaga A
- Johnson ME, *see* Rummans TA
- Johnson MM, *see* Aloia TA
- Johnson PM, Porter GA, Ricciardi R, Baxter NN. Increasing Negative Lymph

AUTHOR INDEX

- Node Count Is Independently Associated With Improved Long-Term Survival in Stage IIIB and IIIC Colon Cancer, 3570
- Johnson PW, *see* Strauss SJ
- Johnson PWM, Radford JA, Cullen MH, Sydes MR, Stenning SP, Hancock BW. Comparison of Outcomes in Studies of Advanced Hodgkin's Lymphoma (correspondence), 3309
- Johnson RD, *see* Mita AC
- Johnston PG. Prognostic Markers of Local Relapse in Rectal Cancer: Are We Any Further Forward? (editorial), 4049
- Jonat W, *see* Kaufmann M
- Jones A, *see* Gaffan J
- Jones BM, *see* Hon C
- Jones C, *see* Konski AA
- Jones CA, *see* Temple WJ
- Jones LA, *see* Small EJ
- Jones LA, Chilton JA, Hajek RA, Iammarino NK, Laufman L. Between and Within: International Perspectives on Cancer and Health Disparities, 2204
- Jones M, *see* Watkins Bruner D
- Jones RJ, *see* Wolff AC
- Jones S, *see* Berry DL
- Jones SE, *see* Fallowfield LJ
- Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippin JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Khandelwal P, Negron AG, Richards DA, Anthony SP, Mennel RG, Boehm KA, Meyer WG, Asmar L. Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer, 5381
- Jones SJM, *see* Griffith OL
- Jonkman S, *see* Perik PJ
- Jonmundsson G, *see* Saarinen-Pihkala UM
- Jöns T, *see* Jüttner S
- Joong Oh S, *see* Lee J
- Jordan S, *see* Lee AM
- Jordanova ES, *see* Dijkman R
- Josse RG, *see* Perez EA
- Jouet J-P, *see* Yakoub-Agha I
- Journeycake JM, Buchanan GR. Catheter-Related Deep Venous Thrombosis and Other Catheter Complications in Children With Cancer, 4575
- Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, Kabbinavar F, Holden SN, Novotny WF, Frantz GD, Hillan KJ, Koeppen H. Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal Cancer, 217
- Juhasz G, *see* O'Brien MER
- Jukic D, *see* Moschos SJ
- Julian aJA, *see* Lee AYY
- Julian JA, *see* Grunfeld E
- Juliar BE, *see* Bedano PM
- Julié C, *see* Benoist S
- Julien J-P, *see* Bijker N
- Julieron M, *see* Bourhis J
- Junck L, *see* Cao Y
see Cloughesy TF
- Jung C, *see* Lee J
- Jung CW, *see* Kim HJ
- Jung I, *see* Nekhlyudov L
- Jung S-M, *see* Chou H-H
- Jurcic JG, *see* Lamanna N
- Jürgens H, *see* Kager L
- Juric D, *see* Bredel M
- Just RG, *see* Redfern CH
- Justice AC, *see* McGinnis KA
- Jüttner S, Wißmann C, Jöns T, Vieth M, Hertel J, Gretschel S, Schlag PM, Kemmner W, Höcker M. Vascular Endothelial Growth Factor-D and Its Receptor VEGFR-3: Two Novel Independent Prognostic Markers in Gastric Adenocarcinoma, 228
- K**
- Kabbinavar F, *see* Jubb AM
- Kabbinavar FF, *see* Sweeney CJ
- Kabbinavar FF, Hambleton J, Mass RD, Sarkar S. In Reply (correspondence), 529
- Kadan-Lottick NS, *see* Bassal M
- Kadota R, *see* Jeha S
- Kaelin C, *see* Burwell SR
- Kaelin CM, *see* Wong JS
- Kafousi M, *see* Xenidis N
- Kagami Y, *see* Asano N
- Kager L, Zoubek A, Kastner U, Kempf-Bielack B, Potratz J, Kotz R, Exner GU, Franzius C, Lang S, Maas R, Jürgens H, Gadner H, Bielack S. Skip Metastases in Osteosarcoma: Experience of the Cooperative Osteosarcoma Study Group, 1535
- Kahl BS, *see* Fisher RI
- Kahlenberg MS, *see* Bear HD
- Kahlert Y, *see* Oberthuer A
- Kahn KL, *see* Malin JL
- Kai I, *see* Takahashi M
- Kaira K, Ishizuka T, Sohara N, Yanagitani N, Sunaga N, Tsuchiya T, Mori M. Small Cell Carcinoma of the Larynx in a Long-Term Survivor of Small-Cell Lung Cancer, 2961
- Kaisary A, *see* Ferrari AC
- Kakinuma R, *see* Niho S
- Kalapurakal JA, *see* Dome JS
- Kalaycio M, *see* Lamanna N
- Kalaycio M, Rybicki L, Pohlman B, Sobechs R, Andresen S, Kuczkowski E, Bolwell B. Risk Factors Before Autologous Stem-Cell Transplantation for Lymphoma Predict for Secondary Myelodysplasia and Acute Myelogenous Leukemia, 3604
- Kalbakis K, *see* Xenidis N
- Kalebic T, *see* Papotti M
- Kalli KR, *see* Knutson KL
- Kalmus J, *see* Hagenbeek A
- Kalyankrishna S, Grandis JR. Epidermal Growth Factor Receptor Biology in Head and Neck Cancer, 2666
- Kamangar F, Dores GM, Anderson WF. Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World, 2137
- Kamat AA, *see* Han LY
- Kamby C, *see* Ejlertsen B
- Kameya T, *see* Asamura H
- Kamezaki K, *see* Nonami A
- Kammerer S, *see* Spinola M
- Kammula US, *see* Beck KE
- Kamoto T, *see* Tsuchiya N
- Kamps WA, *see* De Bont ESJM
see te Loo DMWM
- Kanazawa S, *see* Fujiwara T
- Kanda A, *see* Yasuda H
- Kane JM III, *see* Cornett WR
- Kaneta T, *see* Yasuda H
- Kang C-J, *see* Liu F-Y
see Ng S-H
- Kang TY, Lowe CJ, Sekeres MA. Thalidomide Use and Digital Gangrene, 5328
- Kang WK, *see* Kim HJ
- Kantamnei S, *see* Darabi K
- Kantarjian H, *see* Ault P
see Cortes JE
- Kantarjian HM, *see* Tsimberidou A-M
- Kantoff PW, *see* Febbo PG
see Gilligan T
see Smith MR
- Kao D, *see* Dormady SP

AUTHOR INDEX

- Kaplan MJ, *see* Petrik D
Kaplan RS, *see* Chen HX
Kappelle AC, *see* Hooning MJ
Karam V, *see* Aloia T
Karas KS, *see* Dilts DM
Karlan BY, *see* Gordon MS
 see Guillem JG
Karstens JH, *see* Rades D
Karube K, *see* Nonami A
Kashala O, *see* Fanucchi MP
Kashani-Sabet M, *see* Rangel J
Kasl S, *see* Claus EB
Kastner U, *see* Kager L
Katakami N, *see* Kudoh S
Kates R, *see* Thussbas C
Kato H, *see* Fujiwara T
Kattan MW, *see* Stephenson AJ
Katzenstein H, *see* Malogolowkin MH
Kau S-W, *see* Guarneri V
Kaufman DS, *see* Smith MR
 see Sweeney CJ
Kaufman HL, *see* Cesana GC
Kaufman HL, Wolchok JD. Is Tumor Immunity the Same Thing As Autoimmunity? Implications for Cancer Immunotherapy (editorial), 2230
Kaufman PA, *see* Perez EA
Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, Blohmer J-U, Eiermann W, Jackesz R, Jonat W, Lebeau A, Loibl S, Miller W, Seeber S, Semiglazov V, Smith R, Souchon R, Stearns V, Untch M, von Minckwitz G. Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update, 1940
Kaukel E, *see* Ramlau R
Kawachi I, *see* Kroenke CH
Kawakami K, *see* Ruzzo A
Kay NE, *see* Novak AJ
 see Shanafelt TD
Kaye SB, *see* Crawford SC
 see Ratain MJ
Kazak AE, Alderfer M, Reilly A. In Reply (correspondence), 2216
Kazi A, *see* Sparano JA
Kealy R, *see* Sestak I
Kearney T, *see* Haffty BG
Keating M, *see* Ault P
Keating MJ, *see* Tsimberidou A-M
Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Factors Related to Underuse of Surveillance Mammography Among Breast Cancer Survivors, 85
Keating NL, O'Malley AJ, Smith MR. Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer, 4448
Keilholz U, *see* Ghadjar P
 see Scheibenbogen C
Kelbick N, *see* Morrison C
Kelemen LE, *see* Knutson KL
Keller G, *see* Goecke T
Kellie SJ, *see* Thompson MC
Kelloff GJ, *see* El-Deiry WS
Kellokumpu-Lehtinen P, *see* Tanner M
Kelly K, *see* Fanucchi MP
 see Weiss GJ
Kelly PA, *see* Gordon HS
Kelly WK, *see* O'Connor OA
Kelsen DP, *see* Shah MA
Kemeny N, *see* Locker GY
Kemeny NE, Niedzwiecki D, Hollis DR, Lenz H-J, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE II, Zhang C, Mayer RJ. Hepatic Arterial Infusion Versus Systemic Therapy for Hepatic Metastases From Colorectal Cancer: A Randomized Trial of Efficacy, Quality of Life, and Molecular Markers (CALGB 9481), 1395
Kemmner W, *see* Jüttner S
Kempf-Bielack B, *see* Kager L
Kempin S, *see* Beerepoot LV
Kennedy K, *see* Spiegler BJ
Kennedy P, *see* Govindan R
Kennedy RD, D'Andrea AD. DNA Repair Pathways in Clinical Practice: Lessons From Pediatric Cancer Susceptibility Syndromes, 3799
Kenny C, *see* Horgan AM
Kenyon P, *see* Moll S
Kerbel RS, *see* Shaked Y
Kerber R, *see* Chen S
Kerbl R, Urban CE, Zotter H, Dornbusch HJ, Ladenstein R, Ambros IM, Ambros PF. Treatment Complications in Neuroblastoma Patients: Lessons From Screening Studies (correspondence), e41
Kerbrat P, *see* Roché H
 see Rousseau C
Keresztes RS, *see* Lilienbaum R
Kern W, *see* Büchner T
Kerr KM, *see* Petty RD
Kesari S, *see* Jackman DM
Kessler K, *see* Lewis DA
Kestler HA, *see* Rücker FG
Kezele P, *see* Lin DW
Khambata-Ford S, *see* Lenz H-J
Khandani AH, *see* Stinchcombe TE
Khandelwal P, *see* Jones SE
Khatcheressian J, *see* Smith TJ
Khatcheressian JL, Smith TJ. Randomized Trial of Long-Term Follow-Up for Early-Stage Breast Cancer: A Comparison of Family Physician Versus Specialist Care (editorial), 835
Khatcheressian JL, Wolff AC, Smith TJ, Grunfeld E, Muss HB, Vogel VG, Halberg F, Somerfield MR, Davidson NE. American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting, 5091
Khatri V, *see* Alcalay A
Khazaeli MB, *see* Mamelak AN
Khong P-L, Leung LHT, Fung ASM, Fong DYT, Qiu D, Kwong DLW, Ooi G-C, McAlanon G, Cao G, Chan GCF. White Matter Anisotropy in Post-Treatment Childhood Cancer Survivors: Preliminary Evidence of Association With Neurocognitive Function, 884
Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in Hospitalized Neutropenic Cancer Patients, 484
Khouri I, *see* Tsimberidou A-M
Khuntia D, Brown P, Li J, Mehta MP. Whole-Brain Radiotherapy in the Management of Brain Metastasis, 1295
Khurana KK, *see* Mukhopadhyay S
Khuri F, *see* Tsao AS
Kian Ang K, *see* Pfister DG
Kiechle M, *see* Thussbas C
Kiehna EN, Mulhern RK, Li C, Xiong X, Merchant TE. Changes in Attentional Performance of Children and Young Adults With Localized Primary Brain Tumors After Conformal Radiation Therapy, 5283
Kienast J, *see* Büchner T
Kienle D, *see* Kröber A
Kies MS, *see* Carducci MA
 see Cohen EEW
 see Tsao AS
Kiewe P, *see* Jahnke K
Kikuchi A, *see* Yasuda H
Kim C, *see* Paik S
Kim G, *see* Philip PA
Kim H, *see* Elliott EA
Kim HJ, Jung CW, Kim K, Ahn JS, Kim WS, Park K, Ko YH, Kang WK, Park K.

AUTHOR INDEX

- Isolated Blast Crisis in CNS in a Patient With Chronic Myelogenous Leukemia Maintaining Major Cytogenetic Response After Imatinib, 4028
- Kim K, *see* Kim HJ
see Lee J
- Kim K. Statin and Cancer Risks: From Tasseomancy of Epidemiologic Studies to Meta-Analyses (editorial), 4796
- Kim ST, *see* Motzer RJ
- Kim W, *see* Paik S
- Kim WS, *see* Kim HJ
see Lee J
- Kimmig R, *see* du Bois A
see Pfisterer J
- Kim-Schulze S, *see* Cesana GC
see Cesana G
- Kimura Y, *see* Inoue A
- Kinoshita T, *see* Asano N
- Kinsella K, *see* Kulke MH
- Kirby R, *see* Jones SE
- Kirkova J, Davis MP, Walsh D, Tiernan E, O'Leary N, LeGrand SB, Lagman RL, Russell aKM. Cancer Symptom Assessment Instruments: A Systematic Review, 1459
- Kirkpatrick JP, *see* Koontz BF
- Kirkwood JM, *see* Bedikian AY
see Moschos SJ
- Kishor Ganti A, Sahmoun AE, Potti A. In Reply (correspondence), 2684
- Kitamura K, *see* Asano N
- Kittles RA, *see* Paschka P
- Kiura K, *see* Takigawa N
- Kivelä T, *see* Kytö JP
- Kiviat NB, *see* Hoque MO
- Klasen HA, *see* Jahnke K
- Klastersky J, *see* Paesmans M
- Klastersky J, Paesmans M, Georgala A, Muanza F, Plehiers B, Dubreucq L, Lalami Y, Aoun M, Barette M. Outpatient Oral Antibiotics for Febrile Neutropenic Cancer Patients Using a Score Predictive for Complications, 4129
- Kleber G, *see* Wagner AD
- Kleibeuker JH, *see* van Geelen CM
- Klein A, *see* Stein J
- Klein EA, *see* Kupelian PA
- Klein RJ, *see* Duda DG
- Kleiner D, *see* Beck KE
- Kletter K, *see* Wachter S
- Kletzel M, *see* Dome JS
- Kliffen M, *see* Lamers CHJ
- Klijin JGM, *see* Foekens JA
see Hooning MJ
see Smid M
- Klimstra D, *see* Nissan A
- Klimstra DS, *see* Jarnagin WR
- Kline MP, *see* Novak AJ
- Klingebliel T, *see* Schrauder A
- Kloor M, *see* Goecke T
- Kluin PM, *see* van Imhoff GW
- Kluin-Nelemans HC, *see* van Imhoff GW
- Kluin-Nelemans JC, *see* Noordijk EM
- Knauer M, Konstantiniuk P, Haid A, Wenzl E, Riegler-Keil M, Pöstlberger S, Reitsamer R, Schrenk P. Multicentric Breast Cancer: A New Indication for Sentinel Node Biopsy—A Multi-Institutional Validation Study, 3374
- Knight L, *see* Hirsch FR
- Knijnenburg J, *see* Dijkman R
- Knowles EL, *see* Hernández S
- Knox SK, Kurtin PJ, Steensma DP. Isolated Splenic Sinus Histiocytosis (Rosai-Dorfman disease) in Association With Myelodysplastic Syndrome, 4027
- Knudsen BS, *see* Lin DW
- Knutson KL, Krco CJ, Erskine CL, Goodman K, Kelemen LE, Wettstein PJ, Low PS, Hartmann LC, Kalli KR. T-Cell Immunity to the Folate Receptor Alpha Is Prevalent in Women With Breast or Ovarian Cancer, 4254
- Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Phase II Study of Fixed Dose Rate Gemcitabine With Cisplatin for Metastatic Adenocarcinoma of the Pancreas, 379
- Ko S-F, *see* Ng S-H
- Ko Y, *see* Kröger N
- Ko Y-D, *see* Strasser F
- Ko YH, *see* Kim HJ
see Lee J
- Kobayashi K, *see* Oka S
- Kobayashi T, *see* Yanada M
- Koch WM, *see* Bernier J
- Koch D, *see* Herrlinger U
- Koch P, Liersch R, Willich NA, Reinartz G, Berdel WE. In Reply (correspondence), 2682
- Kocherginsky M, *see* Cohen EEW
- Koczwara B, *see* Arnold SJ
- Koczwara B, Barton MB. The Ideal Oncology Curriculum for Medical Students (correspondence), 5334
- Kodish E, *see* Neff Greenley R
- Koeller JM, *see* Kris MG
- Koeller JM, Grunberg SM, Hesketh PJ, Kris MG. In Reply (correspondence), 5616
- Koelling T, *see* Jaggi R
- Koeppen H, *see* Bonthala Wedam S
see Jubb AM
- Kogevinas M, *see* Hernández S
- Kohli M, *see* Kohli S
- Kohli S, Kohli M. Acute Chemotherapy-Induced Cardiovascular Changes in Patients With Testicular Cancer: Are There Implications for Blood Pressure Management in Patients Receiving Chemotherapy? (correspondence), 2399
- Kohut K, *see* Offit K
- Koizumi S, *see* Saikawa Y
- Koizumi W, *see* Rojo F
- Kolbe K, *see* Kröger N
- Kölbl O, *see* Schäfer C
- Kolch W, *see* Al-Mulla F
- Kolitz JE, *see* Paschka P
- Koller C, *see* Ault P
- Koller S, *see* Pashenkov M
- Kollmannsberger C, *see* McArthur HL
- Komaki R, *see* Lee JJ
see Shelley Wang X
- Kominsky SL, Davidson NE. A “Bone” Fide Predictor of Metastasis? Predicting Breast Cancer Metastasis to Bone (editorial), 2227
- Kondagunta GV, *see* Ronnen EA
- Kondagunta GV, Motzer RJ. Chemotherapy for Advanced Germ Cell Tumors, 5493
- Kondagunta GV, Motzer RJ, Bosl GJ, Sheinfeld J. In Reply (correspondence), 2598
- Konety BR, Allareddy V, Modak S, Smith B. Mortality After Major Surgery for Urologic Cancers in Specialized Urology Hospitals: Are They Any Better? 2006
- König R, *see* Oberthuer A
- Kono K, *see* Nonami A
- Konski AA, Pajak TF, Movsas B, Coyne J, Harris J, Gwede C, Garden A, Spencer S, Jones C, Watkins-Bruner D. Disadvantage of Men Living Alone Participating in Radiation Therapy Oncology Group Head and Neck Trials, 4177
- Konstantiniuk P, *see* Knauer M
- Konstantinopoulos PA, Schlecht HP, Bryan B, Pantanowitz L, Dezube BJ. HIV-Associated Anal Squamous Cell Cancer: An Otherwise Preventable Disease, 4516
- Kontny U, *see* Burkhardt B
- Koon Cheah F, *see* Chuah C
- Koong AC, *see* Petrik D

AUTHOR INDEX

- Koong H-N, *see* Toh C-K
- Koontz BF, Kirkpatrick JP, Clough RW, Prosnitz RG, Gockerman JP, Moore JO, Prosnitz LR. Combined-Modality Therapy Versus Radiotherapy Alone for Treatment of Early-Stage Hodgkin's Disease: Cure Balanced Against Complications, 605
- Koornstra JJ, *see* van Geelen CM
- Koper PCM, *see* Peeters STH
- Koppert LB, *see* Steyerberg EW
- Koralewski P, *see* Paz-Ares L
- Korczak JF, *see* Simon MS
- Korfel A, *see* Jahnke K
- Korkola JE, *see* Houldsworth J
- Koroukian SM, Murray P, Madigan E. Comorbidity, Disability, and Geriatric Syndromes in Elderly Cancer Patients Receiving Home Health Care, 2304
- Kortmann R-D, *see* Herrlinger U
see Mirimanoff R-O
see Timmermann B
- Kosaka T, *see* Takeuchi T
- Koscielniak E, *see* Wachtel M
- Koslin DB, *see* Heinrich MC
- Kosterink JGW, *see* Perik PJ
- Kotz R, *see* Kager L
- Koukourakis MI, Bentzen SM, Giatromanolaki A, Wilson GD, Daley FM, Saunders MI, Dische S, Sivridis E, Harris AL. Endogenous Markers of Two Separate Hypoxia Response Pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) Are Associated With Radiotherapy Failure in Head and Neck Cancer Patients Recruited in the CHART Randomized Trial, 727
- Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL. Lactate Dehydrogenase 5 Expression in Operable Colorectal Cancer: Strong Association With Survival and Activated Vascular Endothelial Growth Factor Pathway—A Report of the Tumour Angiogenesis Research Group, 4301
- Kouroussis C, *see* Xenidis N
- Kovatch AJ, *see* Meropol NJ
- Kowalski D, *see* Weinberger PM
- Kraeber-Bodéré F, *see* Chatal J-F
- Krailo M, *see* Yock TI
- Krailo MD, *see* Fouladi M
see Malogolowkin MH
see Villablanca JG
- Kramer A, *see* McCulloch MF
- Kramer H, *see* Herder GJM
see Thuerigen O
- Kramer K, *see* Kushner BH
- Krasin MJ, *see* Metzger ML
- Kratzik C, *see* Oliver T
- Kraus DH, *see* Pfister DG
- Krause A, *see* Ellis MJ
- Krause FS, *see* Weiss C
- Kraybill WG, *see* Cornett WR
- Kraybill WG, Harris J, Spiro IJ, Ettinger DS, DeLaney TF, Blum RH, Lucas DR, Harmon DC, Letson GD, Eisenberg B. Phase II Study of Neoadjuvant Chemotherapy and Radiation Therapy in the Management of High-Risk, High-Grade, Soft Tissue Sarcomas of the Extremities and Body Wall: Radiation Therapy Oncology Group Trial 9514, 619
- Krco CJ, *see* Knutson KL
- Kreling B, *see* Mandelblatt J
- Kremens B, *see* Schrauder A
- Kresl JJ, *see* Suh JH
- Kretschmer L, Hilgers R. Research Supports the View that Sentinel Node Biopsy Is the Standard of Care in High-Risk Primary Melanoma (correspondence), 2965
- Kreuz F, *see* Gadzicki D
- Krieg AM, *see* Pashenkov M
- Kriner M, *see* Thussbas C
- Kris MG, *see* Herbst RS
see Koeller JM
see Milton DT
see Pham D
- Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006, 2932
- Krishnamurthi K, *see* Tanner B
- Krishnamurthi U, *see* Raab SS
- Krishnan A, *see* Fisher RI
- Kristal AR, *see* Lin DW
- Kröber A, Bloehdorn J, Hafner S, Bühler A, Seiler T, Kienle D, Winkler D, Bangert M, Schlenk RF, Benner A, Lichter P, Döhner H, Stilgenbauer S. Additional Genetic High-Risk Features Such As 11q Deletion, 17p Deletion, and V3-21 Usage Characterize Discordance of ZAP-70 and VH Mutation Status in Chronic Lymphocytic Leukemia, 969
- Kröber A, Döhner H, Stilgenbauer S. In Reply (correspondence), 3219
- Kroenke CH, *see* Nekhlyudov L
- Kroenke CH, Kubzansky LD, Schernhammer ES, Holmes MD, Kawachi I. Social Networks, Social Support, and Survival After Breast Cancer Diagnosis, 1105
- Kroetz DL. Role for Drug Transporters Beyond Tumor Resistance: Hepatic Functional Imaging and Genotyping of Multidrug Resistance Transporters for the Prediction of Irinotecan Toxicity (editorial), 4225
- Kröger N, Frick M, Gluz O, Mohrmann S, Metzner B, Jackisch C, Ko Y, Lindemann H-W, Meier CR, Lohrmann HP, Ruffert U, Hänel M, Bodenstern H, Neubauer A, Ehninger G, Wolf H-H, Kolbe K, Burock K, Zander AR, Nitz U. Randomized Trial of Single Compared With Tandem High-Dose Chemotherapy Followed by Autologous Stem-Cell Transplantation in Patients With Chemotherapy-Sensitive Metastatic Breast Cancer, 3919
- Krohn KA, *see* Linden HM
- Krol ADG, *see* Noordijk EM
- Kros JM, *see* van den Bent MJ
- Krown SE, *see* Dezube BJ
- Krueger G, Canellos G. Where Does Hematology End and Oncology Begin? Questions of Professional Boundaries and Medical Authority, 2583
- Krueger GM, Alexander LL, Whippen DA, Balch CM. Arnoldus Goudsmit, MD, PhD: Chemotherapist, Visionary, Founder of the American Society of Clinical Oncology, 1909-2005, 4033
- Krüger S, *see* Goecke T
- Kruit WHJ, *see* Lamers CHJ
- Krupnick JL, *see* Mandelblatt JS
- Krzakowski M, *see* Ramlau R
- Kubo H, *see* Yasuda H
- Kubota K, *see* Niho S
- Kubzansky LD, *see* Kroenke CH
- Kuczkowski E, *see* Kalaycio M
- Kuderer NM, *see* Khorana AA
- Kudoh S, *see* Saito H
- Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, Shinkai T, Sawa T, Goto I, Semba H, Seto T, Ando M, Satoh T, Yoshimura N, Negoro S, Fukuoka M. Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904), 3657
- Kuendgen A, Strupp C, Aivado M, Hildebrandt B, Haas R, Gattermann N, Germing U. Myelodysplastic Syndromes in Patients Younger Than Age 50, 5358
- Kuonen-Boumeester V, *see* Vermeer-Mens JCJ
- Kuentz M, *see* Yakoub-Agha I
- Kugler aJW, *see* Loprinzi CL
- Kugler JW, *see* Smalley SR
- Kühl J, *see* Timmermann B
- Kuhn J, *see* Cloughesy TF
see Monk JP
- Kuhn W, *see* du Bois A
see Pfisterer J
- Kulke MH, *see* Meyerhardt JA

AUTHOR INDEX

- Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS. Phase II Study of Recombinant Human Endostatin in Patients With Advanced Neuroendocrine Tumors, 3555
- Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS. Phase II Study of Temozolomide and Thadimidomide in Patients With Metastatic Neuroendocrine Tumors, 401
- Kulle B, *see* Liersch T
- Kumar AS, *see* Esserman LJ
- Kumar AS, Campbell M, Benz CC, Esserman LJ. A Call for Clinical Trials: Lipophilic Statins May Prove Effective in Treatment and Prevention of Particular Breast Cancer Subtypes (correspondence), 2127
- Kumar P, *see* Nemunaitis J
- Kunikane H, *see* Onoda S
- Kunitoh H, *see* Takano T
- Kunstmann E, *see* Goecke T
- Kuntz KM, *see* Guadagnolo BA
- Kuo J, *see* Vickers AJ
- Kuo T-t, *see* Tsai K-Y
- Kuo Y-F, *see* Giordano SH
- Kupelian PA, Reddy CA, Reuther AM, Mahadevan A, Ciezki JP, Klein EA. Aggressiveness of Familial Prostate Cancer, 3445
- Kurek R, *see* Ferrari AC
- Kuriyama T, *see* Onoda S
- Kuroiwa Y, *see* Onoda S
- Kurtaran A, *see* Wachter S
- Kurtin PJ, *see* Knox SK
- Kurtzberg J, *see* Eapen M
- Kurzrock R, *see* Braiteh F
- Kushi LH, *see* Clarke CA
- Kushner BH, *see* Cheung N-KV
- Kushner BH, Kramer K, Modak S, Cheung N-KV. Irinotecan Plus Temozolomide for Relapsed or Refractory Neuroblastoma, 5271
- Kusmartseva I, *see* Bepler G
- Kwan L, *see* Ganz PA
see Mandelblatt JS
- Kwan W-h, *see* Leung S-f
- Kwon H-C, *see* Lee J
- Kwong DLW, *see* Khong P-L
- Kyle RA, *see* Barlogie B
- Kytö JP, Kivelä T. Case 4. A Black Eye: Melanoma In Situ of the Conjunctiva, 1013
- L**
- Laberge F, *see* Bezjak A
- Labianca R, *see* Gelibter AJ
- Labopin M, *see* Gorin N-C
see Lapillonne H
- Labuhn M, *see* Urban P
- Lacaine F, *see* Barrier A
- Lacave AJ, *see* Pfisterer J
- Lacombe D, *see* Mirimanoff R-O
see van den Bent MJ
- Lacy AM, *see* Rodríguez-Moranta F
- Ladanyi M, *see* Argani P
see Pham D
- Ladenstein R, *see* Kerbl R
- Laé M, *see* Argani P
- Lafaro KJ, *see* Offit K
- LaFond D, *see* Packer RJ
- Lafrenie RM, *see* Bewick MA
- Lafreniere D, *see* Bernstein ML
- Lagae L, *see* Van Calsteren K
- Lagarde SM, ten Kate FJW, Reitsma JB, Busch ORC, van Lanschot JJB. Prognostic Factors in Adenocarcinoma of the Esophagus or Gastroesophageal Junction, 4347
- Lager JJ, Lyden ER, Anderson JR, Pappo AS, Meyer WH, Breitfeld PP. Pooled Analysis of Phase II Window Studies in Children With Contemporary High-Risk Metastatic Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group, 3415
- Lagios MD, Page DL, Silverstein MJ. Prospective Study of Wide Excision Alone for Ductal Carcinoma In Situ of the Breast (correspondence), 3809
- Lagman RL, *see* Kirkova J
- Lago S, *see* Bezjak A
- Lahn M, *see* Paz-Ares L
- Lai C-H, *see* Chou H-H
- Lai J-L, *see* Lapillonne H
- Lai M, *see* Leung S-f
- Lai R, Chu R, Fraumeni M, Thabane L. Quality of Randomized Controlled Trials Reporting in the Primary Treatment of Brain Tumors, 1136
- Lai SY, Grandis JR. Understanding the Presence and Function of Erythropoietin Receptors on Cancer Cells (editorial), 4675
- Lake S, *see* Pfister DG
- Lalami Y, *see* Klastersky J
- Laloo F, *see* Evans DGR
see Evans GD
- Lally BE, Zelterman D, Colasanto J, Haffty BG, Detterbeck FC, Wilson LD. In Reply (correspondence), 5612
- Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative Radiotherapy for Stage II or III Non-Small-Cell Lung Cancer Using the Surveillance, Epidemiology, and End Results Database, 2998
- Lam JS, Breda A, Belldgrun AS, Figlin RA. Evolving Principles of Surgical Management and Prognostic Factors for Outcome in Renal Cell Carcinoma, 5565
- Lamanna N, Kalaycio M, Maslak P, Jurcic JG, Heaney M, Brentjens R, Zelenetz AD, Horgan D, Gencarelli A, Panageas KS, Scheinberg DA, Weiss MA. Pentostatin, Cyclophosphamide, and Rituximab Is an Active, Well-Tolerated Regimen for Patients With Previously Treated Chronic Lymphocytic Leukemia, 1575
- Lamantia G, *see* Cardinale D
- Lambert J, *see* Verheijen RH
- Lambin P, *see* De Ruyscher D
- Lamborn KR, *see* Cloughesy TF
- Lamers CHJ, Sleijfer S, Vulto AG, Kruit WHJ, Kliffen M, Debets R, Gratama JW, Stoter G, Oosterwijk E. Treatment of Metastatic Renal Cell Carcinoma With Autologous T-Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX: First Clinical Experience (correspondence), e20
- Lammering G, *see* De Ruyscher D
- Lampson B, *see* Byrd JC
- Lamy T, *see* Adès L
- Lancar R, *see* Boué F
- Land SR, *see* Moschos SJ
- Landen CN Jr, *see* Han LY
- Landman-Parker J, *see* Lapillonne H
- Landrum MB, *see* Keating NL
- Lang FF, *see* Gilbert MR
see Lawrence TS
- Lang FF, Gilbert MR. Diffusely Infiltrative Low-Grade Gliomas in Adults, 1236
- Lang S, *see* Kager L
- Lange T, *see* Hegenbart U
- Langebrake C, Creutzig U, Dworzak M, Hrusak O, Mejstrikova E, Griesinger F, Zimmermann M, Reinhardt D. Residual Disease Monitoring in Childhood Acute Myeloid Leukemia by Multiparameter Flow Cytometry: The MRD-AML-BFM Study Group, 3686
- Langer C, *see* Hanna N
see Liersch T
see Weiss GJ
- Langston J, *see* Packer RJ
- Lanier KS, *see* Barlogie B
- Laningham F, *see* Donaldson SS

AUTHOR INDEX

- Lanza G, Gafà R, Santini A, Maestri I, Guerzoni L, Cavazzini L. Immunohistochemical Test for MLH1 and MSH2 Expression Predicts Clinical Outcome in Stage II and III Colorectal Cancer Patients, 2359
- Laperriere N, *see* Cairncross G
- Lapeyre M, *see* Bourhis J
- Lapillonne H, Renneville A, Auvrignon A, Flamant C, Blaise A, Perot C, Lai J-L, Ballerini P, Mazingue F, Fasola S, Dehé A, Bellman F, Adam M, Labopin M, Douay L, Leverger G, Preudhomme C, Landman-Parker J. High WT1 Expression After Induction Therapy Predicts High Risk of Relapse and Death in Pediatric Acute Myeloid Leukemia, 1507
- Lara PN, *see* Berry DL
- Lardinois D. New Horizons in Staging for Non–Small-Cell Lung Cancer (editorial), 1785
- Larouche V, Capra M, Huang A, Bartels U, Bouffet E. Supratentorial Primitive Neuroectodermal Tumors in Young Children (correspondence), 5609
- Larsen J, *see* Schmidt H
- Larson RA, *see* Byrd JC
see Paschka P
see Silverman LR
- Lash TL, *see* Enger SM
- Laskar S, *see* Bahl G
see Palled S
- Lassau N, *see* Faivre S
- Lathan C, *see* Blackstock AW
- Lathan CS, Neville BA, Earle CC. The Effect of Race on Invasive Staging and Surgery in Non–Small-Cell Lung Cancer, 413
- Lathia C, *see* Abou-Alfa GK
- Latronico A, *see* Guerrieri-Gonzaga A
- Latz JE, *see* Mita AC
- Lau CC, *see* Thompson MC
- Lau DHM, *see* Davies AM
see West HL
- Lauer S, *see* Marina N
- Lauer SJ, *see* Barredo JC
- Laufman L, *see* Jones LA
- Laumer M, *see* Mackensen A
- Laurence C, *see* Studer UE
- Laurie F, *see* Yock TI
- Laurie SA, *see* Pfister DG
- Laurie SA, Licitra L. Systemic Therapy in the Palliative Management of Advanced Salivary Gland Cancers, 2673
- Laurin C, *see* Gagnon B
- Lausi P, *see* Papotti M
- Läuter J, *see* Tanner B
- Lauwers GY, *see* Vauthey J-N
- Lavasseur BI, *see* Pockaj BA
- Lavertu P, *see* Adelstein DJ
- Lavori PW, *see* Petrik D
- Law A, *see* Steensma DP
- Lawrence D, *see* Chanan-Khan A
- Lawrence T, *see* Normolle D
- Lawrence TS, *see* Ray ME
- Lawrence TS, Buckner JC, Lang FF. CNS Malignancies: At Last, Real Progress, 1225
- Lawrence WF, *see* Mandelblatt JS
- Lawrence Wickerham D, *see* Paik S
- Lazarus HM, *see* Barlogie B
- Lazorthes F, *see* Portier G
- Le CV, *see* Flood KL
- Le Q-T, *see* Petrik D
- Le T, *see* Pfisterer J
- Leahy MF, Seymour JF, Hicks RJ, Turner JH. Multicenter Phase II Clinical Study of Iodine-131–Rituximab Radioimmunotherapy in Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma, 4418
- Leaman DW, *see* Reu FJ
- Lebeau A, *see* Kaufmann M
- Lebesque JV, *see* Peeters STH
- LeBlanc M, *see* Adelstein DJ
see Press OW
- Leclerc J-M, *see* Barrette S
- Lederlin P, *see* Besson C
- Leduc B, *see* Gérard J-P
- Lee AM, Clear AJ, Calaminici M, Davies AJ, Jordan S, MacDougall F, Matthews J, Norton AJ, G. Gribben J, Lister TA, Goff LK. Number of CD4⁺ Cells and Location of Forkhead Box Protein P3–Positive Cells in Diagnostic Follicular Lymphoma Tissue Microarrays Correlates With Outcome, 5052
- Lee AV, Weiss H, Cui X, Osborne CK, Arpino G, Schiff R. In Reply (correspondence), 2595
- Lee AYY, Levine MN, Butler G, Webb C, Costantini L, Gu C, Julian JA. Incidence, Risk Factors, and Outcomes of Catheter-Related Thrombosis in Adult Patients With Cancer, 1404
- Lee CP, Patel PM, Selby PJ, Hancock BW, Mak I, Pyle L, James MG, Beirne DA, Steeds S, A’Hern R, Gore ME, Eisen T. Randomized Phase II Study Comparing Thalidomide With Medroxyprogesterone Acetate in Patients With Metastatic Renal Cell Carcinoma, 898
- Lee CR, *see* Shaked Y
- Lee D, *see* Sparano JA
- Lee F, *see* Chuah C
- Lee F-C, *see* Ajani JA
- Lee H-J, *see* Ryu J-S
- Lee J, *see* Urba S
- Lee J, Suh C, Hee Park Y, Ko YH, Mee Bang S, Hoon Lee J, Ho Lee D, Huh J, Yong Oh S, Kwon H-C, Jin Kim H, Il Lee S, Han Kim J, Park J, Joong Oh S, Kim K, Jung C, Park K, Kim WS. Extranodal Natural Killer T-Cell Lymphoma; Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study, 612
- Lee JE, *see* Aloia TA
see Cornett WR
see Crane CH
- Lee J-E, *see* Han J-Y
- Lee JH, *see* Izzo JG
see Luthra R
- Lee JJ, *see* Tsao AS
- Lee JJ, Bekele BN, Zhou X, Cantor SB, Komaki R, Lee JS. Decision Analysis for Prophylactic Cranial Irradiation for Patients With Small-Cell Lung Cancer, 3597
- Lee JJ, Low JA, Croarkin E, Parks R, Berman AW, Mannan N, Steinberg SM, Swain SM. Changes in Neurologic Function Tests May Predict Neurotoxicity Caused by Ixabepilone, 2084
- Lee JJ, Swain SM. Peripheral Neuropathy Induced by Microtubule-Stabilizing Agents, 1633
- Lee JS, *see* Han J-Y
see Lee JJ
- Lee JY, *see* Dezube BJ
- Lee L-Y, *see* Ng S-H
- Lee M-S, *see* Liu Q
- Lee P-H, *see* Hsu Y-C
- Lee S, Oktay K. In Reply (correspondence), 5337
- Lee SJ, *see* Oktay KH
- Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, Beck LN, Brennan LV, Oktay K. American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients, 2917
- Lee SM, *see* Ajzensztejn D
- Lee S-p, *see* Berenson JR
- Leek RD, *see* Bates GJ
- Leer J-W, *see* van Tol-Geerdink JJ
- Lefebvre J-L, *see* Pfister DG
- Leffers P, *see* Seute T
- Lefrere F, *see* Besson C
- Legrand C, *see* Bottomley A
see Francart J
- LeGrand SB, *see* Kirkova J

AUTHOR INDEX

- Legros L, *see* Vey N
 Lehrnbecher T, *see* Creutzig U
 Leibel S, *see* Abrey LE
 Leichman CG, *see* Smalley SR
 Leichman L. Neoadjuvant Chemotherapy for Disseminated Colorectal Cancer: Changing the Paradigm (editorial), 3817
 Leigh BR, *see* Davies AM
 Leisenring W, *see* Bowers DC
 Leisenring W, Friedman DL, Flowers MED, Schwartz JL, Deeg HJ. Nonmelanoma Skin and Mucosal Cancers After Hematopoietic Cell Transplantation, 1119
 Leitch AM, *see* Patterson AR
 Lejars O, *see* Oberlin O
 Lejeune M, *see* Álvaro T
 Lemanski C, *see* Bourhis J
 Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N. Oral Uracil and Tegafur Plus Leucovorin Compared With Intravenous Fluorouracil and Leucovorin in Stage II and III Carcinoma of the Colon: Results From National Surgical Adjuvant Breast and Bowel Project Protocol C-06, 2059
 Lemmens VEPP, *see* Steyerberg EW
 Lemoine A, *see* Barrier A
 Leng Tien S, *see* Chuah C
 Lengfelder E, *see* Büchner T
 Lenihan DJ, *see* Guarneri V
 Lenisa L, *see* Cascinelli N
 Lentz M-A, *see* Giacchetti S
 Lenz H-J, *see* Ajani JA
 see Kemeny NE
 Lenz H-J, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z, Mauro DJ, Rowinsky EK. Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines, 4914
 Leonard JP, *see* Fisher RI
 see Redfern CH
 Leondaridis L, *see* Chen S
 Leong SPL, *see* Rangel J
 Leong S-S, *see* Toh C-K
 Lepage E, *see* Besson C
 Lerner S, *see* Tsimberidou A-M
 Lerut T, *see* De Leyn P
 Lesaunier F, *see* Bourhis J
 Lessig R, *see* Tanner B
 Lester EP, *see* Lichtman SM
 Lester SC, *see* Wong JS
 see Wong JS
 Letourneau R, *see* Abou-Alfa GK
 Letsch A, *see* Ghadjar P
 Letson GD, *see* Kraybill WG
 Lette J. A Simple and Innovative Device to Measure Arm Volume at Home for Patients With Lymphedema After Breast Cancer, 5434
 Leung J, *see* Esserman LJ
 Leung LHT, *see* Khong P-L
 Leung S-f, Zee B, Ma BB, Hui EP, Mo F, Lai M, Chan KCA, Chan LYS, Kwan W-h, Lo YMD, Chan ATC. Plasma Epstein-Barr Viral Deoxyribonucleic Acid Quantitation Complements Tumor-Node-Metastasis Staging Prognostication in Nasopharyngeal Carcinoma, 5414
 Leupold N, *see* Pfister DG
 Leuschner I, *see* Wachtel M
 Leverger G, *see* Lapillonne H
 Lévi F, *see* Aloia T
 see Giacchetti S
 Levin AM, *see* Pierce LJ
 Levin B, *see* Herbst RS
 Levine AM, Tulpule A, Quinn DI, Gorospe G III, Smith DL, Hornor L, Boswell WD, Espina BM, Groshen SG, Masood R, Gill PS. Phase I Study of Antisense Oligonucleotide Against Vascular Endothelial Growth Factor: Decrease in Plasma Vascular Endothelial Growth Factor With Potential Clinical Efficacy, 1712
 Levine DA, *see* Black D
 Levine MN, *see* Grunfeld E
 see Lee AYY
 see Wright JR
 Levitt R, *see* Loprinzi CL
 Levnor A, *see* Shah MA
 Levy RL, *see* Redfern CH
 Levy S, *see* Chung CH
 Lewin J, *see* Tsao AS
 Lewin JS, *see* Rosenthal DI
 Lewis AM, *see* Scoggins CR
 Lewis DA, Tann M, Kesler K, McCool A, Foster RS, Einhorn LH. Positron Emission Tomography Scans in Postchemotherapy Seminoma Patients With Residual Masses: A Retrospective Review From Indiana University Hospital (correspondence), e54
 Lewis KD, Robinson WA, McCarter M, Pearlman N, O'Day SJ, Anderson C, Amatruda TT, Baron A, Zeng C, Becker M, Dollarhide S, Matijevich K, Gonzalez R. Phase II Multicenter Study of Neoadjuvant Biochemotherapy for Patients With Stage III Malignant Melanoma, 3157
 Leyland-Jones B, *see* Robert N
 Li Y, *see* Wong SJ
 Li C, *see* Kiehna EN
 Li C-S, *see* Metzger ML
 Li D, Frazier M, Evans DB, Hess KR, Crane CH, Jiao L, Abbruzzese JL. Single Nucleotide Polymorphisms of *RecQ1*, *RAD54L*, and *ATM* Genes Are Associated With Reduced Survival of Pancreatic Cancer, 1720
 Li H-L, *see* Cai Q
 Li J, *see* Khuntia D
 Li JZ, *see* Motzer RJ
 Li S, *see* George RE
 see Wachter S
 Li T, *see* Sparano JA
 Li Y, Elashoff D, Oh M, Sinha U, St John MAR, Zhou X, Abemayor E, Wong DT. Serum Circulating Human mRNA Profiling and Its Utility for Oral Cancer Detection, 1754
 Li Y-X, Yao B, Jin J. In Reply (correspondence), 2685
 Li Y-X, Yao B, Jin J, Wang W-H, Liu Y-P, Song Y-W, Wang S-L, Liu X-F, Zhou L-Q, He X-H, Lu N, Yu Z-H. Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell Lymphoma, 181
 Lianidou ES, *see* Xenidis N
 Liao C-T, *see* Liu F-Y
 see Ng S-H
 Liao J, *see* Harris EER
 Liao Z, *see* Izzo JG
 see Shelley Wang X
 see Wu X
 Liauw SL, Mancuso AA, Amdur RJ, Morris CG, Villaret DB, Werning JW, Mendenhall WM. Postradiotherapy Neck Dissection for Lymph Node-Positive Head and Neck Cancer: The Use of Computed Tomography to Manage the Neck, 1421
 Libbrecht L, *see* Sagaert X
 Lichter P, *see* Kröber A
 see Rücker FG
 see Thuerigen O
 Lichtman SM, Hollis D, Miller AA, Rosner GL, Rhoades CA, Lester EP, Millard F, Byrd J, Cullinan SA, Rosen DM, Parise RA, Ratain MJ, Egorin MJ. Prospective Evaluation of the Relationship of Patient Age and Paclitaxel Clinical Pharmacology: Cancer and Leukemia Group B (CALGB 9762), 1846
 Licitra L, *see* Laurie SA
 Licitra L, Perrone F, Bossi P, Suardi S, Mariani L, Artusi R, Oggionni M, Rossini C, Cantù G, Squadrelli M, Quattrone P, Locati LD, Bergamini C, Olmi P,

AUTHOR INDEX

- Pierotti MA, Pilotti S. High-Risk Human Papillomavirus Affects Prognosis in Patients With Surgically Treated Oropharyngeal Squamous Cell Carcinoma, 5630
- Lieb W, *see* McCulloch MF
see McCulloch M
- Lieberman F, *see* Cloughesy TF
- Liebman HA, *see* O'Connell CL
- Liersch R, *see* Koch P
- Liersch T, Becker H, Goldenberg DM. In Reply (correspondence), 2680
- Liersch T, Langer C, Ghadimi BM, Kulle B, Aust DE, Baretton GB, Schwabe W, Häusler P, Becker H, Jakob C. Lymph Node Status and *TS* Gene Expression Are Prognostic Markers in Stage II/III Rectal Cancer After Neoadjuvant Fluorouracil-Based Chemoradiotherapy, 4062
- Lieskovsky G, *see* Pagliarulo V
- Liewehr DJ, *see* Bonthala Wedam S
- Lilenbaum R, *see* Hanna N
- Lilenbaum R, Socinski MA, Altorki NK, Hart LL, Keresztes RS, Hariharan S, Morrison ME, Fayyad R, Bonomi P. Randomized Phase II Trial of Docetaxel/Irinotecan and Gemcitabine/Irinotecan With or Without Celecoxib in the Second-Line Treatment of Non-Small-Cell Lung Cancer, 4825
- Lilja H, *see* Stephenson AJ
- Lim H-S, *see* Han J-Y
- Lim MK, *see* Min Park S
- Lim W-T, *see* Toh C-K
- Limentani S, *see* Richardson PG
- Limentani SA, *see* Fanucchi MP
- Lin C-T, *see* Chou H-H
- Lin DW, Coleman IM, Hawley S, Dumpit R, Gifford D, Kezele P, Hung H, Knudsen BS, Kristal AR, Nelson PS. Influence of Surgical Manipulation on Prostate Gene Expression: Implications for Molecular Correlates of Treatment Effects and Disease Prognosis, 3763
- Lin J-T, *see* Cheng T-Y
- Lin M-T, *see* Cheng T-Y
- Linch DC, *see* Mudie NY
- Lindeman N, *see* Jackman DM
- Lindemann H-W, *see* Kröger N
- Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, Petra PH, Peterson LM, Schubert EK, Dunnwald LK, Krohn KA, Mankoff DA. Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment in Breast Cancer, 2793
- Lindner D, *see* Reu FJ
- Lingle WL, *see* Goetz MP
see Perez EA
- Link CL, *see* Avis NE
- Link JM, *see* Linden HM
- Link MP, *see* Bernstein ML
- Lipka DB, *see* Rücker FG
- Lippman SM, *see* Ganz PA
- Lis E, *see* Pfister DG
- List AF, *see* Schiller GJ
- List MA, *see* Cohen EEW
see Pfister DG
- Lister TA, *see* Davies JK
see Lee AM
see Strauss SJ
- Litchy S, *see* Hainsworth JD
- Litt HI, *see* Harris EER
- Littlewood T, *see* Gorin N-C
- Liu A, *see* Mamelak AN
- Liu C-G, *see* Roldo C
- Liu F-Y, Chang JT, Wang H-M, Liao C-T, Kang C-J, Ng S-K, Chan S-C, Yen T-C. [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography Is More Sensitive Than Skeletal Scintigraphy for Detecting Bone Metastasis in Endemic Nasopharyngeal Carcinoma at Initial Staging, 599
- Liu I-LA, *see* Geiger AM
- Liu J, *see* Wu X
- Liu L, *see* Nemunaitis J
- Liu M-C, *see* Cheng SH
- Liu PY, *see* Markman M
- Liu Q, Fayad L, Cabanillas F, Hagemester FB, Ayers GD, Hess M, Romaguera J, Rodriguez MA, Tsimberidou AM, Verstovsek S, Younes A, Pro B, Lee M-S, Ayala A, McLaughlin P. Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 Years of Treatment Experience at The University of Texas M.D. Anderson Cancer Center, 1582
- Liu S, *see* Perez EA
- Liu X-F, *see* Li Y-X
- Liu Y, *see* Bowers DC
- Liu Y-P, *see* Li Y-X
- Livak KJ, *see* Ferrari AC
- Livingston RB, *see* Linden HM
see Unger JM
- Lledo G, *see* Tournigand C
- Lloreta J, *see* Hernández S
- Lloyd RE, *see* Glaspy J
- Lo Muzio L, *see* Mignogna MD
- Lo Re G, *see* Giacchetti S
- Lo Russo L, *see* Mignogna MD
- Lo YMD, *see* Leung S-f
- Locati LD, *see* Licitra L
- Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr. ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer, 5313
- Lockwood RA, *see* Recklitis CJ
- Loeffler JS, *see* Batchelor T
- Loeffler M, *see* Goecke T
- Loesch D, *see* Robert N
- Loeser S, *see* Herrlinger U
- Loew TH, *see* Schäfer C
- Loffredo B, *see* D'Amico AV
- Loffredo M, *see* D'Amico AV
- Lohrlich C, Paltiel C, Gelmon K, Speers C, Taylor S, Barnett J, Olivetto IA. Impact on Survival of Time From Definitive Surgery to Initiation of Adjuvant Chemotherapy for Early-Stage Breast Cancer, 4888
- Lohrmann HP, *see* Kröger N
- Loi S, Sotiriou C, Buysse M, Rutgers E, Veer LV, Piccart M, Cardoso F. Molecular Forecasting of Breast Cancer: Time to Move Forward With Clinical Testing (correspondence), 721
- Loibl S, *see* Kaufmann M
- Loidl W, *see* Studer UE
- Lonardi S, *see* Gelibter AJ
- London WB, *see* Haber M
see Malogolowkin MH
see Marina N
- Lonial S, *see* Fisher RI
- Lønning PE, *see* Smith IE
- Loos WJ, de Jongh FE, Sparreboom A, de Wit R, van Boven-van Zomeren DM, Stoter G, Nooter K, Verweij J. Evaluation of an Alternate Dosing Strategy for Cisplatin in Patients With Extreme Body Surface Area Values, 1499
- Lopes A, *see* Verheijen RH
- Lopez A, *see* Han LY
- Lopez C, *see* Álvaro T
- López JM, *see* Quintela-Fandino M
- Lopez M, *see* Ferretti G
see Papaldo P
- Lopez-Alvarez E, *see* Luthra R
- Lopez-Pousa A, *see* Bourhis J
- Loprinzi CL, *see* Bardia A
see Pockaj BA
see Steensma DP
- Loprinzi CL, Barton DL, Sloan JA. Whose Opinion Counts? (editorial), 5183
- Loprinzi CL, Levitt R, Barton D, Sloan JA, Dakhil SR, Nikcevich DA, Bearden

- JD III, Mailliard JA, Tschetter LK, Fitch TR, Kugler JW. Phase III Comparison of Depomedroxyprogesterone Acetate to Venlafaxine for Managing Hot Flashes: North Central Cancer Treatment Group Trial N99C7, 1409
- Loquai C, *see* Pashenkov M
- Lorca FP, *see* Houvenaeghel G
- Lord EM, *see* Coughlin CM
- Lordick F, *see* Ott K
- Lorenz KA, Lynn J, Dy S, Wilkinson A, Mularski RA, Shugarman LR, Hughes R, Asch SM, Rolon C, Rastegar A, Shekelle PG. Quality Measures for Symptoms and Advance Care Planning in Cancer: A Systematic Review, 4933
- Lorenz RR, *see* Adelstein DJ
- Lorusso V, *see* Gennari A
- Lossos IS, Morgensztern D. Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma, 995
- Loud JT, Weissman NE, Peters JA, Giusti RM, Wilfond BS, Burke W, Greene MH. Deliberate Deceit of Family Members: A Challenge to Providers of Clinical Genetics Services, 1643
- Loupakis F, *see* Gelibter AJ
- Louvet C, *see* Tournigand C
- Lovato J, *see* Shaw EG
- Low JA, *see* Bonthala Wedam S
see Lee JJ
- Low PS, *see* Knutson KL
- Low WK, Toh ST, Wee J, Fook-Chong SMC, Wang DY. Sensorineural Hearing Loss After Radiotherapy and Chemoradiotherapy: A Single, Blinded, Randomized Study, 1904
- Lowe CJ, *see* Kang TY
- Lowy I, *see* Beck KE
- Lozahic S, *see* Faivre S
- Lozano J, *see* Sanchez-Carbayo M
- Lozanski G, *see* Byrd JC
- Lu J, *see* Stiff PJ
- Lu JI, Carhart RL, Graziano SL, Gajra A. Acute Coronary Syndrome Secondary to Fluorouracil Infusion, 2959
- Lu N, *see* Li Y-X
- Lualdi E, *see* Modena P
- Luatti S, *see* Soverini S
- Lub-De Hooge MN, *see* Perik PJ
- Luboiniski M, *see* Bourhis J
- Luc Canon J, *see* Giacchetti S
- Lucas DM, *see* Byrd JC
- Lucas DR, *see* Kraybill WG
- Luchtman-Jones L, *see* Jeha S
- Lück H-J, *see* Pfisterer J
- Ludwig H, Mok TSK, Trahan Rieger P. In Reply (correspondence), 5614
- Ludwig KA, *see* Czito BG
- Ludwig W-D, *see* Büchner T
see Burkhardt B
see Schrauder A
- Lueck H-J, *see* du Bois A
- Luftner D, *see* Strasser F
- Luigi Zinzani P, Quagliano P, Pimpinelli N, Berti E, Baliva G, Rupoli S, Martelli M, Alaibac M, Borroni G, Chimenti S, Alterini R, Alinari L, Teresa Fierro M, Cappello N, Pileri A, Soligo D, Paulli M, Pileri S, Santucci M, Bernengo MG. In Reply (correspondence), 4041
- Lund KA, *see* Meropol NJ
- Luo Z, *see* Bouknight RR
- Lupu R, *see* Menendez JA
- Lusinchi A, *see* Bourhis J
- Lutgens L, *see* De Ruyscher D
- Luthra MG, *see* Luthra R
- Luthra R, *see* Izzo JG
- Luthra R, Wu T-T, Luthra MG, Izzo J, Lopez-Alvarez E, Zhang L, Bailey J, Lee JH, Bresalier R, Rashid A, Swisher SG, Ajani JA. Gene Expression Profiling of Localized Esophageal Carcinomas: Association With Pathologic Response to Preoperative Chemoradiation, 259
- Lutman RF, *see* Ceresoli GL
- Lyckholm LJ, *see* Shanafelt T
- Lyden ER, *see* Lager JJ
- Lyman GH, *see* Khorana AA
see Smith TJ
- Lyman GH. Withholding Antibiotics From Patients With Febrile Neutropenia (correspondence), 1221
- Lynch J, *see* Iqbal J
- Lynch T, *see* Hanna N
- Lynch TJ, *see* Kulke MH
- Lynn J, *see* Lorenz KA
- Lyons B, *see* Gordon MS

M

- Ma BB, *see* Leung S-f
- Ma J, *see* Tabori U
- Ma S-Y, *see* Chou H-H
- Ma X-J, Hilsenbeck SG, Wang W, Ding L, Sgroi DC, Bender RA, Osborne CK, Allred DC, Erlander MG. The *HOXB13:IL17BR* Expression Index Is a Prognostic Factor in Early-Stage Breast Cancer, 4611
- Maas R, *see* Kager L
- Mabuchi N, *see* Ohmiya N
- Macdonald JS, *see* Locker GY
see Smalley SR
see Unger JM
- MacDougall F, *see* Lee AM
- Macedo CRD, *see* Petrilli AS
- MacGregor-Cortelli B, *see* O'Connor OA
- Machens A, Dralle H. Pretargeted Anti-Carcinoembryonic-Antigen Radioimmunotherapy for Medullary Thyroid Carcinoma (correspondence), e37
- Machiels J-P, Aydin S, Bonny M-A, Hammouch F, Sempoux C. What Is the Best Way to Predict Disease-Free Survival After Preoperative Radiochemotherapy for Rectal Cancer Patients: Tumor Regression Grading, Nodal Status, or Circumferential Resection Margin Invasion? (correspondence), 1319
- Machtay M, *see* Wong SJ
- Macis D, *see* Bonanni B
- Mack JW, Wolfe J, Grier HE, Cleary PD, Weeks JC. Communication About Prognosis Between Parents and Physicians of Children With Cancer: Parent Preferences and the Impact of Prognostic Information, 5265
- Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R. Phase I Study of Adoptive T-Cell Therapy Using Antigen-Specific CD8⁺ T Cells for the Treatment of Patients With Metastatic Melanoma, 5060
- Mackey JR, *see* Gabos Z
- Mackiewicz R, *see* Gérard J-P
- Macklis RM, *see* Dome JS
- MacLennan K, *see* Hagenbeek A
- MacLeod AR, *see* Reu FJ
- Macrae FA, *see* Southey MC
- MacVicar G, *see* Hussain M
- Madalinska JB, van Beurden M, Bleiker EMA, Valdinarsdottir HB, Hollenstein J, Massuger LF, Gaarenstroom KN, Mourits MJE, Verheijen RHM, van Dorst EBL, van der Putten H, van der Velden K, Boonstra H, Aaronson NK. The Impact of Hormone Replacement Therapy on Menopausal Symptoms in Younger High-Risk Women After Prophylactic Salpingo-Oophorectomy, 3576
- Madhumathi DS, *see* Premalata C
- Madigan E, *see* Koroukian SM
- Maeba H, *see* Saikawa Y
- Maemondo M, *see* Inoue A
- Maestri I, *see* Lanza G
- Mafee MF, *see* Choi YM
- Maggioretto F, *see* Ponzone R
- Magnani M, *see* Ruzzo A
- Mahadevan A, *see* Kupelian PA

AUTHOR INDEX

- Mahamat A, *see* Grabar S
- Maharaj L, *see* Strauss SJ
- Maher EJ, *see* Grunfeld EA
- Maher T, *see* Smalley SR
- Mahoney MR, *see* Philip PA
- Maier T, *see* Dummer R
- Mailliard JA, *see* Loprinzi CL
- Maisonneuve P, *see* Bonanni B
- Maitland ML, DiRienzo A, Ratain MJ. Interpreting Disparate Responses to Cancer Therapy: The Role of Human Population Genetics, 2151
- Majlis A, *see* Van Cutsem E
- Mak I, *see* Lee CP
- Mak T, *see* Evans GD
- Makris A, *see* Kaufmann M
- Malafa M, *see* Sparano JA
- Malats N, *see* Hernández S
- Malhotra U, *see* Izzo JG
- Mali W, *see* Barentsz J
- Malin JL, Schneider EC, Epstein AM, Adams J, Emanuel EJ, Kahn KL. Results of the National Initiative for Cancer Care Quality: How Can We Improve the Quality of Cancer Care in the United States? 626
- Malka D, *see* Pocard M
- Malkin D, *see* Tabori U
- Malmström P, *see* Tanner M
- Malogolowkin M, *see* Dome JS
- Malogolowkin MH, *see* Marina N
- Malogolowkin MH, Katzenstein H, Krailo MD, Chen Z, Bowman L, Reynolds M, Finegold M, Greffe B, Rowland J, Newman K, Womer RB, London WB, Castleberry RP. Intensified Platinum Therapy Is an Ineffective Strategy for Improving Outcome in Pediatric Patients With Advanced Hepatoblastoma, 2879
- Maloisel F, *see* Adès L
- Malone KE, *see* Simon MS
- Maloney D, *see* Hegenbart U
- Maloney DG, *see* Baron F
see Press OW
- Malvey J, *see* Argenziano G
- Mamelak AN, Rosenfeld S, Bucholz R, Raubitschek A, Nabors LB, Fiveash JB, Shen S, Khazaeli MB, Colcher D, Liu A, Osman M, Guthrie B, Schade-Bijur S, Hablitz DM, Alvarez VL, Gonda MA. Phase I Single-Dose Study of Intracavitary-Administered Iodine-131-TM-601 in Adults With Recurrent High-Grade Glioma, 3644
- Mamounas EP, *see* Bear HD
see Taghian AG
see Wapnir IL
- Mancuso AA, *see* Liauw SL
- Mandahl N, *see* Mertens F
- Mandelblatt J, Kreling B, Figueiredo M, Feng S. What Is the Impact of Shared Decision Making on Treatment and Outcomes for Older Women With Breast Cancer? 4908
- Mandelblatt J. Treating Breast Cancer: The Age Old Dilemma of Old Age (editorial), 4369
- Mandelblatt JS, Lawrence WF, Cullen J, Stanton AL, Krupnick JL, Kwan L, Ganz PA. Patterns of Care in Early-Stage Breast Cancer Survivors in the First Year After Cessation of Active Treatment, 77
- Mandeli J, *see* Ferrari AC
- Manegold C, *see* Bottomley A
see Paz-Ares L
- Mangold E, *see* Goecke T
- Manivel C, *see* Argani P
- Mankin HJ. In Reply (correspondence), e2
- Mankoff DA, *see* Linden HM
see Martins RG
- Mann G, *see* Burkhardt B
- Mann GJ, *see* Wong M
- Mannan N, *see* Lee JJ
- Mannel RS, *see* Barakat RR
see Randall ME
- Manola J, *see* Smith MR
- Mansfield PF, *see* Aloia TA
see Cornett WR
- Manske MK, *see* Novak AJ
- Manso L, *see* Quintela-Fandino M
- Manson D, *see* Chow LML
- Mantyh CR, *see* Czito BG
- Manzione L, *see* Gennari A
- Mapes R, *see* Berenson JR
- Maples PB, *see* Nemunaitis J
- Mar Fan HG, Vardy J, Xu W, Tannock IF. In Reply (correspondence), 5171
- Marangolo M, *see* Ceresoli GL
- Marchbanks PA, *see* Simon MS
- Marcucci G, *see* Paschka P
- Marcus K, *see* George RE
- Marcus R, *see* Hagenbeek A
- Margolese R, *see* Bear HD
- Mari D, *see* Ruzzo A
- Maria Ettorre G, *see* Garufi C
- Maria Pasetto L, *see* Toffoli G
- Maria Ruggeri E, *see* Carlini P
see Papaldo P
- Mariani L, *see* Licitra L
- Mariani L, Deiana G, Vassella E, Fathi A-R, Murtin C, Arnold M, Vajtai I, Weis J, Siegenthaler P, Schobesberger M, Reinert MM. Loss of Heterozygosity 1p36 and 19q13 Is a Prognostic Factor for Overall Survival in Patients With Diffuse WHO Grade 2 Gliomas Treated Without Chemotherapy, 4758
- Mariappan MR, *see* Dormady SP
- Marina N, London WB, Frazier AL, Lauer S, Rescorla F, Cushing B, Malogolowkin MH, Castleberry RP, Womer RB, Olson T. Prognostic Factors in Children With Extragenital Malignant Germ Cell Tumors: A Pediatric Intergroup Study, 2544
- Marion MS, *see* Schover LR
- Maris JM, *see* Coughlin CM
see Matthay KK
- Maris MB, *see* Baron F
see Hegenbart U
- Mark LS, *see* O'Connell CL
- Markman M, *see* Herbst RS
- Markman M, Liu PY, Rothenberg ML, Monk BJ, Brady M, Alberts DS. Pretreatment CA-125 and Risk of Relapse in Advanced Ovarian Cancer, 1454
- Markman M, Walker JL. Intraperitoneal Chemotherapy of Ovarian Cancer: A Review, With a Focus on Practical Aspects of Treatment, 988
- Markman M. Normal CA-125 and the Risk of Progression in Ovarian Cancer (correspondence), 3310
- Markowska J, *see* Verheijen RH
- Marks P, *see* O'Connor OA
- Marks R, *see* Illerhaus G
- Marks RS, *see* Buckner JC
- Marolla P, *see* Ferretti G
see Papaldo P
- Marshall GM, *see* Haber M
- Marshall ME, *see* Lembersky BC
- Martelli M, *see* Zinzani PL
- Martens JWM, *see* Smid M
- Martensen J, *see* Rummans TA
- Martenson JA, *see* Smalley SR
- Martin A-L, *see* Roché H
- Martin JM, *see* Oldenburg J
- Martin L-A, *see* Chia S
- Martín R, *see* Ocaña A
- Martin RCG, *see* Scoggins CR

AUTHOR INDEX

- Martinelli G, *see* Cavo M
see Iacobucci I
see Soverini S
- Martínez C, *see* Fernández-Avilés F
- Martínez L, *see* Domínguez G
- Martínez-Iniesta M, *see* Dotor E
- Martino B, *see* Iacobucci I
- Martino S, *see* Perez EA
see Umetani N
see Unger JM
- Martins P, *see* Erlichman C
- Martins RG, Rajendran JG, Capell P, Byrd DR, Mankoff DA. Medullary Thyroid Cancer: Options for Systemic Therapy of Metastatic Disease? (editorial), 1653
- Martus P, *see* Baldus CD
- Maruta A, *see* Yanada M
- Marymont M, *see* Barredo JC
- Marymont MH, *see* Packer RJ
- Marzocchi G, *see* Soverini S
- Mascheroni L, *see* Cascinelli N
- Masetti M, *see* Di Benedetto F
- Masi CM, *see* Blackman DJ
- Maslak P, *see* Lamanna N
- Mason J, *see* Schiller GJ
- Mason M, *see* Oliver T
- Mason W, *see* Mirimanoff R-O
- Masood R, *see* Levine AM
- Mass RD, *see* Kabbinavar FF
- Massey A, *see* Chau I
- Massi D, *see* Argenziano G
- Massimini G, *see* Faivre S
- Massimino M, *see* Modena P
- Masson P, *see* McKiernan JM
- Massuger LF, *see* Madalinska JB
see van Trommel NE
see Verheijen RH
see Verheijen RH
- Masuda N, *see* Onoda S
- Matasar M, *see* Neugut AI
- Matei D, *see* Gordon MS
- Matijevich K, *see* Lewis KD
- Matsui K, *see* Kudoh S
see Saito H
- Matsuno Y, *see* Asamura H
see Tobinai K
- Matsuo K, *see* Asano N
see Yanada M
- Matsusako M, *see* Tobinai K
- Matsuyama R, Reddy S, Smith TJ. Why Do Patients Choose Chemotherapy Near the End of Life? A Review of the Perspective of Those Facing Death From Cancer, 3490
- Mattern D, *see* Henke M
- Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B, Twomey E, Horn B, Patrick Reynolds C, Groshen S, Seeger RC, Maris JM. Phase I Dose Escalation of Iodine-131-Metaiodobenzylguanidine With Myeloablative Chemotherapy and Autologous Stem-Cell Transplantation in Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium Study, 500
- Matthews J, *see* Lee AM
- Matthies A, *see* Reinhardt MJ
- Matulonis UA, *see* Gordon MS
- Mauch C, *see* Pashenkov M
- Mauch PM, *see* Guadagnolo BA
- Maunsell E, *see* Speechley KN
- Maunsell E, Pogany L, Barrera M, Shaw AK, Speechley KN. Quality of Life Among Long-Term Adolescent and Adult Survivors of Childhood Cancer, 2527
- Maurel J, *see* Gérard J-P
see Rodríguez-Moranta F
- Maurichi A, *see* Cascinelli N
- Mauro DJ, *see* Lenz H-J
- Mavros P, *see* Bloechl-Daum B
- Mavroudis D, *see* Xenidis N
- Maximiano C, *see* Domínguez G
- Maxwell LG, *see* Morrison C
- Mayer aRJ, *see* Kemeny NE
- Mayer RJ, *see* Herbst RS
see Lenz H-J
see Meyerhardt JA
see Redston M
see Ryan DP
see Smalley SR
- Maynard K, *see* Agrawal M
- Mayo NE, *see* Gagnon B
- Maze R, *see* Spiegler BJ
- Mazhar D, *see* Bower M
- Maziarz RT, *see* Baron F
see Hegenbart U
- Mazingue F, *see* Lapillonne H
- McAlanon G, *see* Khong P-L
- McAndrews P, *see* Weiss GJ
- McArthur GA, *see* Heinrich MC
- McArthur HL, Dalal BI, Kollmannsberger C. Intravascular Hemolysis As a Complication of Clostridium Perfringens Sepsis, 2387
- McBride R, *see* Neugut AI
- McCabe MS, *see* Oeffinger KC
- McCall LM, *see* Cornett WR
- McCarter H, Furlong W, Whitton AC, Feeny D, DePauw S, Willan AR, Barr RD. Health Status Measurements at Diagnosis As Predictors of Survival Among Adults With Brain Tumors, 3636
- McCarter M, *see* Lewis KD
- McCarthy N, *see* Bonthala Wedam S
- McCool A, *see* Lewis DA
- McCoy J, *see* Barlogie B
see West HL
- McCoy S, *see* Dragovich T
- McCrae K, *see* van Heeckeren WJ
- McCulloch M, See C, Shu X-j, Broffman M, Kramer A, Fan W-y, Gao J, Lieb W, Shieh K, Colford JM Jr. *Astragalus*-Based Chinese Herbs and Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Meta-Analysis of Randomized Trials, 419
- McCulloch MF, See C, Shu X-j, Broffman MD, Kramer A, Fan W-y, Gao J, Lieb W, Shieh K, Colford JM Jr. In Reply (correspondence), 3216
- McCullough C, *see* Robert N
- McCullough LB, *see* Whitney SN
- McDonald JA, *see* Simon MS
- McDonald N, *see* Gagnon B
- McDonough T, *see* Pham D
- McDougall K, *see* Heinrich MC
- McGarry R, *see* Timmerman R
- McGavran L, *see* Chung CH
- McGinnis KA, Fultz SL, Skanderson M, Conigliaro J, Bryant K, Justice AC. Hepatocellular Carcinoma and Non-Hodgkin's Lymphoma: The Roles of HIV, Hepatitis C Infection, and Alcohol Abuse, 5005
- McGregor R, *see* Ferrari AC
- McGuire S, *see* Dilts DM
- McGuire WP, *see* Tummala MK
- McHugh K, *see* Rubie H
- McIntosh MW, *see* Goodell V
- McIntyre KJ, *see* Jones SE
- McKenzie DR, *see* Silverman LR

AUTHOR INDEX

- McKenzie M, *see* Wong RKS
- McKiernan JM, Masson P, Murphy AM, Goetzl M, Olsson CA, Petrylak DP, Desai M, Benson MC. Phase I Trial of Intravesical Docetaxel in the Management of Superficial Bladder Cancer Refractory to Standard Intravesical Therapy, 3075
- McLachlan AJ, *see* Wong M
- McLaughlin P, *see* Liu Q
- McLendon RE, *see* Reardon DA
- McLeod HL, *see* O'Neil BH
- McMahon R, *see* Blum JL
- McMasters KM, *see* Scoggins CR
- McNeil E, *see* Bowers DC
- McNeish I, *see* Murugaesu N
- McSweeney P, *see* Hegenbart U
- McSweeney PA, *see* Baron F
- Mead G, *see* Oliver T
- Meadows AT, *see* Bassal M
- Meadows AT. Pediatric Cancer Survivorship: Research and Clinical Care, 5160
- Medeiros-Nancarrow C, *see* George RE
- Medici M, *see* Toffoli G
- Mediema BE, *see* Ryan DP
- Medina PP, *see* Quintela-Fandino M
- Mee Bang S, *see* Lee J
- Mehmi I, *see* Menendez JA
- Mehta M, *see* Abrey LE
see Cairncross G
see Cloughesy TF
- Mehta MP, *see* Khuntia D
- Mehta MP. Models Support Prophylactic Cranial Irradiation (editorial), 3524
- Meidenbauer N, *see* Mackensen A
- Meier CR, *see* Kröger N
- Meier FA, *see* Raab SS
- Meier W, *see* du Bois A
- Meijer GA, *see* Janmaat ML
- Meijers-Heijboer H, *see* van Dijk S
- Meijnen P, *see* Bijker N
- Meiller T, *see* Badros A
- Meirion Thomas J. In Reply (correspondence), 2966
- Meisner C, *see* Timmermann B
- Meissner W, *see* Strasser F
- Mejia JA, *see* Hess KR
- Mejstrikova E, *see* Langebrake C
- Melck A, *see* Griffith OL
- Melink TJ, *see* Redfern CH
- Mellstedt H, *see* Horning SJ
- Mendenhall WM, *see* Liauw SL
- Mendenhall WM, *see* Pfister DG
- Mendenhall WM, Amdur RJ, Palta JR. Intensity-Modulated Radiotherapy in the Standard Management of Head and Neck Cancer: Promises and Pitfalls, 2618
- Mendes WL, *see* Petrilli AS
- Mendez J, *see* Bickell NA
- Menendez JA, Mehmi I, Lupu R. Trastuzumab in Combination With Heregulin-Activated Her-2 (*erbB-2*) Triggers a Receptor-Enhanced Chemotherapy Sensitivity Effect in the Absence of Her-2 Overexpression, 3735
- Mennel RG, *see* Jones SE
- Menon GS, *see* Dilts DM
- Merajver SD, *see* Pierce LJ
- Merchant TE, *see* Kiehna EN
- Mercier J-P, *see* Suh JH
- Meric F, *see* Guarneri V
- Meropol NJ, *see* Agrawal M
- Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhimi M, Godfrey T, Kovatich AJ, Lund KA, Mitchell E, Schwarting R. Thymidine Phosphorylase Expression Is Associated With Response to Capecitabine Plus Irinotecan in Patients With Metastatic Colorectal Cancer, 4069
- Meropol NJ. Turning Point for Colorectal Cancer Clinical Trials (editorial), 3322
- Merritt J, *see* Tolcher AW
- Merten S, *see* Blum JL
- Mertens AC, *see* Bassal M
- Mertens F, Strömberg U, Rydholm A, Gustafson P, Bauer HCF, Brosjö O, Mandahl N. Prognostic Significance of Chromosome Aberrations in High-Grade Soft Tissue Sarcomas, 315
- Mertens L, *see* Van Calsteren K
- Mesia R, *see* Bourhis J
- Mesnil F, *see* Yakoub-Agha I
- Messinger Y, *see* Priest JR
- Metzger ML, Hudson MM, Somes GW, Shorr RI, Li C-S, Krasin MJ, Shelso J, Pui C-H, Howard SC. White Race As a Risk Factor for Hypothyroidism After Treatment for Pediatric Hodgkin's Lymphoma, 1516
- Metzner B, *see* Kröger N
- Meyer F, *see* Bairati I
- Meyer P, *see* Spinola M
- Meyer WG, *see* Jones SE
- Meyer WH, *see* Lager JJ
see Meza JL
- Meyerhardt JA, *see* Chan JA
see Kulke MH
- Meyerhardt JA, Fuchs CS. In Reply (correspondence), 4669
- Meyerhardt JA, Giovannucci EL, Holmes MD, Chan AT, Chan JA, Colditz GA, Fuchs CS. Physical Activity and Survival After Colorectal Cancer Diagnosis, 3527
- Meyerhardt JA, Heseltine D, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Nelson H, Whittom R, Hantel A, Schilsky RL, Fuchs CS. Impact of Physical Activity on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803, 3535
- Meyerhardt JA, Zhu AX, Enzinger PC, Ryan DP, Clark JW, Kulke MH, Earle CC, Vincitore M, Michelini A, Sheehan S, Fuchs CS. Phase II Study of Capecitabine, Oxaliplatin, and Erlotinib in Previously Treated Patients With Metastatic Colorectal Cancer, 1892
- Meyermann R, *see* Herrlinger U
- Meyer-Monard S, *see* Adès L
- Meyers CA, Brown PD. Role and Relevance of Neurocognitive Assessment in Clinical Trials of Patients With CNS Tumors, 1305
- Meyers PA, *see* Bernstein ML
- Meyerson M, *see* Hayes DN
- Meyskens FL Jr, Ransohoff DF. Predicting Risk for the Appearance of Melanoma (editorial), 3522
- Meza JL, Anderson J, Pappo AS, Meyer WH. Analysis of Prognostic Factors in Patients With Nonmetastatic Rhabdomyosarcoma Treated on Intergroup Rhabdomyosarcoma Studies III and IV: The Children's Oncology Group, 3844
- Michael M, Thompson M, Hicks RJ, Mitchell PL, Ellis A, Milner AD, Di Iulio J, Scott AM, Gurtler V, Hoskins JM, Clarke SJ, Tebbut NC, Foo K, Jefford M, Zalberg JR. Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination, 4228
- Michalak JC, *see* Buckner JC
- Michallet A-S, *see* Ghesquière H
- Michallet M, *see* Yakoub-Agha I
- Michaud LB, *see* Guarneri V
- Michelini A, *see* Kulke MH
see Meyerhardt JA
- Michon J, *see* Navarro S
see Oberlin O
- Middleton L, *see* Guarneri V
see Oh JL
- Miedema BW, *see* Redston M
- Mignogna MD, Lo Russo L, Fedele S, Ciccarelli R, Lo Muzio L. Case 2. Osteonecrosis of the Jaws Associated With Bisphosphonate Therapy, 1475
- Mignotte H, *see* Houvenaeghel G
- Miguel Reyes J, *see* Paz-Ares L

AUTHOR INDEX

- Mikuls TR, Endo JO, Puumala SE, Aoun PA, Black NA, O'Dell JR, Stoner JA, Boleson EC, Bast MA, Bergman DA, Ristow KM, Ooi M, Armitage JO, Habermann TM. Prospective Study of Survival Outcomes in Non-Hodgkin's Lymphoma Patients With Rheumatoid Arthritis, 1597
- Milani M, *see* Bottini A
- Milas L, *see* Wu X
- Milella M, *see* Carlini P
- Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM. Development of Neuropathy in Patients With Myeloma Treated With Thalidomide: Patterns of Occurrence and the Role of Electrophysiologic Monitoring, 4507
- Millard F, *see* Lichtman SM
- Millard L, *see* Strauss SJ
- Miller A, *see* Tolcher AW
- Miller AA, *see* Blackstock AW
see Lichtman SM
- Miller AR, *see* Barcenas CH
- Miller CR, Dunham CP, Scheithauer BW, Perry A. Significance of Necrosis in Grading of Oligodendroglial Neoplasms: A Clinicopathologic and Genetic Study of Newly Diagnosed High-Grade Gliomas, 5419
- Miller FG, *see* Joffe S
- Miller J, *see* Rummans TA
- Miller JR III, *see* Rangel J
- Miller KC, *see* Chanan-Khan A
- Miller S, *see* Rütcker FG
- Miller TP, *see* Press OW
- Miller VA, *see* Milton DT
see Pham D
- Miller W, *see* Kaufmann M
- Miller WR, *see* Ellis MJ
- Mills GB, *see* Barcenas CH
- Millward M, *see* Bedikian AY
- Milner A, *see* James PA
- Milner AD, *see* Michael M
- Milpied N, *see* Yakoub-Agha I
- Milton DT, Riely GJ, Pao W, Miller VA, Kris MG, Heelan RT. Molecular On/Off Switch, 4940
- Min Park S, Lim MK, Ae Shin S, Ho Yun Y. Impact of Prediagnosis Smoking, Alcohol, Obesity, and Insulin Resistance on Survival in Male Cancer Patients: National Health Insurance Corporation Study, 5017
- Minami H, *see* Tobinai K
- Minardi S, *see* Modena P
- Minato H, *see* Saikawa Y
- Mineur L, *see* Tournigand C
- Minken A, *see* De Ruysscher D
- Mino-Kenudson M, *see* Vauthey J-N
- Minsky BD, *see* Nissan A
- Miqueleiz S, *see* Montillo M
- Mira J-P, *see* Pène F
- Miranda EP. Utility of Computed Tomography and Magnetic Resonance Imaging Staging Before Completion Lymphadenectomy in Sentinel Lymph Node-Positive Melanoma (correspondence), 5178
- Mirchandani D, *see* Ingle JN
- Mirimanoff R-O, Gorlia T, Mason W, Van den Bent MJ, Kortmann R-D, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R. Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial, 2563
- Mirsky D, *see* Grunfeld E
- Mirtsching B, *see* Lenz H-J
- Miser JS, *see* Yock TI
- Missiaglia E, *see* Roldo C
- Missmer SA, *see* Eliassen AH
- Mita AC, *see* Takimoto CH
- Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, Tolcher AW, Villalona-Calero M, Sandler A, Chaudhuri T, Molpus K, Latz JE, Simms L, Chaudhary AK, Johnson RD, Rowinsky EK, Takimoto CH. Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function, 552
- Mitcham J, *see* Cesana GC
- Mitchell DG, Snyder B, Coakley F, Reinhold C, Thomas G, Amendola M, Schwartz LH, Woodward P, Pannu H, Hricak H. Early Invasive Cervical Cancer: Tumor Delineation by Magnetic Resonance Imaging, Computed Tomography, and Clinical Examination, Verified by Pathologic Results, in the ACRIN 6651/GOG 183 Intergroup Study, 5687
- Mitchell E, *see* Meropol NJ
see Mohiuddin M
- Mitchell PL, *see* Michael M
- Mitra AP, Datar RH, Cote RJ. Molecular Pathways in Invasive Bladder Cancer: New Insights Into Mechanisms, Progression, and Target Identification, 5552
- Mitra N, *see* Elkin EB
- Mitra SS, Simcock R. Erlotinib Induced Skin Rash Spares Skin in Previous Radiotherapy Field (correspondence), e28
- Mitry E, *see* Benoist S
- Mitsudomi T, *see* Takeuchi T
- Mitsumori K, *see* Tsuchiya N
- Mittal BB, *see* Cohen EEW
- Mitterhauser M, *see* Wachter S
- Miyamoto T, *see* Nonami A
- Miyawaki S, *see* Yanada M
- Miyazaki Y, *see* Yanada M
- Mo F, *see* Leung S-f
- Mobley GM, *see* Shelley Wang X
- Modak S, *see* Konety BR
see Kushner BH
- Modena P, Luaidi E, Facchinetti F, Veltman J, Reid JF, Minardi S, Janssen I, Giangaspero F, Forni M, Finocchiaro G, Genitori L, Giordano F, Riccardi R, Schoenmakers EFP, Massimino M, Sozzi G. Identification of Tumor-Specific Molecular Signatures in Intracranial Ependymoma and Association With Clinical Characteristics, 5223
- Modiano M, *see* Abou-Alfa GK
- Modrak DE, *see* Gold DV
- Moertel CL, *see* Priest JR
- Moeslein G, *see* Goecke T
- Mohiuddin M, Winter K, Mitchell E, Hanna N, Yuen A, Nichols C, Shane R, Hayostek C, Willett C. Randomized Phase II Study of Neoadjuvant Combined-Modality Chemoradiation for Distal Rectal Cancer: Radiation Therapy Oncology Group Trial 0012, 650
- Mohr A, *see* Chanan-Khan A
- Mohrmann S, *see* Kröger N
- Moinpour CM, *see* Berry DL
- Moiseyenko VM, *see* Van Cutsem E
- Mok TSK, *see* Ludwig H
- Moley JF, *see* Guillem JG
- Molina R, *see* Steensma DP
- Moll S, Kenyon P, Bertoli L, De Maio J, Homesley H, Deitcher SR. Phase II Trial of Alfimeprase, a Novel-Acting Fibrin Degradation Agent, for Occluded Central Venous Access Devices, 3056
- Mollevi DG, *see* Dotor E
- Molpus K, *see* Mita AC
- Monawar Hosain GM, *see* Barcenas CH
- Monberg MJ, *see* Socinski MA
- Monconduit M, *see* Noordijk EM
- Monfardini S, *see* Hagenbeek A
- Monk BJ, *see* Markman M
- Monk JP, Phillips G, Waite R, Kuhn J, Schaaf LJ, Otterson GA, Guttridge D, Rhoades C, Shah M, Criswell T, Caligiuri MA, Villalona-Calero MA. Assessment of Tumor Necrosis Factor Alpha Blockade As an Intervention to Improve Tolerability of Dose-Intensive Chemotherapy in Cancer Patients, 1852
- Monnier A, *see* Roché H
- Montag M, *see* von Wolff M
- Montagna M, *see* Montillo M

AUTHOR INDEX

- Montalti R, *see* Di Benedetto F
- Montefusco E, *see* Iacobucci I
- Monti S, *see* Hayes DN
- Montillo M, Tedeschi A, Miqueleiz S, Veronese S, Cairoli R, Intropido L, Ricci F, Colosimo A, Scarpati B, Montagna M, Nichelatti M, Regazzi M, Morra E. Alemtuzumab As Consolidation After a Response to Fludarabine Is Effective in Purging Residual Disease in Patients With Chronic Lymphocytic Leukemia, 2337
- Montrucoli A, *see* Bottini A
- Montserrat E, *see* Fernández-Avilés F
- Mooney M, *see* Chen HX
- Moore RD, *see* Engels EA
- Moore DH, *see* Esserman LJ
see Goodson WH
- Moore JO, *see* Koontz BF
- Mora S, *see* Guerrieri-Gonzaga A
- Morel P, *see* Besson C
- Morengi E, *see* Ceresoli GL
- Moreno V, *see* Dotor E
- Moreno-Romero JA, *see* Argenziano G
- Morey MC, *see* Demark-Wahnefried W
- Morgan JA, *see* Raut CP
- Morganstern DE, *see* Taplin M-E
- Morgensztern D, *see* Govindan R
see Lossos IS
- Morguet AJ, *see* Jaster M
- Mori M, *see* Kaira K
- Mori S, *see* Tobinai K
- Morikawa N, *see* Inoue A
- Morishima Y, *see* Asano N
see Tobinai K
- Morland B, *see* Rubie H
- Moroziewicz D, *see* Cesana GC
- Morra E, *see* Montillo M
- Morris CG, *see* Liauw SL
- Morrison B, *see* Berenson JR
- Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, Maxwell LG, Fowler JM. HER-2 Is an Independent Prognostic Factor in Endometrial Cancer: Association With Outcome in a Large Cohort of Surgically Staged Patients, 2376
- Morrison HI, *see* Speechley KN
- Morrison M, *see* Hanna N
- Morrison ME, *see* Lilenbaum R
- Morrison VA, *see* Habermann TM
- Morrison W, *see* Tsao AS
- Morrow GR, *see* Kris MG
- Morrow JD, *see* Cai Q
- Morrow M, *see* Guillem JG
- Morrow M, Goldstein L. Surgery of the Primary Tumor in Metastatic Breast Cancer: Closing the Barn Door After the Horse Has Bolted? (editorial), 2694
- Morschhauser F, *see* Strauss SJ
- Morse MA, *see* Czito BG
- Morsuillo M, *see* Firenzuoli F
- Mortelmans L, *see* De Leyn P
- Mortimer JE, *see* Bardwell WA
- Morton RF, *see* Goldberg RM
- Mosby K, *see* Chen HX
- Moschos SJ, Edington HD, Land SR, Rao UN, Jukic D, Shipe-Spotloe J, Kirkwood JM. Neoadjuvant Treatment of Regional Stage IIIB Melanoma With High-Dose Interferon Alfa-2b Induces Objective Tumor Regression in Association With Modulation of Tumor Infiltrating Host Cellular Immune Responses, 3164
- Moscovici M, *see* Abou-Alfa GK
- Mosenkis A, *see* Veronese ML
- Moser A, *see* Pashenkov M
- Moses AG, *see* Fearon KCH
- Moskowitz C, *see* O'Connor OA
- Mosseri V, *see* Navarro S
see Rubie H
- Motta T, *see* Went P
- Mottotese M, *see* Papaldo P
- Motzer aRJ, *see* Ronnen EA
- Motzer RJ, *see* Bajorin DF
see Eggener SE
see Kondagunta GV
- Motzer RJ, Bukowski RM. Targeted Therapy for Metastatic Renal Cell Carcinoma, 5601
- Motzer RJ, Dror Michaelson M, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI. Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma, 16
- Moulder S, *see* Sparano JA
- Mouridsen H, *see* Harvey V
- Mouridsen HT, *see* Ejlersen B
- Mourits MJE, *see* Madalinska JB
- Movsas B, *see* Konski AA
- Moynihan TJ, *see* Bardia A
- Mrózek K, *see* Paschka P
- Muanza F, *see* Klastersky J
- Muckaden MA, *see* Bahl G
see Palled S
- Mudie NY, Swerdlow AJ, Higgins CD, Smith P, Qiao Z, Hancock BW, Hoskin PJ, Linch DC. Risk of Second Malignancy After Non-Hodgkin's Lymphoma: A British Cohort Study, 1568
- Mueller P, *see* Han LY
- Mukesh BN, *see* James PA
- Mukhopadhyay S, *see* Mukhopadhyay S
- Mukhopadhyay S, Mukhopadhyay S, El-Zammar O, Khurana KK, Graziano SL. Case 2. Meningeal Metastases From Ovarian Carcinoma, 1010
- Mularski RA, *see* Lorenz KA
- Mulder AA, *see* Dijkman R
- Mulder J, *see* Fowler K
- Mulder NH, *see* van Geelen CM
- Mulhern RK, *see* Kiehna EN
- Muller DC, *see* Braga-Basaria M
- Müller H-H, *see* Jahnke K
- Müller-Hermelink HK, *see* Iqbal J
- Mulligan E, *see* Ferrari AC
- Muñoz-Santos C, *see* Argenziano G
- Munster P, *see* Sparano JA
- Munzer C, *see* Rubie H
- Muraca MG, *see* Bonanni B
- Muraszko K, *see* Packer RJ
- Muratore A, *see* Vauthey J-N
- Murawsky M, *see* Harvey V
- Murphy AM, *see* McKiernan JM
- Murphy BA, *see* Chung CH
- Murray GD, *see* Fearon KCH
- Murray GI, *see* Al-Mulla F
see Petty RD
- Murray J, *see* Ellis MJ
- Murray N, *see* Ho C
- Murray P, *see* Koroukian SM
- Murray PA, *see* Spiro SG
- Murtin C, *see* Mariani L
- Murugaesu N, Schmid P, Dancey G, Agarwal R, Holden L, McNeish I, Savage PM, Newlands ES, Rustin GJS, Seckl MJ. Malignant Ovarian Germ Cell Tumors: Identification of Novel Prognostic Markers and Long-Term Outcome After Multimodality Treatment, 4862
- Mus R, *see* Barentsz J
- Musial L, *see* Chanan-Khan A

AUTHOR INDEX

- Musib L, *see* Carducci MA
Muss H, *see* Randall ME
Muss HB, *see* Khatcheressian JL
Mutch DG, *see* Guillem JG
Mutter GL, *see* Hecht JL
Muzikansky A, *see* Ferrone CR
see Kulke MH
see Zhu AX
Myers J, *see* Tsao AS
- N**
- Na I-K, *see* Ghadjar P
Nabhan C, Bitran JD. Thalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma: Is This Really the Standard of Care? (correspondence), 2967
Nabhan C. A Simple Wish. . . Unfulfilled, 1217
Nabid A, *see* Suh JH
see Wong RKS
Nabors LB, *see* Mamelak AN
Nackaerts K, *see* De Leyn P
Naftalis EZ, *see* Petrek JA
Naftaux P, *see* De Leyn P
Nagafuji K, *see* Nonami A
Nagai K, *see* Asamura H
Nagi CS, *see* Bleiweiss IJ
Nagler A, *see* Gorin N-C
Nahrig J, *see* Thussbas C
Najarian K, *see* Richardson PG
Nakabayashi M, Bartlett RA, Oh WK. Treatment of Bicalutamide-Induced Gynecomastia With Breast-Reduction Surgery in Prostate Cancer, 2958
Nakagawa K, *see* Asamura H
see Kudoh S
see Saito H
Nakagawa T, *see* Umetani N
Nakamura A, *see* Tsuchiya N
Nakamura H, *see* Fujiwara T
Nakamura S, *see* Asano N
see Tobinai K
Nakayama K, *see* Yasuda H
Nakayama K, Ueno NT. American Society of Clinical Oncology Recommendations on Fertility Preservation Should Be Implemented Regardless of Disease Status or Previous Treatments (correspondence), 5334
Nanni O, *see* Gennari A
Naoue T, *see* Yanada M
Naoki K, *see* Hayes DN
Narita S, *see* Tsuchiya N
Narod SA, *see* Pierce LJ
Naso G, *see* Papaldo P
Nast DM, *see* Shanafelt TD
Natale R, *see* Fanucchi MP
Natarajan L, *see* Bardwell WA
Nathan PC, *see* Chow LML
see Spiegler BJ
Naughton M, *see* Eggle S
Naughton MJ, *see* Kemeny NE
see Petrek JA
see Shaw EG
Navarro M, *see* Dotor E
Navarro S, Amann G, Beiske K, Cullinane CJ, d'Amore ESG, Claudio Gambini, Mosseri V, De Bernardi B, Michon J, Peuchmaur M. Prognostic Value of International Neuroblastoma Pathology Classification in Localized Resectable Peripheral Neuroblastic Tumors: A Histopathologic Study of Localized Neuroblastoma European Study Group 94.01 Trial and Protocol, 695
Nawano S, *see* Tobinai K
Needle MN, *see* Pfister DG
Neff Greenley R, Drotar D, Zyzanski SJ, Kodish E. Stability of Parental Understanding of Random Assignment in Childhood Leukemia Trials: An Empirical Examination of Informed Consent, 891
Negaard HFS, Eilertsen AL, Dahm A, Iversen PO, Østenstad B, Sandset PM. Decreased Lung Cancer Survival With Hormone-Replacement Therapy: Caused by a Decreased Tissue Factor Pathway Inhibitor Level? (correspondence), 2683
Neglia JP, *see* Bassal M
Negoro S, *see* Kudoh S
see Saito H
Negron A, *see* Blum JL
Negron AG, *see* Jones SE
Negrouk A, *see* Hagenbeek A
Nekhlyudov L, *see* Geiger AM
Nekhlyudov L, Kroenke CH, Jung I, Holmes MD, Colditz GA. Prospective Changes in Quality of Life After Ductal Carcinoma-in-Situ: Results From the Nurses' Health Study, 2822
Nelson D, *see* Abrey LE
Nelson H, *see* Meyerhardt JA
Nelson MR, *see* Spinola M
Nelson PS, *see* Lin DW
Nelstrop A, *see* Rustin GJS
Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, DeVol E, Maples PB, Liu L, Chamberlin T, Shawler DL, Fakhrai H. Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non-Small-Cell Lung Cancer, 4721
Nemunaitis JJ, *see* Small EJ
Neppalli VT, *see* Iqbal J
Netterville J, *see* Chung CH
Neubauer A, *see* Kröger N
see Sohlbach K
Neubauer M, *see* Blum JL
Neuberg D, *see* George RE
Neugut AI, Matasar M, Wang X, McBride R, Jacobson JS, Tsai W-Y, Grann VR, Hershman DL. Duration of Adjuvant Chemotherapy for Colon Cancer and Survival Among the Elderly, 2368
Neuhaus H, *see* Heinemann V
Neven P, *see* Wildiers H
Neven P, Pochet N, Drijkoningen M, Amant F, De Smet F, Paridaens R, Christiaens M-R, Vergote I. Progesterone Receptor in Estrogen Receptor-Positive Breast Cancer: The Association Between HER-2 and Lymph Node Involvement Is Age Related (correspondence), 2595
Neville BA, *see* Chen AB
see Lathan CS
see Punglia RS
see Steyerberg EW
Nevins JR, *see* Cheng SH
Newlands ES, *see* Murugaesu N
Newman K, *see* Malogolowkin MH
Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP, Colditz GA. Meta-Analysis of Survival in African American and White American Patients With Breast Cancer: Ethnicity Compared With Socioeconomic Status, 1342
Neyroud-Caspar I, *see* Rapiti E
Ng AK, *see* Guadagnolo BA
Ng C, *see* Crane CH
Ng CS, *see* Aloia TA
Ng K, *see* Gordon MS
Ng K-K, *see* Chou H-H
Ng S-H, Yen T-C, Chang JT-C, Chan S-C, Ko S-F, Wang H-M, Lee L-Y, Kang C-J, Wong AM-C, Liao C-T. Prospective Study of [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography and Magnetic Resonance Imaging in Oral Cavity Squamous Cell Carcinoma With Palpably Negative Neck, 4371

AUTHOR INDEX

- Ng S-K, *see* Liu F-Y
- Nguyen B, *see* Weiss GJ
- Nguyen-Tân F, *see* Elliott EA
- Nicci C, *see* Cavo M
- Nichelatti M, *see* Montillo M
- Nicholas R, *see* Bernstein ML
- Nichols C, *see* Mohiuddin M
- Nicholson S. Not So “SMART” (correspondence), 3511
- Nicol SJ, *see* Sweeney CJ
- Nicolson MC, *see* Petty RD
- Nieder C. Influence of Whole-Brain Radiotherapy on Remission of Brain Metastases (correspondence), 4037
- Niederwieser D, *see* Baron F
see Hegenbart U
- Niedzwiecki D, *see* Kemeny NE
see Meyerhardt JA
see Redston M
see Ryan DP
- Niell HB, *see* Blackstock AW
- Nielsen DL, *see* Ejlertsen B
- Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J. Study of Failure Pattern Among High-Risk Breast Cancer Patients With or Without Postmastectomy Radiotherapy in Addition to Adjuvant Systemic Therapy: Long-Term Results From the Danish Breast Cancer Cooperative Group DBCG 82 b and c Randomized Studies, 2268
- Nielsen TO, *see* Cheang MCU
see Ring BZ
- Niemeyer CM, *see* Creutzig U
- Niethammer D, *see* Schrauder A
- Nieto Y, *see* Woodward WA
- Niggli F, *see* Burkhardt B
see Schrauder A
- Niggli FK, *see* Wachtel M
- Niho S, Kubota K, Goto K, Yoh K, Ohmatsu H, Kakinuma R, Saijo N, Nishiwaki Y. First-Line Single Agent Treatment With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Phase II Study, 64
- Nikcevic DA, *see* Ingle JN
see Loprinzi CL
see Steensma DP
- Nikolova Z, *see* Heinrich MC
- Niland JC, *see* Buchholz TA
- Nilsson J, *see* Tanner M
- Nimer SD. Clinical Management of Myelodysplastic Syndromes With Interstitial Deletion of Chromosome 5q, 2576
- Nippert I, *see* Gadzicki D
- Nishiwaki Y, *see* Niho S
- Nissan A, Stojadinovic A, Shia J, Hoos A, Guillem JG, Klimstra D, Cohen AM, Minsky BD, Paty PB, Wong WD. Predictors of Recurrence in Patients With T2 and Early T3, N0 Adenocarcinoma of the Rectum Treated by Surgery Alone, 4078
- Nisticò C, *see* Papaldo P
- Nitenberg G, *see* Pène F
- Nitz U, *see* Kröger N
- Niwa Y, *see* Ohmiya N
- Noble J, *see* Bezjak A
- Noda M, *see* Gega M
- Noens L, *see* Van Calsteren K
- Noguchi M, *see* Asamura H
- Nogues C, *see* Andrieu N
- Nonami A, Takenaka K, Harada N, Kono K, Kamezaki K, Numata A, Karube K, Miyamoto T, Nagafuji K, Ohshima K, Harada M. Primary Hepatic Lymphoma 1 Year After Resection of Hepatocellular Carcinoma, 5784
- Noordijk EM, Carde P, Dupouy N, Hagenbeek A, Krol ADG, Kluin-Nelemans JC, Tirelli U, Monconduit M, Thomas J, Eghbali H, Aleman BMP, Bosq J, Vovk M, Verschuere TAM, Pény A-M, Girinsky T, Raemaekers JMM, Henry-Amar M. Combined-Modality Therapy for Clinical Stage I or II Hodgkin’s Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials, 3128
- Nooter K, *see* Loos WJ
- Nordlinger B, *see* Benoist S
see Bilchik AJ
see Portier G
- Nordlinger B, Benoist S. Benefits and Risks of Neoadjuvant Therapy for Liver Metastases (editorial), 4954
- Norman AR, *see* Chau I
- Normolle D, Lawrence T. Designing Dose-Escalation Trials With Late-Onset Toxicities Using the Time-to-Event Continual Reassessment Method, 4426
- Noronha V, Fynan TM, Duffy T. Flare in Neuropathy Following Rituximab Therapy for Waldenström’s Macroglobulinemia (correspondence), e3
- Norris MD, *see* Haber M
- Norton AJ, *see* Lee AM
- Nos C, *see* Houvenaeghel G
- Nosrati M, *see* Rangel J
- Noutsias M, *see* Ghadjar P
- Novak AJ, Grote DM, Ziesmer SC, Kline MP, Manske MK, Slager S, Witzig TE, Shanafelt T, Call TG, Kay NE, Jelinek DF, Cerhan JR, Gross JA, Harder B, Dillon SR, Ansell SM. Elevated Serum B-Lymphocyte Stimulator Levels in Patients With Familial Lymphoproliferative Disorders, 983
- Novello S, *see* Papotti M
- Novotny PJ, *see* Pockaj BA
see Steensma DP
- Novotny WF, *see* Jubb AM
- Nowakowski G, *see* Shanafelt TD
- Noyes RD, *see* Cornett WR
- Nukiwa T, *see* Fujiwara T
see Inoue A
- Numata A, *see* Nonami A
- Nuver J, *see* de Haas EC
see van den Belt-Dusebout AW
- Nuzzo C, *see* Carlini P

O

- Oakervee H, *see* Davies JK
- Oates J, *see* Chau I
- Obasaju CK, *see* Paz-Ares L
see Socinski MA
see Sweeney CJ
- Oberlin O, Rey A, Desfachelles AS, Philip T, Plantaz D, Schmitt C, Plouvier E, Lejars O, Rubie H, Terrier P, Michon J. Impact of High-Dose Busulfan Plus Melphalan As Consolidation in Metastatic Ewing Tumors: A Study by the Société Française des Cancers de l’Enfant, 3997
- Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, Ernestus K, König R, Haas S, Eils R, Schwab M, Brors B, Westermann F, Fischer M. Customized Oligonucleotide Microarray Gene Expression–Based Classification of Neuroblastoma Patients Outperforms Current Clinical Risk Stratification, 5070
- O’Brien MER, Ciuleanu T-E, Tsekov H, Shparyk Y, Čučević B, Juhasz G, Thatcher N, Ross GA, Dane GC, Crofts T. Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer, 5441
- O’Brien S, *see* Ault P
see Tsimberidou A-M
- Ocaña A, Delgado C, Rodríguez CA, Bellido L, Izquierdo N, Martín R, Cruz JJ. Case 3. Upper Limb Lymphangiosarcoma Following Breast Cancer Therapy, 1477
- O’Connell CL, Boswell WD, Duddalwar V, Caton A, Mark LS, Vigen C, Liebman HA. Unsuspected Pulmonary Emboli in Cancer Patients: Clinical Correlates and Relevance, 4928
- O’Connell MJ, *see* Haller DG
see Lembersky BC

AUTHOR INDEX

- O'Connor OA, *see* Fisher RI
- O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C, Portlock C, Horwitz S, Zelenetz AD, Frankel S, Richon V, Marks P, Kelly WK. Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies, 166
- O'Day SJ, *see* Lewis KD
- O'Dell JR, *see* Mikuls TR
- Odermatt B, *see* Wachtel M
- Odone Filho V, *see* Petrilli AS
- O'Donnell KM, *see* Spiro SG
- O'Dwyer aPJ, *see* Veronese ML
- O'Dwyer PJ, *see* Ratain MJ
- O'Dwyer PJ, Catalano RB. Uridine Diphosphate Glucuronosyltransferase (UGT) 1A1 and Irinotecan: Practical Pharmacogenomics Arrives in Cancer Therapy, 4534
- Oeffinger KC, *see* Bowers DC
- Oeffinger KC, McCabe MS. Models for Delivering Survivorship Care, 5117
- O'Fallon JR, *see* Buckner JC
- Offit K, *see* Ganz PA
see Guillem JG
- Offit K, Kohut K, Clagett B, Wadsworth EA, Lafaro KJ, Cummings S, White M, Sagi M, Bernstein D, Davis JG. Cancer Genetic Testing and Assisted Reproduction, 4775
- Ogawa O, *see* Tsuchiya N
- Ogawa Y, *see* Tobinai K
- Oggionni M, *see* Licitra L
- Ogura M, *see* Tobinai K
- Ogura T, *see* Onoda S
- Oh DS, Troester MA, Usary J, Hu Z, He X, Fan C, Wu J, Carey LA, Perou CM. Estrogen-Regulated Genes Predict Survival in Hormone Receptor-Positive Breast Cancers, 1656
- Oh JL, Dryden MJ, Woodward WA, Yu T-K, Tereffe W, Strom EA, Perkins GH, Middleton L, Hunt KK, Giordano SH, Oswald MJ, Domain D, Buchholz TA. Locoregional Control of Clinically Diagnosed Multifocal or Multicentric Breast Cancer After Neoadjuvant Chemotherapy and Locoregional Therapy, 4971
- Oh M, *see* Li Y
- Oh WK, *see* Gilligan T
see Nakabayashi M
see Smith MR
- Ohashi Y, *see* Tobinai K
- Ohe Y, *see* Takano T
- Ohmatsu H, *see* Niho S
- Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, Goto H. *MDM2* Promoter Polymorphism Is Associated With Both an Increased Susceptibility to Gastric Carcinoma and Poor Prognosis, 4434
- Ohno R, *see* Yanada M
- Ohshima K, *see* Nonami A
- Ohtake S, *see* Yanada M
- Ohtani S, *see* Fujiwara T
- Ohtsu A, *see* Rojo F
- Ohtsu A, Yoshida S, Saijo N. Disparities in Gastric Cancer Chemotherapy Between the East and West, 2188
- Oka S, Yokote T, Hiraiwa T, Akioka T, Hara S, Kobayashi K, Hirata Y, Yamano T, Tanimoto K, Tsuji M, Hanafusa T. Hyperthyroidism Associated With Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia, 3500
- Okamoto H, *see* Onoda S
- Okamoto I, *see* Ando M
- Okawara GS, *see* Ajani JA
- Okazaki T, *see* Yasuda H
- Okcu MF, *see* Wang L
- Oksenhendler E, *see* Boulanger E
- Oktay K, *see* Lee SJ
see Lee S
- Oktay K, Oktem O, Reh A, Vahdat L. Measuring the Impact of Chemotherapy on Fertility in Women With Breast Cancer (correspondence), 4044
- Oktay KH, Lee SJ. In Reply (correspondence), 4221
- Oktem O, *see* Oktay K
- Olbricht S, *see* du Bois A
see Pfisterer J
- Oldenburg J, Martin JM, Fossá SD. Late Relapses of Germ Cell Malignancies: Incidence, Management, and Prognosis, 5503
- O'Leary N, *see* Kirkova J
- Oliveira AM, Chou MM, Perez-Atayde AR, Rosenberg AE. Aneurysmal Bone Cyst: A Neoplasm Driven by Upregulation of the *USP6* Oncogene (correspondence), e1
- Oliveira CR, *see* Petrilli AS
- Oliveira-Frick V, *see* Rubie C
- Oliver T, Mead G, Mason M, Stenning S, Dieckmann K, Steiner H, De Santis M, Aparicio J, Skoneczna I, Kratzik C. The Sword of Damocles and the Treatment of Stage I Seminoma (correspondence), 2599
- Oliviero P, *see* Bonanni B
- Olivotto IA, *see* Cheang MCU
see Lohrisch C
see Pierce LJ
- Olmi P, *see* Licitra L
- Olopade OI, *see* Bradbury A
see Hall MJ
see Pierce LJ
see Polite BN
- Olopade OI, Schwartzmann G, Saijo N, Thomas CR Jr. Disparities in Cancer Care: A Worldwide Perspective and Roadmap for Change, 2135
- Olson T, *see* Marina N
- Olsson CA, *see* McKiernan JM
- Oluwole S, *see* Bickell NA
- Olvera N, *see* Black D
- O'Malley AJ, *see* Keating NL
- O'Malley BO, *see* Pfister DG
- O'Neil BH, McLeod HL. Thymidine Phosphorylase and Capecitabine: A Predictive Marker for Therapy Selection? (editorial), 4051
- Oniga F, *see* Paccagnella A
- Onoda S, Masuda N, Seto T, Eguchi K, Takiguchi Y, Isobe H, Okamoto H, Ogura T, Yokoyama A, Seki N, Asaka-Amano Y, Harada M, Tagawa A, Kunikane H, Yokoba M, Uematsu K, Kuriyama T, Kuroiwa Y, Watanabe K. Phase II Trial of Amrubicin for Treatment of Refractory or Relapsed Small-Cell Lung Cancer: Thoracic Oncology Research Group Study 0301, 5448
- Ooi G-C, *see* Khong P-L
- Ooi M, *see* Mikuls TR
- Ooi WS, *see* Clemons MJ
- Oosterwijk E, *see* Lamers CHJ
- Ord R, *see* Badros A
- O'Reilly S, *see* Horgan AM
- O'Reilly E, *see* Shah MA
- O'Reilly EM, *see* Abou-Alfa GK
- O'Reilly M, *see* Crane CH
- Orfeuvre H, *see* du Bois A
- Orlowski RZ, *see* Richardson PG
- Ornella Nicoletto M, *see* Paccagnella A
- Ortega J, *see* Petrilli AS
- Ortega JJ, *see* Eapen M
- Ortiz J, *see* van Heeckeren WJ
- Osada H, *see* Takeuchi T
- Osborne CK, *see* Lee AV
see Ma X-J
- O'Shaughnessy JA, *see* Blum JL
see Jones SE
- Oshima T, *see* Gega M
- Oshiro A, *see* Asano N
- Osman M, *see* Mamelak AN
- Østenstad B, *see* Negaard HFS

AUTHOR INDEX

- Ostertag C, *see* Illerhaus G
 Oswald MJ, *see* Oh JL
 Ott G, *see* Iqbal J
 Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, Wieder H, Fink U, Schwaiger M, Siewert J-R. Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction, 4692
 Ott OJ, *see* Weiss C
 Ottaviani E, *see* Iacobucci I
 Otte AP, *see* Bachmann IM
 Otten W, *see* van Dijk S
 Otterson GA, *see* Monk JP
 Ottesen R, *see* Buchholz TA
 Otto SJ, Schröder FH, de Koning HJ. Risk of Cardiovascular Mortality in Prostate Cancer Patients in the Rotterdam Randomized Screening Trial, 4184
 Ou W-b, *see* Heinrich MC
 Oude Nijhuis C, *see* De Bont ESJM
 Oudkerk M, *see* Barentsz J
 Ouvrier M-J, Thery J-C, Blot E. Outpatient Oral Antibiotics for Febrile Neutropenic Cancer Patients (correspondence), 5614
 Overgaard J, *see* Nielsen HM
 Overgaard M, *see* Nielsen HM
 Oyen W, *see* Barentsz J
 Oza AM, *see* Agulnik M
 Ozcelik T, *see* Ali R
 Ozer H, *see* Smith TJ
 Ozkalemkas F, *see* Ali R
 Ozkan A, *see* Ali R
 Ozkocaman V, *see* Ali R
 Ozols RF, *see* Herbst RS
 Ozyar E, Genc M. Relapse Pattern of GOG 122 Trial Should Be More Informative (correspondence), 3709
- P**
- Paccagnella A, Oniga F, Bearz A, Favaretto A, Clerici M, Barbieri F, Riccardi A, Chella A, Tirelli U, Ceresoli G, Tumolo S, Ridolfi R, Bion R, Ornella Nicoletto M, Belloni P, Veglia F, Grazia Ghi M. Adding Gemcitabine to Paclitaxel/Carboplatin Combination Increases Survival in Advanced Non-Small-Cell Lung Cancer: Results of a Phase II-III Study, 681
 Packer RJ, *see* Bowers DC
 Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, Bayer L, LaFond D, Donahue BR, Marymont MH, Muraszko K, Langston J, Sposto R. Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma, 4202
 Padmanabhan S, *see* Chanan-Khan A
 Paesmans M, *see* Klastersky J
 Paesmans M, Bleiberg H. Are We Cautious Enough When We Interpret Results of Randomized But Underpowered Comparisons? (correspondence), 1964
 Paesmans M, Klastersky J. In Reply (correspondence), 5614
 Paganelli G, *see* Goldenberg DM
 Page DL, *see* Carter BA
 see Lagios MD
 Page N, *see* Govindan R
 Pagenstecher A, *see* Sohlbach K
 Pagenstecher C, *see* Goecke T
 Pagliarulo V, Hawes D, Brands FH, Groshen S, Cai J, Stein JP, Lieskovsky G, Skinner DG, Cote RJ. Detection of Occult Lymph Node Metastases in Locally Advanced Node-Negative Prostate Cancer, 2735
 Paik S, *see* Bear HD
 Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Lawrence Wickerham D, Wolmark N. Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer, 3726
 Pajak TF, *see* Konski AA
 Pajonk F, *see* Henke M
 Palandri F, *see* Soverini S
 Palled S, Bedre G, Muckaden MA, Ramadwar M, Bhagwat R, Banavali S, Laskar S. Primary Burkitt's Lymphoma of Frontal Bone: A Rare Presentation, 4521
 Pallis T, *see* Xenidis N
 Palmer JL, *see* Bruera E
 Palmer MJ, *see* Perez EA
 Palta aJR, *see* Mendenhall WM
 Paltiel C, *see* Lohrisch C
 Palumbo JS, *see* Widemann BC
 Panageas KS, *see* Abrey LE
 see Elkin EB
 see Lamanna N
 Panasci L, *see* Chia S
 Panasci LC. Effect of Tamoxifen After Chemotherapy in Hormone Receptor-Positive, Node-Negative Breast Cancer (correspondence), 2392
 Pane F, *see* Iacobucci I
 Panetta JC, *see* Furman WL
 Pannu H, *see* Mitchell DG
 Pantanowitz L, *see* Konstantinopoulos PA
 Panwalkar AW, *see* Ganti AK
 Pao W, *see* Milton DT
 see Pham D
 Paolini S, *see* Soverini S
 Paolo Piccaluga P, *see* Went P
 Papadimitrakopoulou V, *see* Tsao AS
 Papai Z, *see* Eckardt JR
 Papaldo P, *see* Carlini P
 see Ferretti G
 Papaldo P, Ferretti G, Di Cosimo S, Giannarelli D, Marolla P, Lopez M, Cortesi E, Antimi M, Terzoli E, Carlini P, Vici P, Botti C, Di Lauro L, Naso G, Nisticò C, Mottolese M, Di Filippo F, Maria Ruggeri E, Ceribelli A, Cognetti F. Does Granulocyte Colony-Stimulating Factor Worsen Anemia in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide? 3048
 Papiez L, *see* Timmerman R
 Papotti M, Kalebic T, Volante M, Chiusa L, Bacillo E, Cappia S, Lausi P, Novello S, Borasio P, Scagliotti GV. Bone Sialoprotein Is Predictive of Bone Metastases in Resectable Non-Small-Cell Lung Cancer: A Retrospective Case-Control Study, 4818
 Pappas TN, *see* Czito BG
 Pappen B, *see* Nemunaitis J
 Pappo AS, *see* Lager JJ
 see Meza JL
 see Spunt SL
 Paradiso A, *see* Foekens JA
 Parda DS, *see* Taghian AG
 Pareja L, *see* Dotor E
 Parekh DJ, Bochner BH, Dalbagni G. Superficial and Muscle-Invasive Bladder Cancer: Principles of Management for Outcomes Assessments, 5519
 Paridaens R, *see* Neven P
 see Van Calsteren K
 see Wildiers H
 Parikh P, *see* Hirsch FR
 Parise RA, *see* Lichtman SM
 Park J, *see* Lee J
 Park K, *see* Kim HJ
 see Lee J
 Park YH, *see* Han J-Y
 Parker J, *see* Chung CH
 Parker N, *see* Chung CH
 Parker PA, *see* Baile WF
 Parks R, *see* Lee JJ
 Parmigiani G, *see* Chen S
 see Hayes DN
 Parnes HL, *see* Gulley JL
 Parsons LL, *see* Temple WJ

AUTHOR INDEX

- Parton M, Gore M, Eisen T. Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer, 5584
- Partridge AH, *see* Lee SJ
see Tolaney SM
- Parums D, *see* Hirsch FR
- Pascal Sappino A, *see* Rapiti E
- Paschka P, Marcucci G, Ruppert AS, Mrózek K, Chen H, Kittles RA, Vukosavljevic T, Perrotti D, Vardiman JW, Carroll AJ, Kolitz JE, Larson RA, Bloomfield CD. Adverse Prognostic Significance of *KIT* Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study, 3904
- Pashenkov M, Goëss G, Wagner C, Hörmann M, Jandl T, Moser A, Britten CM, Smolle J, Koller S, Mauch C, Tantcheva-Poor I, Grabbe S, Loquai C, Esser S, Franckson T, Schneeberger A, Haarmann C, Krieg AM, Stingl G, Wagner SN. Phase II Trial of a Toll-Like Receptor 9–Activating Oligonucleotide in Patients With Metastatic Melanoma, 5716
- Paskett ED, *see* Blackstock AW
see Petrek JA
- Pastorino U, *see* Spinola M
- Patel PM, *see* Lee CP
- Patel R, *see* Glaspy J
- Patel S, *see* Pfister DG
- Patel SR, Benjamin RS. Desmoid Tumors Respond to Chemotherapy: Defying the Dogma in Oncology (editorial), 11
- Pater J, *see* Wong RKS
- Pater JL, *see* Whelan TJ
- Paternoster SF, *see* Shanafelt TD
- Patnaik A, *see* Mita AC
see Ratain MJ
see Tolcher AW
- Patrick CC, *see* Furman WL
- Patrick Reynolds C, *see* Matthay KK
- Patrizio P, *see* Lee SJ
- Patterson AR, Leitch AM, Weatherall P, Zhou X-P, Eng C, Tomlinson GE. Case 4. Fibrocystic Breast Disease in a 16-Year-Old Female With *PTEN* Hamartoma Tumor Syndrome, 525
- Patuzzo R, *see* Cascinelli N
- Paty PB, *see* Nissan A
- Paul J, *see* Crawford SC
- Paul MA, *see* Herder GJM
- Paul N, *see* Wong RKS
- Paul S, *see* Weiss GJ
- Pauler Ankerst D, *see* Berry DL
- Pauletti G, *see* Hurley J
- Paulli M, *see* Went P
see Zinzani PL
- Pavlick AC, *see* Bedikian AY
- Pawel BR, *see* Coughlin CM
- Pawlik TM, *see* Vauthey J-N
- Paz-Ares L, Douillard J-Y, Koralewski P, Manegold C, Smit EF, Miguel Reyes J, Chang G-C, John WJ, Peterson PM, Obasaju CK, Lahn M, Gandara DR. Phase III Study of Gemcitabine and Cisplatin With or Without Aprinocarsen, a Protein Kinase C-Alpha Antisense Oligonucleotide, in Patients With Advanced-Stage Non–Small-Cell Lung Cancer, 1428
- Pearlman N, *see* Lewis KD
- Pedersen J, *see* Smalley SR
- Peeters STH, Heemsbergen WD, Koper PCM, van Putten WLJ, Slot A, Dielwart MFH, Bonfrer JMG, Incrocci L, Lebesque JV. Dose-Response in Radiotherapy for Localized Prostate Cancer: Results of the Dutch Multicenter Randomized Phase III Trial Comparing 68 Gy of Radiotherapy With 78 Gy, 1990
- Pegram CN, *see* Reardon DA
- Pegram MD, *see* Gordon MS
see Hurley J
- Pehamberger H, *see* Bedikian AY
- Peinado MA, *see* Dotor E
- Peles-Borz A, *see* Stein J
- Pellegrino C, *see* Sparano JA
- Pelosi G, *see* Guerrieri-Gonzaga A
- Peña C, *see* Domínguez G
- Pena W, *see* Petrilli AS
- Pène F, Aubron C, Azoulay E, Blot F, Thiéry G, Raynard B, Schlemmer B, Nitenberg G, Buzyn A, Arnaud P, Socié G, Mira J-P. Outcome of Critically Ill Allogeneic Hematopoietic Stem-Cell Transplantation Recipients: A Reappraisal of Indications for Organ Failure Supports, 643
- Penna C, *see* Benoist S
- Pennacchioli E, *see* Cascinelli N
- Penner L, *see* Eggly S
- Penner LA, *see* Eggly S
- Pentz RD, Joffe S, Emanuel EJ, Schnipper LE, Haskell CM, Tannock IF. ASCO Core Values, 5780
- Pény A-M, *see* Noordijk EM
- Peock S, *see* Andrieu N
- Pepe M, *see* Henke M
- Perez EA, *see* Goetz MP
see Ingle JN
- Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE. Effect of Letrozole Versus Placebo on Bone Mineral Density in Women With Primary Breast Cancer Completing 5 or More Years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA.17, 3629
- Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, Flynn PJ, Ingle JN, Visscher D, Jenkins RB. *HER2* Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial, 3032
- Perez-Atayde AR, *see* Oliveira AM
- Perez-Staub N, *see* Tournigand C
- Péricles P, *see* Petrilli AS
- Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WTA, de Korte MA, Jonkman S, Kosterink JGW, van Veldhuisen DJ, Sleijfer DT, Jager PL, de Vries EGE. Indium-111–Labeled Trastuzumab Scintigraphy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer, 2276
- Periman PO, *see* Smalley SR
- Perkins GH, *see* Oh JL
- Perl A, *see* Steere J
- Perlman EJ, *see* Bernstein ML
see Dome JS
- Perot C, *see* Lapillonne H
- Perou C, *see* Hayes DN
- Perou CM, *see* Oh DS
- Perraki M, *see* Xenidis N
- Perrone F, *see* Licitra L
- Perrone G, *see* Cavo M
- Perrotti D, *see* Paschka P
- Perry A, *see* Miller CR
- Perry MC. Responses to Topoisomerase-I Inhibitors in Extensive Small-Cell Lung Cancer: Chance or Chromosomes? (editorial), 1980
- Perry MC. Thoracic Radiation Therapy in Limited Stage Small-Cell Lung Cancer: Timing Is Everything Isn't It? (editorial), 3815
- Personeni N. Epidermal Growth Factor Receptor Gene Copy Number in Esophageal Cancer and Outcome Prediction to Gefitinib: Does Intratumoral Heterogeneity Matter? (correspondence), 5465
- Peshkin BN, *see* Chen S
- Pessa S, *see* Toffoli G
- Pession A, *see* Brandes AA
- Petak I. In Reply (correspondence), 4037
- Peters C, *see* Schrauder A
- Peters JA, *see* Loud JT
- Peters LJ, *see* Rischin D
- Peterse J, *see* van Apeldoorn MJ
- Peterse JL, *see* Bijker N
- Petersen F, *see* Hegenbart U

AUTHOR INDEX

- Petersen RP, *see* Cornett WR
- Peterson A, *see* Eggly S
- Peterson BA, *see* Habermann TM
- Peterson BL, *see* Byrd JC
see Silverman LR
- Peterson LE, *see* Chen S
- Peterson LM, *see* Linden HM
- Peterson PM, *see* Paz-Ares L
- Petkov V, *see* Grünberger B
- Petra PH, *see* Linden HM
- Petrek JA, Naughton MJ, Case LD, Paskett ED, Naftalis EZ, Singletary SE, Sukumvanich P. Incidence, Time Course, and Determinants of Menstrual Bleeding After Breast Cancer Treatment: A Prospective Study, 1045
- Petrelli NJ, *see* Lembersky BC
- Petrik D, Lavori PW, Cao H, Zhu Y, Wong P, Christofferson E, Kaplan MJ, Pinto HA, Sutphin P, Koong AC, Giaccia AJ, Le Q-T. Plasma Osteopontin Is an Independent Prognostic Marker for Head and Neck Cancers, 5291
- Petrilli AS, de Camargo B, Odone Filho V, Bruniera P, Brunetto AL, Jesus-Garcia R, Camargo OP, Pena W, Péricles P, Davi A, Prospero JD, Alves MTS, Oliveira CR, Macedo CRD, Mendes WL, Almeida MTA, Borsato ML, dos Santos TM, Ortega J, Consentino E. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: Prognostic Factors and Impact on Survival, 1161
- Petrillo G, *see* Argenziano G
- Petruzella S, *see* Claus EB
- Petrylak DP, *see* Berry DL
see McKiernan JM
- Pettus JA, *see* Eggener SE
- Petty RD, Kerr KM, Murray GI, Nicolson MC, Rooney PH, Bissett D, Collie-Duguid ESR. Tumor Transcriptome Reveals the Predictive and Prognostic Impact of Lysosomal Protease Inhibitors in Non-Small-Cell Lung Cancer, 1729
- Peuchmaur M, *see* Navarro S
- Pfeiffer RM, *see* Fears TR
- Pfister DG, *see* Forastiere AA
- Pfister DG, Laurie SA, Weinstein GS, Mendenhall WM, Adelstein DJ, Kian Ang K, Clayman GL, Fisher SG, Forastiere AA, Harrison LB, Lefebvre J-L, Lempold N, List MA, O'Malley BO, Patel S, Posner MR, Schwartz MA, Wolf GT. American Society of Clinical Oncology Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer, 3693
- Pfister DG, Ridge JA. Induction Chemotherapy for Larynx Preservation: Patient Selection or Therapeutic Effect? (editorial), 540
- Pfister DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB, Zahalsky AJ, Lake S, Needle MN, Shaha AR, Shah JP, Zelefsky MJ. Concurrent Cetuximab, Cisplatin, and Concomitant Boost Radiotherapy for Locoregionally Advanced, Squamous Cell Head and Neck Cancer: A Pilot Phase II Study of a New Combined-Modality Paradigm, 1072
- Pfisterer J, *see* du Bois A
see Greimel ER
- Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück H-J, Rochon J, Zimmermann AH, Eisenhauer E. Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG, 4699
- Pham D, Kris MG, Riely GJ, Sarkaria IS, McDonough T, Chuai S, Venkatraman ES, Miller VA, Ladanyi M, Pao W, Wilson RK, Singh B, Rusch VW. Use of Cigarette-Smoking History to Estimate the Likelihood of Mutations in Epidermal Growth Factor Receptor Gene Exons 19 and 21 in Lung Adenocarcinomas, 1700
- Pham TQ, *see* Gordon MS
- Phan AT, *see* Ajani JA
- Pharoah PDP, *see* Antoniou AC
- Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C. Phase II Study of Erlotinib in Patients With Advanced Biliary Cancer, 3069
- Philip T, *see* Oberlin O
- Phillips G, *see* Monk JP
- Pia Brizzi M, *see* Bottini A
- Picard MH, *see* Hayes DF
- Picardi A, *see* Gentilucci UV
- Picaluga PP, *see* Soverini S
- Piccart M, *see* Loi S
- Piccart MJ, *see* Rustin GJS
- Piccioli M, *see* Went P
- Piccirillo J, *see* Govindan R
- Pichert G, *see* Stirling D
- Picus J, *see* Philip PA
- Piderman K, *see* Rummans TA
- Piedbois P, *see* Portier G
- Pieper CF, *see* Demark-Wahnefried W
- Pierce JP, *see* Bardwell WA
- Pierce LJ, *see* Jagsi R
- Pierce LJ, Levin AM, Rebeck TR, Ben-David MA, Friedman E, Solin LJ, Harris EE, Gaffney DK, Haffty BG, Dawson LA, Narod SA, Olivetto IA, Eisen A, Whelan TJ, Olopade OI, Isaacs C, Merajver SD, Wong JS, Garber JE, Weber BL. Ten-Year Multi-Institutional Results of Breast-Conserving Surgery and Radiotherapy in *BRCA1/2*-Associated Stage I/II Breast Cancer, 2437
- Pierotti MA, *see* Licitra L
- Pietsch T, *see* Timmermann B
- Pignatiello C, *see* Spinola M
- Pigneux A, *see* Adès L
- Pijls-Johannesma M, *see* De Ruyscher D
- Pikhart H, *see* Blazeby JM
- Pileri A, *see* Zinzani PL
- Pileri S, *see* Zinzani PL
- Pileri SA, *see* Went P
- Pili R, *see* Carducci MA
- Pillon M, *see* Axia G
- Piloti S, *see* Licitra L
- Pimpinelli N, *see* Zinzani PL
- Pingpank JF, *see* Cornett WR
- Pinkel D, *see* Curtin JA
- Pinkus GS, *see* Coughlin CM
- Pinkus JL, *see* Coughlin CM
- Piñol V, *see* Rodríguez-Moranta F
- Pinto BM, *see* Demark-Wahnefried W
- Pinto HA, *see* Petrik D
- Pippas AW, *see* Lenz H-J
- Pippen JE, *see* Jones SE
- Piqué JM, *see* Rodríguez-Moranta F
- Pisters PWT, *see* Ajani JA
see Crane CH
- Pisters PWT. Preoperative Chemotherapy and Split-Course Radiation Therapy for Patients With Localized Soft Tissue Sarcomas: Home Run, Base Hit, or Strike Out? (editorial), 549
- Pitney A, *see* Widemann BC
- Pitot HC, *see* Goldberg RM
see Philip PA
- Pittman J, *see* Cheng SH
- Pizzo PA, *see* Smith TJ
- Plantaz D, *see* Oberlin O
- Plante M, *see* Pfisterer J
- Plasse M, *see* Aloia T
- Plehiars B, *see* Klastersky J
- Plehn J, *see* Bonthala Wedam S
- Plouvier E, *see* Oberlin O
- Plukker JT, *see* van Geelen CM
- Pocard M, den Eynde MV, Goere D, Boige V, Malka D. Sentinel Lymph Node

- Sampling and Analysis in Colon Cancer: What Is the Question? (correspondence), 3712
- Pochet N, *see* Neven P
- Pockaj BA, Gallagher JG, Loprinzi CL, Stella PJ, Barton DL, Sloan JA, Lavasseur BI, Rao RM, Fitch TR, Rowland KM, Novotny PJ, Flynn PJ, Richelson E, Fauq AH. Phase III Double-Blind, Randomized, Placebo-Controlled Cross-over Trial of Black Cohosh in the Management of Hot Flashes: NCCTG Trial N01CC¹, 2836
- Poehling K, *see* Fowler K
- Poerio A, *see* Iacobucci I
- Pogany L, *see* Maunsell E
- Pohlman B, *see* Kalaycio M
- Poinsot R, *see* This P
- Pol S, *see* Besson C
- Polge E, *see* Gorin N-C
- Polite BN, Dignam JJ, Olopade OI. Colorectal Cancer Model of Health Disparities: Understanding Mortality Differences in Minority Populations, 2179
- Pollack IF, Hamilton RL, Sobol RW, Burnham J, Yates AJ, Holmes EJ, Zhou T, Finlay JL. O⁶-Methylguanine-DNA Methyltransferase Expression Strongly Correlates With Outcome in Childhood Malignant Gliomas: Results From the CCG-945 Cohort, 3431
- Pollack JR, *see* Rücker FG
- Pöllinger B, *see* Huber RM
- Pols HAP, *see* Siemes C
- Pond GR, *see* Agulnik M
see Chia S
- Pons LE, *see* Álvaro T
- Ponzzone R, Maggiorotto F, Robba C, Fuso L, Sismondi aP. Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Status: An Independent Influence on the Efficacy of Endocrine Therapy in Breast Cancer? (correspondence), 1481
- Porceddu S, *see* Rischin D
- Porteous ME, *see* Stirling D
- Porter CW, *see* Chanan-Khan A
- Porter GA, *see* Johnson PM
- Porter LS, *see* Fallowfield LJ
- Portier G, Elias D, Bouche O, Rougier P, Bosset J-F, Saric J, Belghiti J, Piedbois P, Guimbaud R, Nordlinger B, Bugat R, Lazorthes F, Bedenne L. Multicenter Randomized Trial of Adjuvant Fluorouracil and Folinic Acid Compared With Surgery Alone After Resection of Colorectal Liver Metastases: FFCD ACHBTH AURC 9002 Trial, 4976
- Portlock C, *see* O'Connor OA
- Posner M, *see* Raut CP
- Posner MR, *see* Pfister DG
- Possinger K, *see* Strasser F
- Pöstlberger S, *see* Knauer M
- Postmus PE, *see* Herder GJM
- Poston G, *see* Bilchik AJ
- Poston G, Adam R, Vauthey J-N. Downstaging or Downsizing: Time for a New Staging System in Advanced Colorectal Cancer? 2702
- Potratz J, *see* Kager L
- Pötter R, *see* Wachter S
- Potti A, *see* Ganti AK
see Kishor Ganti A
- Potts HW, *see* Grunfeld EA
- Poulin DL, DeCaprio JA. Is There a Role for SV40 in Human Cancer? 4356
- Prabhu SS, *see* Wang L
- Prados MD, *see* Cloughesy TF
- Prager D, *see* Socinski MA
- Prasad KN, Cole WC. Antioxidants in Cancer Therapy (correspondence), e8
- Premalata C, Devi L, Madhumathi DS, Appaji L. Chediak-Higashi Syndrome Masquerading As Acute Leukemia: The Significance of Lymphocyte Inclusions, 3505
- Press MF, *see* Simon MS
- Press OW, Unger JM, Brazier RM, Maloney DG, Miller TP, LeBlanc M, Fisher RI. Phase II Trial of CHOP Chemotherapy Followed by Tositumomab/Iodine I-131 Tositumomab for Previously Untreated Follicular Non-Hodgkin's Lymphoma: Five-Year Follow-Up of Southwest Oncology Group Protocol S9911, 4143
- Preudhomme C, *see* Lapillonne H
- Price MH, *see* Fallowfield LJ
- Priest JR, Hill DA, Williams GM, Moertel CL, Messenger Y, Finkelstein MJ, Dehner LP. Type I Pleuropulmonary Blastoma: A Report From the International Pleuropulmonary Blastoma Registry, 4492
- Prieto VG, *see* Baptista MZ
- Prince HM, *see* Cachin F
see Mileschkin L
- Prince M, *see* Urba S
- Pritchard KI, *see* Clemons MJ
see Grunfeld E
see Perez EA
- Pro B, *see* Liu Q
- Proia AD, *see* Ellis MJ
- Prokop LJ, *see* Bardia A
- Propping P, *see* Goecke T
- Prosnitz LR, *see* Koontz BF
- Prosnitz RG, *see* Koontz BF
- Prospero JD, *see* Petrilli AS
- Prout M, *see* Enger SM
- Provencio M, Sánchez A, Bonilla F, España P. Association Between Hepatitis C Virus and Non-Hodgkin's Lymphomas (correspondence), 3513
- Provenzale JM, *see* Reardon DA
- Prowell TM, Stearns V, Trock B. Lipophilic Statins Merit Additional Study for Breast Cancer Chemoprevention (correspondence), 2128
- Pruim J, *see* Herder GJM
- Psyrrri A, *see* Weinberger PM
- Puespoek A, *see* Grünberger B
see Raderer M
- Pui C-H, *see* Metzger ML
- Puig S, *see* Argenziano G
- Pujade-Lauraine E, *see* du Bois A
- Pullen J, *see* Barredo JC
- Pulsipher M, *see* George RE
- Pulsipher MA, *see* Baron F
see Eapen M
- Punglia RS, *see* Guadagnolo BA
- Punglia RS, Weeks JC, Neville BA, Earle CC. Radiation Therapy After Mastectomy Between 1991 and 1999 in Elderly Women: Response to Clinical Trial Information, 3474
- Purner M, *see* Berenson JR
- Pusztai L, *see* Hess KR
- Puumala SE, *see* Mikuls TR
- Pyle L, *see* Lee CP

Q

- Qiao Z, *see* Mudie NY
- Qiu D, *see* Khong P-L
- Quaglino P, *see* Zinzani PL
- Quattrocchi CC, Sammarra M, Carassiti M, Vincenzi B, Tonini G, Francesco Grasso R, Beomonte Zobel B. Azygo-Tracheal Fistula in a Complete Implantable Central Venous System, 4029
- Quattrone P, *see* Licitra L
- Quezado M, *see* Beck KE
- Quietzsch D, *see* Heinemann V
- Quinn DI, *see* Levine AM
- Quinn JA, *see* Reardon DA
- Quinn MJ, *see* Shaw HM
- Quinn SE, *see* Erlichman C
- Quintela-Fandino M, Hitt R, Medina PP, Gamarra S, Manso L, Cortes-Funes H, Sanchez-Céspedes M. DNA-Repair Gene Polymorphisms Predict Favor-

- able Clinical Outcome Among Patients With Advanced Squamous Cell Carcinoma of the Head and Neck Treated With Cisplatin-Based Induction Chemotherapy, 4333
- Quintela-Fandino M, López JM, Hitt R, Gamarra S, Jimeno A, Ayala R, Hornedo J, Guzman C, Gilsanz F, Cortés-Funes H. Breast Cancer–Specific mRNA Transcripts Presence in Peripheral Blood After Adjuvant Chemotherapy Predicts Poor Survival Among High-Risk Breast Cancer Patients Treated With High-Dose Chemotherapy With Peripheral Blood Stem Cell Support, 3611
- Quintini C, *see* Di Benedetto F
- R**
- Raab SS, Meier FA, Zarbo RJ, Jensen DC, Geisinger KR, Booth CN, Krishnamurti U, Stone CH, Janosky JE, Grzybicki DM. The “Big Dog” Effect: Variability Assessing the Causes of Error in Diagnoses of Patients With Lung Cancer, 2808
- Raap AK, *see* Dijkman R
- Rackoff WR, *see* Razzouk BI
- Radema SA, *see* Beerepoot LV
- Rademaker-Lakhai JM, Crul M, Zuur L, Baas P, Beijnen JH, Simis YJW, van Zandwijk N, Schellens JHM. Relationship Between Cisplatin Administration and the Development of Ototoxicity, 918
- Raderer aM, *see* Grünberger B
- Raderer M, *see* Wöhrer S
- Raderer M, Wöhrer S, Streubel B, Troch M, Turetschek K, Jäger U, Skrabs C, Gaiger A, Drach J, Poespock A, Formanek M, Hoffmann M, Hauff W, Chott A. Assessment of Disease Dissemination in Gastric Compared With Extra-gastric Mucosa-Associated Lymphoid Tissue Lymphoma Using Extensive Staging: A Single-Center Experience, 3136
- Rades D, Fehlauer F, Schulte R, Veninga T, Stalpers LJA, Basic H, Bajrovic A, Hoskin PJ, Tribius S, Wildfang I, Rudat V, Engenhart-Cabilic R, Karstens JH, Alberti W, Dunst J, Schild SE. Prognostic Factors for Local Control and Survival After Radiotherapy of Metastatic Spinal Cord Compression, 3388
- Radford JA, *see* Johnson PWM
see Strauss SJ
- Radlwimmer B, *see* Rücker FG
- Rae JM, *see* Goetz MP
- Raemaekers JMM, *see* Noordijk EM
- Raez LE, *see* Fanucchi MP
- Raffoux C, *see* Yakoub-Agha I
- Raffoux E, *see* Adès L
- Raghavan D, *see* Herbst RS
see Hussain M
- Raghavan D, Suh T. Cancer in the Elderly Population: The Protection Racket (editorial), 1795
- Rahman A, White RM. Cytotoxic Anticancer Agents and Renal Impairment Study: The Challenge Remains (editorial), 533
- Rahman A, White RM. In Reply (correspondence), 3510
- Raizer JJ, *see* Cloughesy TF
- Raj GV, Iasonos A, Herr H, Donat SM. Formulas Calculating Creatinine Clearance Are Inadequate for Determining Eligibility for Cisplatin-Based Chemotherapy in Bladder Cancer, 3095
- Rajendran JG, *see* Martins RG
- Rajkumar SV, *see* Richardson PG
- Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group, 431
- Raju R, *see* Robert N
- Ramadwar M, *see* Palled S
- Ramanathan RK, *see* Goldberg RM
see Shah MA
- Rambaldi A, *see* Gorin N-C
- Ramirez AJ, *see* Grunfeld EA
- Ramirez N, *see* Morrison C
- Ramiro L, *see* Fernández-Avilés F
- Ramlau R, Gervais R, Krzakowski M, von Pawel J, Kaukel E, Abratt RP, Dharan B, Grotzinger KM, Ross G, Dane G, Shepherd FA. Phase III Study Comparing Oral Topotecan to Intravenous Docetaxel in Patients With Pretreated Advanced Non–Small-Cell Lung Cancer, 2800
- Randall ME, Filiaci VL. In Reply (correspondence), 3710
- Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, Thigpen JT, Benda JA. Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study, 36
- Rangel J, Torabian S, Shaikh L, Nosrati M, Baehner FL, Haqq C, Leong SPL, Miller JR III, Sagebiel RW, Kashani-Sabet M. Prognostic Significance of Nuclear Receptor Coactivator-3 Overexpression in Primary Cutaneous Melanoma, 4565
- Ransohoff DF, *see* Meyskens FL Jr
- Rao RD, *see* Jaeckle KA
- Rao RM, *see* Pockaj BA
- Rao UN, *see* Moschos SJ
- Raphael M, *see* Boué F
- Rapiti E, Verkooijen HM, Vlastos G, Fioretta G, Neyroud-Caspar I, Pascal Sappino A, Chappuis PO, Bouchardy C. Complete Excision of Primary Breast Tumor Improves Survival of Patients With Metastatic Breast Cancer at Diagnosis, 2743
- Rapoport A, *see* Badros A
- Rapp aSR, *see* Shaw EG
- Rashid A, *see* Luthra R
- Rastegar A, *see* Lorenz KA
- Ratain MJ, *see* Innocenti F
see Lichtman SM
see Maitland ML
- Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O’Dwyer PJ. Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma, 2505
- Ratain MJ. In Reply (correspondence), 4670
- Rau B, *see* Rubie C
- Raubitschek A, *see* Mamelak AN
- Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, Fletcher CDM, Demetri GD, Bertagnolli MM. Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors, 2325
- Ray ME, Lawrence TS. Radiation Therapy for Aggressive Fibromatosis (desmoid tumor) (correspondence), 3714
- Raymond E, *see* Faivre S
- Raynard B, *see* Pène F
- Razzouk BI, *see* Jeha S
- Razzouk BI, Hord JD, Hockenberry M, Hinds PS, Feusner J, Williams D, Rackoff WR. Double-Blind, Placebo-Controlled Study of Quality of Life, Hematologic End Points, and Safety of Weekly Epoetin Alfa in Children With Cancer Receiving Myelosuppressive Chemotherapy, 3583
- Read W, *see* Govindan R
- Real FX, *see* Hernández S
- Reale LD, *see* Tsai SC
- Reaman GH, *see* Herbst RS
see Villablanca JG
- Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE II, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburg JJ, Desjardins A, Guruangan S, Badrudoja M, Dowell JM, Wong TZ, Zhao X-G, Zalutsky MR, Bigner DD. Salvage Radioimmunotherapy With Murine Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results, 115
- Reardon DA, Rich JN, Friedman HS, Bigner DD. Recent Advances in the Treatment of Malignant Astrocytoma, 1253

AUTHOR INDEX

- Rebbeck TR, *see* Pierce LJ
- Rebbeck TR, Hughes Halbert C, Sankar P. Genetics, Epidemiology, and Cancer Disparities: Is it Black and White? 2164
- Rebbeck TR. Inherited Genetic Markers and Cancer Outcomes: Personalized Medicine in the Postgenome Era (editorial), 1972
- Rech J, *see* Strauss SJ
- Recht A. Which Breast Cancer Patients Should *Really* Worry About Radiation-Induced Heart Disease—And How Much? (editorial), 4059
- Recht LD, *see* Bredel M
- Reck M, *see* Bezjak A
- Recklitis CJ, Lockwood RA, Rothwell MA, Diller LR. Suicidal Ideation and Attempts in Adult Survivors of Childhood Cancer, 3852
- Reddy CA, *see* Kupelian PA
- Reddy S, *see* Matsuyama R
- Redfern CH, *see* Small EJ
- Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, Leonard JP, Levy RL, Just RG, Smith MR, Rosenfelt FP, Wiernik PH, Carter WD, Gold DP, Melink TJ, Gutheil JC, Bender JF. Phase II Trial of Idiotype Vaccination in Previously Treated Patients With Indolent Non-Hodgkin's Lymphoma Resulting in Durable Clinical Responses, 3107
- Redman BG, *see* Motzer RJ
- Redston M, Bertagnolli MM. In Reply (correspondence), 3713
- Redston M, Compton CC, Miedema BW, Niedzwiecki D, Dowell JM, Jewell SD, Flesher JM, Bem J, Mayer RJ, Bertagnolli MM. Analysis of Micrometastatic Disease in Sentinel Lymph Nodes From Resectable Colon Cancer: Results of Cancer and Leukemia Group B Trial 80001, 878
- Regan MM, *see* Taplin M-E
- Regazzi M, *see* Montillo M
- Reh A, *see* Oktay K
- Rehman W, *see* Hord JD
- Reichle A, *see* Büchner T
- Reid JF, *see* Modena P
- Reid JM, *see* Villablanca JG
- Reif M, *see* Strasser F
- Reifenberger G, *see* Herrlinger U
- Reilly A, *see* Kazak AE
- Reimers H-J, *see* Fanucchi MP
- Reinartz G, *see* Koch P
- Reinert MM, *see* Mariani L
- Reinhardt D, *see* Creutzig U
see Langebrake C
- Reinhardt MJ, Joe AY, Jaeger U, Huber A, Matthies A, Buceri J, Roedel R, Strunk H, Bieber T, Biersack H-J, Tüting T. Diagnostic Performance of Whole Body Dual Modality ¹⁸F-FDG PET/CT Imaging for N- and M-Staging of Malignant Melanoma: Experience With 250 Consecutive Patients, 1178
- Reinhold C, *see* Mitchell DG
- Reintgen DS, *see* Scoggins CR
- Reis I, *see* Hurley J
- Reiss M, *see* Haffty BG
- Reiter A, *see* Burkhardt B
see Creutzig U
see Schrauder A
- Reitsamer R, *see* Knauer M
- Reitsma JB, *see* Lagarde SM
- Remick SC, *see* van Heeckeren WJ
- Reni M, *see* Brandes AA
see Mirimanoff R-O
- Renneberg H, *see* Ferrari AC
- Renneville A, *see* Lapillonne H
- Renshaw AA, *see* D'Amico AV
- Renshaw L, *see* Ellis MJ
- Renzulli M, *see* Cavo M
- Repetto L, Audisio RA. Elderly Patients Have Become the Leading Drug Consumers: It's High Time to Properly Evaluate New Drugs Within the Real Targeted Population (correspondence), e62
- Repp R, *see* Strauss SJ
- Resche I, *see* Rousseau C
- Rescorla F, *see* Marina N
- Retkin R, *see* Fleishman SB
- Retsky MW, *see* Demicheli R
- Reu FJ. In Bae S, Cherkassky L, Leaman DW, Lindner D, Beaulieu N, MacLeod AR, Borden EC. Overcoming Resistance to Interferon-Induced Apoptosis of Renal Carcinoma and Melanoma Cells by DNA Demethylation, 3771
- Reusch J, *see* Dilts DM
- Reuter VE, *see* Argani P
- Reuther AM, *see* Kupelian PA
- Rey A, *see* Oberlin O
- Reyes F, *see* Besson C
- Reynes J, *see* Boué F
- Reynolds C, *see* Goetz MP
- Reynolds M, *see* Malogolowkin MH
- Reynolds PC, *see* Villablanca JG
- Reznek R, *see* Barentsz J
- Rheingold S, *see* Jeha S
- Rhoades C, *see* Monk JP
- Rhoades CA, *see* Lichtman SM
- Ribeiro M, *see* Fanucchi MP
- Ribero D, *see* Vauthey J-N
- Ribero D, Abdalla EK, Vauthey J-N. In Reply (correspondence), 5467
- Ribrag V, *see* Vey N
- Ricaud M, *see* Rousseau C
- Riccardi A, *see* Paccagnella A
- Riccardi R, *see* Modena P
- Ricci F, *see* Montillo M
- Ricci S, *see* Abou-Alfa GK
- Ricciardi R, *see* Johnson PM
- Rich JN, *see* Reardon DA
- Rich TA, *see* Ajani JA
see Smalley SR
- Richards DA, *see* Jones SE
- Richards MA, *see* Grunfeld EA
- Richards WG, Zellos L, Bueno R, Jaklitsch MT, Jänne PA, Chirieac LR, Yeap BY, Dekkers RJ, Hartigan PM, Capalbo L, Sugarbaker DJ. Phase I to II Study of Pleurectomy/Decortication and Intraoperative Intracavitary Hyperthermic Cisplatin Lavage for Mesothelioma, 1561
- Richardson J, *see* Rummans TA
- Richardson P, Anderson K. Thalidomide and Dexamethasone: A New Standard of Care for Initial Therapy in Multiple Myeloma (editorial), 334
- Richardson PG, *see* Anderson KC
- Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orłowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA. Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib, 3113
- Richardson S, *see* O'Connor OA
- Richel DJ, *see* Janmaat ML
- Richelson E, *see* Pockaj BA
- Richon V, *see* O'Connor OA
- Richter B, *see* du Bois A
- Riddle J, *see* Carducci MA
- Ridge JA, *see* Pfister DG
- Ridolfi R, *see* Paccagnella A
- Rieger J, *see* Herrlinger U
- Riegler-Keil M, *see* Knauer M
- Riehm H, *see* Burkhardt B
see Schrauder A
- Riely GJ, *see* Milton DT
see Pham D
- Rigal-Huguet F, *see* Adès L
- Rimm DL, *see* Weinberger PM
- Ring BZ, Seitz RS, Beck R, Shasteen WJ, Tarr SM, Cheang MCU, Yoder BJ,

AUTHOR INDEX

- Budd GT, Nielsen TO, Hicks DG, Estopinal NC, Ross DT. Novel Prognostic Immunohistochemical Biomarker Panel for Estrogen Receptor–Positive Breast Cancer, 3039
- Rini BI, *see* Motzer RJ
- Rio B, *see* Hegenbart U
- Rios MB, *see* Ault P
- Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, Peters LJ. Prognostic Significance of [¹⁸F]-Misonidazole Positron Emission Tomography–Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer Randomly Assigned to Chemoradiation With or Without Tirapazamine: A Substudy of Trans-Tasman Radiation Oncology Group Study 98.02, 2098
- Risio M, *see* Vauthey J-N
- Risse M-L, *see* Van Cutsem E
- Ristow KM, *see* Mikuls TR
- Ritchev AK, *see* Barredo JC
- Ritchev K, *see* Jeha S
- Ritchev ML, *see* Dome JS
- Ritter J, *see* Creutzig U
- Rivera E, *see* Avis NE
see Esmaeli B
- Rivera F, *see* Bourhis J
see Tournigand C
- Rivera JA, *see* Domínguez P
- Rives M, *see* Bourhis J
- Rivory LP, *see* Wong M
- Rizzieri D, *see* Schiller GJ
- Robba C, *see* Ponzzone R
- Robbins ME, *see* Shaw EG
- Robert A, *see* Francart J
- Robert C, *see* Faivre S
- Robert F, *see* Fanucchi MP
- Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L, Slamon D. Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer, 2786
- Roberts PJ, *see* Heinrich MC
- Roberts R, *see* Jagsi R
- Robertson C, *see* Guerrieri-Gonzaga A
- Robertson JM, *see* Smalley SR
- Robertson MJ, *see* Fisher RI
- Robertson PL, *see* Packer RJ
- Robidoux A, *see* Bear HD
- Robins HI, *see* Cloughesy TF
- Robinson BA, *see* Harvey V
- Robinson WA, *see* Lewis KD
- Robison LL, *see* Bassal M
see Bowers DC
- Rocco JR, *see* Soares M
- Rocha Lima CMSP, Flores AM. Gemcitabine Doublets in Advanced Pancreatic Cancer: Should We Move On? (editorial), 327
- Rocha V, *see* Gorin N-C
- Roché H, Fumoleau P, Spielmann M, Canon J-L, Delozier T, Serin D, Symann M, Kerbrat P, Soulié P, Eichler F, Viens P, Monnier A, Vindevoghel A, Campone M, Goudier M-J, Bonnetterre J, Ferrero J-M, Martin A-L, Genève J, Asselain B. Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial, 5664
- Rochon J, *see* du Bois A
see Pfisterer J
- Rock CL, *see* Bardwell WA
- Rodari M, *see* Ceresoli GL
- Rödel C, *see* Weiss C
- Rödel C, Sauer R. In Reply (correspondence), 1320
- Rödel C, Weiss C, Sauer R. Trimodality Treatment and Selective Organ Preservation for Bladder Cancer, 5536
- Rodgers A, *see* Chia S
- Rodrigues A, *see* Van Cutsem E
- Rodrigues Pereira J, *see* Hirsch FR
- Rodríguez CA, *see* Ocaña A
- Rodríguez JA, *see* Janmaat ML
- Rodríguez MA, *see* Liu Q
- Rodríguez-Bigas MA, *see* Guillem JG
- Rodríguez-Galindo C, *see* Furman WL
- Rodríguez-Moranta F, Saló J, Arcusa À, Boadas J, Piñol V, Bessa X, Batiste-Alentorn E, Lacy AM, Delgado S, Maurel J, Piqué JM, Castells A. Postoperative Surveillance in Patients With Colorectal Cancer Who Have Undergone Curative Resection: A Prospective, Multicenter, Randomized, Controlled Trial, 386
- Rodrigus PTR, *see* van den Belt-Dusebout AW
- Roedel R, *see* Reinhardt MJ
- Roggin K, *see* Jarnagin WR
- Rohatiner A, *see* Strauss SJ
- Rohmer V, *see* Chatal J-F
- Rojo F, Tabernero J, Albanell J, Van Cutsem E, Ohtsu A, Doi T, Koizumi W, Shirao K, Takiuchi H, Cajal SR, Baselga J. Pharmacodynamic Studies of Gefitinib in Tumor Biopsy Specimens From Patients With Advanced Gastric Carcinoma, 4309
- Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, Calin GA, Volinia S, Liu C-G, Scarpa A, Croce CM. MicroRNA Expression Abnormalities in Pancreatic Endocrine and Acinar Tumors Are Associated With Distinctive Pathologic Features and Clinical Behavior, 4677
- Rolnick SJ, *see* Geiger AM
- Rolon C, *see* Lorenz KA
- Romaguera J, *see* Liu Q
- Roman L, *see* Gordon MS
- Ronckers CM, *see* Bassal M
- Rondoni M, *see* Soverini S
- Ronnen EA, Kondagunta GV, Motzer aRJ. Medullary Renal Cell Carcinoma and Response to Therapy With Bortezomib (correspondence), e14
- Rookus MA, *see* Andrieu N
- Rooney PH, *see* Petty RD
- Rorke-Adams L, *see* Packer RJ
- Rosa DD, Harris J, Jayson GC. The Best Guess Approach to Phase I Trial Design, 206
- Rosa DD, Ismael GFV, de Azambuja E, Braga S, Cardoso F, Bleiberg H. OPTIMO1 in Advanced Colorectal Cancer: Lack of Evidence for a Stop-and-Go Strategy (correspondence), 5176
- Rosdhal R, *see* Shaw EG
- Rosell R, *see* Weiss GJ
- Rosen DM, *see* Lichtman SM
- Rosen F, *see* Cohen EEW
- Rosen LS, *see* Bilchik AJ
- Rosen LS, Abdi E, Davis ID, Gutheil J, Schnell FM, Zalberg J, Cesano A, Gayko U, Chen M-G, Clarke S. Palifermin Reduces the Incidence of Oral Mucositis in Patients With Metastatic Colorectal Cancer Treated With Fluorouracil-Based Chemotherapy, 5194
- Rosen M, *see* Schnall M
- Rosenbaum E, *see* Hoque MO
- Rosenberg AE, *see* Oliveira AM
- Rosenberg C, *see* Dijkman R
- Rosenberg SA, *see* Beck KE
- Rosenfeld S, *see* Mamelak AN
- Rosenfelt FP, *see* Redfern CH
- Rosenthal DI, Lewin JS, Eisbruch aA. Prevention and Treatment of Dysphagia and Aspiration After Chemoradiation for Head and Neck Cancer, 2636
- Rosenthal DN, *see* Chow AY
- Rosenthal E, *see* Grabar S
- Rosenthal M. Career Advice for Oncology Trainees (correspondence), e53
- Rosenwald A, *see* Iqbal J
- Rosenzweig MQ. The Oncology Nurse Practitioner: A Unique Provider for the Follow-Up for Early-Stage Breast Cancer (correspondence), 3710

AUTHOR INDEX

- Roser F, *see* Barrier A
 Rosine D, *see* Bourhis J
 Rosner GL, *see* Lichtman SM
see Ratain MJ
 Ross DT, *see* Ring BZ
 Ross G, *see* Eckardt JR
see Ramlau R
 Ross GA, *see* O'Brien MER
 Ross JS, *see* Hess KR
 Ross MI, *see* Aloia TA
see Cornett WR
see Scoggins CR
 Ross PJ, *see* Chau I
 Rossi G, *see* Glaspy J
 Rossini C, *see* Licitra L
 Rost A, *see* Heinemann V
 Rosti G, *see* Iacobucci I
see Soverini S
 Roth BJ, *see* Sweeney CJ
 Roth RB, *see* Spinola M
 Rothenberg ML, *see* Goldberg RM
see Markman M
 Rothman N, *see* Cai Q
 Rothwell MA, *see* Recklitis CJ
 Rotmensch N, *see* Bonanni B
 Rouanet P, *see* Bijker N
see Houvenaeghel G
 Rougier P, *see* Benoist S
see Bilchik AJ
see Portier G
 Rouquette S, *see* Rousseau C
 Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, Ricaud M, Bourbouloux E, Doutriaux I, Clouet M, Berton-Rigaud D, Bouriel C, Delecroix V, Garin E, Rouquette S, Resche I, Kerbrat P, Chatal JF, Campone M. Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography, 5366
 Rouzier R, *see* Hess KR
 Rovira M, *see* Fernández-Avilés F
 Rowinsky E, *see* Ratain MJ
 Rowinsky EK, *see* Erlichman C
see Lenz H-J
see Mita AC
see Tolcher AW
 Rowinsky EK. Lately, It Occurs to Me What a Long, Strange Trip It's Been for the Farnesyltransferase Inhibitors (editorial), 2981
 Rowland J, *see* Malogolowkin MH
 Rowland JH, Hewitt M, Ganz PA. Cancer Survivorship: A New Challenge in Delivering Quality Cancer Care, 5101
 Rowland Jr KM, *see* Steensma DP
 Rowland KM, *see* Ingle JN
see Pockaj BA
 Royal RE, *see* Beck KE
 Royce M, *see* Woodward WA
 Rubie C, Oliveira-Frick V, Rau B, Schilling M, Wagner M. Chemokine Receptor CCR6 Expression in Colorectal Liver Metastasis (correspondence), 5173
 Rubie H, *see* Oberlin O
 Rubie H, Chisholm J, Defachelles AS, Morland B, Munzer C, Valteau-Couanet D, Mosseri V, Bergeron C, Weston C, Coze C, Auvrignon A, Djafari L, Hobson R, Baunin C, Dickinson F, Brisse H, McHugh K, Biassoni L, Giammarile F, Vassal G. Phase II Study of Temozolomide in Relapsed or Refractory High-Risk Neuroblastoma: A Joint Société Française des Cancers de l'Enfant and United Kingdom Children Cancer Study Group—New Agents Group Study, 5259
 Rubinstein L, *see* Chen HX
 Rubinstein P, *see* Eapen M
 Ruckdeschel JC, *see* Eggly S
 Rucker FG, Bullinger L, Schwaenen C, Lipka DB, Wessendorf S, Fröhling S, Bentz M, Miller S, Scholl C, Schlenk RF, Radlwimmer B, Kestler HA, Pollack JR, Lichter P, Döhner K, Döhner H. Disclosure of Candidate Genes in Acute Myeloid Leukemia With Complex Karyotypes Using Microarray-Based Molecular Characterization, 3887
 Rudat V, *see* Rades D
 Rudd RM, *see* Spiro SG
 Rudlowski C, *see* Thuerigen O
 Rueschoff J, *see* Goecke T
 Ruffert U, *see* Kröger N
 Ruhstaller T, *see* Strasser F
see von Moos R
 Ruiz de Elvira MC, *see* Spiro SG
 Rummans TA, Clark MM, Sloan JA, Frost MH, Bostwick JM, Atherton PJ, Johnson ME, Gamble G, Richardson J, Brown P, Martensen J, Miller J, Piderman K, Huschka M, Girardi J, Hanson J. Impacting Quality of Life for Patients With Advanced Cancer With a Structured Multidisciplinary Intervention: A Randomized Controlled Trial, 635
 Runge T, *see* Wachtel M
 Rupoli S, *see* Zinzani PL
 Ruppert AS, *see* Paschka P
 Rusch VW, *see* Pham D
 Russell aKM, *see* Kirkova J
 Russell ML, *see* Temple WJ
 Russo A, *see* Toffoli G
 Russo D, *see* Iacobucci I
 Russo J, *see* Watkins Bruner D
 Russo P, *see* Dalbagni G
see Eggener SE
 Rustemeijer C, *see* van Apeldoorn MJ
 Rustin GJS, *see* Murugaesu N
 Rustin GJS, Timmers P, Nelstrop A, Shreeves G, Bentzen SM, Baron B, Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Eisenhauer E. Comparison of CA-125 and Standard Definitions of Progression of Ovarian Cancer in the Intergroup Trial of Cisplatin and Paclitaxel Versus Cisplatin and Cyclophosphamide, 45
 Rutgers E, *see* Loi S
 Rutgers EJT, *see* Bijker N
 Rutka J, *see* Tabori U
 Rutkowski S, *see* Timmermann B
 Ruzzo A, Graziano F, Kawakami K, Watanabe G, Santini D, Catalano V, Bissoni R, Canestrari E, Ficarella R, Tito Menichetti E, Mari D, Testa E, Silva R, Vincenzi B, Giordani P, Cascinu S, Giustini L, Tonini G, Magnani M. Pharmacogenetic Profiling and Clinical Outcome of Patients With Advanced Gastric Cancer Treated With Palliative Chemotherapy, 1883
 Ryan CJ. In Reply (correspondence), 2965
 Ryan DP, *see* Kulke MH
see Meyerhardt JA
see Zhu AX
 Ryan DP, Niedzwiecki D, Hollis D, Mediema BE, Wadler S, Tepper JE, Goldberg RM, Mayer RJ. Phase I/II Study of Preoperative Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy in Patients With Locally Advanced Rectal Cancer: Cancer and Leukemia Group B 89901, 2557
 Rybicki L, *see* Kalaycio M
 Rybicki LA, *see* Adelstein DJ
 Rydholm A, *see* Mertens F
 Rytting M, *see* Jeha S
 Ryu J, *see* Elliott EA
 Ryu J-S, Lee H-J. Effects of Comorbidity and Smoking on the Survival of Lung Cancer Patients (correspondence), 5468
- ## S
- Saarinen-Pihkala UM, Heilmann C, Winiarski J, Glomstein A, Abrahamsson J, Arvidson J, Békássy AN, Forestier E, Jonmundsson G, Schroeder H, Vetten-

AUTHOR INDEX

- ranta K, Wesenberg F, Gustafsson G. Pathways Through Relapses and Deaths of Children With Acute Lymphoblastic Leukemia: Role of Allogeneic Stem-Cell Transplantation in Nordic Data, 5750
- Saarto T, *see* Vehmanen L
- Sabbatini E, *see* Went P
- Sabbatini P, Spriggs DR. Consolidation for Ovarian Cancer in Remission (editorial), 537
- Sadler K, *see* Berenson JR
- Safgren SL, *see* Goetz MP
- Sagaert X, de Paepe P, Libbrecht L, Vanhentenrijk V, Verhoef G, Thomas J, Wlodarska I, De Wolf-Peeters C. Forkhead Box Protein P1 Expression in Mucosa-Associated Lymphoid Tissue Lymphomas Predicts Poor Prognosis and Transformation to Diffuse Large B-Cell Lymphoma, 2490
- Sagan C, *see* Rousseau C
- Sagebiel RW, *see* Fears TR
see Rangel J
- Sagi M, *see* Offit K
- Saglio G, *see* Iacobucci I
see Soverini S
- Sahmoun AE, *see* Ganti AK
see Kishor Ganti A
- Saijo N, *see* Niho S
see Ohtsu A
see Olopade OI
- Saijo Y, *see* Fujiwara T
see Inoue A
- Saikawa Y, Tone Y, Ikawa Y, Maeba H, Koizumi S, Minato H. Hemophagocytic Alveolar Rhabdomyosarcoma, 5783
- Saint F, *see* Sanchez-Carbayo M
- Saito H, Takada Y, Ichinose Y, Eguchi K, Kudoh S, Matsui K, Nakagawa K, Takada M, Negoro S, Tamura K, Ando M, Tada T, Fukuoka M. Phase II Study of Etoposide and Cisplatin With Concurrent Twice-Daily Thoracic Radiotherapy Followed by Irinotecan and Cisplatin in Patients With Limited-Disease Small-Cell Lung Cancer: West Japan Thoracic Oncology Group 9902, 5247
- Salama A, *see* Badros A
- Salamina S, *see* Ceresoli GL
- Salazar LG, *see* Goodell V
- Saleh M, *see* Schiller GJ
- Salles G, *see* Ghesquières H
- Salluh JIF, *see* Soares M
- Salmon SE, *see* Barlogie B
- Saló J, *see* Rodríguez-Moranta F
- Saltz L, *see* Bilchik AJ
- Saltz LB, *see* Abou-Alfa GK
see Chung KY
see Meyerhardt JA
- Salvadó M-T, *see* Álvaro T
- Salvesen HB, *see* Bachmann IM
- Salzer WL, *see* Widemann BC
- Sammarra M, *see* Quattrocchi CC
- Samson Y, *see* Barrette S
- Sánchez A, *see* Provencio M
- Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining Molecular Profiles of Poor Outcome in Patients With Invasive Bladder Cancer Using Oligonucleotide Microarrays, 778
- Sanchez-Cespedes M, *see* Quintela-Fandino M
- Sandau K, *see* Heinrich MC
- Sandbach J, *see* Jones SE
- Sandler A, *see* Govindan R
see Hanna N
see Mita AC
- Sandler AB, *see* Dilts DM
- Sandler HM, *see* Buckner JC
- Sandler HM. Exploring Dose-Intensity: Carefully Comparing High-Dose With Low-Dose External-Beam Radiotherapy for Prostate Cancer (editorial), 1975
- Sandmaier BM, *see* Baron F
see Hegebart U
- Sandri P, *see* Toffoli G
- Sandset PM, *see* Negaard HFS
- Sankar P, *see* Rebbeck TR
- Sanson M, *see* van den Bent MJ
- Santana VM, *see* Furman WL
- Santen RJ, *see* Smith IE
- Santillan A, Bristow RE. In Reply (correspondence), 3310
- Santinami M, *see* Cascinelli N
- Santini A, *see* Lanza G
- Santini D, *see* Gentilucci UV
see Ruzzo A
see Vincenzi B
- Santoro A, *see* Abou-Alfa GK
see Ceresoli GL
- Santoro A, *see* Ceresoli GL
- Santucci M, *see* Zinzani PL
- Sargent D, *see* Haller DG
- Sargent DJ, *see* Goldberg RM
- Saric J, *see* Portier G
- Sarkar S, *see* Kabbinar FF
- Sarkaria IS, *see* Pham D
- Sasaki C, *see* Weinberger PM
- Sasaki H, *see* Yasuda H
- Sasaki T, *see* Yasuda H
- Sato T, *see* Fujiwara T
- Satoh T, *see* Kudoh S
- Sauer R, *see* Rödel C
see Weiss C
- Sauerland M-C, *see* Büchner T
- Saunders MI, *see* Koukourakis MI
- Sausville E, *see* Badros A
- Savady R, *see* Yan TD
- Savage PM, *see* Murugaesu N
- Savin MA, *see* Jones SE
- Sawa T, *see* Kudoh S
- Sawaya R, *see* Herbst RS
- Sawka C, *see* Grunfeld E
- Sawyer D, *see* Dilts DM
- Saxton JP, *see* Adelstein DJ
see Elliott EA
- Sayre R, *see* Robert N
- Scadden DT, *see* Duda DG
- Scagliotti GV, *see* Papotti M
- Scaradavou A, *see* Eapen M
- Scardino PT, *see* Stephenson AJ
- Scarpa A, *see* Roldo C
- Scarpati B, *see* Montillo M
- Schaaf LJ, *see* Monk JP
- Schacherer CW, *see* Aloia TA
- Schackert HK, *see* Goecke T
- Schade-Bijur S, *see* Mamelak AN
- Schaefer PL, *see* Brown PD
see Steensma DP
- Schäfer BW, *see* Wachtel M
- Schäfer C, Dietl B, Loew TH, Kölbl O. What About the Family When a Terminally Ill Cancer Patient Makes a Request for Euthanasia? (correspondence), 3211
- Schäfer D, *see* Gadzicki D
- Schagen SB, van Dam FSAM. Does Cognitive Impairment After Chemotherapy for Breast Cancer Improve Over Time or Does Practice Make Perfect? (correspondence), 5170
- Schagen van Leeuwen JH, *see* Slee PHThJ
- Schalhorn A, *see* Heinemann V
- Schapira L, *see* Baile WF

AUTHOR INDEX

- Scharf O, Colevas AD. Adverse Event Reporting in Publications Compared With Sponsor Database for Cancer Clinical Trials, 3933
- Scheck AC, *see* Bredel M
- Scheibenbogen C, *see* Ghadjar P
- Scheibenbogen C, Ghadjar P, Keilholz U. In Reply (correspondence), 5174
- Scheier MF, Helgeson VS. Really, Disease Doesn't Matter? A Commentary on Correlates of Depressive Symptoms in Women Treated for Early-Stage Breast Cancer (editorial), 2407
- Schein P. Paul Calabresi, MD, 2406
- Scheinberg DA, *see* Lamanna N
- Scheithauer B, *see* Cairncross G
- Scheithauer BW, *see* Buckner JC
see Miller CR
- Scheithauer W, *see* Gruenberger T
- Schelhammer PF, *see* Hussain M
- Schellens JHM, *see* Rademaker-Lakhai JM
see Siegel-Lakhai WS
- Schellhammer PF, *see* Small EJ
- Schenkein D, *see* Berenson JR
see Strauss SJ
- Schernhammer ES, *see* Kroenke CH
- Schiff D, *see* Cloughesy TF
- Schiff R, *see* Lee AV
- Schiffer CA, *see* Smith TJ
- Schiffer IB, *see* Tanner B
- Schijf CP, *see* van Trommel NE
- Schild SE, *see* Rades D
- Schilder RJ, *see* Gordon MS
- Schildkraut JM, *see* Chen S
- Schiller GJ, Slack J, Hainsworth JD, Mason J, Saleh M, Rizzieri D, Douer D, List AF. Phase II Multicenter Study of Arsenic Trioxide in Patients With Myelodysplastic Syndromes, 2456
- Schiller JH, *see* Fanucchi MP
- Schilling M, *see* Rubie C
- Schillinger B, *see* Ko AH
- Schilsky RL, *see* Dilts DM
see Meyerhardt JA
- Schimmel EC, *see* van den Belt-Dusebout AW
see van Tol-Geerdink JJ
- Schirmer M, *see* DeJaco C
- Schittulli F, *see* Foekens JA
- Schlag PM, *see* Jüttner S
- Schlecht HP, *see* Konstantinopoulos PA
- Schlegelberger B, *see* Gadzicki D
- Schlemmer B, *see* Pène F
- Schlenk RF, *see* Kröber A
see Rücker FG
- Schmandt R, *see* Han LY
- Schmid P, *see* Murugaesu N
- Schmidt H, Johansen JS, Sjoegren P, Christensen IJ, Sorensen BS, Fode K, Larsen J, von der Maase H. Serum YKL-40 Predicts Relapse-Free and Overall Survival in Patients With American Joint Committee on Cancer Stage I and II Melanoma, 798
- Schmidt J, *see* Carducci MA
- Schmidt M, *see* Huber RM
see Tanner B
- Schmidt ML, *see* Hord JD
- Schmiegel W, *see* Goecke T
- Schmitt C, *see* Oberlin O
- Schmitt M, *see* Foekens JA
- Schmitz KH, *see* Ahmed RL
- Schnall M, Rosen M. Primer on Imaging Technologies for Cancer, 3225
- Schneeberger A, *see* Pashenkov M
- Schneeweiss A, *see* Thuerigen O
- Schneider A, *see* Badros A
- Schneider EC, *see* Malin JL
- Schneider KA, *see* Farkas Patenaude A
- Schneider P, *see* Jaster M
- Schnell FM, *see* Rosen LS
- Schnelle M, *see* Strasser F
- Schnipper LE, *see* Pentz RD
- Schnitt SJ, *see* Wong JS
- Schnitt SJ. Estrogen Receptor Testing of Breast Cancer in Current Clinical Practice: What's the Question? 1797
- Schnittger S, *see* Büchner T
- Schobesberger M, *see* Mariani L
- Schoch C, *see* Büchner T
- Schoenmakers EFP, *see* Modena P
- Scholl C, *see* Rücker FG
- Scholl S, *see* Kaufmann M
- Schomberg PJ, *see* Buckner JC
- Schönbuchner I, *see* Gadzicki D
- Schönekas H, *see* Heinemann V
- Schonfeld TL, *see* Anderson JR
- Schormann W, *see* Tanner B
- Schott A, *see* Hagenbeek A
- Schover LR, *see* Lee SJ
- Schover LR, Jenkins R, Sui D, Adams JH, Marion MS, Eubanks Jackson K. Randomized Trial of Peer Counseling on Reproductive Health in African American Breast Cancer Survivors, 1620
- Schover LR. Is the Fault in Our Steroids or in Our Selves? (editorial), 3519
- Schrag D, *see* Bickell NA
see Elkin EB
- Schrappé M, *see* Burkhardt B
see Schrauder A
- Schrauder A, Reiter A, Gadner H, Niethammer D, Klingebiel T, Kremens B, Peters C, Ebell W, Zimmermann M, Niggli F, Ludwig W-D, Riehm H, Welte K, Schrappé M. Superiority of Allogeneic Hematopoietic Stem-Cell Transplantation Compared With Chemotherapy Alone in High-Risk Childhood T-Cell Acute Lymphoblastic Leukemia: Results From ALL-BFM 90 and 95, 5742
- Schrenk P, *see* Knauer M
- Schröder FH, *see* Otto SJ
- Schroeder H, *see* Saarinen-Pihkala UM
- Schroeder W, *see* du Bois A
- Schrott K-M, *see* Weiss C
- Schubert EK, *see* Linden HM
- Schuchter LM, *see* Herbst RS
- Schueler A, *see* Bourhis J
- Schueller J, *see* Giacchetti S
- Schuetz F, *see* Thuerigen O
- Schulmann K, *see* Goecke T
- Schulte R, *see* Rades D
- Schultheiss H-P, *see* Jaster M
- Schultz C, *see* Abrey LE
- Schuster M, *see* Richardson PG
- Schuuring E, *see* van Imhoff GW
- Schwab M, *see* Oberthuer A
- Schwabe W, *see* Liersch T
- Schwaenen C, *see* Rücker FG
- Schwager S, *see* Shanafelt TD
- Schwaiger M, *see* Ott K
- Schwartz R, *see* Meropol NJ
see Tsai SC
- Schwartzmann G, *see* Olopade OI
- Schwartz AG, *see* Simon MS
- Schwartz B, *see* Abou-Alfa GK
see Ratain MJ
- Schwartz GK, *see* Shah MA
- Schwartz JL, *see* Leisenring W
- Schwartz L, *see* Abou-Alfa GK
see O'Connor OA
see Shah MA

AUTHOR INDEX

- Schwartz LH, *see* Mitchell DG
 Schwartz MA, *see* Pfister DG
 Schwartz S, *see* Baldus CD
 Schwartzberg L, *see* Govindan R
 see Smith TJ
 Schwarzenberger PO, *see* Nemunaitis J
 Scigalla P, *see* Faivre S
 Scoggins CR, Ross MI, Reintgen DS, Dirk Noyes R, Goydos JS, Beitsch PD, Urist MM, Ariyan S, Scott Davidson B, Sussman JJ, Edwards MJ, Martin RCG, Lewis AM, Stromberg AJ, Conrad AJ, Hagendoorn L, Albrecht J, McMasters KM. Prospective Multi-Institutional Study of Reverse Transcriptase Polymerase Chain Reaction for Molecular Staging of Melanoma, 2849
 Scoggins M, *see* Dilts DM
 Scolyer RA, *see* Shaw HM
 Scott AM, *see* Michael M
 Scott C, *see* James PA
 Scott Davidson B, *see* Scoggins CR
 Scott L, *see* Al-Mulla F
 Seay TE, *see* Lembersky BC
 Sebagh M, *see* Aloia T
 Sebag-Montefiore D, *see* Glynn-Jones R
 Sebt SM, *see* Sparano JA
 Seckl MJ, *see* Murugaesu N
 See C, *see* McCulloch MF
 see McCulloch M
 Seeber S, *see* Kaufmann M
 Seeger RC, *see* Matthay KK
 Segawa T, *see* Tsuchiya N
 Segura S, *see* Argenziano G
 see Fernández-Avilés F
 Sehoul J, *see* Tanner B
 Seiden MV, *see* Verheijen RH
 Seiler T, *see* Kröber A
 Seitz J-F, *see* Gérard J-P
 Seitz RS, *see* Ring BZ
 Sekeres MA, *see* Kang TY
 Seki N, *see* Onoda S
 Seki N, Uematsu K, Shibakuki R, Eguchi K. Promising New Treatment Schedule for Gefitinib Responders After Severe Hepatotoxicity With Daily Administration (correspondence), 3213
 Sekine I, *see* Takano T
 Selby JV, *see* Clarke CA
 Selby PJ, *see* Lee CP
 Semba H, *see* Kudoh S
 Semiglazov V, *see* Harvey V
 see Kaufmann M
 Sempoux C, *see* Machiels J-P
 Senn H-J, *see* Urban P
 Senzer N, *see* Nemunaitis J
 see Suh JH
 Sera F, *see* Argenziano G
 Serena M, Guido C, Emanuela B, Enrico G, Simona S, Daniela C, Giovanni M. The First Case of an AIDS Patient With Systemic Mast Cell Disease Associated With Eosinophilia *FIP1*-Positive Treated With Imatinib Mesylate Therapy (correspondence), e6
 Serin D, *see* Roché H
 Seriu T, *see* Tobinai K
 Serra C, *see* Hernández S
 Serrano D, *see* Guerrieri-Gonzaga A
 Serrano T, *see* Dotor E
 Serve HL, *see* Büchner T
 Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J. Influence of Hormone Replacement Therapy on Tamoxifen-Induced Vasomotor Symptoms, 3991
 Seto T, *see* Ando M
 see Kudoh S
 see Onoda S
 Seute T, Leffers P, Wilmink JT, ten Velde GPM, Twijnstra A. Response of Asymptomatic Brain Metastases From Small-Cell Lung Cancer to Systemic First-Line Chemotherapy, 2079
 Seymour JF, *see* Leahy MF
 see Mileskin L
 Seymour L, *see* Bezjak A
 Sgroi DC, *see* Ma X-J
 see Wong JS
 Shah JP, *see* Pfister DG
 Shah M, *see* Monk JP
 Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, Schwartz GK, Kelsen DP. Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, 5201
 Shaha AR, *see* Pfister DG
 Shaikh L, *see* Rangel J
 Shak S, *see* Paik S
 Shaked Y, Bertolini F, Emmenegger U, Lee CR, Kerbel RS. On the Origin and Nature of Elevated Levels of Circulating Endothelial Cells After Treatment With a Vascular Disrupting Agent (correspondence), 4040
 Shamberger RC, *see* Dome JS
 see George RE
 Shan X, *see* Coughlin CM
 Shanafelt T, *see* Novak AJ
 Shanafelt T, Chung H, White H, Lyckholm LJ. Shaping Your Career to Maximize Personal Satisfaction in the Practice of Oncology, 4020
 Shanafelt TD, Jelinek D, Tschumper R, Schwager S, Nowakowski G, DeWald GW, Kay NE. Cytogenetic Abnormalities Can Change During the Course of the Disease Process in Chronic Lymphocytic Leukemia (correspondence), 3218
 Shanafelt TD, Witzig TE, Fink SR, Jenkins RB, Paternoster SF, Smoley SA, Stockero KJ, Nast DM, Flynn HC, Tschumper RC, Geyer S, Zent CS, Call TG, Jelinek DF, Kay NE, Dewald GW. Prospective Evaluation of Clonal Evolution During Long-Term Follow-Up of Patients With Untreated Early-Stage Chronic Lymphocytic Leukemia, 4634
 Shane R, *see* Mohiuddin M
 Shapiro GI. Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment, 1770
 Sharf BF, *see* Gordon HS
 Sharif S, Ferner R, Birch JM, Gillespie JE, Gattamaneni HR, Baser ME, Evans DGR. Second Primary Tumors in Neurofibromatosis 1 Patients Treated for Optic Glioma: Substantial Risks After Radiotherapy, 2570
 Sharkey RM, *see* Chatal J-F
 see Gold DV
 see Goldenberg DM
 Sharma A, *see* Bepler G
 Sharma S, *see* Bepler G
 Sharma S. Phase I Trials May Not Need to Be Viewed As Extraordinarily Different From Other Clinical Research (correspondence), e47
 Shasteen WJ, *see* Ring BZ
 Shaw AK, *see* Maunsell E
 see Speechley KN
 Shaw E, *see* Cairncross G
 see Suh JH
 Shaw EG, Rosdhal R, D'Agostino RB Jr, Lovato J, Naughton MJ, Robbins ME, Rapp SR. Phase II Study of Donepezil in Irradiated Brain Tumor Patients: Effect on Cognitive Function, Mood, and Quality of Life, 1415
 Shaw HM, Quinn MJ, Scolyer RA, Thompson JF. Survival in Patients With Desmoplastic Melanoma (correspondence), e12
 Shawler DL, *see* Nemunaitis J
 Shea TC, *see* Stiff PJ
 Sheehan S, *see* Meyerhardt JA
 see Zhu AX
 Sheib RG, *see* Tolaney SM
 Sheinfeld J, *see* Dalbagni G
 see Kondagunta GV

AUTHOR INDEX

- Shek TW, *see* Hon C
- Shekelle PG, *see* Lorenz KA
- Shelley Wang X, Fairclough DL, Liao Z, Komaki R, Chang JY, Mobley GM, Cleeland CS. Longitudinal Study of the Relationship Between Chemoradiation Therapy for Non-Small-Cell Lung Cancer and Patient Symptoms, 4485
- Shelso J, *see* Metzger ML
- Shen L, *see* Bruera E
- Shen S, *see* Mamelak AN
- Shen V, *see* Jeha S
- Sheng S, *see* Fanucchi MP
- Shenkier TN, *see* Perez EA
- Shepherd F, *see* Weiss GJ
- Shepherd FA, *see* Bezjak A
see Ramlau R
- Shepherd FA, Tsao M-S. Unraveling the Mystery of Prognostic and Predictive Factors in Epidermal Growth Factor Receptor Therapy (correspondence), 1219
- Shepherd L, *see* Whelan TJ
- Shepherd LE, *see* Perez EA
- Sherman M, *see* Bonthala Wedam S
- Sherry RM, *see* Beck KE
- Shi H, *see* Fisher RI
- Shia J, *see* Nissan A
- Shibakuki R, *see* Seki N
- Shieh K, *see* McCulloch MF
see McCulloch M
- Shih JH, *see* Tsurutani J
- Shimbo M, *see* Tsuchiya N
- Shimoyama Y, *see* Asano N
- Shin ES, *see* Han J-Y
- Shinkai T, *see* Kudoh S
- Shipe-Spotloe J, *see* Moschos SJ
- Shirao K, *see* Rojo F
- Shiratori K, *see* Sohlbach K
- Shizuru JA, *see* Baron F
see Hegenbart U
- Shorr RI, *see* Metzger ML
- Short PF, Vargo MM. Responding to Employment Concerns of Cancer Survivors, 5138
- Shparyk Y, *see* O'Brien MER
- Shreeves G, *see* Rustin GJS
- Shu X-j, *see* McCulloch MF
see McCulloch M
- Shu X-O, *see* Cai Q
- Shugarman LR, *see* Lorenz KA
- Shun C-T, *see* Cheng T-Y
- Sica DA. Angiogenesis Inhibitors and Hypertension: An Emerging Issue (editorial), 1329
- Sidor C, *see* Kulke MH
- Sidransky D, *see* Hoque MO
- Siegel DS, *see* Richardson PG
- Siegel-Lakhai WS, Crul M, De Porre P, Zhang S, Chang I, Boot H, Beijnen JH, Schellens JHM. Clinical and Pharmacologic Study of the Farnesyltransferase Inhibitor Tipifarnib in Cancer Patients With Normal or Mildly or Moderately Impaired Hepatic Function, 4558
- Siegenthaler P, *see* Mariani L
- Siegfried JM. Hormone Replacement Therapy and Decreased Lung Cancer Survival (editorial), 9
- Siemes C, Visser LE, Coebergh J-WW, Splinter TAW, Witteman JCM, Uitterlinden AG, Hofman A, Pols HAP, Stricker BHCh. C-Reactive Protein Levels; Variation in the C-Reactive Protein Gene, and Cancer Risk: The Rotterdam Study, 5216
- Sieuwerts AM, *see* Foekens JA
see Smid M
- Siewert J-R, *see* Ott K
- Sigal-Zafrani B, *see* This P
- Sigman CC, *see* El-Deiry WS
- Sigurdson ER, *see* Kemeny NE
- Sikic BI, *see* Bredel M
- Silliman RA, *see* Enger SM
- Silliman RA, Ganz PA. Adjuvant Chemotherapy Use and Outcomes in Older Women With Breast Cancer: What Have We Learned? (editorial), 2697
- Silva J, *see* Domínguez G
- Silva O, *see* Hurley J
- Silva R, *see* Ruzzo A
- Silver BJ, *see* Wong JS
- Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, Larson RA. Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B, 3895
- Silverstein MJ, *see* Lagios MD
- Simantov R, *see* Ratain MJ
- Simard J, *see* Andrieu N
- Simcock R, *see* Mitra SS
- Simis YJW, *see* Rademaker-Lakhai JM
- Simms L, *see* Mita AC
- Simon G, *see* Bepler G
- Simon MS, *see* Newman LA
- Simon MS, Korczak JF, Yee CL, Malone KE, Ursin G, Bernstein L, McDonald JA, Deapen D, Strom BL, Press MF, Marchbanks PA, Burkman RT, Weiss LK, Schwartz AG. Breast Cancer Risk Estimates for Relatives of White and African American Women With Breast Cancer in the Women's Contraceptive and Reproductive Experiences Study, 2498
- Simona Pino M, *see* Ferretti G
- Simona S, *see* Serena M
- Simonelli C, Tedeschi R, Gloghini A, Spina M, Talamini R, De Paoli P, Tirelli U, Carbone A. Prognostic Factors in Human Herpesvirus 8-Related Lymphoproliferative Disorders Associated With HIV Infection (correspondence), 209
- Simunovic MR, *see* Wright JR
- Sinard R, *see* Chung CH
- Singh B, *see* Jarnagin WR
see Pham D
- Singh DA, *see* Ajani JA
- Singhal S, *see* Richardson PG
- Singletary SE, *see* Petrek JA
- Sinha R, *see* Gabos Z
- Sinha U, *see* Li Y
- Sinha V, *see* Carducci MA
- Sinn H-P, *see* Thuerigen O
- Sipos L, *see* van den Bent MJ
- Sismondi aP, *see* Ponzzone R
- Sitaras NM, *see* Bonovas S
- Siu LL, *see* Agulnik M
- Sivridis E, *see* Koukourakis MI
see Koukourakis MI
- Sjoegren P, *see* Schmidt H
- Skanderson M, *see* McGinnis KA
- Skinner DG, *see* Pagliarulo V
- Skinneider BF, *see* Al-Tourah AJ
- Skoneczna I, *see* Oliver T
- Skrabs C, *see* Raderer M
- Slack J, *see* Schiller GJ
- Slager S, *see* Novak AJ
- Slamon D, *see* Robert N
- Slamon DJ, *see* Hurley J
- Slavin S, *see* Gorin N-C
- Slebos RJC, *see* Chung CH
- Slee PHThJ, Verzijlbergen FJ, Schagen van Leeuwen JH, van der Waal RIF. Case 2. Acquired Hypertrichosis: A Rare Paraneoplastic Syndrome in Various Cancers, 523

AUTHOR INDEX

- Sleijfer DT, *see* de Haas EC
see de Haas EC
see Perik PJ
- Sleijfer S, *see* Hamberg P
see Lamers CHJ
- Sloan JA, *see* Loprinzi CL
see Pockaj BA
see Rummans TA
see Steensma DP
- Sloane R, *see* Demark-Wahnefried W
- Slot A, *see* Peeters STH
- Smaaland R, *see* Giacchetti S
- Small EJ, *see* Hussain M
- Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer, 3089
- Smalley SR, Benedetti JK, Williamson SK, Robertson JM, Estes NC, Maher T, Fisher B, Rich TA, Martenson JA, Kugler JW, Benson AB III, Haller DG, Mayer RJ, Atkins JN, Cripps C, Pedersen J, Periman PO, Tanaka MS Jr, Leichman CG, Macdonald JS. Phase III Trial of Fluorouracil-Based Chemotherapy Regimens Plus Radiotherapy in Postoperative Adjuvant Rectal Cancer: GI INT 0144, 3542
- SMART Study Group T, *see* Verheijen RH
- Smetzer L, *see* Tolcher AW
- Smid M, Wang Y, Klijn JGM, Siewerts AM, Zhang Y, Atkins D, Martens JWM, Foekens JA. Genes Associated With Breast Cancer Metastatic to Bone, 2261
- Smit AJ, *see* de Haas EC
- Smit EF, *see* Herder GJM
see Paz-Ares L
- Smit HJM, *see* Timmer-Bonte JNH
- Smith B, *see* Konety BR
- Smith BD, *see* Wilson LD
- Smith BD, Haffty BG, Hurria A, Galusha DH, Gross CP. Postmastectomy Radiation and Survival in Older Women With Breast Cancer, 4901
- Smith BL, *see* Wong JS
- Smith DL, *see* Levine AM
- Smith IE, *see* Dowsett M
- Smith IE, Dowsett M, Yap Y-S, Walsh G, Lønning PE, Santen RJ, Hayes D. Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines, 2444
- Smith J, *see* Haber M
- Smith KW, *see* Avis NE
- Smith MR, *see* Keating NL
see Redfern CH
- Smith MR, Manola J, Kaufman DS, Oh WK, Bublely GJ, Kantoff PW. Celecoxib Versus Placebo for Men With Prostate Cancer and a Rising Serum Prostate-Specific Antigen After Radical Prostatectomy and/or Radiation Therapy, 2723
- Smith P, *see* Mudie NY
- Smith R, *see* Kaufmann M
- Smith RE, *see* Bear HD
see Lembersky BC
- Smith SC, *see* Tsimberidou A-M
- Smith TJ, *see* Khatcheressian JL
see Matsuyama R
- Smith TJ, Khatcheressian J, Hillner B. In Reply (correspondence), 5616
- Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline, 3187
- Smoley SA, *see* Shanafelt TD
- Smolle J, *see* Pashenkov M
- Snee M, *see* Spiro SG
- Sneed PK, *see* Butowski NA
- Sneed PK. Efavoxiral: Should We Hold Our Breath? (editorial), 13
- Sneige N, *see* Hess KR
- Snowdon CF, *see* Fallowfield LJ
- Snyder B, *see* Mitchell DG
- Snyder ME, *see* Eggenner SE
- Soares M, Salluh JIF, Carvalho MS, Darmon M, Rocco JR, Spector N. Prognosis of Critically Ill Patients With Cancer and Acute Renal Dysfunction, 4003
- Sobecks R, *see* Kalaycio M
- Sober A, *see* Livestro DP
- Sobol RW, *see* Pollack IF
- Socci ND, *see* Sanchez-Carbayo M
- Socié G, *see* Pène F
see Yakoub-Agha I
- Socinski MA, *see* Blackstock AW
see Hayes DN
see Lilenbaum R
see Stinchcombe TE
- Socinski MA, Weissman C, Hart LL, Beck JT, Choksi JK, Hanson JP, Prager D, Monberg MJ, Ye Z, Obasaju CK. Randomized Phase II Trial of Pemetrexed Combined With Either Cisplatin or Carboplatin in Untreated Extensive-Stage Small-Cell Lung Cancer, 4840
- Sogani P, *see* Dalbagni G
- Sohara N, *see* Kaira K
- Sohlbach K, Heinze S, Shiratori K, Sure U, Pagenstecher A, Neubauer A. Encephalopathy in a Patient After Long-Term Treatment With Thalidomide, 4942
- Sohn C, *see* Thuerigen O
- Solal-Celigny P, *see* Strauss SJ
- Soligo D, *see* Zinzani PL
- Solin LJ, *see* Harris EER
see Pierce LJ
- Solin LJ. Is Excision Alone Adequate Treatment for Low-Risk Ductal Carcinoma-in-Situ of the Breast? (editorial), 1017
- Somerfield MR, *see* Ganz PA
see Khatcheressian JL
see Kris MG
see Locker GY
see Smith TJ
- Somes GW, *see* Metzger ML
- Somlo G, *see* Smith TJ
- Sommer C, *see* Herrlinger U
- Song KW, *see* Foltz LM
- Song Y-W, *see* Li Y-X
- Sonpavde G, Hutson TE, Galsky MD, Berry WR. Problems With the Randomized Discontinuation Design (correspondence), 4669
- Sood AK, *see* Han LY
- Soon Tiong Lim A, *see* Chuah C
- Soong R, *see* Chuah C
- Soper JT, *see* Verheijen RH
- Soran A, *see* Bear HD
see Lembersky BC
- Sorensen BS, *see* Schmidt H
- Sorrer M, *see* Baron F
- Soslow RA, *see* Black D
- Sotiriou C, *see* Loi S
- Soto Parra HJ, *see* Ceresoli GL
- Soucek S, *see* Balducci CD
- Soucek J, *see* Gordon HS
- Souchon R, *see* Kaufmann M
- Souhami L, *see* Cairncross G
see Wong RKS
- Soudi A-K, *see* Bernstein ML
- Soulié P, *see* Roché H

AUTHOR INDEX

- Southey MC, Jenkins MA, Hopper JL, Macrae FA, Giles GG. In Reply (correspondence), 1962
- Soverini S, *see* Iacobucci I
- Soverini S, Martinelli G, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni N, Iacobucci I, Cilloni D, Saglio G, Baccarani M. Presence or the Emergence of a *F317L BCR-ABL* Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome-Positive Leukemia (correspondence), e51
- Sowers R, *see* Cheung N-KV
- Soyer HP, *see* Argenziano G
- Sozzi G, *see* Modena P
- Span PN, *see* Foekens JA
- Spaner D, *see* Chanan-Khan A
- Sparano JA, Moulder S, Kazi A, Vahdat L, Li T, Pellegrino C, Munster P, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, Wright JJ, Sebt SM. Targeted Inhibition of Farnesyltransferase in Locally Advanced Breast Cancer: A Phase I and II Trial of Tipifarnib Plus Dose-Dense Doxorubicin and Cyclophosphamide, 3013
- Sparling TG. Caring for Fatima, 2589
- Sparreboom A, *see* Baker SD
see Loos WJ
- Speake D, *see* Evans GD
- Specht K, *see* Foekens JA
- Spector N, *see* Soares M
- Speechley KN, *see* Maunsell E
- Speechley KN, Barrera M, Shaw AK, Morrison HI, Maunsell E. Health-Related Quality of Life Among Child and Adolescent Survivors of Childhood Cancer, 2536
- Speers C, *see* Lohrisch C
- Speers CH, *see* Cheang MCU
- Speights R, *see* Fouladi M
- Spencer S, *see* Konski AA
- Spencer SA, *see* Bonner JA
- Spiegel G, *see* Verheijen RH
- Spiegler BJ, Kennedy K, Maze R, Greenberg ML, Weitzman S, Hitzler JK, Nathan PC. Comparison of Long-Term Neurocognitive Outcomes in Young Children With Acute Lymphoblastic Leukemia Treated With Cranial Radiation or High-Dose or Very High-Dose Intravenous Methotrexate, 3858
- Spielberger R, *see* Stiff PJ
- Spielmann M, *see* Roché H
- Spigel DR, *see* Hainsworth JD
- Spina M, *see* Simonelli C
- Spinola M, Meyer P, Kammerer S, Falvella FS, Boettger MB, Hoyal CR, Pignatiello C, Fischer R, Roth RB, Pastorino U, Haeussinger K, Nelson MR, Dierkesmann R, Dragani TA, Braun A. Association of the *PDCD5* Locus With Lung Cancer Risk and Prognosis in Smokers, 1672
- Spiro IJ, *see* Kraybill WG
- Spiro SG, James LE, Rudd RM, Trask CW, Tobias JS, Snee M, Gilligan D, Murray PA, Ruiz de Elvira MC, O'Donnell KM, Gower NH, Harper PG, Hackshaw AK. Early Compared With Late Radiotherapy in Combined Modality Treatment for Limited Disease Small-Cell Lung Cancer: A London Lung Cancer Group Multicenter Randomized Clinical Trial and Meta-Analysis, 3823
- Spirtos NM, *see* Barakat RR
see Randall ME
- Spitz R, *see* Oberthuer A
- Spitznagel EL, *see* Govindan R
- Splinter TAW, *see* Siemes C
- Sposto R, *see* Packer RJ
- Sprague JR, Wood ME. Statins and Breast Cancer Prevention: Time for Randomized Controlled Trials (correspondence), 2129
- Sprangers M, *see* Blazeby JM
- Spriggs DR, *see* Sabbatini P
- Spunt SL, Pappo AS. Childhood Nonrhabdomyosarcoma Soft Tissue Sarcomas Are Not Adult-Type Tumors (correspondence), 1958
- Spunt SL, Pappo AS. In Reply (correspondence), 4043
- Squadrelli M, *see* Licitra L
- Srkalovic G, *see* Richardson PG
- St John MAR, *see* Li Y
- Staab-Renner E, *see* Hagenbeek A
- Stadler WM, *see* Ratain MJ
- Stadler WM. New Targets, Therapies, and Toxicities: Lessons to Be Learned (editorial), 4
- Stadtmauer EA, *see* Fisher RI
- Stähle A, *see* Pfisterer J
- Staub P, *see* Büchner T
- Stalmeier PFM, *see* van Tol-Geerdink JJ
- Stalpers LJA, *see* Rades D
- Stamatis G, *see* Van Schil P
- Stamp G, *see* Verheijen RH
- Stange KC, *see* Acheson LS
- Stanton AL, *see* Mandelblatt JS
- Stanton AL. Psychosocial Concerns and Interventions for Cancer Survivors, 5132
- Stark R, *see* Mileschkin L
- Starostik P, *see* Chanan-Khan A
- Stary J, *see* Creutzig U
- Stathopoulos S, *see* Xenidis N
- Stathopoulou A, *see* Xenidis N
- Staudt LM, *see* Iqbal J
- Stea B, *see* Suh JH
- Stearns V, *see* Kaufmann M
see Prowell TM
see Wolff AC
- Stebbing J, *see* Bower M
- Steeds S, *see* Lee CP
- Steel M, *see* Stirling D
- Steele D, *see* Gaynon PS
- Steensma DP, *see* Knox SK
- Steensma DP, Loprinzi CL. Epoetin Alfa and Darbepoetin Alfa Go Head to Head (editorial), 2233
- Steensma DP, Molina R, Sloan JA, Nikcevic DA, Schaefer PL, Rowland Jr KM, Dentshev T, Novotny PJ, Tschetter LK, Alberts SR, Hogan TF, Law A, Loprinzi CL. Phase III Study of Two Different Dosing Schedules of Erythropoietin in Anemic Patients With Cancer, 1079
- Steere J, Perl A, Tomczak E, Bagg A. Large B-Cell Lymphoma Masquerading As Acute Leukemia, 1950
- Stefansson IM, *see* Bachmann IM
- Stegmaier S, *see* Wachtel M
- Stein H, *see* Jahnke K
- Stein J, Peles-Borz A, Buchval I, Klein A, Yaniv I. The Bereavement Visit in Pediatric Oncology, 3705
- Stein JP, *see* Pagliarulo V
- Steinbach JP, *see* Herrlinger U
- Steinberg SM, *see* Bonthala Wedam S
see Lee JJ
- Steiner E, *see* Tanner B
- Steiner H, *see* Oliver T
- Steinherz L, *see* Jeha S
- Steinherz P, *see* Jeha S
- Stekhova SA, *see* Linden HM
- Stella P, *see* Lenz H-J
- Stella PJ, *see* Pockaj BA
- Stenning S, *see* Oliver T
- Stenning SP, *see* Johnson PWM
- Stenson KM, *see* Cohen EEW
- Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ Jr, Lilja H, Scardino PT. Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition, 3973
- Stern J, *see* Hoque MO
- Stern K, *see* Tanner B

AUTHOR INDEX

- Sternberg CN. Are Nomograms Better Than Currently Available Stage Groupings in Bladder Cancer? (editorial), 3819
- Stevens C, *see* Eapen M
- Stevens JL, *see* Harlan LC
- Stevenson JP, *see* Veronese ML
- Stewart CF, *see* Fouladi M
see Furman WL
- Stewart FA, *see* Dorresteijn LD
- Steyerberg EW, Neville BA, Koppert LB, Lemmens VEPP, Tilanus HW, Coebergh J-WW, Weeks JC, Earle CC. Surgical Mortality in Patients With Esophageal Cancer: Development and Validation of a Simple Risk Score, 4277
- Sticca RP. Is There Clinical Value to Sentinel Lymph Node Sampling in Colon Cancer? (editorial), 841
- Stickley M, *see* Whiteman DC
- Stiff PJ, Emmanouilides C, Bensingier WI, Gentile T, Blazar B, Shea TC, Lu J, Isitt J, Cesano A, Spielberger R. Palifermin Reduces Patient-Reported Mouth and Throat Soreness and Improves Patient Functioning in the Hematopoietic Stem-Cell Transplantation Setting, 5186
- Stilgenbauer S, *see* Kröber A
see Kröber A
- Stinchcombe TE, Socinski MA, Gangarosa LM, Khandani AH. Lung Cancer Presenting With a Solitary Colon Metastasis Detected on Positron Emission Tomography Scan, 4939
- Stine K, *see* Bernstein ML
- Stingl G, *see* Pashenkov M
- Stirling D, Porteous ME, Evans DG, Pichert G, Steel M. Familial Ovarian Cancer Screening (correspondence), e11
- Stock R, *see* Ferrari AC
- Stockero KJ, *see* Shanafelt TD
- Stojadinovic A, *see* Nissan A
- Stone CH, *see* Raab SS
- Stone NN, *see* Ferrari AC
- Stone RM. Is Intravenous Arsenic Trioxide a Useful Therapy in Myelodysplastic Syndromes? (editorial), 2414
- Stoner JA, *see* Mikuls TR
- Stoppa AM, *see* Adès L
- Storb R, *see* Baron F
see Hegenbart U
- Storer B, *see* Hegenbart U
- Storer BE, *see* Baron F
- Stoter G, *see* Lamers CHJ
see Loos WJ
- Stoutenburg J, *see* Cesana GC
- Stovall E, *see* Hoffman B
- Stovall M, *see* Bassal M
see Bowers DC
- Stram DO, *see* Gaynon PS
- Strasberg S, *see* Bilchik AJ
- Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, Ko Y-D, Schnelle M, Reif M, Cerny T. Comparison of Orally Administered Cannabis Extract and Delta-9-Tetrahydrocannabinol in Treating Patients With Cancer-Related Anorexia-Cachexia Syndrome: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial From the Cannabis-In-Cachexia-Study-Group, 3394
- Straume O, *see* Bachmann IM
- Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, Vinnecombe S, Millard L, Rohatiner A, Boral A, Trehu E, Schenkein D, Balkwill F, Joel SP, Lister TA. Bortezomib Therapy in Patients With Relapsed or Refractory Lymphoma: Potential Correlation of In Vitro Sensitivity and Tumor Necrosis Factor Alpha Response With Clinical Activity, 2105
- Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL, Engert A, Coiffier B, Hoelzer DF, Wegener WA, Teoh NKW, Goldenberg DM, Lister TA. Multicenter Phase II Trial of Immunotherapy With the Humanized Anti-CD22 Antibody, Epratuzumab, in Combination With Rituximab, in Refractory or Recurrent Non-Hodgkin's Lymphoma, 3880
- Street RL Jr, *see* Gordon HS
- Streiff MB, *see* Gerber DE
- Streit S, *see* Thussbas C
- Streubel B, *see* Grünberger B
see Raderer M
- Stricker BHCh, *see* Siemes C
- Strom BL, *see* Simon MS
- Strom EA, *see* Oh JL
- Stromberg AJ, *see* Scoggins CR
- Strömberg U, *see* Mertens F
- Strome M, *see* Adelstein DJ
- Strong LC, *see* Barcenas CH
see Chen S
- Stroobants S, *see* De Leyn P
- Stroux A, *see* Ghadjar P
- Strowitzki T, *see* von Wolff M
- Strumberg D, *see* Ajani JA
- Strunk H, *see* Reinhardt MJ
- Strupp C, *see* Kuendgen A
- Stuart G, *see* Pfisterer J
see Rustin GJS
- Stuart K, *see* Kulke MH
see Zhu AX
- Stubbs RS. Portal Hypertension and Liver Surgery Following Selective Internal Radiation Therapy With ⁹⁰Yttrium Microspheres (correspondence), e15
- Studer UE, Laurence C. In Reply (correspondence), 5173
- Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, Loidl W, Isorna S, Sundaram SK, Debois M, Collette L. Immediate or Deferred Androgen Deprivation for Patients With Prostate Cancer Not Suitable for Local Treatment With Curative Intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891, 1868
- Stupp R, *see* Mirimanoff R-O
- Su YB, *see* Pfister DG
- Suardi S, *see* Licitra L
- Suarez F, *see* Besson C
- Sugarbaker DJ, *see* Richards WG
- Sugarbaker PH, *see* Yan TD
- Sugiura I, *see* Yanada M
- Suh C, *see* Lee J
- Suh JH, *see* Vogelbaum MA
- Suh JH, Stea B, Nabid A, Kresl JJ, Fortin A, Mercier J-P, Senzer N, Chang EL, Boyd AP, Cagnoni PJ, Shaw E. Phase III Study of Efavoxiraxin As an Adjunct to Whole-Brain Radiation Therapy for Brain Metastases, 106
- Suh T, *see* Raghavan D
- Sui D, *see* Schover LR
- Sukovic T, *see* Clemons MJ
- Sukumvanich P, *see* Petrek JA
- Sullivan R, *see* Carducci MA
- Suman VJ, *see* Ingle JN
see Perez EA
- Sun Z, *see* Yang P
- Sunaga N, *see* Kaira K
- Sundaram SK, *see* Studer UE
- Sundgren PC, *see* Cao Y
- Sung L, *see* Dekker A
- Sure U, *see* Sohlbach K
- Sussman J, *see* Wright JR
- Sussman JJ, *see* Cornett WR
see Scoggins CR
- Sutphin P, *see* Petrik D
- Suzuki H, *see* Tsuchiya N
- Suzuki R, *see* Asano N
- Suzuki T, *see* Inoue A
see Yasuda H
- Swain SM, *see* Bonthala Wedam S
see Lee JJ
see Walshe JM

AUTHOR INDEX

- Swain SM. A Step in the Right Direction (editorial), 3717
- Swann RS, *see* Elliott EA
- Swarte NB, *see* van der Lee ML
- Sweeney CJ, *see* Mita AC
- Sweeney CJ, Roth BJ, Kabbinnar FF, Vaughn DJ, Arning M, Curiel RE, Obasaju CK, Wang Y, Nicol SJ, Kaufman DS. Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the Urothelium, 3451
- Sweep FC, *see* van Trommel NE
- Sweep FCGJ, *see* Foekens JA
- Sweetenham JW, *see* Herbst RS
- Swensen RE, *see* Goodell V
- Swerdlow AJ, *see* Mudie NY
- Swift R, *see* Berenson JR
- Swisher SG, *see* Izzo JG
see Luthra R
see Wu X
- Sydes MR, *see* Johnson PWM
- Sylvester R, *see* Francart J
- Symann M, *see* Roché H
- Syme R, *see* Duchesne GM
- Szechtman B, *see* Grunfeld E
- Szuhai K, *see* Dijkman R
- T**
- Tabah-Fisch I, *see* Goldberg RM
see Tournigand C
- Tabata M, *see* Takigawa N
- Tabernero J, *see* Rojo F
- Tabori U, Ma J, Carter M, Zielenska M, Rutka J, Bouffet E, Bartels U, Malkin D, Hawkins C. Human Telomere Reverse Transcriptase Expression Predicts Progression and Survival in Pediatric Intracranial Ependymoma, 1522
- Tacchetti P, *see* Cavo M
- Tada H, *see* Asamura H
- Tada T, *see* Saito H
- Tagawa A, *see* Onoda S
- Taghian AG, Jeong J-H, Mamounas EP, Parda DS, Deutsch M, Costantino JP, Wolmark N. Low Locoregional Recurrence Rate Among Node-Negative Breast Cancer Patients With Tumors 5 cm or Larger Treated by Mastectomy, With or Without Adjuvant Systemic Therapy and Without Radiotherapy: Results From Five National Surgical Adjuvant Breast and Bowel Project Randomized Clinical Trials, 3927
- Taguchi A, *see* Ohmiya N
- Tai P, *see* Woodward WA
- Taioli E, *see* Vogel VG
- Tait D, *see* Chau I
- Tajima K, *see* Asamura H
- Takada M, *see* Kudoh S
see Saito H
- Takada Y, *see* Saito H
- Takahashi H, *see* Yasuda H
- Takahashi M, Kai I, Hisata M, Higashi Y. Attitudes and Practices of Breast Cancer Consultations Regarding Sexual Issues: A Nationwide Survey of Japanese Surgeons, 5763
- Takahashi S, *see* Barentsz J
- Takahashi T, *see* Takeuchi T
- Takano T, Ohe Y, Sekine I, Kunitoh H, Yoshida T, Tamura T. In Reply (correspondence), 1221
- Takeda K, *see* Ando M
see Kudoh S
- Takenaka K, *see* Nonami A
- Takeshita K, *see* Chanan-Khan A
- Takeuchi J, *see* Yanada M
- Takeuchi M, *see* Yanada M
- Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, Yanagisawa K, Mitsudomi T, Takahashi T. Expression Profile-Defined Classification of Lung Adenocarcinoma Shows Close Relationship With Underlying Major Genetic Changes and Clinicopathologic Behaviors, 1679
- Takigawa N, Kiura K, Tabata M, Tanimoto M. Fractionated Administration of Irinotecan and Cisplatin in Japanese Patients With Extensive-Stage-Disease Small-Cell Lung Cancer (correspondence), 5175
- Takiguchi Y, *see* Onoda S
- Takimoto C, *see* Tolcher AW
- Takimoto CH, *see* Mita AC
- Takimoto CH, Mita AC. Design, Conduct, and Interpretation of Organ Impairment Studies in Oncology Patients (correspondence), 3509
- Takita C, *see* Elliott EA
- Takiuchi H, *see* Rojo F
- Talamini R, *see* Simonelli C
- Talantov D, *see* Foekens JA
- Talavera JR, *see* Goffin JR
- Talcott JA, *see* Clark JA
- Talpaz M, *see* Ault P
- Tamaru J-I, *see* Asano N
- Tamm EP, *see* Crane CH
- Tampellini M, *see* Giacchetti S
- Tamura K, *see* Ando M
see Gega M
see Saito H
- Tamura T, *see* Takano T
- Tan E-H, *see* Toh C-K
- Tan JC, *see* Matthy KK
- Tan T-C, *see* Herrlinger U
- Tanabe KK, *see* Livestro DP
- Tanaka MS Jr, *see* Smalley SR
- Tanaka N, *see* Fujiwara T
- Tan-Chiu E, *see* Wapnir IL
- Tang G, *see* Paik S
- Tangen CM, *see* Hussain M
- Tanimoto K, *see* Oka S
- Tanimoto M, *see* Takigawa N
- Taniwaki M, *see* Tobinai K
- Tann M, *see* Lewis DA
- Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, Brulport M, Bauer A, Schiffer IB, Gebhard S, Schmidt M, Steiner E, Sehouli J, Edelmann J, Läuter J, Lessig R, Krishnamurthi K, Ullrich A, Hengstler JG. Erbb-3 Predicts Survival in Ovarian Cancer, 4317
- Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J. Topoisomerase II α Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in *HER-2/neu*-Amplified Breast Cancer: Scandinavian Breast Group Trial 9401, 2428
- Tannock IF, *see* Brade AM
see Mar Fan HG
see Pentz RD
- Tantcheva-Poor I, *see* Pashenkov M
- Tanvetyanon T, Garrity ER, Albain KS. Acute Lung Injury Associated With Vinorelbine, 1952
- Tao Y, *see* Ellis MJ
- Taphoorn MJB, *see* van den Bent MJ
- Taplin ME, *see* Berry DL
- Taplin M-E, Xie W, Bublely GJ, Ernstoff MS, Walsh W, Morganstern DE, Regan MM. Docetaxel, Estramustine, and 15-Month Androgen Deprivation for Men With Prostate-Specific Antigen Progression After Definitive Local Therapy for Prostate Cancer, 5408
- Tarbell NJ, *see* Yock TI
- Tardón A, *see* Hernández S
- Tarr SM, *see* Ring BZ
- Taussig DC, *see* Davies JK
- Taylor GS, *see* Fearon KCH
- Taylor I, *see* Abou-Alfa GK

AUTHOR INDEX

- Taylor J, *see* Urba S
 Taylor L, *see* Bassal M
 Taylor MD, *see* Thompson MC
 Taylor S, *see* Lohrisch C
 Tchekmedyan NS, *see* Abou-Alfa GK
 Tchinda J, *see* Büchner T
 te Loo DMWM, Kamps WA, van der Does-van den Berg A, van Wering ER, de Graaf SSN. Prognostic Significance of Blasts in the Cerebrospinal Fluid Without Pleiocytosis or a Traumatic Lumbar Puncture in Children With Acute Lymphoblastic Leukemia: Experience of the Dutch Childhood Oncology Group, 2332
 Tebbut NC, *see* Michael M
 Tebbutt N, *see* Chau I
 Teck Lim W, Govindan R. Case 3. Benign Pleural Nodules in a Patient With Esophageal Cancer, 525
 Tedeschi A, *see* Montillo M
 Tedeschi R, *see* Simonelli C
 Tee Goh Y, *see* Chuah C
 Teige B, *see* Gadzicki D
 Teknos T, *see* Urba S
 Tempero MA, *see* Ko AH
 Temple WJ, Russell ML, Parsons LL, Huber SM, Jones CA, Bankes J, Eliasziw M. Conservation Surgery for Breast Cancer As the Preferred Choice: A Prospective Analysis, 3367
 ten Bokkel Huinink WW, *see* van den Belt-Dusebout AW
 ten Kate FJW, *see* Lagarde SM
 ten Kate-Booij MJ, *see* van Trommel NE
 ten Velde GPM, *see* Seute T
 Tendulkar KK, *see* Ganti AK
 Tensen CP, *see* Dijkman R
 TenVergert EM, *see* De Bont ESJM
 Teodorovic I, *see* Hagenbeek A
 Teoh NKW, *see* Strauss SJ
 Tepper JE, *see* Ryan DP
 Terauchi T, *see* Tobinai K
 Tereffe W, *see* Oh JL
 Teresa Fierro M, *see* Zinzani PL
 Terragna C, *see* Cavo M
 see Iacobucci I
 Terrier P, *see* Oberlin O
 Terzoli E, *see* Ferretti G
 see Garufi C
 see Papaldo P
 Testa E, *see* Ruzzo A
 Testoni N, *see* Cavo M
 see Iacobucci I
 see Soverini S
 Teule GJ, *see* Herder GJM
 Tews B, *see* Thuerigen O
 Thabane L, *see* Lai R
 Thatcher N, *see* Hirsch FR
 see O'Brien MER
 Thayer SP, *see* Ferrone CR
 Theorin N, *see* Gorin N-C
 Theriault RL, *see* Buchholz TA
 see Hess KR
 Thery J-C, *see* Ouvrier M-J
 Theuer CP, *see* Motzer RJ
 Thieblemont C, *see* Ghesquière H
 Thiede C, *see* Baldus CD
 Thiel E, *see* Baldus CD
 see Ghadjar P
 see Jahnke K
 Thiéry G, *see* Pène F
 Thigpen JT, *see* Randall ME
 Thirugnanam A, *see* Toh C-K
 This P, de la Rochefordière A, Bredart A, Asselain B, Poinso R, Dolbeault S, Sigal-Zafrani B. Quality of Life in a Randomized Control Trial? Comments Concerning MA 17 (correspondence), 4038
 Thomas CM, *see* van Trommel NE
 Thomas CR Jr, *see* Olopade OI
 Thomas G, *see* Mitchell DG
 Thomas J, *see* Ellis MJ
 see Meyerhardt JA
 see Noordijk EM
 see Philip PA
 see Sagaert X
 Thomas T, *see* Beerepoot LV
 Thomas W, *see* Ahmed RL
 Thomas X, *see* Adès L
 Thomasson D, *see* Bonthala Wedam S
 Thompson JA, *see* Dummer R
 Thompson JF, *see* Shaw HM
 Thompson M, *see* Michael M
 Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, Chintagumpala M, Adesina A, Ashley DM, Kellie SJ, Taylor MD, Curran T, Gajjar A, Gilbertson RJ. Genomics Identifies Medulloblastoma Subgroups That Are Enriched for Specific Genetic Alterations, 1924
 Thornton DE, *see* Carducci MA
 Thuerigen O, Schneeweiss A, Toedt G, Warnat P, Hahn M, Kramer H, Brors B, Rudlowski C, Benner A, Schuetz F, Tews B, Eils R, Sinn H-P, Sohn C, Lichter P. Gene Expression Signature Predicting Pathologic Complete Response With Gemcitabine, Epirubicin, and Docetaxel in Primary Breast Cancer, 1839
 Thurston D, *see* Verheijen RH
 Thussbas C, Nahrig J, Streit S, Bange J, Kriner M, Kates R, Ulm K, Kiechle M, Hoefler H, Ullrich A, Harbeck N. *FGFR4* Arg388 Allele Is Associated With Resistance to Adjuvant Therapy in Primary Breast Cancer, 3747
 Thwin SS, *see* Enger SM
 Tibben A, *see* van Dijk S
 Tiernan E, *see* Kirkova J
 Tierney R, *see* Govindan R
 Tijssen CC, *see* van den Bent MJ
 Tilanus HW, *see* Steyerberg EW
 Tilly H, *see* Besson C
 Timmer-Bonte JNH, Adang EMM, Smit HJM, Biesma B, Wilschut FA, Bootsma GP, de Boo TM, Tjan-Heijnen VCG. Cost-Effectiveness of Adding Granulocyte Colony-Stimulating Factor to Primary Prophylaxis With Antibiotics in Small-Cell Lung Cancer, 2991
 Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, Ewing M, Abdulrahman R, DesRosiers C, Williams M, Fletcher J. Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer, 4833
 Timmermann B, Kortmann R-D, Kühl J, Rutkowski S, Meisner C, Pietsch T, Deinlein F, Urban C, Warmuth-Metz M, Bamberg M. Role of Radiotherapy in Supratentorial Primitive Neuroectodermal Tumor in Young Children: Results of the German HIT-SKK87 and HIT-SKK92 Trials, 1554
 Timmermann B, Kortmann R-D, Rutkowski S. In Reply (correspondence), 5609
 Timmermans DRM, *see* van Dijk S
 Timmers P, *see* Rustin GJS
 Tirelli U, *see* Di Benedetto F
 see Noordijk EM
 see Paccagnella A
 see Simonelli C
 Tisdale MJ, *see* Fearon KCH
 Tito Menichetti E, *see* Ruzzo A
 Tjan-Heijnen VCG, *see* Foekens JA
 see Timmer-Bonte JNH
 Tjulandin S, *see* Van Cutsem E
 Tobias JS, *see* Spiro SG

AUTHOR INDEX

- Tobin P, *see* Jubb AM
- Tobinai K, Watanabe T, Ogura M, Morishima Y, Ogawa Y, Ishizawa K-i, Minami H, Utsunomiya A, Taniwaki M, Terauchi T, Nawano S, Matsusako M, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Hayashi M, Seriu T, Hotta T. Phase II Study of Oral Fludarabine Phosphate in Relapsed Indolent B-Cell Non-Hodgkin's Lymphoma, 174
- Toedt G, *see* Thuerigen O
- Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D'Andrea M, Maria Pasetto L, Pessa S, Errante D, De Pangher V, Giusto M, Medici M, Gaion F, Sandri P, Galligioni E, Bonura S, Boccalon M, Biason P, Frustaci S. The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer, 3061
- Toh C-K, Gao F, Lim W-T, Leong S-S, Fong K-W, Yap S-P, Hsu AAL, Eng P, Koong H-N, Thirugnanam A, Tan E-H. Never-Smokers With Lung Cancer: Epidemiologic Evidence of a Distinct Disease Entity, 2245
- Toh C-K, Lim W-T, Leong S-S, Tan E-H. In Reply (correspondence), 5469
- Toh ST, *see* Low WK
- Tolaney SM, Partridge AH, Sheib RG, Burstein HJ, Winer EP. *Pneumocystis Carinii* Pneumonia During Dose-Dense Chemotherapy for Breast Cancer, 5330
- Tolcher AW, *see* Mita AC
- Tolcher AW, Hao D, de Bono J, Miller A, Patnaik A, Hammond LA, Smetzer L, Van Wart Hood J, Merritt J, Rowinsky EK, Takimoto C, Von Hoff D, Eckhardt SG. Phase I, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered Ad5CMV-p53, an Adenoviral Vector Containing the Wild-Type p53 Gene, in Patients With Advanced Cancer, 2052
- Tomczak E, *see* Steere J
- Tomek S, *see* Wachter S
- Tomida S, *see* Takeuchi T
- Tomita D, *see* Glaspy J
- Tomita N, *see* Yasuda H
- Tomlinson G, *see* Chen S
- Tomlinson GE, *see* Barcenas CH
see Patterson AR
- Tomova A, *see* Eckardt JR
- Tone Y, *see* Saikawa Y
- Tong A, *see* Nemunaitis J
- Tonini G, *see* Gentilucci UV
see Quattrocchi CC
see Ruzzo A
see Vincenzi B
- Topalian SL, *see* Beck KE
- Toppmeyer D, *see* Haffty BG
- Torabian S, *see* Rangel J
- Tornos C, *see* Black D
- Torsello A, *see* Garufi C
- Tortochaux J, *see* Bourhis J
- Tosi P, *see* Cavo M
- Tosoni A, *see* Brandes AA
- Toure P, *see* Hoque MO
- Tournigand C, *see* de Gramont A
see Goldberg RM
- Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne P-L, Rivera F, Chirivella I, Perez-Staub N, Louvet C, André T, Tabah-Fisch I, de Gramont A. OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study, 394
- Townsend RR, *see* Veronesi ML
- Tozer RG, *see* Perez EA
- Tragni G, *see* Cascinelli N
- Trahan Rieger P, *see* Ludwig H
- Trajkovic A, *see* Bezjak A
- Tran KQ, *see* Beck KE
- Trask CW, *see* Spiro SG
- Travaglini R, *see* Bonanni B
- Traverse-Glehen A, *see* Ghesquière H
- Travis WD, *see* Tsurutani J
- Treaba DO, *see* Cheang MCU
- Trefzer U, *see* Bedikian AY
- Trehu E, *see* Strauss SJ
- Tremolada M, *see* Axia G
- Treuner J, *see* Wachtel M
- Tribius S, *see* Rades D
- Trigg ME, *see* Gaynon PS
- Trink B, *see* Hoque MO
- Troch M, *see* Raderer M
see Wöhrer S
- Trock B, *see* Prowell TM
- Trocola R, *see* Shah MA
- Troester MA, *see* Oh DS
- Trotti A, *see* Forastiere AA
- Troyan SL, *see* Wong JS
- Trudeau M, *see* Clemons MJ
- Truong M, *see* Carducci MA
- Tsai K-Y, Yang C-H, Kuo T-t, Hong H-S, Chang JWC. Hand-Foot Syndrome and Seborrheic Dermatitis-Like Rash Induced by Sunitinib in a Patient With Advanced Renal Cell Carcinoma, 5786
- Tsai SC, Reale LD, Flomenberg N, Schwarting R, Enck RE. Alveolar Rhabdomyosarcoma Mimicking a Lymphoma at Presentation, 4031
- Tsai SY, *see* Cheng SH
- Tsai W-Y, *see* Neugut AI
- Tsang PWK, *see* Al-Tourah AJ
- Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri F, Zinner R, Myers J, Papadimitrakopoulou V, Lewin J, Clayman GL, Ang KK, Glisson BS. Phase I/II Study of Docetaxel, Cisplatin, and Concomitant Boost Radiation for Locally Advanced Squamous Cell Cancer of the Head and Neck, 4163
- Tsao M-S, *see* Shepherd FA
- Tsavaris N, *see* Bonovas S
- Tschetter LK, *see* Loprinzi CL
see Steensma DP
- Tschumper R, *see* Shanafelt TD
- Tschumper RC, *see* Shanafelt TD
- Tse A, *see* Shah MA
- Tse C, *see* Barrier A
- Tsekov H, *see* O'Brien MER
- Tsien CL, *see* Cao Y
- Tsimberidou AM, *see* Liu Q
- Tsimberidou A-M, O'Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R, Wen S, Do K-A, Smith SC, Lerner S, Freireich EJ, Keating MJ. Clinical Outcomes and Prognostic Factors in Patients With Richter's Syndrome Treated With Chemotherapy or Chemoimmunotherapy With or Without Stem-Cell Transplantation, 2343
- Tsou M-H, *see* Cheng SH
- Tsuchihashi Z, *see* Lenz H-J
- Tsuchiya N, Wang L, Suzuki H, Segawa T, Fukuda H, Narita S, Shimbo M, Kamoto T, Mitsumori K, Ichikawa T, Ogawa O, Nakamura A, Habuchi T. Impact of *IGF-I* and *CYP19* Gene Polymorphisms on the Survival of Patients With Metastatic Prostate Cancer, 1982
- Tsuchiya T, *see* Kaira K
- Tsuji M, *see* Oka S
- Tsukamoto K, *see* Gega M
- Tsurutani H, *see* Tsurutani J
- Tsurutani J, Ballas MS, Dennis PA. Overestimating the Influence of the 1999 WHO Classification of Lung Tumors on Survival in Bronchioloalveolar Carcinoma (correspondence), 1963
- Tsurutani J, Fukuoka J, Tsurutani H, Shih JH, Hewitt SM, Travis WD, Jen J, Dennis PA. Evaluation of Two Phosphorylation Sites Improves the Prognostic Significance of Akt Activation in Non-Small-Cell Lung Cancer Tumors, 306
- Tu D, *see* Bezjak A
see Perez EA
see Whelan TJ

AUTHOR INDEX

Tucker MA, *see* Fears TR
 Tudor K, *see* Timmerman R
 Tulpule A, *see* Levine AM
 Tummala MK, Hausner PF, McGuire WP, Gipson T, Berkman A. Case 1. Testis:
 A Sanctuary Site in Merkel Cell Carcinoma, 1008
 Tumolo S, *see* Paccagnella A
 Tunn U, *see* Ferrari AC
 Turetschek K, *see* Raderer M
 Turner JH, *see* Leahy MF
 Tüting T, *see* Reinhardt MJ
 Twijnstra A, *see* Seute T
 Twomey E, *see* Matthay KK
 Tworoger SS, *see* Eliassen AH
 Tyler DS, *see* Cornett WR
 see Czito BG
 Tzekova V, *see* Eckardt JR

U

Ueda Y, *see* Yanada M
 Uematsu K, *see* Onoda S
 see Seki N
 Ueno NT, *see* Nakayama K
 see Woodward WA
 Uitterlinden AG, *see* Siemes C
 Ulcickas Yood M, *see* Enger SM
 Ullrich A, *see* Tanner B
 see Thussbas C
 Ulm K, *see* Huber RM
 see Thussbas C
 Umehani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, Martino S,
 Hoon DSB. Prediction of Breast Tumor Progression by Integrity of Free
 Circulating DNA in Serum, 4270
 Unger JM, *see* Press OW
 Unger JM, Coltman CA Jr, Crowley JJ, Hutchins LF, Martino S, Livingston RB,
 Macdonald JS, Blanke CD, Gandara DR, Crawford ED, Albain KS. Impact of
 the Year 2000 Medicare Policy Change on Older Patient Enrollment to
 Cancer Clinical Trials, 141
 Unger P, *see* Ferrari AC
 Untch M, *see* Kaufmann M
 Untereiner M, *see* Gérard J-P
 Uratsu CS, *see* Clarke CA
 Urba S, Wolf G, Eisbruch A, Worden F, Lee J, Bradford C, Teknos T, Chepeha
 D, Prince M, Hogikyan N, Taylor J. Single-Cycle Induction Chemotherapy
 Selects Patients With Advanced Laryngeal Cancer for Combined Chemora-
 diation: A New Treatment Paradigm, 593
 Urba SG, *see* Dragovich T
 Urban C, *see* Timmermann B
 Urban CE, *see* Kerbl R
 Urban N, *see* Goodell V
 Urban P, Vuaroqueaux V, Labuhn M, Delorenzi M, Wirapati P, Wight E, Senn
 H-J, Benz C, Eppenberger U, Eppenberger-Castori S. Increased Expression
 of Urokinase-Type Plasminogen Activator mRNA Determines Adverse
 Prognosis in ErbB2-Positive Primary Breast Cancer, 4245
 Urbano-Ispizua A, *see* Fernández-Avilés F
 Urist MM, *see* Scoggins CR
 Urruticoechea A, *see* Dowsett M
 Ursin G, *see* Simon MS
 Usary J, *see* Oh DS
 Usui N, *see* Yanada M
 Uthgenannt D, *see* Heinemann V
 Utsunomiya A, *see* Tobinai K
 Utsunomiya J, *see* Gega M
 Uyl-de Groot CA, *see* Herder GJM

V

Vadhan-Raj S, *see* Glaspy J
 Vahdat L, *see* Oktay K
 see Sparano JA
 Vahdat LT, *see* Herbst RS
 Vajtai I, *see* Mariani L
 Valagussa P, *see* Kaufmann M
 Valdimarsdottir HB, *see* Madalinska JB
 Valentine E, *see* Robert N
 Valero V, *see* Bruera E
 see Esmaeli B
 see Guarneri V
 see Hanrahan EO
 see Hess KR
 Valone FH, *see* Small EJ
 Valteau-Couanet D, *see* Rubie H
 Valverde M, *see* Fernández-Avilés F
 van Apeldoorn MJ, Rustemeijer C, Voerman BJ, Peterse J. Mesothelioma of the
 Tunica Vaginalis Complicated by Chyluria, 5329
 van Asperen CJ, *see* van Dijk S
 van Beurden M, *see* Madalinska JB
 van Boven-van Zomeren DM, *see* Loos WJ
 Van Calsteren K, Berteloot P, Hanssens M, Vergote I, Amant F, Ganame J, Claus
 P, Mertens L, Lagae L, Delforge M, Paridaens R, Noens L, Humblet Y,
 Vandermersch B, De Muylder X. In Utero Exposure to Chemotherapy:
 Effect on Cardiac and Neurologic Outcome (correspondence), e16
 Van Cutsem E, *see* Lenz H-J
 see Rojo F
 Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C,
 Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse M-L, Ajani JA. Phase III
 Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin
 and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A
 Report of the V325 Study Group, 4991
 Van Cutsem E. Progress With Biological Agents in Metastatic Colorectal Cancer
 Leads to Many Challenges (editorial), 3325
 van Daal WAJ, *see* van Tol-Geerdink JJ
 van Dam FSAM, *see* Schagen SB
 van de Velde H, *see* Dubois D
 van den Belt-Dusebout AW, Nuver J, de Wit R, Gietema JA, ten Bokkel Huinink
 WW, Rodrigus PTR, Schimmel EC, Aleman BMP, van Leeuwen FE. Long-
 Term Risk of Cardiovascular Disease in 5-Year Survivors of Testicular Cancer,
 467
 Van den Bent MJ, *see* Mirimanoff R-O
 van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJB,
 Bernsen HJJA, Frenay M, Tjssens CC, Grisold W, Sipos L, Haaxma-Reiche H,
 Kros JM, van Kouwenhoven MCM, Vecht CJ, Allgeier A, Lacombe D, Gorlia
 T. Adjuvant Procarbazine, Lomustine, and Vincristine Improves
 Progression-Free Survival but Not Overall Survival in Newly Diagnosed
 Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European
 Organisation for Research and Treatment of Cancer Phase III Trial,
 2715
 van den Berg MP, *see* de Haas EC
 Van den Block L, Bilsen J, Deschepper R, Van Der Kelen G, Bernheim JL,
 Deliëns L. End-of-Life Decisions Among Cancer Patients Compared With
 Noncancer Patients in Flanders, Belgium, 2842
 van den Bout J, *see* van der Lee ML
 van der Bom JG, *see* van der Lee ML
 van der Does-van den Berg A, *see* te Loo DMWM
 Van der Graaf WTA, *see* De Bont ESJM
 van der Graaf WTA, *see* Perik PJ
 van der Holt B, *see* van Imhoff GW
 Van Der Kelen G, *see* Van den Block L
 van der Lee ML, van der Bom JG, Swarte NB, Heintz APM, de Graeff A, van den
 Bout J. In Reply (correspondence), 3212
 van der Putten H, *see* Madalinska JB

AUTHOR INDEX

- van der Velden K, *see* Madalinska JB
van der Ven H, *see* von Wolff M
van der Waal RIF, *see* Slee PHTHJ
van Dijk S, Timmermans DRM, Meijers-Heijboer H, Tibben A, van Asperen CJ, Otten W. Clinical Characteristics Affect the Impact of an Uninformative DNA Test Result: The Course of Worry and Distress Experienced by Women Who Apply for Genetic Testing for Breast Cancer, 3672
van Doorn J, *see* Hamberg P
van Dorst EBL, *see* Madalinska JB
van Geelen CM, Westra JL, de Vries EG, Boersma-van Ek W, Zwart N, Hollema H, Boezen HM, Mulder NH, Plukker JT, de Jong S, Kleibeuker JH, Koornstra JJ. Prognostic Significance of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand and Its Receptors in Adjuvantly Treated Stage III Colon Cancer Patients, 4998
Van Glabbeke M, *see* Francart J
van Glabbeke M, *see* Hagenbeek A
Van Groeningen C, *see* Janmaat ML
van Heeckeren WJ, Bhakta S, Ortiz J, Duerk J, Cooney MM, Dowlati A, McCrae K, Remick SC. Promise of New Vascular-Disrupting Agents Balanced With Cardiac Toxicity: Is It Time for Oncologists to Get to Know Their Cardiologists? (editorial), 1485
Van Hoof A, *see* Besson C
Van Hoorebeek I, *see* Bijker N
van Imhoff GW, Boerma E-JG, van der Holt B, Schuurin E, Verdonck LF, Kluijn-Nelemans HC, Kluijn PM. Prognostic Impact of Germinal Center–Associated Proteins and Chromosomal Breakpoints in Poor-Risk Diffuse Large B-Cell Lymphoma, 4135
van Kouwenhoven MCM, *see* van den Bent MJ
van Lanschot JJB, *see* Lagarde SM
Van Leeuwen FE, *see* Andrieu N
van Leeuwen FE, *see* Hooning MJ
see van den Belt–Dusebout AW
van Lin ENJT, *see* van Tol–Geerdink JJ
Van Meerbeek J, *see* Bottomley A
van Meerbeek JP, *see* Francart J
van Meerbeek JP, Bottomley A. In Reply (correspondence), 4667
van Oosterom AT, *see* Heinrich MC
van Putten WLJ, *see* Peeters STH
Van Raemdonck D, *see* De Leyn P
Van Schil P, Stamatis G. Sensitivity of Remediastinoscopy: Influence of Adhesions, Multilevel N2 Involvement, or Surgical Technique? (correspondence), 5338
van Tinteren H, *see* Herder GJM
van Tol–Geerdink JJ, Stalmeier PFM, van Lin ENJT, Schimmel EC, Huizenga H, van Daal WAJ, Leer J-W. Do Patients With Localized Prostate Cancer Treatment Really Want More Aggressive Treatment? 4581
van Trommel NE, Massuger LF, Schijf CP, ten Kate-Booij MJ, Sweep FC, Thomas CM. Early Identification of Resistance to First-Line Single-Agent Methotrexate in Patients With Persistent Trophoblastic Disease, 52
van Veldhuisen DJ, *see* Perik PJ
Van Wart Hood J, *see* Tolcher AW
van Wering ER, *see* te Loo DMWM
van Zandwijk N, *see* Rademaker-Lakhai JM
Vance BA, *see* Coughlin CM
Vance R, *see* West HL
Vandermeersch B, *see* Van Calsteren K
Vanhentenrijk V, *see* Sagaert X
Vanni B, *see* Garufi C
Vansteenkiste J, *see* De Leyn P
see De Ruyscher D
Van't Veer L, *see* Andrieu N
Vardiman JW, *see* Paschka P
Vardy J, *see* Mar Fan HG
Varela-Garcia M, *see* Chung CH
see Hirsch FR
Vargo MM, *see* Short PF
Vasey PA, *see* Crawford SC
Vassal G, *see* Rubie H
Vassella E, *see* Mariani L
Vaughn DJ, *see* Sweeney CJ
Vauthey J-N, *see* Abdalla EK
see Poston G
see Ribero D
Vauthey J-N, Pawlik TM, Ribero D, Wu T-T, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino-Kenudson M, Risio M, Muratore A, Capussotti L, Curley SA, Abdalla EK. Chemotherapy Regimen Predicts Steatohepatitis and an Increase in 90-Day Mortality After Surgery for Hepatic Colorectal Metastases, 2065
Veatch J, *see* Matthyay KK
Vecht CJ, *see* van den Bent MJ
Veer LV, *see* Loi S
Veglia F, *see* Paccagnella A
Vehling-Kaiser U, *see* Heinemann V
Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen Treatment After Adjuvant Chemotherapy Has Opposite Effects on Bone Mineral Density in Premenopausal Patients Depending on Menstrual Status, 675
Vekhoff A, *see* Adès L
Velez P, *see* Hurley J
Vellenga E, *see* De Bont ESJM
Veltman J, *see* Modena P
Vena D, *see* Chen HX
Veninga T, *see* Rades D
Venkatraman ES, *see* Pham D
Venook AP, *see* Ko AH
see Kulke MH
Venturini M, *see* Del Mastro L
Vera K, *see* Faivre S
Verboom P, *see* Herder GJM
Verdonck LF, *see* van Imhoff GW
Vergote I, *see* Gore M
see Neven P
see Pfisterer J
see Van Calsteren K
Verhagen S, *see* Gielissen MFM
Verheijen RH, Massuger LF, Benigno BB, Epenetos AA, Lopes A, Soper JT, Markowska J, Vyzula R, Jobling T, Stamp G, Spiegel G, Thurston D, Falke T, Lambert J, Seiden MV. Phase III Trial of Intraperitoneal Therapy With Yttrium-90–Labeled HMFG1 Murine Monoclonal Antibody in Patients With Epithelial Ovarian Cancer After a Surgically Defined Complete Remission, 571
Verheijen RH, Massuger LF, Benigno BB, Lopes A, Seiden MV, SMART Study Group T. In Reply (correspondence), 3512
Verheijen RHM, *see* Madalinska JB
Verhoef G, *see* Sagaert X
Verjee SS, *see* Small EJ
Verkooijen HM, *see* Rapiti E
Verma S, *see* Clemons MJ
see Grunfeld E
Vermeer MH, *see* Dijkman R
Vermeer-Mens JCJ, Goemaere NNT, Kuenen-Boumeester V, de Muinck Keizer-Schrama SMPF, Zwaan CM, Devos AS, de Krijger RR. Childhood Papillary Thyroid Carcinoma With Miliary Pulmonary Metastases, 5788
Vermeulen KM, *see* De Bont ESJM
Vermorken JB, *see* Bernier J
Vernant J-P, *see* Yakoub-Agha I
Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, O'Dwyer PJ. Mechanisms of Hypertension Associated With BAY 43-9006, 1363
Veronese S, *see* Montillo M
Veronesi U, *see* Bonanni B
Verrelle P, *see* Bourhis J
Verschuere TAM, *see* Noordijk EM

AUTHOR INDEX

- Verstovsek S, *see* Liu Q
- Vervenne WL, *see* Janmaat ML
- Verweij J, *see* Hamberg P
see Loos WJ
- Verzylbergen FJ, *see* Slee PHTH
- Vescio RA, *see* Berenson JR
- Vesole D, *see* Rajkumar SV
- Vettenranta K, *see* Saarinen-Pihkala UM
- Vey N, Bosly A, Guerci A, Feremans W, Dombret H, Dreyfus F, Bowen D, Burnett A, Dennis M, Ribrag V, Casadevall N, Legros L, Fenaux P. Arsenic Trioxide in Patients With Myelodysplastic Syndromes: A Phase II Multi-center Study, 2465
- Vezina G, *see* Packer RJ
- Viala M, *see* Dubois D
- Vici P, *see* Papaldo P
- Vickers AJ, *see* Cheung N-KV
- Vickers AJ, Kuo J, Cassileth BR. Unconventional Anticancer Agents: A Systematic Review of Clinical Trials, 136
- Vidaurre T, *see* Hess KR
- Viens P, *see* Roché H
- Vieth M, *see* Jüttner S
- Vigen C, *see* O'Connell CL
- Vilardell F, *see* Dotor E
- Villa S, *see* Mirimanoff R-O
- Villablanca JG, *see* Matthay KK
- Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds PC. Phase I Trial of Oral Fenretinide in Children With High-Risk Solid Tumors: A Report From the Children's Oncology Group (CCG 09709), 3423
- Villalona-Calero M, *see* Mita AC
- Villalona-Calero MA, *see* Monk JP
- Villaluna D, *see* Gaynon PS
- Villanueva A, *see* Dotor E
- Villaret DB, *see* Liauw SL
- Vincent M, *see* Bottomley A
- Vincenzi B, *see* Gentilucci UV
see Quattrocchi CC
see Ruzzo A
- Vincenzi B, Santini D, Tonini G. New Issues on Cetuximab Mechanism of Action in Epidermal Growth Factor Receptor–Negative Colorectal Cancer: The Role of Vascular Endothelial Growth Factor (correspondence), 1957
- Vincitore M, *see* Kulke MH
see Meyerhardt JA
- Vindevooghel A, *see* Roché H
- Vinh-Hung V, *see* Woodward WA
- Vinnecombe S, *see* Strauss SJ
- Vinson LV, *see* Berry DL
- Visscher D, *see* Perez EA
- Visscher DW, *see* Goetz MP
- Visser LE, *see* Siemes C
- Vitolo U, *see* Hagenbeek A
- Vivat B, *see* Grunfeld EA
- Vlahiotis A, *see* Govindan R
- Vlastos G, *see* Rapiti E
see Woodward WA
- Voerman BJ, *see* van Apeldoorn MJ
- Voest EE, *see* Beerepoot LV
- Vogel H, *see* Bredel M
- Vogel VG, *see* Khatcheressian JL
- Vogel VG, Taioli E. Have We Found the Ultimate Risk Factor for Breast Cancer? (editorial), 1791
- Vogelbaum MA, Suh JH. Resectable Brain Metastases, 1289
- Vogelsang H, *see* Goecke T
- Vogelzang NJ. Treatment Options in Metastatic Renal Carcinoma: An Embarrassment of Riches (editorial), 1
- Vogl S, *see* Mackensen A
- Voigtländer T, *see* Gadzick D
- Vokes EE, *see* Blackstock AW
see Cohen EEW
see Herbst RS
see Innocenti F
- Volante M, *see* Papotti M
- Volinia S, *see* Roldo C
- Volk B, *see* Illerhaus G
- von der Maase H, *see* Donskov F
see Schmidt H
- Von Hoff D, *see* Tolcher AW
- von Mehren M, *see* Heinrich MC
- von Minckwitz G, *see* Kaufmann M
- von Moos R, Ruhstaller T, Fretz C. Case 3. Red Eye in Sjögren's Syndrome Due to Underlying Mucosa-Associated Lymphoid Tissue Lymphoma, 1011
- von Pawel J, *see* Bezzak A
see Eckardt JR
see Hirsch FR
see Ramlau R
- von Wolff M, Strowitzki T, van der Ven H, Montag M. In Vitro Maturation Is an Efficient Technique to Generate Oocytes and Should Be Considered in Combination With Cryopreservation of Ovarian Tissue for Preservation of Fertility in Women (correspondence), 5336
- Vonderheide RH, *see* Coughlin CM
- Vormoor J, *see* Burkhardt B
- Vose JM, *see* Iqbal J
- Vovk M, *see* Noordijk EM
- Voznyi E, *see* Harvey V
see Van Cutsem E
- Vredenburg JJ, *see* Reardon DA
- Vuarioqueaux V, *see* Urban P
- Vuillez J-P, *see* Chatal J-F
- Vukelja S, *see* Jones SE
- Vukosavljevic T, *see* Paschka P
- Vulto AG, *see* Lamers CHJ
- Vyzula R, *see* Verheijen RH

W

- Wachtel M, Runge T, Leuschner I, Stegmaier S, Koscielniak E, Treuner J, Odermatt B, Behnke S, Niggli FK, Schäfer BW. Subtype and Prognostic Classification of Rhabdomyosarcoma by Immunohistochemistry, 816
- Wachter S, Tomek S, Kurtaran A, Wachter-Gerstner N, Djavan B, Becherer A, Mitterhauser M, Dobrozemsky G, Li S, Pötter R, Dudczak R, Kletter K. ¹¹C-Acetate Positron Emission Tomography Imaging and Image Fusion With Computed Tomography and Magnetic Resonance Imaging in Patients With Recurrent Prostate Cancer, 2513
- Wachter-Gerstner N, *see* Wachter S
- Wade J, *see* Baron F
- Wade JC, *see* Smith TJ
- Wade JL, *see* Smith TJ
- Wadler S, *see* Ryan DP
- Wadsworth EA, *see* Offit K
- Wagner AD, Fleig WE, Haerting J. In Reply (correspondence), 5474
- Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data, 2903
- Wagner C, *see* Pashenkov M
- Wagner JE, *see* Eapen M
- Wagner M, *see* Rubie C
- Wagner SN, *see* Pashenkov M
- Wagner T, *see* Andrieu N
- Wagner U, *see* du Bois A
see Pfisterer J
- Wainer IW, *see* Bernstein ML
- Waite R, *see* Monk JP

AUTHOR INDEX

- Waldman FM, *see* Goodson WH
- Waldron JN. Fluorodeoxyglucose Positron Emission Tomography for the Preoperative Staging of Oral Cavity Cancers: Only One Piece of the Puzzle (editorial), 4367
- Wale C, *see* Dowsett M
- Walker G, *see* Grunfeld EA
- Walker JL, *see* Markman M
- Wallace AM, *see* Woodward WA
- Wallace K, Fleshner N, Jewett M, Basiuk J, Crook J. Impact of a Multidisciplinary Patient Education Session on Accrual to a Difficult Clinical Trial: The Toronto Experience With the Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial, 4158
- Wallace P, *see* Chanan-Khan A
- Wallace WH, *see* Lee SJ
- Walsh D, *see* Kirkova J
- Walsh G, *see* Smith IE
- Walsh W, *see* Taplin M-E
- Walsh JM, Denduluri N, Swain SM. Amenorrhea in Premenopausal Women After Adjuvant Chemotherapy for Breast Cancer, 5769
- Wanders R, *see* De Ruyscher D
- Wang B, *see* Hanna N
- Wang DY, *see* Low WK
- Wang H-M, *see* Liu F-Y
see Ng S-H
- Wang H-P, *see* Cheng T-Y
- Wang J, *see* Dragovich T
- Wang JJ, *see* Bickell NA
- Wang L, *see* Tsuchiya N
- Wang L, Wei Q, Wang L-E, Aldape KD, Cao Y, Okcu MF, Hess KR, El-Zein R, Gilbert MR, Woo SY, Prabhu SS, Fuller GN, Bondy ML. Survival Prediction in Patients With Glioblastoma Multiforme by Human Telomerase Genetic Variation, 1627
- Wang L-E, *see* Wang L
- Wang S-L, *see* Li Y-X
- Wang T-E, *see* Cheng T-Y
- Wang W, *see* Ma X-J
- Wang W-H, *see* Li Y-X
- Wang X, *see* Neugut AI
- Wang Y, *see* Foekens JA
see Smid M
see Sweeney CJ
- Wapnir IL, Anderson SJ, Mamounas EP, Geyer CE Jr, Jeong J-H, Tan-Chiu E, Fisher B, Wolmark N. Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Five National Surgical Adjuvant Breast and Bowel Project Node-Positive Adjuvant Breast Cancer Trials, 2028
- Ward P, *see* Grunfeld EA
- Ware RE, *see* Cachin F
- Warmuth-Metz M, *see* Timmermann B
- Warnat P, *see* Oberthuer A
see Thuerigen O
- Warner E, Weinroth J. Family Physician Versus Specialist Care for Breast Cancer Follow-Up (correspondence), 3710
- Warren RS, *see* Kemeny NE
- Warshaw AL, *see* Fernandez-del Castillo C
see Ferrone CR
- Watanabe G, *see* Ruzzo A
- Watanabe H, *see* Inoue A
- Watanabe K, *see* Onoda S
- Watanabe T, *see* Tobinai K
- Waterston AM, Graham J. Effect of Adjuvant Trastuzumab on Pregnancy (correspondence), 321
- Watkins Bruner D, Jones M, Buchanan D, Russo J. Reducing Cancer Disparities for Minorities: A Multidisciplinary Research Agenda to Improve Patient Access to Health Systems, Clinical Trials, and Effective Cancer Therapy, 2209
- Watkins C, *see* Hirsch FR
- Watkins-Bruner D, *see* Konski AA
- Watson D, *see* Paik S
- Watt P, *see* Whiteman DC
- Weatherall P, *see* Patterson AR
- Webb C, *see* Lee AYY
- Weber B, *see* du Bois A
- Weber BHF, *see* Gadzicki D
- Weber BL, *see* Chen S
see Guillem JG
see Pierce LJ
- Weber WA, *see* Ott K
- Weber WA. Positron Emission Tomography As an Imaging Biomarker, 3282
- Wee J, *see* Low WK
- Weeks JC, *see* Buchholz TA
see Kemeny NE
see Mack JW
see Punglia RS
see Steyerberg EW
- Weetman RM, *see* Dome JS
- Wegener WA, *see* Strauss SJ
- Wei F, *see* Enger SM
- Wei Q, *see* Wang L
- Weidhaas J, *see* Haffty BG
- Weikel D, *see* Badros A
- Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A. Molecular Classification Identifies a Subset of Human Papillomavirus-Associated Oropharyngeal Cancers With Favorable Prognosis, 736
- Weinroth J, *see* Warner E
- Weinshilboum RM, *see* Yang P
- Weinstein GS, *see* Pfister DG
- Weis J, *see* Mariani L
- Weisenburger DD, *see* Iqbal J
- Weiss C, *see* Rödel C
- Weiss C, Wolze C, Engehausen DG, Ott OJ, Krause FS, Schrott K-M, Dunst J, Sauer R, Rödel C. Radiochemotherapy After Transurethral Resection for High-Risk T1 Bladder Cancer: An Alternative to Intravesical Therapy or Early Cystectomy? 2318
- Weiss GJ, Langer C, Rosell R, Hanna N, Shepherd F, Einhorn LH, Nguyen B, Paul S, McAndrews P, Bunn PA Jr, Kelly K. Elderly Patients Benefit From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized Phase III Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer, 4405
- Weiss GR, *see* Davies AM
- Weiss H, *see* Lee AV
- Weiss LK, *see* Simon MS
- Weiss MA, *see* Lamanna N
- Weissenberger C, *see* Henke M
- Weissman C, *see* Socinski MA
- Weissman NE, *see* Loud JT
- Weitman S, *see* Jeha S
- Weitzel J, *see* Guillem JG
- Weitzman S, *see* Chow LML
see Spiegler BJ
- Weller EA, *see* Habermann TM
- Weller M, *see* Herrlinger U
- Welling A, *see* Herder GJM
- Welling B, *see* Gadzicki D
- Welte K, *see* Schrauder A
- Wen PY, *see* Cloughesy TF
see Jackman DM
see Richardson PG
- Wen S, *see* Tsimberidou A-M
- Wen W, *see* Cai Q
- Went P, Agostinelli C, Gallamini A, Paolo Piccaluga P, Ascani S, Sabattini E, Bacci F, Falini B, Motta T, Paulli M, Artusi T, Piccioli M, Zinzani PL, Pileri

AUTHOR INDEX

- SA. Marker Expression in Peripheral T-Cell Lymphoma: A Proposed Clinical-Pathologic Prognostic Score, 2472
- Wenzl E, *see* Knauer M
- Werner M, *see* Henke M
- Werning JW, *see* Liauw SL
- Wesenberg F, *see* Saarinen-Pihkala UM
- Wessendorf S, *see* Rucker FG
- West CN, *see* Geiger AM
- West HL, Franklin WA, McCoy J, Gumerlock PH, Vance R, Lau DHM, Chan-sky K, Crowley JJ, Gandara DR. Gefitinib Therapy in Advanced Bronchioloalveolar Carcinoma: Southwest Oncology Group Study S0126, 1807
- West M, *see* Cheng SH
- Westcombe AM, *see* Grunfeld EA
- Westermann F, *see* Oberthuer A
- Weston C, *see* Rubie H
- Westra JL, *see* van Geelen CM
- Wettstein PJ, *see* Knutson KL
- Wexler MH, *see* Coughlin CM
- Wheatley K, Hills RK, Burnett AK. Problems With Up-Front Randomization in Clinical Trials (correspondence), 5471
- Wheeler C, *see* Beerepoot LV
- Whelan P, *see* Studer UE
- Whelan T, *see* Grunfeld E
- Whelan TJ, *see* Pierce LJ
see Wright JR
- Whelan TJ, Goss PE, Ingle JN, Tu D, Shepherd L, Pater JL. In Reply (correspondence), 4038
- Whippen DA, *see* Krueger GM
- Whitcomb P, *see* Widemann BC
- White H, *see* Shanafelt T
- White M, *see* Offit K
- White RH, *see* Alcalay A
- White RL Jr, *see* Cornett WR
- White RM, *see* Rahman A
- White S, *see* Ellis MJ
- Whitehead M, *see* Wong RKS
- Whiteman DC, Stickle M, Watt P, Celia Hughes M, Davis MB, Green AC. Anatomic Site, Sun Exposure, and Risk of Cutaneous Melanoma, 3172
- Whitney SN, Berg SL, Ethier AM, Frugé E, McCullough LB, Hockenberry M. In Reply (correspondence), 2131
- Whitney SN, Ethier AM, Frugé E, Berg S, McCullough LB, Hockenberry M. Decision Making in Pediatric Oncology: Who Should Take the Lead? The Decisional Priority in Pediatric Oncology Model, 160
- Whitton R, *see* Meyerhardt JA
- Whitton AC, *see* McCarter H
- Wibault P, *see* Bourhis J
- Wick W, *see* Herrlinger U
- Wickerham DL, *see* Bear HD
- Widemann BC, Salzer WL, Arceci RJ, Blaney SM, Fox E, End D, Gillespie A, Whitcomb P, Palumbo JS, Pitney A, Jayaprakash N, Zannikos P, Balis FM. Phase I Trial and Pharmacokinetic Study of the Farnesyltransferase Inhibitor Tipifarnib in Children With Refractory Solid Tumors or Neurofibromatosis Type I and Plexiform Neurofibromas, 507
- Wieand HS, *see* Lembersky BC
- Wieder H, *see* Ott K
- Wiernik PH, *see* Darabi K
see Redfern CH
- Wiernikowski J, *see* Goldspiel B
- Wiesner GL, *see* Acheson LS
- Wight E, *see* Urban P
- Wiklund T, *see* Tanner M
- Wildfang I, *see* Rades D
- Wildiers H, Neven P, Amant F, D'hooghe T, Paridaens R. Fertility Preservation in (Breast) Cancer Patients: Is it Safe? (correspondence), 5335
- Wilding G, *see* Hussain M
see Motzer RJ
- Wilfond BS, *see* Loud JT
- Wilke D, *see* Wong RKS
- Wilking N, *see* Tanner M
- Wilkinson A, *see* Lorenz KA
- Wilkowski R, *see* Heinemann V
- Willan AR, *see* McCarter H
- Willemze R, *see* Dijkman R
- Willett C, *see* Ajani JA
see Mohiuddin M
- Willett CG, *see* Czito BG
see Duda DG
- Willey J, *see* Bruera E
- Williams B, *see* Brain K
- Williams C, *see* Govindan R
- Williams D, *see* Razzouk BI
- Williams GM, *see* Priest JR
- Williams M, *see* Timmerman R
- Williams R, *see* Cohen EEW
- Williams SD, *see* Bedano PM
- Williamson SK, *see* Goldberg RM
see Smalley SR
- Willich NA, *see* Koch P
- Willim R, *see* O'Connor OA
- Willner J, *see* Huber RM
- Wilnink JT, *see* Seute T
- Wilschut FA, *see* Timmer-Bonte JNH
- Wilson C, *see* Grunfeld EA
- Wilson D, *see* Wong RKS
- Wilson GD, *see* Koukourakis MI
- Wilson J, *see* Berenson JR
- Wilson LD, *see* Lally BE
- Wilson LD, Smith BD. Primary Cutaneous B-Cell Lymphoma (correspondence), 4041
- Wilson RK, *see* Pham D
- Winchester DJ, *see* Cornett WR
- Winer EP, *see* Keating NL
see Tolaney SM
- Wingen LU, *see* Gadzicki D
- Winiarski J, *see* Saarinen-Pihkala UM
- Winick N, *see* Barredo JC
- Winkler D, *see* Kröber A
- Winn R, *see* Ferrell BR
- Winn RJ, *see* Herbst RS
see Smith TJ
- Winter K, *see* Ajani JA
see Mohiuddin M
- Wirapati P, *see* Urban P
- Wiseman SM, *see* Griffith OL
- Wißmann C, *see* Jüttner S
- Wissel P, *see* Eckardt JR
- Witjes F, *see* Gielissen MFM
- Witt ME, *see* Cohen EEW
- Wittteman JCM, *see* Siemes C
- Witteveen EO, *see* Beerepoot LV
see Beerepoot LV
- Witzig TE, *see* Novak AJ
see Shanafelt TD
- Wlodarska I, *see* Sagaert X
- Woda B, *see* Habermann TM
- Woessmann W, *see* Burkhardt B
- Wöhrer S, *see* Grünberger B
see Raderer M
- Wöhrer S, Troch M, Raderer M. Treatment of Localized Primary Gastric Lymphoma (correspondence), 2682
- Wolchok JD, *see* Kaufman HL
- Wolden SL, *see* Pfister DG

AUTHOR INDEX

- Wolf G, *see* Urba S
- Wolf GT, *see* Pfister DG
- Wolf H-H, *see* Kröger N
- Wolfe J, *see* Mack JW
- Wolff AC, *see* Khatcheressian JL
see Smith TJ
- Wolff AC, Davidson NE. Still Waiting After 110 Years: The Optimal Use of Ovarian Ablation As Adjuvant Therapy for Breast Cancer (editorial), 4949
- Wolff AC, Jones RJ, Davidson NE, Jeter SC, Stearns V. Myeloid Toxicity in Breast Cancer Patients Receiving Adjuvant Chemotherapy With Pegfilgrastim Support (correspondence), 2392
- Wolff RA, *see* Crane CH
- Wolmark N, *see* Bear HD
see Haller DG
see Lembersky BC
see Paik S
see Taghian AG
see Wapnir IL
- Wolverton D, *see* Esserman LJ
- Wolze C, *see* Weiss C
- Womer RB, *see* Malogolowkin MH
see Marina N
- Wong AM-C, *see* Ng S-H
- Wong BYL, *see* Clemons MJ
- Wong DT, *see* Li Y
- Wong JS, *see* Pierce LJ
- Wong JS, Kaelin CM, Troyan SL, Gadd MA, Gelman R, Lester SC, Schnitt SJ, Sgroi DC, Silver BJ, Harris JR, Smith BL. Prospective Study of Wide Excision Alone for Ductal Carcinoma in Situ of the Breast, 1031
- Wong JS, Lester SC, Smith BL. In Reply (correspondence), 3811
- Wong M, Balleine RL, Blair EYL, McLachlan AJ, Ackland SP, Garg MB, Evans S, Farlow D, Collins M, Rivory LP, Hoskins JM, Mann GJ, Clarke CL, Gurney H. Predictors of Vinorelbine Pharmacokinetics and Pharmacodynamics in Patients With Cancer, 2448
- Wong P, *see* Petrik D
- Wong RKS, Paul N, Ding K, Whitehead M, Brundage M, Fyles A, Wilke D, Nabid A, Fortin A, Wilson D, McKenzie M, Ackerman I, Souhami L, Chabot P, Pater J. 5-Hydroxytryptamine-3 Receptor Antagonist With or Without Short-Course Dexamethasone in the Prophylaxis of Radiation Induced Emesis: A Placebo-Controlled Randomized Trial of the National Cancer Institute of Canada Clinical Trials Group (SC19), 3458
- Wong SJ, Machtay M, Li aY. Locally Recurrent, Previously Irradiated Head and Neck Cancer: Concurrent Re-Irradiation and Chemotherapy, or Chemotherapy Alone? 2653
- Wong TZ, *see* Reardon DA
- Wong WD, *see* Nissan A
- Woo SY, *see* Wang L
- Wood BG, *see* Adelstein DJ
- Wood M, *see* Grunfeld E
- Wood ME, *see* Sprague JR
- Wood T, *see* Hoque MO
- Wood WC, *see* Guillem JG
- Woods WG, *see* Barrette S
- Woodward P, *see* Mitchell DG
- Woodward WA, *see* Oh JL
- Woodward WA, Vinh-Hung V, Ueno NT, Chung Cheng Y, Royce M, Tai P, Vlastos G, Wallace AM, Hortobagyi GN, Nieto Y. Prognostic Value of Nodal Ratios in Node-Positive Breast Cancer, 2910
- Worden F, *see* Urba S
- Wörmann B, *see* Büchner T
- Wörmann BJ, *see* Büchner T
- Wotherspoon A, *see* Chau I
- Wouters B, *see* De Ruysscher D
- Wozniak AJ, *see* Davies AM
see Smith TJ
- Wright G, *see* Iqbal J
- Wright J, *see* Cloughesy TF
see Fouladi M
see Gulley JL
- Wright JJ, *see* Sparano JA
- Wright JR, *see* Elliott EA
- Wright JR, Bouma S, Dayes I, Sussman J, Simunovic MR, Levine MN, Whelan TJ. The Importance of Reporting Patient Recruitment Details in Phase III Trials, 843
- Wu A, *see* Dilts DM
- Wu E, *see* Hislop TG
- Wu H, *see* Fowler K
- Wu J, *see* Furman WL
see Oh DS
- Wu M-S, *see* Cheng T-Y
- Wu T-I, *see* Chou H-H
- Wu T-T, *see* Izzo JG
see Luthra R
see Vauthey J-N
see Wu X
- Wu X, Gu J, Wu T-T, Swisher SG, Liao Z, Correa AM, Liu J, Etzel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN, Ajani JA. Genetic Variations in Radiation and Chemotherapy Drug Action Pathways Predict Clinical Outcomes in Esophageal Cancer, 3789
- Wu Y-C, *see* Chou H-H
- Wun T, *see* Alcalay A

X

- Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, Kalbakis K, Androulakis N, Kouroussis C, Pallis T, Christophylakis C, Argryraki K, Lianidou ES, Stathopoulos S, Georgoulas V, Mavroudis D. Predictive and Prognostic Value of Peripheral Blood Cytokeratin-19 mRNA-Positive Cells Detected by Real-Time Polymerase Chain Reaction in Node-Negative Breast Cancer Patients, 3756
- Xia C, *see* Ratain MJ
- Xie W, *see* Taplin M-E
- Xiong HQ, *see* Crane CH
see Ratain MJ
see Vauthey J-N
- Xiong X, *see* Kiehna EN
- Xu W, *see* Mar Fan HG

Y

- Yagasaki F, *see* Yanada M
- Yahalom J, *see* Abrey LE
see Gavrilovic IT
- Yahalom J. Don't Throw Out the Baby With the Bathwater: On Optimizing Cure and Reducing Toxicity in Hodgkin's Lymphoma (editorial), 544
- Yakoub-Agha I, Mesnil F, Kuentz M, Boiron JM, Ifrah N, Milpied N, Chehata S, Esperou H, Vernant J-P, Michallet M, Buzyn A, Gratecos N, Cahn JY, Bourhis JH, Chir Z, Raffoux C, Socié G, Golmard JL, Jouet J-P. Allogeneic Marrow Stem-Cell Transplantation From Human Leukocyte Antigen-Identical Siblings Versus Human Leukocyte Antigen-Allelic-Matched Unrelated Donors (10/10) in Patients With Standard-Risk Hematologic Malignancy: A Prospective Study From the French Society of Bone Marrow Transplantation and Cell Therapy, 5695
- Yamamoto N, *see* Ando M
- Yamamura T, *see* Gega M
- Yamanda S, *see* Yasuda H
- Yamano T, *see* Oka S
- Yamasaki M, *see* Yasuda H
- Yamaya M, *see* Yasuda H
- Yan TD, Black D, Savady R, Sugarbaker PH. Systematic Review on the Efficacy

AUTHOR INDEX

- of Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis From Colorectal Carcinoma, 4011
- Yan TD, Sugarbaker PH, Brun EA. Pseudomyxoma Peritonei From Mucinous Adenocarcinoma of the Urachus, 4944
- Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, Kobayashi T, Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Emi N, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R. High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed *BCR-ABL*-Positive Acute Lymphoblastic Leukemia: A Phase II Study by the Japan Adult Leukemia Study Group, 460
- Yanagi H, *see* Gega M
- Yanagihara R, *see* Ajani JA
- Yanagisawa K, *see* Takeuchi T
- Yanagitani N, *see* Kaira K
- Yang C-H, *see* Tsai K-Y
- Yang G, *see* Cai Q
- Yang HH, *see* Berenson JR
- Yang J. In Reply (correspondence), 5470
- Yang JC, *see* Beck KE
- Yang JC, Childs R. Immunotherapy for Renal Cell Cancer, 5576
- Yang P, Ebbert JO, Sun Z, Weinschilboum RM. Role of the Glutathione Metabolic Pathway in Lung Cancer Treatment and Prognosis: A Review, 1761
- Yang Q, *see* Haffty BG
- Yang S-D, *see* Hsu Y-C
- Yang SX, *see* Bonthala Wedam S
- Yang Y, *see* Abdel-Rahman MH
- Yanik GA, *see* Matthay KK
- Yaniv I, *see* Stein J
- Yao B, *see* Li Y-X
- Yao JC, *see* Ajani JA
- Yap S-P, *see* Toh C-K
- Yap Y-S, *see* Smith IE
- Yarbrough WG, *see* Chung CH
- Yasuda H, Yamaya M, Nakayama K, Sasaki T, Ebihara S, Kanda A, Asada M, Inoue D, Suzuki T, Okazaki T, Takahashi H, Yoshida M, Kaneta T, Ishizawa K, Yamanda S, Tomita N, Yamasaki M, Kikuchi A, Kubo H, Sasaki H. Randomized Phase II Trial Comparing Nitroglycerin Plus Vinorelbine and Cisplatin With Vinorelbine and Cisplatin Alone in Previously Untreated Stage IIIB/IV Non-Small-Cell Lung Cancer, 688
- Yasui YY, *see* Bassal M
- Yatabe Y, *see* Takeuchi T
- Yates AJ, *see* Pollack IF
- Ye Z, *see* Socinski MA
- Yeap BY, *see* Richards WG
- Yee CL, *see* Simon MS
- Yee D, *see* Ahmed RL
- Yellin M, *see* Beck KE
- Yen T-C, *see* Chou H-H
see Liu F-Y
see Ng S-H
- Yiannoutsos C, *see* Timmerman R
- Ying Z, *see* Gold DV
- Yock TI, Krailo M, Fryer CJ, Donaldson SS, Miser JS, Chen Z, Bernstein M, Laurie F, Gebhardt MC, Grier HE, Tarbell NJ. Local Control in Pelvic Ewing Sarcoma: Analysis From INT-0091—A Report From the Children's Oncology Group, 3838
- Yoder BJ, *see* Ring BZ
- Yogendran G, *see* Clemons MJ
- Yoh K, *see* Niho S
- Yokoba M, *see* Onoda S
- Yokose T, *see* Asamura H
- Yokote T, *see* Oka S
- Yokoyama A, *see* Onoda S
- Yong Oh S, *see* Lee J
- Yoo K, *see* Dummer R
- Yoo Y-K, *see* Han J-Y
- Yoshida M, *see* Yasuda H
- Yoshida S, *see* Ohtsu A
- Yoshida T, *see* Takano T
- Yoshikawa R, *see* Gega M
- Yoshimura K, *see* Fujiwara T
- Yoshimura N, *see* Kudoh S
- Yoshino T, *see* Asano N
- Yossepowitch O, *see* Eggen SE
- Yothers G, *see* Lembersky BC
- Younes A, *see* Liu Q
- Young M-A, *see* James PA
see James PA
- Young O, *see* Ellis MJ
- Young T, *see* Grunfeld EA
- Yu D, *see* Czito BG
- Yu M, *see* Hoque MO
- Yu RX, *see* Bredel M
- Yu T-K, *see* Oh JL
- Yu Z, *see* Weinberger PM
- Yu Z-H, *see* Li Y-X
- Yuen A, *see* Mohiuddin M
- Yung WKA, *see* Cloughesy TF

Z

- Zacharchuk C, *see* Erlichman C
- Zahalsky AJ, *see* Pfister DG
- Zahrieh D, *see* Raut CP
- Zalaudek I, *see* Argenziano G
- Zalberg J, *see* Rosen LS
- Zalberg JR, *see* Michael M
- Zalutsky MR, *see* Reardon DA
- Zamagni E, *see* Cavo M
- Zanagnolo V, *see* Morrison C
- Zanchini R, *see* Argenziano G
- Zander AR, *see* Kröger N
- Zaner KS, *see* Dragovich T
- ZanESCO L, *see* Axia G
- Zannikos P, *see* Widemann BC
- Zarbo RJ, *see* Raab SS
- Zee B, *see* Leung S-f
- Zee BC-Y. Planned Equivalence or Noninferiority Trials Versus Unplanned Noninferiority Claims: Are They Equal? (editorial), 1026
- Zeldis JB, *see* Mileskin L
- Zelevsky MJ, *see* Pfister DG
- Zelenetz AD, *see* Lamanna N
see O'Connor OA
- Zell JA, Ignatius Ou S-H, Ziogas A, Anton-Culver H. In Reply (correspondence), 1963
- Zellos L, *see* Richards WG
- Zelterman D, *see* Lally BE
see Lally BE
- Zeng C, *see* Lewis KD
- Zent CS, *see* Shanafelt TD
- Zhang C, *see* Kemeny NE
- Zhang L, *see* Luthra R
- Zhang M-J, *see* Eapen M
- Zhang S, *see* Siegel-Lakhai WS
- Zhang T, *see* Bruera E
- Zhang Y, *see* Foekens JA
see Smid M
- Zhao X-G, *see* Reardon DA
- Zheng W, *see* Cai Q
- Zhou H, *see* Alcalay A

AUTHOR INDEX

- Zhou K, *see* Dilts DM
Zhou L-Q, *see* Li Y-X
Zhou T, *see* Pollack IF
Zhou X, *see* Barcenas CH
 see Lee JJ
 see Li Y
Zhou X-P, *see* Abdel-Rahman MH
 see Patterson AR
Zhu AX, *see* Kulke MH
 see Meyerhardt JA
Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, Stuart K. Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma, 1898
Zhu Y, *see* Petrik D
Zielenska M, *see* Tabori U
Ziesmer SC, *see* Novak AJ
Zimmermann AH, *see* Pfisterer J
Zimmermann M, *see* Burkhardt B
 see Creutzig U
 see Langebrake C
 see Schrauder A
Zinner R, *see* Tsao AS
Zinzani PL, *see* Strauss SJ
 see Went P
Zinzani PL, Quagliano P, Pimpinelli N, Berti E, Baliva G, Rupoli S, Martelli M, Alaibac M, Borroni G, Chimenti S, Alterini R, Alinari L, Fierro MT, Cappello N, Pileri A, Soligo D, Paulli M, Pileri S, Santucci M, Grazia Bernengo aM. Prognostic Factors in Primary Cutaneous B-Cell Lymphoma: The Italian Study Group for Cutaneous Lymphomas, 1376
Ziogas A, *see* Zell JA
Zipf T, *see* Gaynon PS
Zito AF, *see* Foekens JA
Zong J, *see* Barcenas CH
Zorzi D, *see* Vauthey J-N
Zotter H, *see* Kerbl R
Zoubek A, *see* Kager L
Zucali PA, *see* Ceresoli GL
Zujewski J, *see* Bonthala Wedam S
Zukin M, *see* Bezjak A
Zuur L, *see* Rademaker-Lakhai JM
Zwaan CM, *see* Vermeer-Mens JCJ
Zwart N, *see* van Geelen CM
Zwiebel J, *see* Chen HX
Zyzanski SJ, *see* Acheson LS
 see Neff Greenley R